



US009315576B2

(12) **United States Patent**
Dreier et al.

(10) **Patent No.:** US 9,315,576 B2
(45) **Date of Patent:** Apr. 19, 2016

(54) **ANTIGEN BINDING POLYPEPTIDES**(71) Applicant: **arGEN-X B.V.**, Rotterdam (NL)(72) Inventors: **Torsten Dreier**, Sint Martens Latem (BE); **Christophe Frederic Jerome Blanchetot**, Gouda (NL); **Johannes Joseph Wilhelmus De Haard**, Oudelande (NL)(73) Assignee: **ARGEN-X N.V.**, Breda (NL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/607,949**(22) Filed: **Jan. 28, 2015**(65) **Prior Publication Data**

US 2015/0252105 A1 Sep. 10, 2015

Related U.S. Application Data

(62) Division of application No. 13/233,345, filed on Sep. 15, 2011, which is a division of application No. 12/497,239, filed on Jul. 2, 2009, now Pat. No. 8,444,976.

(60) Provisional application No. 61/077,730, filed on Jul. 2, 2008, provisional application No. 61/110,161, filed on Oct. 31, 2008.

(30) **Foreign Application Priority Data**

Jul. 2, 2008 (GB) 0812120.4

(51) **Int. Cl.**

C12P 21/04 (2006.01)
C12P 21/08 (2006.01)
C07K 16/24 (2006.01)
C07K 16/28 (2006.01)
C12Q 1/68 (2006.01)
C07K 16/46 (2006.01)
C12P 21/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/245** (2013.01); **C07K 16/2866** (2013.01); **C07K 16/462** (2013.01); **C12P 21/00** (2013.01); **C12Q 1/6883** (2013.01); **C07K 2317/22** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/55** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/76** (2013.01); **C12Q 2600/158** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,759,518 B1	7/2004	Kontermann et al.
7,371,849 B2	5/2008	Honda et al.
8,444,976 B2	5/2013	Dreier et al.

2003/0190598 A1 *	10/2003	Tanha	C07K 16/00
			435/5
2004/0214990 A1	10/2004	Tribouley et al.	
2005/0037421 A1	2/2005	Honda et al.	
2006/0194212 A1	8/2006	Skurkovich et al.	
2006/0246058 A1	11/2006	Tanha et al.	
2007/0178082 A1	8/2007	Silence et al.	
2009/0111126 A1	4/2009	Akamatsu et al.	
2011/0300140 A1	12/2011	Dreier et al.	
2012/0148607 A1	6/2012	Hultberg et al.	
2012/0156206 A1	6/2012	Hultberg et al.	

FOREIGN PATENT DOCUMENTS

EP 584421	2/1994
EP 1433793 A1	6/2004
WO WO 94/04678 A1	3/1994
WO WO 01/32714 A1	11/2001
WO WO 01/90190 A2	11/2001
WO WO 03/025020 A1	3/2003
WO WO 03/035694 A2	5/2003
WO WO 03/050531 A2	6/2003
WO WO 2004003019 A2	1/2004
WO WO 2004/041862 A2	5/2004
WO WO 2004/041863 A2	5/2004
WO WO 2004/041865 A2	5/2004
WO WO 2004/041867 A2	5/2004
WO WO 2004/062551 A2	7/2004
WO WO 2005/037989 A2	4/2005
WO WO 2005/044858 A1	5/2005
WO WO 2006/040153 A2	4/2006
WO WO 2006/074947 A2	7/2006
WO WO 2006/079372 A1	8/2006
WO WO 2006/122786 A2	11/2006
WO WO 2006/122825 A2	11/2006

(Continued)

OTHER PUBLICATIONS

Casadevall, A. et al., Passive antibody therapy for infectious diseases, Nat Rev Microbiol. Sep. 2004;2(9):695-703.

(Continued)

Primary Examiner — Michael Burkhart

(74) Attorney, Agent, or Firm — Lathrop & Gage LLP; James H. Velema; Andrew T. Wilkins

(57)

ABSTRACT

The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.

(56)

References Cited**FOREIGN PATENT DOCUMENTS**

WO	WO 2007/025977	A2	3/2007
WO	WO 2007/042289	A2	4/2007
WO	WO 2007/104529	A2	9/2007
WO	WO 2007/110219	A1	10/2007
WO	WO 2007/118670	A1	10/2007
WO	WO 2007/136525	A2	11/2007
WO	WO 2008/020079	A1	2/2008
WO	WO 2008/028977	A2	3/2008
WO	WO 2008/043821	A1	4/2008
WO	WO 2008/043822	A2	4/2008
WO	WO 2008/049897	A1	5/2008
WO	WO 2008/068280	A1	6/2008
WO	WO 2008/070344	A2	6/2008
WO	WO 2008/071447	A2	6/2008
WO	WO 2008/071685	A1	6/2008
WO	WO 2008/074839	A2	6/2008
WO	WO 2008/074840	A2	6/2008
WO	WO 2008/074867	A2	6/2008
WO	WO 2008/074868	A1	6/2008
WO	WO 2008/077945	A2	7/2008
WO	WO 2008/101985	A2	8/2008
WO	WO 2008/142164	A2	11/2008
WO	WO 2008/142165	A1	11/2008
WO	WO 2009/004065	A2	1/2009
WO	WP 2009/004066	A2	1/2009
WO	WO 2009/027391	A1	3/2009
WO	WO 2009/030285	A1	3/2009
WO	WO 2009/068625	A2	6/2009
WO	WO 2009/068627	A2	6/2009
WO	WO 2009/068628	A1	6/2009
WO	WO 2009/068630	A1	6/2009
WO	WO 2009/068631	A1	6/2009
WO	WO 2010/001251	A2	1/2010

OTHER PUBLICATIONS

- Glennie, M.J. et al., Clinical trials of antibody therapy, Aug. 2000;21(8):403-10.
- Borson et al., "Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies," J. Immunol. 163:6694-6701 (1999) D.
- Brummell et al., "Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy chain CDR3 residues," Biochemistry 32: 1180-1187 (1993) D.
- Burks et al., "In Vitro scanning saturation mutagenesis of an antibody binding pocket," PNAS, 1997, 94:412-417.
- Casset et al., "A peptide mimetic of an anti-CD4 monoclonal antibody by rational design," BBRC, 2003, vol. 307, 198-205.
- Chen et al., "Selection and Analysis of an Optimized anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," J. Mol. Bio., 1999, 293, 865-881.
- Coleman "Effects of amino acid sequence changes on antibody-antigen interactions," Research in Immunol., 145:33-36 (1994).
- De Pascalis, R. et al.; "Grafting of "Abbreviated" Complementarity—Determining Regions Containing Specificity—Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody" The Journal of Immunology (2002) 169, 3076-3084.
- De Simone et al., "Development of ELISAs for the measurement of IgM and IgG subclasses in sera from llamas (*Lama glama*) and assessment of the humoral immune response against different antigens," Vet. Immunol. Immunopathol. 126(1-2):64-73 (Nov. 5, 2008).
- Decanniere et al., "Canonical Antigen-binding Loop Structures in Immunoglobulins: More Structures, More Canonical Classes?," J. Mol. Biol., 300:83-91 (2000).
- Fenwick et al., "Hybrid Monte Carlo with Multidimensional Replica Exchanges: Conformational Equilibria of hypervariable Regions of a Llama VHH Antibody Domain," Biopolymers, 68:160-177 (2003).
- Holm et al., "Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1," Mol. Immunol., 2007, 44: 1075-1084.
- Jang et al., "The structural basis for DNA binding by an anti-DNA autoantibody," Molec. Immunol., 35:1207-1217 (1998).
- Hwang, William Ying Khee et al., "Use of human germline genes in a CDR homology-based approach to antibody humanization," Methods, vol. 36:35-42 (2005).
- Kobayashi et al., "Tryplophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," Protein Engineering 12:879-844 (1999).
- Kumar et al., "Molecular Cloning and Expression of the Fabs of Human Autoantibodies in *Escherichia coli*," J. Bioi. Chem. 275:(45) 35129-35136 (2000).
- Morea, Veronica et al., "Antibody Modeling: Implications for Engineering and Design," Methods, vol. 20:267-279 Mar. 2000.
- Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc Nail Acad Sci, USA 1982 vol. 79 page(1979) D.
- Smith-Gill et al., "Contributions of Immunoglobulin Heavy and Light Chains to Antibody Specificity for Lysozyme and Two Haptens," J. Immunol., 139:4135-4144 (1987).
- Song et al., "Light Chain of Natural Antibody Plays a Dominant Role in Protein Antigen Binding," Biochem Biophys Res Comm, 2000, vol. 268, pp. 390-394.
- Vajdos et al., "Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," J. Mol. Bioi., 2002, vol. 320, pp. 415-428.
- Wu et al., "Humanization of a Murine Monoclonal Antibody by simultaneous Optimization of Framework and CDR Residues," J. Mol. Bioi., 1999, vol. 294, pp. 251-162.
- Christele, Martinez-Jean et al., "I MGT Repertoire (IG and TR) Protein display: Arabian camel (*Camelus dromedarius*) IGH C-Regions," I MGT, Immunogenetics Information Systems, retrieved online at: <http://www.imgt.org> (2002).
- De Genst, Erwin et al., "Antibody repertoire development in camelids," Developmental and Comparative Immunology, vol. 30:187-198 (2006).
- Gonzales, Noreen R. et al., "Minimizing the Immunogenicity of Antibodies for Clinical Application," TumorBiology, vol. 26:31-43 (2005).
- Hamers-Casterman, C. et al., "Naturally occurring antibodies devoid of light chains," Nature, vol. 363:446-448 (1993).
- Harmsen, Michiel M. et al., "Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins," Vaccine, vol. 23:4926-4934 (2005).
- Kim, Sang Jick et al., "Antibody Engineering for the Development of Therapeutic Antibodies," Molecules and Cells, vol. 20(1) : 17-29 (2005).
- Leggsyter, Ilham, "The camel (*Camelus dromedarius*) Immunoglobulin Light Chains," Thesis, Vrije Universiteit 8 Brussel, Faculty of Sciences, Institute for Molecular Biology and Biotechnology, Laboratory of Ultrastructure, Academic year 2001-2002.
- Nguyen Viet Khong et al., "Camel heavy-chain antibodies: diverse germ line VHH and specific mechanisms enlarge the antigen-binding repertoire," The EMBO Journal, vol. 19(5):921-930 (2000).
- Rahbarizadeh, Fatemeh et al., "The Production and Characterization of Novel Heavy-Chain Antibodies Against the Tandem Repeat Region of MUC1 Mucin," ImmunologicalInvesti. ations, vol. 34:431-452 (2005).
- Scaviner, Dominique, "Protein display: Llama (*Lama glama*)IGH V-REGIONS," retrieved online at: http://www.imgt.org/lextes/IMGTrertoire/Proteins/protein/Lama/IGH/IGHV/Lg_IGHV (2002), 1 page.
- Scaviner, Dominique, "Protein display: Llama (*Lama glama*) IGH J-REGIONS," retrieved online at: http://imgt.cines.fr/textes/IMGTrertoire/Proteins/protein/Lama/IGH/IGHJ/Lg_IGHJallq . . . (2002), 1 page.
- Scaviner, Dominique, "Table of alleles: Llama (*Lama glama*)IGHV," retrieved online at: http://www.imgt.org/lextes/IMGTrertoire/Proteins/protein/laballeles/lama/IGH/IGHV/Ig_IGH . . . (2002), 2 pages.
- Shen, Juqun et al., "Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies," Journal of Immunological Methods, vol. 318:65-74 (2007).

(56)

References Cited

OTHER PUBLICATIONS

- Su, Chen et al., "Adaptive Evolution of Variable Region Genes Encoding an Unusual Type of Immuno*lobulin in Camelids," *Mol. Biol. Evol.*, vol. 19(3):205-215 (2002).
- Tanha, Jamshid et al., "Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties," *Journal of Immunological Methods*, vol. 263:97-109 2002.
- Vu, Khoa Bang et al., "Comparison of Llama VH Sequences from Conventional and Heavy Chain Antibodies," *Molecular Immunology*, vol. 34(16-17):1121-1131 (1997).
- Written Opinion for Application No. PCT/1B2009/006329, mailed Jan. 25, 2010, 9pages.
- International Search Report for Application No. PCT/1B2009/006329, mailed Jan. 25, 2010, 8 pages.
- Great Britain Examination Report for Application No. GB0812120. 4, dated Oct. 21, 2009, 3 pages.

- Great Britain Examination Report for Application No. GB0812120. 4, dated Mar. 2, 2010, 3 pages.
- Great Britain Examination Report for Application No. GB0812120. 4, dated Dec. 4, 2008, 5 pages.
- Christele, Martinez-Jean et al., "IMGT Repertoire (IG and TR) Protein display: Arabian camel (*Camelus dromedarius*) IGH C-REGIONS," IMGT, Immunogenetics Informations systems, retrieved online at: <http://www.imgt.org> (2002) 3 pages.
- MacCallum, R.W. et al., Antibody-antigen Interactions: Contact Analysis and Binding Site Topography, *J. Mol. Biol.* (1996) 262, 732-745.
- Saerens et al. (Sep. 23, 2005) "Identification of a universal VHH framework to craft non-canonical antigen binding loops of camel single domain antibodies," *J. Mol. Biol.* 352:597-607.
- Ward et al. (Oct. 12, 1989) "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*," *Nature*. 341:544-546.

* cited by examiner




Fig. 1

Humanization VH 1F2 and 1E2

IGHV Gene		FR1 (1-25)	CDR H1 (26-35)	FR2 (39-55)	CDR H2 (56-65)	FR3 (66-94)	CDR H3 (95-101)	FR4 (103-113)
1	13	20	33	43	50	60	70	90
IF2 VH		EVQVLLSGGGVLYQFGSRLRSCLAS GFTFSYIYAS WVRQAPGKSEWAVS L						
IF2 VH Hum								
Wild Type VH 1F2								
Humanized VH 1F2								
Safe variant VH 1F2								
902218, IgM3-66								
1E2 VH		EVQVLLSGGGVLYQFGSRLRSCLAS GFTFSYIYAS WVRQAPGKSEWAVS A						
1E2 VH Hum								
Wild Type VL 1E2								
Humanized VL 1E2								
Safe variant VL 1E2								
902218, IgM3-66								

Humanization VL 1F2 and 1E2

IGLV Gene		FR1 (1-73)	CDR L1 (74-34)	FR2 (35-49)	CDR L2 (50-56)	FR3 (57-88)	CDR L3 (89-97)	F34 (98-107)
1	13	20	30	40	50	60	70	90
IF2 VL		QTVNTQEPS...FVSFPGGVYLTC GLSSGSVSTSYPS WYQQT-SQAPRTLY SYNTES GV>PRFGS LGRKALITTA QANDSSTYIC VYMAGSI... QAVVTEEP...FVSFPGGVYLTC GLSSGSVSTSYPS WYQQT-SQAPRTLY SYNTES GV>PRFGS LGRKALITTA QANDSSTYIC VYMAGSI...						
IF2 VL Hum								
Wild Type VL 1E2								
Humanized VL 1E2								
Safe variant VL 1E2								
902218, IgM3-66								

IGLV Gene		FR1 (1-23)	L1 (24-34)	F32 (35-49)	L2 (50-56)	FR3 (57-88)	L3 (89-97)	FR4 (98-107)
1	10	20	30	40	50	60	70	90
273650, IgLV8-61	ORVVOQEPS...FVSFPGGVYLTC GLSSGSVSTSYPS WYQQT-SQAPRTLY SYNTES GVDREPSILKANQADDESYIC VLYXMSGI...							
1E2 VL								
IF2 VL Hum								
Wild Type VL 1E2								
Humanized VL 1E2								
Safe variant VL 1E2								
902218, IgM3-66								

Numbering according to Kabat

Fig.2




Fig. 3




Fig.4




Fig. 5

ANTIGEN BINDING POLYPEPTIDES

RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No. 13/233,345, filed Sep. 15, 2011, which is a Divisional of U.S. patent application Ser. No. 12/497,239, filed Jul. 2, 2009, issued as U.S. Pat. No. 8,444,976 on May 21, 2013, which claims the benefit of priority of U.S. Provisional Application Ser. No. 61/077,730, filed Jul. 2, 2008, and U.S. Provisional Application Ser. No. 61/110,161, each of which is incorporated by reference in its entirety. This application also claims the benefit of foreign priority to GB 0812120.4, filed Jul. 2, 2008, which is incorporated by reference in its entirety.

FIELD OF THE INVENTION

The invention relates to a novel platform for generation of antigen binding polypeptides, including monoclonal antibodies, which share a high degree of sequence and structural homology with the variable domains of human antibodies.

BACKGROUND TO THE INVENTION

Monoclonal antibodies have many applications as research tools and, increasingly, as therapeutic or diagnostic agents. Currently more than 20 different monoclonal antibodies have received regulatory approval to treat a variety of different diseases, including cancer, inflammation, auto-immune disorders, infectious disease, asthma, cardiovascular diseases and transplant rejection and the number of monoclonal antibody drugs in the development pipeline is increasing year-on-year.

The utility of rodent (specifically murine) monoclonal antibodies in human therapy is limited because of problems associated with their non-human origin, in particular their immunogenicity in a human host. In order to minimize the human immune response against therapeutic antibody drugs, monoclonal antibody technology has evolved from full mouse antibodies to chimeric antibodies (mouse variable domains grafted on a human IgG backbone), to humanized antibodies (mouse CDRs grafted on a human IgG backbone), to "fully human" antibodies derived from synthetic libraries or immunized transgenic mice expressing part of the human IgG repertoire.

A number of technology platforms have been developed which allow production of fully human or "humanized" monoclonal antibodies against target antigens of therapeutic interest. Each of these platforms has its own particular characteristics and potential shortcomings.

Humanisation of mouse monoclonal antibodies was initially achieved by combining mouse variable domains with human constant domains, creating so called chimeric antibodies having about 70% of human content. A further degree of humanization was subsequently achieved by grafting the complementarity-determining regions (CDRs) of mouse monoclonal antibodies onto human framework regions of the variable antibody domains of human antibodies. In addition, several amino acid residues present in those framework regions were identified as interacting with the CDRs or antigen and were back mutated in the humanized antibody to improve binding. (Almagro et al. *Frontiers in Bioscience*. 13: 1619-1633 (2008)). Monoclonal antibodies engineered using this approach have a relatively high degree of primary sequence homology to human VH and VL domain sequences after humanisation, but a drawback is the possibility of ending up with hypervariable loops not having human-like structure,

because not all mouse-encoded CDRs use canonical folds, and canonical fold combinations, which are not found in human antibodies (Almagro et al., *Mol. Immunol.* 34:1199-1214 (1997); Almagro et al., *Immunogen*. 47:355-63 (1998)).

- 5 A further drawback is the large number of mutations typically required to humanise such antibodies (the procedure for which is complex and time-consuming), with the consequent risk of losing affinity and potency as a result of the number of changes needed for humanisation and, the fact that VKappa
 10 domains are mainly used in the murine repertoire, whereas approximately half of all human antibodies possess VLambda domains.

As a potential improvement on humanised mouse monoclonal antibodies, "fully human" monoclonal antibodies can
 15 be produced by two very different approaches. The first approach is selection from a fully synthetic human combinatorial antibody library (for example HuCAL®, MorphoSys). The potential drawback of this approach is that the synthetic library only approximates the functional diversity naturally
 20 present in the human germline, thus the diversity is somewhat limited. Also, antibodies generated using this approach are not derived from in vivo selection of CDRs via active immunisation, and typically affinity maturation has to be done in order to improve affinity for the target antigen. Affinity maturation is a lengthy process which may add considerable time to the antibody discovery process. Also, in the process of affinity maturation certain amino acid residues may be changed which may negatively affect the binding specificity or stability of the resulting antibody (Wu et al., *J. Mol. Biol.*
 30 368: 652-65 (2007)).

Alternative "fully human" platforms are based on transgenic mice which have been engineered to replace the murine immunoglobulin encoding region with antibody-encoding sequences from the human germline (for example HuMab, Medarex). These systems have the advantage that antibodies are raised by active immunisation, with the target antigen, i.e. they have a high starting affinity for the antigen, and that no or only minimal antibody engineering of the original antibodies is required in order to make them more human-like. However,
 35 40 the transgenic mouse strains are by definition highly inbred and this has adverse consequences for the strength and diversity of the antibody response. Another drawback with this platform may be impaired B cell maturation due to human Fc/mouse Fc receptor interaction in some transgenic mouse systems.

45 A further platform is based on immunisation of non-human primates, specifically cynomolgous monkeys. Due to the high degree of amino acid sequence identity between monkey and human immunoglobulins it is postulated that antibodies raised in monkeys will require little or no additional "humanisation" in the variable domains in order to render them useful as human therapeutics (see WO 9302108).

SUMMARY OF THE INVENTION

55 The present inventors have recognised the need for a "humanised" monoclonal antibody (antigen binding polypeptide) platform which avoids some or all of the shortcomings they have observed with prior art humanised or fully 60 human antibody platforms and which enables the production of antibodies of high specificity and affinity against a broad range of target antigens of therapeutic importance whilst minimising immunogenicity in a human host.

The present inventors have observed that both the VH and 65 the VL domains of conventional antibodies from the family Camelidae exhibit a high degree of amino acid sequence identity with the VH and VL domains of human antibodies

over the framework regions. In fact, the degree of sequence identity between camelid conventional VH domains and human VH domains, and between camelid conventional VL domains and human VL domains can approach that observed between humans and other primate species, e.g. cynomolgous monkeys, and is much higher than might be expected given the phylogenetic distance between humans and camelids. This finding is surprising given that the variable domains of heavy-chain camelid antibodies (VHH) do not show this high degree of sequence homology with human variable domains.

In addition, the inventors have observed that the hypervariable loops (H1, H2, L1, L2 and L3) of camelid VH and VL domains often exhibit a high degree of structural homology with the hypervariable loops of human VH and VL domains, which is again unexpected given the evolutionary distance between humans and camelids. The high degree of structural homology between camelid conventional antibodies (or rather the hypervariable loops of such antibodies) and human antibodies is also surprising since the hypervariable loops of heavy-chain camelid antibodies have been reported to vary substantially in conformation and length from the corresponding loops in human and mouse VH (see review De Genst et al., *Develop Comp. Immunol.* 30:187-98 (2006)).

The high degree of primary amino acid sequence homology with the framework regions of human antibodies, coupled with the high degree of structural homology of the antigen binding sites comprising the hypervariable loops with the binding sites of human antibodies, plus the fact that Camelidae conventional antibodies can be raised by active immunisation of an outbred animal population, which are phylogenetically quite distant from humans, has led the present inventors to surmise that conventional antibodies from the family Camelidae are an attractive starting point for engineering monoclonal antibodies having potential utility as human therapeutics.

Therefore, in accordance with a first aspect of the invention there is provided an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.

In one embodiment the antigen binding polypeptide of the invention may be immunoreactive with a target antigen. In another embodiment the antigen binding polypeptide may bind specifically to a target antigen.

In a non-limiting embodiment the antigen binding polypeptide of the invention may be a recombinant polypeptide.

In a non-limiting embodiment the antigen binding polypeptide of the invention may be a chimeric polypeptide.

In a non-limiting embodiment the antigen binding polypeptide of the invention may be a monoclonal antibody.

In a non-limiting embodiment the antigen binding polypeptide of the invention may be a recombinantly expressed chimeric monoclonal antibody.

In a non-limiting embodiment the antigen binding polypeptide according to the invention may comprise hypervariable loops or complementarity determining regions which have been obtained by active immunisation of a species in the family Camelidae.

In a second aspect the invention provides a process for preparing an antigen binding polypeptide immunoreactive with a target antigen, said process comprising:

- determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining

region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and

(b) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).

In a third aspect the invention provides a process for preparing a recombinant antigen binding polypeptide that is immunoreactive with (or specifically binds to) a target antigen, said antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a species in the family Camelidae, said process comprising the steps of:

(a) isolating Camelidae nucleic acid encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen;

(b) preparing a polynucleotide comprising a nucleotide sequence encoding hypervariable loop(s) or complementarity determining region(s) having amino acid sequence identical to the hypervariable loop(s) or complementarity determining region(s) encoded by the nucleic acid isolated in step (a), which polynucleotide encodes an antigen binding polypeptide comprising a VH domain and a VL domain that is immunoreactive with (or specifically binds to) said target antigen; and

(c) expressing said antigen binding polypeptide from the recombinant polynucleotide of step (b).

The polynucleotide prepared in step (b) is preferably recombinant.

The invention further provides a polynucleotide comprising a nucleotide sequence which encodes an antigen binding polypeptide according to the first aspect of the invention, or which encodes a fragment of said antigen binding polypeptide, which fragment comprises at least one hypervariable loop or complementarity determining region (CDR) obtained from a VH or VL domain of a species in the family Camelidae.

The invention also provides an expression vector comprising the polynucleotide defined above operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system, a host cell or cell-free expression system containing the expression vector, and a method of producing a recombinant antigen binding polypeptide which comprises culturing the host cell or cell free expression system under conditions which permit expression of the antigen binding polypeptide and recovering the expressed antigen binding polypeptide.

Still further, the invention provides a test kit comprising an antigen binding polypeptide according to the first aspect of the invention and a pharmaceutical formulation comprising an antigen binding polypeptide according to the first aspect of the invention and at least one pharmaceutically acceptable diluent, excipient or carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1—shows the results of an ELISA in which sera from

llamas immunised with IL1-Beta were tested for the presence of antibodies against IL1-Beta, on day 0 and day 28 following immunisation.

FIG. 2—illustrates the amino acid sequences of “humanized” variants of two Fabs immunoreactive with IL-1 Beta, coded 1E2 and 1F2. Based on the alignment against the closest human germlines, mutations in the VH and VL framework regions of 1E2 and 1F2 were proposed. Besides the fully humanized (hum) and the wild type (wt) V regions, also a “safe variant” with only three wild type residues remaining was proposed (safe).

FIG. 3—shows the results of an ELISA in which recombinantly expressed Fabs were tested for their ability to bind biot-IL-1 Beta. For this the Fabs were captured on an anti-myc coated Maxisorp plate. Biotinylated human IL-1 Beta was added and bound cytokine was detected using HRP-conjugated streptavidin.

FIG. 4—shows the results of phage ELISA in which phage displaying humanized variants of Fabs 1E2 and 1F2 were tested for binding to IL-1 Beta.

FIG. 5—shows the results of ELISA in which chimeric 1E2 was tested for binding to IL-1 Beta.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to a new platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform.

Thus, in a first aspect the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.

In the following passages different aspects of the invention are defined in more detail. Each aspect so-defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

DEFINITIONS

The term “antigen binding polypeptide” refers to any polypeptide comprising a VH domain and a VL domain which is immunoreactive with, exhibits specific binding to, a target antigen. Exemplary antigen binding polypeptides include antibodies and immunoglobulins, and also antibody fragments, as discussed elsewhere herein.

The term “antigen”, when referring to the “target antigen” against which the antigen binding polypeptide is immunoreactive, takes its normal meaning to a person of ordinary skill in the art, and includes, *inter alia*, polypeptide, peptide, polysaccharide, glycoprotein, polynucleotide (e.g. DNA), or synthetic chemical antigens.

The term “antigen” can also be used to describe the material employed in the immunisation of animals (e.g. camelids) during the manufacture of antigen binding polypeptides of the invention. In this context the term “antigen” may take a wider meaning, and could encompass purified forms of the antigen, and also crude or semi-purified preparations of the antigen, such as for example cells, cell lysates or supernatants, cell fractions, e.g. cell membranes, etc., plus haptens conjugated with an appropriate carrier protein. The “antigen” used in an immunisation protocol is not necessarily structurally identical to the “target antigen” with which the resulting

antigen binding polypeptide is to immunoreact. Typically the “antigen” used for immunisation may be a truncated form of the “target antigen”, e.g. a fragment containing an immunogenic epitope. Further characteristics of “antigens” used for active immunisation are described elsewhere herein, and would be generally known to a person skilled in the art.

“Specific binding” between an antigen binding polypeptide and a target antigen refers to immunological specificity. An antigen binding polypeptide binds “specifically” to its target antigen if it binds an epitope on the target antigen in preference to other epitopes. “Specific binding” does not exclude cross-reactivity with other antigens bearing similar antigenic epitopes.

“Antibodies” (Abs) and “immunoglobulins” (Igs) are glycoproteins which exhibit binding specificity to a (target) antigen.

The camelid species are known to possess two different types of antibodies; the classical or “conventional” antibodies and also the heavy-chain antibodies.

As used herein, the term “conventional antibody” refers to antibodies of any isotype, including IgA, IgG, IgD, IgE or IgM. Native or naturally occurring “conventional” camelid antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end (N-terminal) a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain (VL) at one end (N-terminal) and a constant domain (CL) at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.

The term “heavy-chain antibody” refers to the second type of antibodies known to occur naturally in camelid species, such antibodies being naturally devoid of light chains (Hammers-Casterman, et al. Nature. 1993; 363; 446-8). The heavy-chain antibodies (abbreviated to HCAb) are composed of two heavy chains linked by a covalent disulphide bond. Each heavy chain in the HCAb has a variable domain at one end. The variable domains of HCAbs are referred to as “VHH” in order to distinguish them from the variable domains of the heavy chains of “conventional” camelid antibodies (VH). The VHH domains and VH domains are entirely distinct and are encoded by different gene segments in the camelid genome.

The VL domains in the polypeptide of the invention may be of the VLambda type or the VKappa type. The term “VL domain” therefore refers to both VKappa and VLambda isotypes from Camelidae, and engineered variants thereof which contain one or more amino acid substitutions, insertions or deletions relative to a Camelidae VL domain.

The term “VH domain” refers to a VH domain of any known heavy chain isotype of Camelidae, including γ , ϵ , δ , α or μ isotypes, as well as engineered variants thereof which contain one or more amino acid substitutions, insertions or deletions relative to a Camelidae VH domain. The term “VH domain” refers only to VH domains of camelid conventional antibodies and does not encompass camelid VHH domains.

The term “variable” refers to the fact that certain portions of the variable domains VH and VL differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its target antigen.

However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called “hypervariable loops” in each of the VL domain and the VH domain which form part of the antigen binding site. The first, second and third hypervariable loops of the VLambda light chain domain are referred to herein as L1(λ), L2(λ) and L3(λ) and may be defined as comprising residues 24-33 (L1(λ), consisting of 9, 10 or 11 amino acid residues), 49-53 (L2(λ), consisting of 3 residues) and 90-96 (L3(λ), consisting of 5 residues) in the VL domain (Morea et al., Methods 20:267-279 (2000)). The first, second and third hypervariable loops of the VKappa light chain domain are referred to herein as UM, L2(κ) and L3(κ) and may be defined as comprising residues 25-33 (L1(κ), consisting of 6, 7, 8, 11, 12 or 13 residues), 49-53 (L2(κ), consisting of 3 residues) and 90-97 (L3(κ), consisting of 6 residues) in the VL domain (Morea et al., Methods 20:267-279 (2000)). The first, second and third hypervariable loops of the VH domain are referred to herein as H1, H2 and H3 and may be defined as comprising residues 25-33 (H1, consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4 residues) and 91-105 (H3, highly variable in length) in the VH domain (Morea et al., Methods 20:267-279 (2000)).

Unless otherwise indicated, the terms L1, L2 and L3 respectively refer to the first, second and third hypervariable loops of a VL domain, and encompass hypervariable loops obtained from both Vkappa and Vlambda isotypes from Camelidae. The terms H1, H2 and H3 respectively refer to the first, second and third hypervariable loops of the VH domain, and encompass hypervariable loops obtained from any of the known heavy chain isotypes from Camelidae, including γ, ε, δ, α or μ.

The hypervariable loops L1, L2, L3, H1, H2 and H3 may each comprise part of a “complementarity determining region” or “CDR”. The terms “hypervariable loop” and “complementarity determining region” are not strictly synonymous, since the hypervariable loops (HVs) are defined on the basis of structure, whereas complementarity determining regions (CDRs) are defined based on sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1983) and the limits of the HVs and the CDRs may be different in some VH and VL domains.

The CDRs of the VL and VH domains can typically be defined as comprising the following amino acids: residues 24-34 (CDRL1), 50-56 (CDRL2) and 89-97 (CDRL3) in the light chain variable domain, and residues 31-35 or 31-35b (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). Thus, the HVs may be comprised within the corresponding CDRs and references herein to the “hypervariable loops” of VH and VL domains should be interpreted as also encompassing the corresponding CDRs, and vice versa, unless otherwise indicated.

The more highly conserved portions of variable domains are called the framework region (FR). The variable domains of native heavy and light chains each comprise four FRs (FR1, FR2, FR3 and FR4, respectively), largely adopting a β-sheet configuration, connected by the three hypervariable loops. The hypervariable loops in each chain are held together in close proximity by the FRs and, with the hypervariable loops from the other chain, contribute to the formation of the antigen-binding site of antibodies. Structural analysis of antibodies revealed the relationship between the sequence and the shape of the binding site formed by the complementarity

determining regions (Chothia et al., J. Mol. Biol. 227: 799-817 (1992)); Tramontano et al., J. Mol. Biol. 215:175-182 (1990)). Despite their high sequence variability, five of the six loops adopt just a small repertoire of main-chain conformations, called “canonical structures”. These conformations are first of all determined by the length of the loops and secondly by the presence of key residues at certain positions in the loops and in the framework regions that determine the conformation through their packing, hydrogen bonding or the ability to assume unusual main-chain conformations.

The constant domains are not involved directly in binding of an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity (ADCC) or complement-dependent cytotoxicity (CDC).

In all aspects and embodiments of the invention, the Camelidae (or camelid) species (from which the hypervariable loops or CDRs of the antigen binding polypeptide of the invention are obtained) can be camel, llama, dromedary, vicuna, guanaco or alpaca and any crossings thereof. Llama (*Lama glama*) and alpaca (*Lama pacos*) are the preferred Camelidae species for all aspects of the invention.

The antigen binding polypeptides of the invention are characterised in that they contain at least one hypervariable loop or complementarity determining region which is obtained from a VH domain or a VL domain of a species in the family Camelidae. For the avoidance of doubt, the terms “VH domain” “VL domain” refer to domains derived from camelid conventional antibodies. This definition excludes the camelid heavy chain only VHH antibodies, and recombinant constructs containing solely HVs or CDRs of camelid VHH domains, which are not encompassed within the scope of the present invention.

By “hypervariable loop or complementarity determining region obtained from a VH domain or a VL domain of a species in the family Camelidae” is meant that that hypervariable loop (HV) or CDR has an amino acid sequence which is identical, or substantially identical, to the amino acid sequence of a hypervariable loop or CDR which is encoded by a Camelidae immunoglobulin gene. In this context “immunoglobulin gene” includes germline genes, immunoglobulin genes which have undergone rearrangement, and also somatically mutated genes. Thus, the amino acid sequence of the HV or CDR obtained from a VH or VL domain of a Camelidae species may be identical to the amino acid sequence of a HV or CDR present in a mature Camelidae conventional antibody. The term “obtained from” in this context implies a structural relationship, in the sense that the HVs or CDRs of the antigen binding polypeptide of the invention embody an amino acid sequence (or minor variants thereof) which was originally encoded by a Camelidae immunoglobulin gene. However, this does not necessarily imply a particular relationship in terms of the production process used to prepare the antigen binding polypeptide of the invention. As will be discussed below, there are several processes which may be used to prepare antigen binding polypeptides comprising HVs or CDRs with amino acid sequences identical to (or substantially identical to) sequences originally encoded by a Camelidae immunoglobulin gene.

For the avoidance of doubt, the terms “VH domain of a conventional antibody of a camelid” and “VH domain obtained from a species of Camelidae” are used synonymously and encompass VH domains which are the products of synthetic or engineered recombinant genes (including codon-optimised synthetic genes), which VH domains have an amino acid sequence identical to (or substantially identical to) the amino acid sequence of a VH domain encoded by a

Camelidae immunoglobulin gene (germline, rearranged or somatically mutated). Similarly, the terms “VL domain of a conventional antibody of a camelid” and “VL domain obtained from a species of Camelidae” are used synonymously and encompass VL domains which are the products of synthetic or engineered recombinant genes (including codon-optimised synthetic genes), which VL domains have an amino acid sequence identical to (or substantially identical to) the amino acid sequence of a VL domain encoded by a Camelidae immunoglobulin gene (germline, rearranged or somatically mutated).

The antigen binding polypeptides of the invention are typically recombinantly expressed polypeptides, and may be chimeric polypeptides. The term “chimeric polypeptide” refers to an artificial (non-naturally occurring) polypeptide which is created by juxtaposition of two or more peptide fragments which do not otherwise occur contiguously. Included within this definition are “species” chimeric polypeptides created by juxtaposition of peptide fragments encoded by two or more species, e.g. camelid and human.

The antigen binding polypeptides of the invention are not naturally occurring human antibodies, specifically human autoantibodies, due to the requirement for at least one hypervariable loop (or CDR) from camelid. By “naturally occurring” human antibody is meant an antibody which is naturally expressed within a human subject. Antigen binding polypeptides having an amino acid sequence which is 100% identical to the amino acid sequence of a naturally occurring human antibody, or a fragment thereof, which natural antibody or fragment is not chimeric and has not been subject to any engineered changes in amino acid sequence (excluding somatic mutations) are excluded from the scope of the invention.

The antigen binding polypeptides according to the invention comprise both a heavy chain variable (VH) domain and a light chain variable (VL) domain, and are characterised in that at least one hypervariable loop or complementarity determining region in either the VH domain or the VL domain is obtained from a species in the family Camelidae.

In alternative embodiments, either H1 or H2, or both H1 and H2 in the VH domain may be obtained from a species in the family Camelidae, and independently either L1 or L2 or both L1 and L2 in the VL domain may be obtained from a species in the family Camelidae. In further embodiments H3 in the VH domain or L3 in the VL domain may also be obtained from a species in the family Camelidae. All possible permutations of the foregoing are permitted.

In one specific embodiment each of the hypervariable loops H1, H2, H3, L1, L2 and L3 in both the VH domain and the VL domain may be obtained from a species in the family Camelidae.

In one embodiment the entire VH domain and/or the entire VL domain may be obtained from a species in the family Camelidae. The Camelidae VH domain and/or the Camelidae VL domain may then be subject to protein engineering, in which one or more amino acid substitutions, insertions or deletions are introduced into the Camelidae sequence. These engineered changes preferably include amino acid substitutions relative to the Camelidae sequence. Such changes include “humanisation” or “germlining” wherein one or more amino acid residues in a camelid-encoded VH or VL domain are replaced with equivalent residues from a homologous human-encoded VH or VL domain.

In certain embodiments, Camelidae hypervariable loops (or CDRs) may be obtained by active immunisation of a species in the family Camelidae with a desired target antigen. As discussed and exemplified in detail herein, following

immunisation of Camelidae (either the native animal or a transgenic animal engineered to express the immunoglobulin repertoire of a camelid species) with the target antigen, B cells producing (conventional Camelidae) antibodies having specificity for the desired antigen can be identified and polynucleotide encoding the VH and VL domains of such antibodies can be isolated using known techniques.

Thus, in a specific embodiment, the invention provides a recombinant antigen binding polypeptide immunoreactive with a target antigen, the polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae, which antigen binding polypeptide is obtainable by a process comprising the steps of:

- (a) immunising a species in the family Camelidae with a target antigen or with a polynucleotide encoding said target antigen and raising an antibody to said target antigen;
- (b) determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and
- (c) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).

Isolated Camelidae VH and VL domains obtained by active immunisation can be used as a basis for engineering antigen binding polypeptides according to the invention. Starting from intact Camelidae VH and VL domains, it is possible to engineer one or more amino acid substitutions, insertions or deletions which depart from the starting Camelidae sequence. In certain embodiments, such substitutions, insertions or deletions may be present in the framework regions of the VH domain and/or the VL domain. The purpose of such changes in primary amino acid sequence may be to reduce presumably unfavourable properties (e.g. immunogenicity in a human host (so-called humanization), sites of potential product heterogeneity and/or instability (glycosylation, deamidation, isomerisation, etc.) or to enhance some other favourable property of the molecule (e.g. solubility, stability, bioavailability, etc.). In other embodiments, changes in primary amino acid sequence can be engineered in one or more of the hypervariable loops (or CDRs) of a Camelidae VH and/or VL domain obtained by active immunisation. Such changes may be introduced in order to enhance antigen binding affinity and/or specificity, or to reduce presumably unfavourable properties, e.g. immunogenicity in a human host (so-called humanization), sites of potential product heterogeneity and/or instability, glycosylation, deamidation, isomerisation, etc., or to enhance some other favourable property of the molecule, e.g. solubility, stability, bioavailability, etc.

Thus, in one embodiment, the invention provides a recombinant antigen binding polypeptide which contains at least one amino acid substitution in at least one framework or CDR region of either the VH domain or the VL domain in comparison to a Camelidae VH or VL domain obtained by active immunisation of a species in the family Camelidae with a target antigen. This particular embodiment excludes antigen binding polypeptides containing native Camelidae VH and VL domains produced by active immunisation.

11

As an alternative to “active immunisation” with a target antigen (or a composition comprising the target antigen or a polynucleotide encoding it) it is also possible to make use of immune responses in diseased Camelidae animals or naturally occurring immune responses within Camelidae species as a source of VH and/or VL domains which can be used as components of antigen binding polypeptides with the desired antigen-binding properties. Such VH/VL domains may also be used as the starting point for engineering antigen-binding polypeptides in an analogous manner to VH/VL domains obtained by active immunisation. The invention still further encompasses the use of non-immune libraries, and to antigen-binding polypeptides obtained/derived therefrom.

In other embodiments, the invention encompasses “chimeric” antibody molecules comprising VH and VL domains from Camelidae (or engineered variants thereof) and one or more constant domains from a non-camelid antibody, for example human-encoded constant domains (or engineered variants thereof). The invention also extends to chimeric antigen binding polypeptides (e.g. antibody molecules) wherein one of the VH or the VL domain is camelid-encoded, and the other variable domain is non-camelid (e.g. human). In such embodiments it is preferred that both the VH domain and the VL domain are obtained from the same species of camelid, for example both VH and VL may be from *Lama glama* or both VH and VL may be from *Lama pacos* (prior to introduction of engineered amino acid sequence variation). In such embodiments both the VH and the VL domain may be derived from a single animal, particularly a single animal which has been actively immunised.

As an alternative to engineering changes in the primary amino acid sequence of Camelidae VH and/or VL domains, individual Camelidae hypervariable loops or CDRs, or combinations thereof, can be isolated from Camelidae VH/VL domains and transferred to an alternative (i.e. non-Camelidae) framework, e.g. a human VH/VL framework, by CDR grafting.

Sequence Identity/Homology with Human Variable Domains

The present inventors have observed that Camelidae germline and somatically mutated DNA sequences encoding both the VH and the VL domains of conventional antibodies from species in the family Camelidae exhibit a high degree of sequence identity/sequence homology with the human germline DNA sequences which encode VH and VL domains of human antibodies, over the framework regions.

Thus, the antigen binding polypeptides of the invention are characterised in that they exhibit a high degree of amino acid sequence homology with VH and VL domains of human antibodies.

In one embodiment the VH domain of the antigen binding polypeptide according to the invention may exhibit an amino acid sequence identity or sequence homology of 80% or greater with one or more human VH domains across the framework regions FR1, FR2, FR3 and FR4. In other embodiments the amino acid sequence identity or sequence homology between the VH domain of the polypeptide of the invention and one or more human VH domains may be 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100%, of course with the proviso that at least one hypervariable loop or CDR is obtained from Camelidae, i.e. has an amino acid sequence which is identical (or substantially identical) to the amino acid sequence of a hypervariable loop or CDR encoded by a Camelidae VH or VL gene.

In one embodiment the VH domain of the polypeptide of the invention may contain one or more amino acid sequence mis-matches across the framework regions FR1, FR2, FR3

12

and FR4, in comparison to the closest matched human VH sequence. This latter embodiment would expressly exclude polypeptides comprising a VH domain, or both VH and VL domains, in which the framework region has entirely human sequence.

In another embodiment the VL domain of the antigen binding polypeptide according to the invention may exhibit a sequence identity or sequence homology of 80% or greater with one or more human VL domains across the framework regions FR1, FR2, FR3 and FR4. In other embodiments the amino acid sequence identity or sequence homology between the VL domain of the polypeptide of the invention and one or more human VL domains may be 80% or greater 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100%.

In one embodiment the VL domain of the polypeptide of the invention may contain one or more amino acid sequence mis-matches across the framework regions FR1, FR2, FR3 and FR4, in comparison to the closest matched human VL sequence. This latter embodiment would expressly exclude polypeptides comprising VL domain, or both VL and VH domains in which the framework region has entirely human sequence.

The antigen binding polypeptide of the invention may comprise a “fully human” VH or VL domain, provided that only one fully human variable domain is present, and then in combination with a variable domain comprising hypervariable loop(s) or CDR(s) obtained from Camelidae.

Representative alignments of Camelidae and human germline sequences included in the accompanying examples reveal that the conventional camelid VH and VL domains exhibit a remarkably high sequence homology to their human counterparts. From these examples it can be concluded that typically less than 8, and often only as few as 5 amino acid residues present in the framework regions of a VH or VL domain differ in a given position from the closest human germline-encoded sequences. Given that there are no structural limitations associated with those positions, humanization by site directed mutagenesis is expected to be straightforward.

Therefore, in a particular embodiment, the antigen binding polypeptides of the invention may comprise VH and/or VL domains of conventional Camelidae antibodies, for example conventional Camelidae antibodies obtained (obtainable) by active immunisation of camelidae with a target antigen (or polynucleotide encoding the target antigen), wherein said VH and VL domains have been (independently) engineered to introduce a total of between 1 and 10, i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions across the framework regions FR1, FR2, FR3 and FR4 in either one or both of the VH domain and the VL domain. Such amino acid substitutions may include (but are not limited to) substitutions which result in “humanisation”, by replacing mis-matched amino acid residues in a starting Camelidae VH or VL domain with the equivalent residue found in a human germline-encoded VH or VL domain. It is also possible to independently make amino acid substitutions in the hypervariable loops (CDRs) of said camelid-derived VH and VL domains, and such variants may form part of the present invention. References herein to “amino acid substitutions” include substitutions in which a naturally occurring amino acid is replaced with a non-natural amino acid, or an amino acid subjected to post-translational modification.

Before analyzing the percentage sequence identity between Camelidae and human germline VH and VL, the canonical folds may be determined, which allows the identification of the family of human germline segments with the

13

identical combination of canonical folds for H1 and H2 or L1 and L2 (and L3). Subsequently the human germline family member that has the highest degree of sequence homology with the Camelidae variable region of interest is chosen for scoring the sequence homology. The determination of Chothia canonical classes of hypervariable loops L1, L2, L3, H1 and H2 was performed with the bioinformatics tools publicly available on webpage www.bioinf.org.uk/abs/chothia.html. The output of the program shows the key residue requirements in a datafile. In these datafiles, the key residue positions are shown with the allowed amino acids at each position. The sequence of the variable region of the antibody is given as input and is first aligned with a consensus antibody sequence to assign the Kabat numbering scheme. The analysis of the canonical folds uses a set of key residue templates derived by an automated method developed by Martin and Thornton (Martin et al., *J. Mol. Biol.* 263:800-815 (1996)).

With the particular human germline V segment known, which uses the same combination of canonical folds for H1 and H2 or L1 and L2 (and L3), the best matching family member in terms of sequence homology was determined. With bioinformatics tools the percentage sequence identity between Camelidae VH and VL domain framework amino acid sequences and corresponding sequences encoded by the human germline can be determined, but actually manual aligning of the sequences can be applied as well. Human immunoglobulin sequences can be identified from several protein data bases, such as VBase (<http://vbase.mrc-cpe.cam.ac.uk/>) or the Pluckthun/Honegger database (<http://www.bioc.unizh.ch/antibody/Sequences/Germlines>). To compare the human sequences to the V regions of Camelidae VH or VL domains a sequence alignment algorithm such as available via websites like www.expasy.ch/tools/#align can be used, but also manual alignment with the limited set of sequences can be performed. Human germline light and heavy chain sequences of the families with the same combinations of canonical folds and with the highest degree of homology with the framework regions 1, 2, and 3 of each chain are selected and compared with the Camelidae variable region of interest; also the FR4 is checked against the human germline JH and JK or JL regions. Note that in the calculation of overall percent sequence homology the residues of FR1, FR2 and FR3 are evaluated using the closest match sequence from the human germline family with the identical combination of canonical folds. Only residues different from the closest match or other members of the same family with the same combination of canonical folds are scored (NB—excluding any primer-encoded differences). However, for the purposes of humanization, residues in framework regions identical to members of other human germline families, which do not have the same combination of canonical folds, can be considered “human”, despite the fact that these are scored “negative” according to the stringent conditions described above. This assumption is based on the “mix and match” approach for humanization, in which each of FR1, FR2, FR3 and FR4 is separately compared to its closest matching human germline sequence and the humanized molecule therefore contains a combination of different FRs as was done by Qu and colleagues (Qu et al., *Clin. Cancer Res.* 5:3095-3100 (1999)) and Ono and colleagues (Ono et al., *Mol. Immunol.* 36:387-395 (1999)).

The boundaries of the individual framework regions may be assigned using the IMGT numbering scheme, which is an adaptation of the numbering scheme of Chothia (Lefranc et al., *NAR* 27: 209-212 (1999); <http://imgt.cines.fr>).

Despite the unexpectedly high sequence homology between Camelidae and human across the framework regions

14

of the VH and VL domains, it is nevertheless possible to distinguish camelid-encoded hypervariable loops (CDRs) from human-encoded hypervariable loops (CDRs) by straightforward sequence comparison with camelid and human germline VH and VL sequences.

Structural Homology with Human-Encoded VH and VL Domains

A preferred embodiment is also to use Camelid hypervariable loops or CDRs having human or human-like canonical folds, as discussed in detail below.

Thus, in one embodiment at least one hypervariable loop or CDR in either the VH domain or the VL domain of the antigen binding polypeptide of the invention is obtained from a VH or VL domain obtained from a species of Camelidae, yet exhibits a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.

It is well established in the art that although the primary amino acid sequences of hypervariable loops present in both VH domains and VL domains encoded by the human germline are, by definition, highly variable, all hypervariable loops, except CDR H3 of the VH domain, adopt only a few distinct structural conformations, termed canonical folds (Chothia et al., *J. Mol. Biol.* 196:901-917 (1987); Tramontano et al. *Proteins* 6:382-94 (1989)), which depend on both the length of the hypervariable loop and presence of the so-called canonical amino acid residues (Chothia et al., *J. Mol. Biol.* 196:901-917 (1987)). Actual canonical structures of the hypervariable loops in intact VH or VL domains can be determined by structural analysis (e.g. X-ray crystallography), but it is also possible to predict canonical structure on the basis of key amino acid residues which are characteristic of a particular structure (discussed further below). In essence, the specific pattern of residues that determines each canonical structure forms a “signature” which enables the canonical structure to be recognised in hypervariable loops of a VH or VL domain of unknown structure; canonical structures can therefore be predicted on the basis of primary amino acid sequence alone.

Based on analysis of germline and somatically mutated VH and VL sequences, the present inventors predict that the hypervariable loops of Camelidae VH and VL domains (with the exception of H3 in the VH domain and sometimes also L3 in the VL domain) also adopt canonical fold structures which are substantially identical to canonical fold structures adopted by the hypervariable loops of human antibodies.

The predicted canonical fold structures for the hypervariable loops of any given VH or VL sequence in an antigen binding polypeptide can be analysed using algorithms which are publicly available from www.bioinf.org.uk/abs/chothia.html, www.biochem.ucl.ac.uk/~martin/antibodies.html and www.bioc.unizh.ch/antibody/Sequences/Germlines/Vbase_hV.html. These tools permit query VH or VL sequences to be aligned against human VH or VL domain sequences of known canonical structure, and a prediction of canonical structure made for the hypervariable loops of the query sequence.

In the case of the VH domain, H1 and H2 loops derived from Camelidae may be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if at least the first, and preferable both, of the following criteria are fulfilled:

1. An identical length, determined by the number of residues, to the closest matching human canonical structural class.
2. At least 33% identity, preferably at least 50% identity with the key amino acid residues described for the corresponding human H1 and H2 canonical structural classes. (note for the

15

purposes of the foregoing analysis the H1 and H2 loops are treated separately and each compared against its closest matching human canonical structural class)

The foregoing analysis relies on prediction of the canonical structure of the Camelidae H1 and H2 loops. If the actual structure of the H1 and H2 loops is known, for example based on X-ray crystallography, then the H1 and H2 loops derived from Camelidae may also be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if the length of the loop differs from that of the closest matching human canonical structural class (typically by ± 1 or ± 2 amino acids) but the actual structure of the Camelidae H1 and H2 loops matches the structure of a human canonical fold.

Key amino acid residues found in the human canonical structural classes for the first and second hypervariable loops of human VH domains (H1 and H2) are described by Chothia et al., J. Mol. Biol. 227:799-817 (1992), the contents of which are incorporated herein in their entirety by reference. In particular, Table 3 on page 802 of Chothia et al., which is specifically incorporated herein by reference, lists preferred amino acid residues at key sites for H1 canonical structures found in the human germline, whereas Table 4 on page 803, also specifically incorporated by reference, lists preferred amino acid residues at key sites for CDR H2 canonical structures found in the human germline.

The accompanying examples contain an analysis of germline VH sequences from Camelidae species (specifically llama and dromedary) comparing the actual amino acid residues found in Camelidae versus the amino acid residues in the closest human germline VH sequence, for each of the positions in H1 and H2, and underlying framework regions, considered to be key for the canonical fold structure according to the criteria of Chothia et al., J Mol Biol. 227:799-817 (1992). It is observed that the number of identical key residues between camelid and human is most often above 33%, and typically in the range of from 50 to 100%.

In one embodiment, both H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, yet exhibit a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.

The inventors surmise that it is important not only for the hypervariable loops, specifically H1 and H2 in the VH domain, individually to have canonical structures of a type which occurs naturally in human antibodies, it is also important for H1 and H2 in any given VH domain to form a combination of canonical fold structures which is identical to a combination of canonical structures known to occur in at least one human germline VH domain. It has been observed that only certain combinations of canonical fold structures at H1 and H2 actually occur in VH domains encoded by the human germline. The present inventors were surprised to discover that every available Camelidae germline or somatically mutated VH sequence which could be analysed exhibited not only individual canonical fold structures at H1 and H2 substantially identical to those used in human antibodies, but also the correct combinations of structures at H1 and H2 to match combinations found in human antibodies. This represents a distinct advantage over other platforms for production of antibodies for potential therapeutic use in humans which may produce antibodies having “correct” human-like canonical fold structures at H1 and H2 but in a combination which does not occur in human antibodies. By way of example, the inventors’ own analysis of the structure of antibodies derived from non-human primates (Biogen IDEC’s galiximab (anti-CD80)

16

an lumiliximab (anti-CD23) and the non-human primate mAb against Anthrax Toxin from Pelat et al., J. Mol. Biol. 384:1400-7 (2008)) indicates that structurally they are not consistently very close to the human antibody structure, particularly having regard to the combination of canonical folds. The absence of a correct combination of canonical folds at H1 and H2 could lead to a given antigen binding polypeptide (which is “humanised” in the framework regions) being immunogenic in a human host.

Thus, in a further embodiment H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, yet form a combination of predicted or actual canonical fold structures which is identical to a combination of canonical fold structures known to occur in a human germline or somatically mutated VH domain.

In non-limiting embodiments H1 and H2 in the VH domain of the antigen binding polypeptide of the invention are obtained from a VH domain of a Camelidae species, and form one of the following canonical fold combinations: 1-1, 1-2, 1-3, 1-6, 1-4, 2-1, 3-1 and 3-5.

It is preferred that the VH domain of the antigen binding polypeptide of the invention exhibit both high sequence identity/sequence homology with human VH, and also that the hypervariable loops in the VH domain exhibit structural homology with human VH.

It may be advantageous for the canonical folds present at H1 and H2 in the VH domain of the antigen binding polypeptide according to the invention, and the combination thereof, to be “correct” for the human VH germline sequence which represents the closest match with the VH domain of the antigen binding polypeptide of the invention in terms of overall primary amino acid sequence identity. By way of example, if the closest sequence match is with a human germline VH3 domain, then it may be advantageous for H1 and H2 (obtained from Camelidae) to form a combination of canonical folds which also occurs naturally in a human VH3 domain.

Thus, in one embodiment the VH domain of the antigen binding polypeptide of the invention may exhibit a sequence identity or sequence homology of 80% or greater, 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100% with a human VH domain across the framework regions FR1, FR2, FR3 and FR4, and in addition H1 and H2 in the same antigen binding polypeptide are obtained from a VH domain of a Camelidae species, but form a combination of predicted or actual canonical fold structures which is the same as a canonical fold combination known to occur naturally in the same human VH domain.

In other embodiments, L1 and L2 in the VL domain of the antigen binding polypeptide of the invention are each obtained from a VL domain of a Camelidae species, and each exhibit a predicted or actual canonical fold structure which is substantially identical to a canonical fold structure which occurs in human antibodies.

As with the VH domains, the hypervariable loops of VL domains of both VLambda and VKappa types can adopt a limited number of conformations or canonical structures, determined in part by length and also by the presence of key amino acid residues at certain canonical positions.

L1, L2 and L3 loops obtained from a VL domain of a Camelidae species, yet may be scored as having a canonical fold structure “substantially identical” to a canonical fold structure known to occur in human antibodies if at least the first, and preferable both, of the following criteria are fulfilled:

17

1. An identical length, determined by the number of residues, to the closest matching human structural class.
2. At least 33% identity, preferably at least 50% identity with the key amino acid residues described for the corresponding human L1 or L2 canonical structural classes, from either the VLambda or the VKappa repertoire.
(note for the purposes of the foregoing analysis the L1 and L2 loops are treated separately and each compared against its closest matching human canonical structural class)

The foregoing analysis relies on prediction of the canonical structure of the Camelidae L1, L2 and L3 loops. If the actual structure of the L1, L2 and L3 loops is known, for example based on X-ray crystallography, then L1, L2 or L3 loops derived from Camelidae may also be scored as having a canonical fold structure "substantially identical" to a canonical fold structure known to occur in human antibodies if the length of the loop differs from that of the closest matching human canonical structural class (typically by ± 1 or ± 2 amino acids) but the actual structure of the Camelidae loops matches a human canonical fold.

Key amino acid residues found in the human canonical structural classes for the CDRs of human VLambda and VKappa domains are described by Morea et al. Methods, 20: 267-279 (2000) and Martin et al., J. Mol. Biol., 263:800-815 (1996). The structural repertoire of the human VKappa domain is also described by Tomlinson et al. EMBO J. 14:4628-4638 (1995), and that of the VLambda domain by Williams et al. J. Mol. Biol., 264:220-232 (1996). The contents of all these documents are to be incorporated herein by reference.

The accompanying examples contain an analysis of germline VL sequences or both kappa and lambda type from Camelidae species (specifically llama and dromedary), comparing the actual amino acid residues found in Camelidae versus the amino acid residues in the closest human germline VLambda or VKappa sequence, for each of the positions in L1 and L2 considered to be key for the canonical fold structure. It is observed that the number of identical key residues between camelid and human is typically in the range of from 33 to 100%, more often between 50 to 100%, typically closer to 100%.

L1 and L2 in the VL domain may form a combination of predicted or actual canonical fold structures which is identical to a combination of canonical fold structures known to occur in a human germline VL domain.

In non-limiting embodiments L1 and L2 in the VLambda domain may form one of the following canonical fold combinations: 11-7, 13-7(A,B,C), 14-7(A,B), 12-11, 14-11 and 12-12 (as defined in Williams et al. J. Mol. Biol. 264:220-32 (1996) and as shown on http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVL.html). In non-limiting embodiments L1 and L2 in the Vkappa domain may form one of the following canonical fold combinations: 2-1, 3-1, 4-1 and 6-1 (as defined in Tomlinson et al. EMBO J. 14:4628-38 (1995) and as shown on http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVK.html).

In a further embodiment, all three of L1, L2 and L3 in the VL domain may exhibit a substantially human structure. Most human V κ germline segments encode also a single conformation of the L3 loop (type 1), which is stabilized by the conserved cis-proline on position 95, but other conformations in rearranged sequences are possible due to the process of V-J joining and the potential loss of this proline residue. The publicly available somatically mutated dromedary V κ sequences have a type 1 canonical fold for L3(k) like is found in human kappa germline sequences, and Proline on position 95 occurs in six out of seven dromedary V κ domains. There-

18

fore, where the antigen binding polypeptide contains a V κ domain, this domain may possess the conserved Proline residue on position 95.

The structural repertoire of the human VL germline sequences was analyzed by Williams and colleagues (Williams et al., J. Mol. Biol. 264:220-232 (1996)). The three families analyzed here encode identical conformations of the L2 loop. The L3 loop conformation is thought to be more highly variable, as there is some length variation and no cis-proline residue. Indeed the available somatically mutated dromedary V λ sequences show a high variability in the length of L3. Most of these have a canonical fold for L3 (f.i. VLambda 3-1 family members Camvl19(10A) and Camvl20(1/9A), VLambda 2-18 family members Camvl5, 17, 30, 36 and 52 (all 10B) and VLambda 1-40 family member Camvl44(5/11A)).

It is preferred that the VL domain of the antigen binding polypeptide of the invention exhibit both high sequence identity/sequence homology with human VL, and also that the hypervariable loops in the VL domain exhibit structural homology with human VL.

In one embodiment, the VL domain of the antigen binding polypeptide of the invention may exhibit a sequence identity of 80% or greater, 85% or greater, 90% or greater, 95% or greater, 97% or greater, or up to 99% or even 100% with a human VL domain across the framework regions FR1, FR2, FR3 and FR4, and in addition hypervariable loop L1 and hypervariable loop L2 may form a combination of predicted or actual canonical fold structures which is the same as a canonical fold combination known to occur naturally in the same human VL domain.

It is, of course, envisaged that VH domains exhibiting high sequence identity/sequence homology with human VH, and also structural homology with hypervariable loops of human VH will be combined with VL domains exhibiting high sequence identity/sequence homology with human VL, and also structural homology with hypervariable loops of human VL to provide antigen binding polypeptides containing (camelid-derived) VH/VL pairings with maximal sequence and structural homology to human-encoded VH/VL pairings. A particular advantage of the camelid platform provided by the invention is that both the VH domain and the VL domain exhibit high sequence and structural homology with the variable domains of human antibodies.

45 Structure of the Antigen Binding Polypeptide

The antigen binding polypeptide of the invention can take various different embodiments, provided that both a VH domain and a VL domain are present. Thus, in non-limiting embodiments the antigen binding polypeptide may be an immunoglobulin, an antibody or antibody fragment. The term "antibody" herein is used in the broadest sense and encompasses, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), so long as they exhibit the appropriate specificity for a target antigen. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes) on the antigen, each monoclonal antibody is directed against a single determinant or epitope on the antigen.

19

"Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable domain thereof. Examples of antibody fragments include Fab, Fab', F(ab')2, bi-specific Fab's, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, a single chain variable fragment (scFv) and multispecific antibodies formed from antibody fragments (see Holliger and Hudson, *Nature Biotechnol.* 23:1126-36 (2005), the contents of which are incorporated herein by reference).

In non-limiting embodiments, antibodies and antibody fragments according to the invention may comprise CH1 domains and/or CL domains, the amino acid sequence of which is fully or substantially human. Where the antigen binding polypeptide of the invention is an antibody intended for human therapeutic use, it is typical for the entire constant region of the antibody, or at least a part thereof, to have fully or substantially human amino acid sequence. Therefore, an antibody of the invention must comprise VH and VL domains, at least one of which includes at least one hypervariable loop derived from Camelidae, but one or more or any combination of the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4 domain if present) may be fully or substantially human with respect to its amino acid sequence.

Advantageously, the CH1 domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4 domain if present) may all have fully or substantially human amino acid sequence. In the context of the constant region of a humanised or chimeric antibody, or an antibody fragment, the term "substantially human" refers to an amino acid sequence identity of at least 90%, or at least 95%, or at least 97%, or at least 99% with a human constant region. The term "human amino acid sequence" in this context refers to an amino acid sequence which is encoded by a human immunoglobulin gene, which includes germline, rearranged and somatically mutated genes. The invention also contemplates polypeptides comprising constant domains of "human" sequence which have been altered, by one or more amino acid additions, deletions or substitutions with respect to the human sequence.

As discussed elsewhere herein, it is contemplated that one or more amino acid substitutions, insertions or deletions may be made within the constant region of the heavy and/or the light chain, particularly within the Fc region. Amino acid substitutions may result in replacement of the substituted amino acid with a different naturally occurring amino acid, or with a non-natural or modified amino acid. Other structural modifications are also permitted, such as for example changes in glycosylation pattern (e.g. by addition or deletion of N- or O-linked glycosylation sites). Depending on the intended use of the antibody, it may be desirable to modify the antibody of the invention with respect to its binding properties to Fc receptors, for example to modulate effector function. For example cysteine residue(s) may be introduced in the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., *J. Exp. Med.* 176:1191-1195 (1992) and Shope, *B. J. Immunol.* 148:2918-2922 (1992). Alternatively, an antibody can be engineered which has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design* 3:219-230 (1989). The invention also contemplates immunoconjugates comprising an antibody as described herein conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin,

20

or fragments thereof), or a radioactive isotope (i.e., a radioconjugate). Fc regions may also be engineered for half-life extension.

The invention can, in certain embodiments, encompass chimeric Camelidae/human antibodies, and in particular chimeric antibodies in which the VH and VL domains are of fully camelid sequence (e.g. Llama or alpaca) and the remainder of the antibody is of fully human sequence. In preferred embodiments the invention also encompasses "humanised" or "germlined" Camelidae antibodies, and Camelidae/human chimeric antibodies, in which the VH and VL domains contain one or more amino acid substitutions in the framework regions in comparison to Camelidae VH and VL domains obtained by active immunisation. Such "humanisation"

increases the % sequence identity with human germline VH or VL domains by replacing mis-matched amino acid residues in a starting Camelidae VH or VL domain with the equivalent residue found in a human germline-encoded VH or VL domain.

The invention still further encompasses CDR-grafted antibodies in which CDRs (or hypervariable loops) derived from a Camelidae antibody, for example an Camelidae antibody

raised by active immunisation with a target antigen, or otherwise encoded by a camelid gene, are grafted onto a human VH and VL framework, with the remainder of the antibody also being of fully human origin. However, given the high degree of amino acid sequence homology and structural homology they have observed between Camelidae and human immunoglobulins, the inventors anticipate that in the majority of cases

it will be possible to achieve the levels of human homology required for in vivo therapeutic use via "humanisation" of the framework regions of camelid-derived VH and VL domains without the need for CDR grafting or via CDR grafting on to limited number of backbone sequences without the need for veneering (also see Almagro et al, *Frontiers in Bioscience* 13: 1619-1633 (2008), the contents of which are incorporated herein by reference).

Humanised, chimeric and CDR-grafted antibodies according to the invention, particularly antibodies comprising hypervariable loops derived from active immunisation of Camelidae with a target antigen, can be readily produced using conventional recombinant DNA manipulation and expression techniques, making use of prokaryotic and eukaryotic host cells engineered to produce the polypeptide of interest and including but not limited to bacterial cells, yeast cells, mammalian cells, insect cells, plant cells, some of them as described herein and illustrated in the accompanying examples.

The invention also encompasses antigen binding polypeptides wherein either one or other of the VH or VL domain is obtained from Camelidae, or contains at least one CDR or hypervariable region derived from Camelidae, and the "other" variable domain has non-camelid, e.g. human, amino acid sequence. Thus, it is contemplated to pair a camelid VH domain with a human VL domain, or to pair a human VH domain with a camelid VL domain. Such pairings may increase the available antigen-binding repertoire from which to select high affinity binders with the desired antigen binding properties.

The invention still further extends to antigen binding polypeptides wherein the hypervariable loop(s) or CDR(s) of the VH domain and/or the VL domain are obtained from Camelidae, but wherein at least one of said (camelid-derived) hypervariable loops or CDRs has been engineered to include one or more amino acid substitutions, additions or deletions relative to the camelid-encoded sequence. Such changes include "humanisation" of the hypervariable loops/CDRs.

Camelid-derived HVs/CDRs which have been engineered in this manner may still exhibit an amino acid sequence which is "substantially identical" to the amino acid sequence of a camelid-encoded HV/CDR. In this context, "substantial identity" may permit no more than one, or no more than two amino acid sequence mis-matches with the camelid-encoded HV/CDR.

Antibodies according to the invention may be of any isotype. Antibodies intended for human therapeutic use will typically be of the IgA, IgD, IgE IgG, IgM type, often of the IgG type, in which case they can belong to any of the four sub-classes IgG1, IgG2a and b, IgG3 or IgG4. Within each of these sub-classes it is permitted to make one or more amino acid substitutions, insertions or deletions within the Fc portion, or to make other structural modifications, for example to enhance or reduce Fc-dependent functionalities.

Antigen binding polypeptides according to the invention may be useful in a wide range of applications, both in research and in the diagnosis and/or treatment of diseases. Because of the high degree of amino acid sequence identity with the VH and VL domains of natural human antibodies, and the high degree of structural homology (specifically the correct combinations of canonical folds as are found in human antibodies) the antigen binding polypeptides of the invention, particularly in the form of monoclonal antibodies, will find particular utility as human therapeutic agents.

The invention provides a platform for production of antigen binding polypeptides, and specifically monoclonal antibodies, against a wide range of antigens and in its broadest aspect the invention is not intended to be limited with respect to the exact identity of the target antigen, nor indeed the specificity or affinity of binding to the target antigen. However, in particular, non-limiting, embodiments the target antigen may be a non-camelid antigen, a bacterial antigen, a viral antigen or a human antigen. In a preferred embodiment the target antigen may be an antigen of particular therapeutic importance. The term "target of therapeutic importance" refers to a target involved in formation, onset, progression, mediation of human or animal diseases or of the effects related to the respective disease. Included within this definition are targets wherein the expression levels and/or activity of the target are modulated by antibody binding (e.g. receptors whose activity may be modulated by binding of agonist or antagonist antibodies), and targets wherein the activity and/or expression of the target has a direct or indirect impact on a disease.

By way of example, "human antigens" may include naturally occurring human polypeptides (proteins) which function as receptors, receptor ligands, cell-signalling molecules, hormones, cytokines or cytokine receptors, neurotransmitters, etc. By "naturally occurring" is meant that the polypeptide is expressed within the human body, at any stage of its development, including polypeptides expressed by the human body during the course of a disease.

Non-limiting embodiments of the antigen binding polypeptide of the invention include the following:

A chimeric antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A recombinantly expressed antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained

from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A monoclonal antibody comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

An antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae and wherein said antigen binding polypeptide is immunoreactive with a target antigen of therapeutic or diagnostic importance. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A chimeric antigen binding polypeptide comprising or consisting of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and one or more constant domains of a human antibody. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A chimeric antigen binding polypeptide immunoreactive with a target antigen of therapeutic or diagnostic importance, which antigen binding polypeptide comprises or consists of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and one or more constant domains of a human antibody. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A chimeric antibody comprising or consisting of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and the constant domains of a human antibody of an isotype selected from the group consisting of: IgG, IgM, IgD, IgE and IgA. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

A chimeric antigen binding polypeptide immunoreactive with a target antigen of therapeutic or diagnostic importance, which antigen binding polypeptide comprises or consists of a VH domain of a conventional antibody of a camelid (in particular Llama or alpaca), a VL domain of a conventional antibody of a camelid (in particular Llama or alpaca) and the constant domains of a human antibody of an isotype selected from the group consisting of: IgG, IgM, IgD, IgE, IgA. In a particular embodiment both the VH domain and the VL domain are obtained from Llama (*Lama glama*).

In particular embodiments of the foregoing, both the VH and the VL domain may be from the same species of camelid (in particular Llama or alpaca), and may even be from the same animal within this species, for example a single animal which has been actively immunised. In particular, both the VH domain and the VL domain may be obtained from a single actively immunised Llama. However, it is not excluded that the VH and VL domain may be obtained from different animals, or non-immune libraries.

In the foregoing embodiments, the terms "VH domain of a conventional antibody of a camelid" and "VL domain of a conventional antibody of a camelid" are intended to encompass variants which have been engineered to introduce one or more changes in amino acid sequence, such as variants which

have been "humanised" or "germlined" in one or more framework regions, as described elsewhere herein, and also encompass the products of synthetic (e.g. codon-optimised) genes, as described elsewhere herein.

Polynucleotides, Vectors and Recombinant Expression

The invention also provides a polynucleotide molecule encoding the antigen binding polypeptide of the invention, an expression vector containing a nucleotide sequence encoding the antigen binding polypeptide of the invention operably linked to regulatory sequences which permit expression of the antigen binding polypeptide in a host cell or cell-free expression system, and a host cell or cell-free expression system containing this expression vector.

Polynucleotide molecules encoding the antigen binding polypeptide of the invention include, for example, recombinant DNA molecules.

The terms "nucleic acid", "polynucleotide" or a "polynucleotide molecule" as used herein interchangeably and refer to any DNA or RNA molecule, either single- or double-stranded and, if single-stranded, the molecule of its complementary sequence. In discussing nucleic acid molecules, a sequence or structure of a particular nucleic acid molecule may be described herein according to the normal convention of providing the sequence in the 5' to 3' direction. In some embodiments of the invention, nucleic acids or polynucleotides are "isolated." This term, when applied to a nucleic acid molecule, refers to a nucleic acid molecule that is separated from sequences with which it is immediately contiguous in the naturally occurring genome of the organism in which it originated. For example, an "isolated nucleic acid" may comprise a DNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the genomic DNA of a prokaryotic or eukaryotic cell or non-human host organism. When applied to RNA, the term "isolated polynucleotide" refers primarily to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been purified/separated from other nucleic acids with which it would be associated in its natural state (i.e., in cells or tissues). An isolated polynucleotide (either DNA or RNA) may further represent a molecule produced directly by biological or synthetic means and separated from other components present during its production.

For recombinant production of an antigen binding polypeptide according to the invention, a recombinant polynucleotide encoding it may be prepared (using standard molecular biology techniques) and inserted into a replicable vector for expression in a chosen host cell, or a cell-free expression system. Suitable host cells may be prokaryote, yeast, or higher eukaryote cells, specifically mammalian cells. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); mouse myeloma cells SP2/0-AG14 (ATCC CRL 1581; ATCC CRL 8287) or NS0 (HPA culture collections no. 85110503); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC

CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2), as well as DSM's PERC-6 cell line. Expression vectors suitable for use in each of these host cells are also generally known in the art.

It should be noted that the term "host cell" generally refers to a cultured cell line. Whole human beings into which an expression vector encoding an antigen binding polypeptide according to the invention has been introduced are explicitly excluded from the scope of the invention.

In an important aspect, the invention also provides a method of producing a recombinant antigen binding polypeptide which comprises culturing a host cell (or cell free expression system) containing polynucleotide (e.g. an expression vector) encoding the recombinant antigen binding polypeptide under conditions which permit expression of the antigen binding polypeptide, and recovering the expressed antigen binding polypeptide. This recombinant expression process can be used for large scale production of antigen binding polypeptides according to the invention, including monoclonal antibodies intended for human therapeutic use. Suitable vectors, cell lines and production processes for large scale manufacture of recombinant antibodies suitable for in vivo therapeutic use are generally available in the art and will be well known to the skilled person.

Further aspects of the invention relate to test kits, including diagnostic kits etc. comprising an antigen binding polypeptide according to the invention, and also pharmaceutical formulations comprising an antigen binding polypeptide according to the invention.

Where the antigen binding polypeptide is intended for diagnostic use, for example where the antigen binding polypeptide is specific for an antigen which is a biomarker of a disease state or a disease susceptibility, then it may be convenient to supply the antigen binding polypeptide as a component of a test kit. Diagnostic tests typically take the form of standard immunoassays, such as ELISA, radioimmunoassay, Elispot, etc. The components of such a test kit may vary depending on the nature of the test or assay it is intended to carry out using the antigen binding polypeptide of the invention, but will typically include additional reagents required to carry out an immunoassay using the antigen binding polypeptide of the invention. Antigen binding polypeptides for use as diagnostic reagents may carry a revealing label, such as for example a fluorescent moiety, enzymatic label, or radiolabel.

Antigen binding polypeptides intended for in vivo therapeutic use are typically formulated into pharmaceutical dosage forms, together with one or more pharmaceutically acceptable diluents, carriers or excipients (Remington's Pharmaceutical Sciences, 16th edition., Osol, A. Ed. 1980). Antigen binding polypeptides according to the invention are typically formulated as sterile aqueous solutions, to be administered intravenously, or by intramuscular, intraperitoneal, intra-cerebrospinal, intratumoral, oral, peritumoral, subcutaneous, intra-synovial, intrathecal, topical, sublingual or inhalation routes, to a mammalian subject, typically a human patient, in need thereof. For the prevention or treatment of disease, the appropriate dosage of antigen binding polypeptide will depend on the type of disease to be treated, the severity and clinical course of the disease, plus the patient's age, weight and clinical history, and will be determined by the judgement of the attending physician.

25

Processes for the Production of Antigen Binding Polypeptides

A key aspect of the present invention relates to processes for the production of high affinity antigen binding polypeptides, and specifically monoclonal antibodies, against a target antigen of interest.

Accordingly, the invention provides a process for preparing an antigen binding polypeptide immunoreactive with a target antigen, said process comprising:

- (a) determining the nucleotide sequence encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen; and
- (b) expressing an antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).

In one embodiment, the antigen binding polypeptide expressed in part (b) is not identical to the Camelidae conventional antibody of part (a).

In one non-limiting embodiment, the invention provides a process for preparing a recombinant antigen binding polypeptide that is immunoreactive with (or specifically binds to) a target antigen, said an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a species in the family Camelidae, said process comprising the steps of:

- (a) isolating Camelidae nucleic acid encoding at least one hypervariable loop or complementarity determining region (CDR) of the VH and/or the VL domain of a Camelidae conventional antibody immunoreactive with said target antigen;
- (b) preparing a recombinant polynucleotide comprising a nucleotide sequence encoding hypervariable loop(s) or complementarity determining region(s) having amino acid sequence identical to the hypervariable loop(s) or complementarity determining region(s) encoded by the nucleic acid isolated in step (a), which recombinant polynucleotide encodes an antigen binding polypeptide comprising a VH domain and a VL domain that is immunoreactive with (or specifically binds to) said target antigen; and
- (c) expressing said antigen binding polypeptide from the recombinant polynucleotide of step (b).

In one embodiment, the antigen binding polypeptide expressed in part (c) is not identical to the Camelidae conventional antibody of part (a).

The foregoing methods may be referred to herein as "general processes" for preparing antigen binding polypeptides.

The first step of either process may involve active immunisation of a species in the family Camelidae in order to elicit an immune response against the target antigen, thereby raising camelid conventional antibodies immunoreactive with the target antigen. Protocols for immunisation of camelids are described in the accompanying examples. The antigen preparation used for immunisation may be a purified form of the target antigen, for example recombinantly expressed polypeptide, or an immunogenic fragment thereof. However, it is also possible to immunise with crude preparations of the antigen, such as like isolated cells or tissue preparations expressing or encoding the target antigen, cell lysates, cell

26

supernatants or fractions such as cell membranes, etc., or with a polynucleotide encoding said target antigen (a DNA immunisation).

The process will typically involve immunisation of animals of a Camelidae species (including, but limited to, llamas and alpacas), and advantageously these animals will belong to an outbred population. However, it is also contemplated to use transgenic animals (e.g. transgenic mice) containing the Camelid conventional Ig locus, or at least a portion thereof.

A topic of increasing interest seems to be the difference between the complementarity determining regions (CDRs) of in vivo and in vitro generated antibodies. The inventors surmise that the in vivo selection has a favourable impact on the immunogenicity, functionality, stability and therefore improved manufacturability of the resulting antibodies, whilst synthetic CDRs generated and selected in vitro may have a disadvantage from this point of view. This is important since a given therapeutic antibody risks to be neutralized by the so called anti-idiotypic antibody response from the patient (Lonberg, *Nature Biotechnology*, 23: 1117-1125, (2005)).

A key advantage of processes according to the invention based on active immunisation of camelids stems from the fact that all species of Camelidae can be maintained in large outbred populations where the individual animals have a different genetic background. It is therefore possible to use active immunisation to elicit a strong and diverse immune response against the antigen of interest from which a diverse pool of potential antigen binding molecules can be obtained. As illustrated in the accompanying examples, the present inventors have observed that active immunisation of camelids can generate Fab fragments binding to a target antigen with a high degree of immunodiversity. Without wishing to be bound by theory, the inventors surmise that the phylogenetic distance between humans and camelids may be important for production of a diverse immune response against a given target antigen. In contrast, the non-human primates are phylogenetically close to humans, thus targets with high homology between non-human primates and humans may elicit only a limited immune response in terms of strength and diversity in non-human primates.

The ability to use active immunisation in an outbred population which is phylogenetically distant from human would not be particularly advantageous if the antibodies so-produced were to exhibit a low sequence and structural homology with human antibodies such that substantial "protein engineering" would be required to create a candidate antibody with therapeutic potential. It is therefore extremely important that the inventors have shown that the Camelidae germline (and somatically mutated sequences) encodes both VH and VL domains with a very high degree of sequence and structural homology with human VH and VL domains (as explained above). This high degree of homology in combination with the availability of large outbred populations results in a very powerful platform for development of monoclonal antibodies for use as human therapeutics.

Following active immunisation with the target antigen, peripheral blood lymphocytes or biopsies such as lymph nodes or spleen biopsies may be isolated from the immunised animal and screened for production of conventional camelid antibodies against the target antigen. Techniques such as enrichment using panning or FACS sorting may be used at this stage to reduce the complexity of the B cell repertoire to be screened, as illustrated in the examples. Antigen-specific B cells are then selected and used for total RNA extraction and subsequent cDNA synthesis. Nucleic acid encoding the native camelid VH and VL domains (specific for the target antigen) can be isolated by PCR.

It is not essential to use active immunisation in order to identify camelid convention antibodies immunoreactive with a target of interest. In other embodiments it may be possible to make use of the camelid's own immune response, either the immunodiversity naturally present in the animal, or for example a diseased animal or animal which has been naturally exposed to a particular pathogen, e.g. by normal infection routes. In this regard, the invention encompasses the use of non-immune libraries. If "natural" immune responses within the camelid already give rise to antibodies which bind the target antigen of interest, then it is possible to make use of the genetic engineering techniques described herein, and other standard techniques known in the art, in order to culture and isolate B cells producing such antibodies, or produce monoclonal cultures of such antibodies, and/or to determine the nucleotide sequence of the camelid gene segments encoding the VH and/or VL domains of such antibodies. Armed with this sequence information, it is then possible to engineer recombinant DNA constructs encoding antigen binding polypeptides which embody the camelid derived VH and/or VL, or the hypervariable loops (or CDRs) thereof.

Nucleic acid encoding camelid VH and VL domains (whether obtained by active immunisation or by other means) may be cloned directly into an expression vector for the production of an antigen binding polypeptide according to the invention. In particular, these sequences could be cloned into an expression vector which also encodes a human antibody constant region, or a portion thereof, in order to produce a chimeric antibody. However, it is typical to carry out further manipulations on the isolated camelid VH and VL sequences before cloning and expression with human constant region sequences.

As a first step, candidate camelid VH and VL sequences (including sequences isolated following the active immunisation) may be used to prepare a camelid libraries (e.g. Fab libraries, as described in the accompanying examples). The library may then be screened (e.g. using phage display) for binding to the target antigen. Promising lead candidates can be further tested for target antigen binding, for example using Biacore or a suitable bioassay. Finally, the sequences encoding the VH and VL domains of the most promising leads can be cloned as an in-frame fusion with sequences encoding a human antibody constant region.

It is not essential that the polynucleotide sequence used to encode the (camelid-derived) HVs/CDRs (e.g. for recombinant expression of the antigen binding polypeptide of the invention) is identical to the native polynucleotide sequence which naturally encodes the HVs/CDRs in the camelid. Therefore, the invention encompasses/permits codon optimisation, and other changes in polynucleotide sequence related to cloning and/or expression, which do not alter the encoded amino acid sequence.

In certain embodiments, "chain shuffling" may be performed in which a particular variable domain known to bind the antigen of interest is paired with each of a set of variable domains of the opposite type (i.e. VH paired with VL library or vice versa), to create libraries, and the resulting "promiscuous" combinations of VH/VL tested for antigen binding affinity and/or specificity. Alternatively, a library of VH domains could be paired with a library of VL domains, either randomly or in a hierarchical manner, and the resulting combinations tested (see Clackson et al., *Nature*, Vol. 352, pp 624-638, 1991). In this process, the libraries may be libraries of rearranged VH and VL (V_k or V_λ) from camelids which display immunity to the antigen of interest (including animals which have been actively immunised). The chain shuffling

process can increase immunodiversity and produce pairings with significantly enhanced affinity.

The invention also contemplates performing epitope imprinted selection (so-called "guided selection") starting from a camelid VH or VL domain, wherein the other variable domain is taken from a non-camelid species, e.g. human. Thus, in one embodiment a camelid VH domain may be "shuffled" with a library of human-encoded VL domains, to replace the native camelid-encoded VL domain, resulting in camelid VH/human VL pairings. One or more of these pairings may then be subjected a second chain shuffling step in which the human VL domain is shuffled against a library of VH domains, which may be human-encoded. This second step may produce human-encoded VH/VL combinations which have the epitope imprint of the original camelid-encoded VH/VL combination.

Also included within the scope of the invention is the reverse "chain shuffling" process, starting with non-camelid (preferably human)-encoded VH/VL domain combination which binds to an antigen of interest. This could be, for example, a fully human therapeutic antibody against a validated disease target. Starting from this VH/VL combination, it is possible to carry out a first round of selection in which the VH domain is "shuffled" with a library of camelid-encoded VL domains (or vice versa), and the pairings tested for antigen binding. Selected non-camelid (e.g. human) VH/camelid VL pairings may then be subjected to a second round of selection in which the camelid-encoded VL is shuffled against a library of camelid-encoded VH, and the resulting pairings tested for antigen binding. As a result, it may be possible to produce a camelid VH/camelid VL combination which carries the epitope imprint of the starting VH/VL combination. This camelid VH/VL combination could be further engineered/modified and combined with human-encoded constant domains as required, using any of the processes described herein.

In the processes of the invention, "native" camelid-derived VH and VL domains may be subject to protein engineering in which one or more selective amino acid substitutions are introduced, typically in the framework regions. The reasons for introducing such substitutions into the "wild type" camelid sequence can be (i) humanisation of the framework region, (ii) improvement in stability, bioavailability, product uniformity, tissue penetration, etc., or (iii) optimisation of target antigen binding.

"Humanisation" of camelid-derived VH and VL domains by selective replacement of one or more amino acid residues in the framework regions may be carried out according to well-established principles (as illustrated in the accompanying examples, and reviewed by Almagro et al. *Frontiers in Bioscience* 13:1619-1633 (2008), the contents of which are specifically incorporated herein by reference). It will be appreciated that the precise identity of the amino acid changes made to achieve acceptable "humanisation" of any given VH domain, VL domain or combination thereof will vary on a case-by-case basis, since this will depend upon the sequence of the framework regions derived from Camelidae and the starting homology between these framework regions and the closest aligning human germline (or somatically mutated) framework region, and possible also on the sequence and conformation of the hypervariable loops which form the antigen binding site.

The overall aim of humanisation is to produce a molecule in which the VH and VL domains exhibit minimal immunogenicity when introduced into a human subject, whilst retaining the specificity and affinity of the antigen binding site formed by the parental VH and VL domains encoded by

Camelidae (e.g. camelid VH/VL obtained by active immunisation). There are a number of established approaches to humanisation which can be used to achieve this aim. Techniques can be generally classified as either rational approaches or empirical approaches. Rational approaches include CDR-grafting, resurfacing or veneering, superhumanization and human string content optimisation. Empirical approaches include the FR library approach, guided selection, FR shuffling and humaneering. All of these techniques are reviewed in Almagro, *Frontiers in Bioscience* 2008, *ibid.* and any of these techniques, or combinations or modifications thereof, can be used to prepare "humanised" antigen binding polypeptides according to the invention.

Methods of Library Construction

In a related aspect, the invention also encompasses a method of producing a library of expression vectors encoding VH and/or VL domains of camelid conventional antibodies, said method comprising the steps:

- a) amplifying regions of nucleic acid molecules encoding VH and/or VL domains of camelid conventional antibodies to obtain amplified gene segments, each gene segment containing a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody, and
- b) cloning the gene segments obtained in a) into expression vectors, such that each expression vector contains at least a gene segment encoding a VH domain and/or a gene segment encoding a VL domain, whereby a library of expression vectors is obtained.

The above methods of "library construction" may also form part of the general process for production of antigen binding polypeptides of the invention, described above. Hence, any feature described as being preferred or advantageous in relation to this aspect of the invention may also be taken as preferred or advantageous in relation to the general process, and vice versa, unless otherwise stated.

In one embodiment, the nucleic acid amplified in step a) comprises cDNA or genomic DNA prepared from lymphoid tissue of a camelid, said lymphoid tissue comprising one or more B cells, lymph nodes, spleen cells, bone marrow cells, or a combination thereof. Circulating B cells are particularly preferred. The present inventors have surprisingly found that peripheral blood lymphocytes (PBLs) can be used as a source of nucleic acid encoding VH and VL domains of conventional camelid antibodies, i.e. there is sufficient quantity of plasma cells (expressing antibodies) present in a sample of PBLs to enable direct amplification. This is advantageous because PBLs can be prepared from a whole blood sample taken from the animal (camelid). This avoids the need to use invasive procedures to obtain tissue biopsies (e.g. from spleen or lymph node), and means that the sampling procedure can be repeated as often as necessary, with minimal impact on the animal. For example, it is possible to actively immunise the camelid, remove a first blood sample from the animal and prepare PBLs, then immunise the same animal a second time, either with a "boosting" dose of the same antigen or with a different antigen, then remove a second blood sample and prepare PBLs.

Accordingly, a particular embodiment of this method of the invention may involve: preparing a sample containing PBLs from a camelid, preparing cDNA or genomic DNA from the PBLs and using this cDNA or genomic DNA as a template for amplification of gene segments encoding VH or VL domains of camelid conventional antibodies.

In one embodiment the lymphoid tissue (e.g. circulating B cells) is obtained from a camelid which has been actively immunised, as described elsewhere herein. However, this

embodiment is non-limiting and it is also contemplated to prepare non-immune libraries and libraries derived from lymphoid tissue of diseased camelids, also described elsewhere herein.

5 Conveniently, total RNA (or mRNA) can be prepared from the lymphoid tissue sample (e.g. peripheral blood cells or tissue biopsy) and converted to cDNA by standard techniques. It is also possible to use genomic DNA as a starting material.

10 This aspect of the invention encompasses both a diverse library approach, and a B cell selection approach for construction of the library. In a diverse library approach, repertoires of VH and VL-encoding gene segments may be amplified from nucleic acid prepared from lymphoid tissue without any prior selection of B cells. In a B cell selection approach,

15 B cells displaying antibodies with desired antigen-binding characteristics may be selected, prior to nucleic acid extraction and amplification of VH and VL-encoding gene segments.

20 Various conventional methods may be used to select camelid B cells expressing antibodies with desired antigen-binding characteristics. For example, B cells can be stained for cell surface display of conventional IgG with fluorescently labelled monoclonal antibody (mAb, specifically recognizing conventional antibodies from llama or other camelids) and with target antigen labelled with another fluorescent dye. Individual double positive B cells may then be isolated by FACS, and total RNA (or genomic DNA) extracted from individual cells. Alternatively cells can be subjected to in

25 vitro proliferation and culture supernatants with secreted IgG can be screened, and total RNA (or genomic DNA) extracted from positive cells. In a still further approach, individual B cells may be transformed with specific genes or fused with tumor cell lines to generate cell lines, which can be grown "at will", and total RNA (or genomic DNA) subsequently prepared from these cells.

30 Instead of sorting by FACS, target specific B cells expressing conventional IgG can be "panned" on immobilized monoclonal antibodies (directed against camelid conventional antibodies) and subsequently on immobilized target antigen. RNA (or genomic DNA) can be extracted from pools of antigen specific B cells or these pools can be transformed and individual cells cloned out by limited dilution or FACS.

35 B cell selection methods may involve positive selection, or negative selection.

40 Whether using a diverse library approach without any B cell selection, or a B cell selection approach, nucleic acid (cDNA or genomic DNA) prepared from the lymphoid tissue is subject to an amplification step in order to amplify gene segments encoding individual VH domains or VL domains.

45 Total RNA extracted from the lymphoid tissue (e.g. peripheral B cells or tissue biopsy) may be converted into random primed cDNA or oligo dT primer can be used for cDNA synthesis, alternatively Ig specific oligonucleotide primers 50 can be applied for cDNA synthesis, or mRNA (i.e. poly A RNA) can be purified from total RNA with oligo dT cellulose prior to cDNA synthesis. Genomic DNA isolated from B cells can be used for PCR.

PCR amplification of heavy chain and light chain (kappa and lambda) gene segments encoding at least VH or VL can be performed with FR1 primers annealing to the 5' end of the variable region in combination with primers annealing to the 3' end of CH1 or Cκappa/Cλambda region with the advantage that for these constant region primers only one primer is needed for each type. This approach enables camelid Fab to be cloned. Alternatively sets of FR4 primers annealing to the 3' end of the variable regions can be used, again for cloning as

31

Fabs (fused to vector encoded constant regions) or as scFv (single chain Fv, in which the heavy and light chain variable regions are linked via a flexible linker sequence); alternatively the variable regions can be cloned in expression vectors allowing the production of full length IgG molecules displayed on mammalian cells.

In general the amplification is performed in two steps; in the first step with non-tagged primers using a large amount of cDNA (to maintain diversity) and in the second step the amplicons are re-amplified in only a few cycles with tagged primers, which are extended primers with restriction sites introduced at the 5' for cloning. Amplicons produced in the first amplification step (non-tagged primers) may be gel-purified to remove excess primers, prior to the second amplification step. Alternatively, promoter sequences may be introduced, which allow transcription into RNA for ribosome display. Instead of restriction sites recombination sites can be introduced, like the Cre-Lox or TOPO sites, that permit the site directed insertion into appropriate vectors.

Amplified gene segments encoding camelid conventional VH and VL domains may then be cloned into vectors suitable for expression of VH/VL combinations as functional antigen binding polypeptides. By way of example, amplified VHCH1/VKCK/VLCL gene segments from pools of B cells (or other lymphoid tissue not subject to any B cell selection) may be first cloned separately as individual libraries (primary libraries), then in a second step Fab or scFV libraries may be assembled by cutting out the light chain fragments and ligating these into vectors encoding the heavy chain fragments. The two step procedure supports the generation of large libraries, because the cloning of PCR products is relatively inefficient (due to suboptimal digestion with restriction enzymes). scFv encoding DNA fragments can be generated by splicing-by-overlap extension PCR (SOE) based on a small overlap in sequence in amplicons; by mixing VH and VL encoding amplicons with a small DNA fragment encoding the linker in a PCR a single DNA fragment is formed due to the overlapping sequences.

Amplicons comprising VH and VL-encoding gene segments can be cloned in phage or phagemid vectors, allowing selection of target specific antibody fragments by using phage display based selection methods. Alternatively amplicons can be cloned into expression vectors which permit display on yeast cells (as Fab, scFv or full length IgG) or mammalian cells (as IgG).

In other embodiments, cloning can be avoided by using the amplicons for ribosome display, in which a T7 (or other) promoter sequence and ribosome binding site is included in the primers for amplification. After selection for binding to target antigen, pools are cloned and individual clones are analyzed. In theory, larger immune repertoires can be sampled using this approach as opposed to a phage display library approach, because cloning of libraries and selection with phage is limited to 10^{10} to 10^{12} clones.

When applying B cell sorting, amplicons contain VH or VL-encoding gene segments of individual target specific B cells can be cloned directly into bacterial or mammalian expression vectors for the production of antibody fragments (scFVs or Fabs) or even full length IgG.

In a particular, non-limiting, embodiment of the "library construction" process, the invention provides a method of producing a library of expression vectors encoding VH and VL domains of camelid conventional antibodies, said method comprising the steps:

a) actively immunising a camelid, thereby raising conventional camelid antibodies against a target antigen;

32

b) preparing cDNA or genomic DNA from a sample comprising lymphoid tissue (e.g. circulating B cells) from said immunised camelid (including, but not limited to, Llama or alpaca);
 c) amplifying regions of said cDNA or genomic DNA to obtain amplified gene segments, each gene segment comprising a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody; and
 d) cloning the gene segments obtained in c) into expression vectors, such that each expression vector contains a gene segment encoding a VH domain and a gene segment encoding a VL domain and directs expression of an antigen binding polypeptide comprising said VH domain and said VL domain, whereby a library of expression vectors is obtained.

The foregoing methods may be used to prepare libraries of camelid-encoded VH and VL domains (in particular Llama and alpaca VH and VL domains), suitable for expression of VH/VL combinations as functional antigen-binding polypeptides, e.g. in the form of scFVs, Fabs or full-length antibodies.

Libraries of expression vectors prepared according to the foregoing process, and encoding camelid (including but not limited to Llama or alpaca) VH and VL domains, also form part of the subject-matter of the present invention.

In a particular embodiment the invention provides a library of phage vectors encoding Fab or scFV molecules, wherein each Fab or scFV encoded in the library comprises a VH domain of a camelid conventional antibody and a VL domain of a camelid conventional antibody.

In one embodiment the library is a "diverse" library, in which the majority of clones in the library encode VH domains of unique amino acid sequence, and/or VL domains of unique amino acid sequence, including diverse libraries of camelid VH domains and camelid VL domains. Therefore, the majority (e.g. >90%) of clones in a diverse library encode a VH/VL pairing which differs from any other VH/VL pairing encoded in the same library with respect to amino acid sequence of the VH domain and/or the VL domain.

The invention also encompasses expression vectors containing VH and VL-encoding gene segments isolated from a single selected B cell of a camelid (e.g. Llama or alpaca).

In a further aspect, the present invention also provides a method of selecting an expression vector encoding an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:

i) providing a library of expression vectors, wherein each vector in said library comprises a gene segment encoding a VH domain and a gene segment encoding a VL domain, wherein at least one of said VH domain or said VL domain is from a camelid conventional antibody, and wherein each vector in said library directs expression of an antigen binding polypeptide comprising said VH domain and VL domain;
 ii) screening antigen binding polypeptides encoded by said library for immunoreactivity with said target antigen, and thereby selecting an expression vector encoding an antigen binding polypeptide immunoreactive with said target antigen.

This method of the invention encompasses screening/selection of clones immunoreactive with target antigen, from a library of clones encoding VH/VL pairings. The method may also encompass library construction, which may be carried out using the library construction method described above. Optional downstream processing/optimisation steps may be carried out on selected clones, as described below. This method of selection and screening, may also form part of the general process for production of antigen binding polypeptides of the invention, described above. Hence, any feature described as being preferred or advantageous in relation to this aspect of the invention may also be taken as preferred or

advantageous in relation to the general process, and vice versa, unless otherwise stated.

Screening and Selection of Clones Immunoreactive with Target Antigen

Screening/selection typically involves contacting expression products encoded by clones in the library (ie. VH/VL pairings in the form of antigen binding polypeptides, e.g. Fabs, scFVs or antibodies) with a target antigen, and selecting one or more clones which encode a VH/VL pairings exhibiting the desired antigen binding characteristics.

Phage display libraries may be selected on immobilized target antigen or on soluble (often biotinylated) target antigen. The Fab format allows affinity driven selection due to its monomeric appearance and its monovalent display on phage, which is not possible for scFv (as a consequence of aggregation and multivalent display on phage) and IgG (bivalent format). Two to three rounds of selections are typically needed to get sufficient enrichment of target specific binders.

Affinity driven selections can be performed by lowering the amount of target antigen in subsequent rounds of selection, whereas extended washes with non-biotinylated target enables the identification of binders with extremely good affinities.

The selection procedure allows the user to home in on certain epitopes; whereas the classical method for elution of phage clones from the immobilized target is based on a pH shock, which denatures the antibody fragment and/or target, competition with a reference mAb against the target antigen or soluble receptor or cytokine leads to the elution of phage displaying antibody fragments binding to the relevant epitope of the target (this is of course applicable to other display systems as well, including the B cells selection method).

Individual clones taken from the selection outputs may be used for small scale production of antigen-binding polypeptides (e.g. antibody fragments) using periplasmic fractions prepared from the cells or the culture supernatants, into which the fragments “leaked” from the cells. Expression may be driven by an inducible promoter (e.g. the lac promoter), meaning that upon addition of the inducer (IPTG) production of the fragment is initiated. A leader sequence ensures the transport of the fragment into the periplasm, where it is properly folded and the intramolecular disulphide bridges are formed.

The resulting crude protein fractions may be used in target binding assays, such as ELISA. For binding studies, phage prepared from individual clones can be used to circumvent the low expression yields of Fabs, which in general give very low binding signals. These protein fractions can also be screened using in vitro receptor—ligand binding assays to identify antagonistic antibodies; ELISA based receptor—ligand binding assays can be used, also high throughput assays like Alphascreen are possible. Screening may be performed in radiolabelled ligand binding assays, in which membrane fractions of receptor overexpressing cell lines are immobilized; the latter assay is extremely sensitive, since only picomolar amounts of radioactive cytokine are needed, meaning that minute amounts of antagonistic Fabs present in the crude protein fraction will give a positive read-out. Alternatively, FACS can be applied to screen for antibodies, which inhibit binding of a fluorescently labelled cytokine to its receptor as expressed on cells, while FMAT is the high throughput variant of this.

Fabs present in periplasmic fractions or partially purified by IMAC on its hexahistidine tag or by protein G (known to bind to the CH1 domain of Fabs) can be directly used in bioassays using cells, which are not sensitive to bacterial impurities; alternatively, Fabs from individual *E. coli* cells

can be recloned in mammalian systems for the expression of Fabs or IgG and subsequently screened in bioassays.

Following identification of positive expression vector clones, i.e. clones encoding a functional VH/VL combination which binds to the desired target antigen, it is a matter of routine to determine the nucleotide sequences of the variable regions, and hence deduce the amino acid sequences of the encoded VH and VL domains.

If desired, the Fab (or scFV) encoding region may be 10 recloned into an alternative expression platform, e.g. a bacterial expression vector (identical to the phagemid vector, but without the gene 3 necessary for display on phage), which allows larger amounts of the encoded fragment to be produced and purified.

15 The affinity of target binding may be determined for the purified Fab (or scFV) by surface plasmon resonance (e.g. Biacore) or via other methods, and the neutralizing potency tested using in vitro receptor ligand binding assays and cell based assays.

20 Families of antigen-binding, and especially antagonistic Fabs (or scFVs) may be identified on the basis of sequence analysis (mainly of VH, in particular the length and amino acid sequence of CDR3 of the VH domain).

Potency Optimisation

25 Clones identified by screening/selection as encoding a VH/VL combination with affinity for the desired target antigen may, if desired, be subject to downstream steps in which the affinity and/or neutralising potency is optimised.

Potency optimization of the best performing member of 30 each VH family can be achieved via light chain shuffling, heavy chain shuffling or a combination thereof, thereby selecting the affinity variants naturally occurring in the animal. This is particularly advantageous in embodiments where the original camelid VH/VL domains were selected from an actively immunised camelid, since it is possible to perform chain shuffling using the original library prepared from the same immunised animal, thereby screening affinity variants arising in the same immunised animal.

For light chain shuffling the gene segment encoding the VH 40 region (or VHCH1) of VH/VL pairing with desirable antigen binding characteristics (e.g. an antagonistic Fab) may be used to construct a library in which this single VH-encoding gene segment is combined with the light chain repertoire of the library from which the clone was originally selected. For example, if the VH-encoding segment was selected from a library (e.g. Fab library) prepared from a camelid animal actively immunised to elicit an immune response against a target antigen, then the “chain shuffling” library may be constructed by combining this VH-encoding segment with the light chain (VL) repertoire of the same immunised camelid. The resulting library may then be subject to selection of the target antigen, but under stringent conditions (low concentrations of target, extensive washing with non-biotinylated target in solution) to ensure the isolation of the best affinity 50 variant. Off-rate screening of periplasmic fractions may also assist in the identification of improved clones. After sequence analysis and recloning into a bacterial production vector, purified selected Fabs may be tested for affinity (e.g. by surface plasmon resonance) and potency (e.g. by bioassay).

55 Heavy chain shuffling can be performed by cloning back the gene segment encoding the light chain (VL) of a clone selected after light-chain shuffling into the original heavy chain library from the same animal (from which the original VH/VL-encoding clone was selected). Alternatively a CDR3 specific oligonucleotide primer can be used for the amplification of the family of VH regions, which can be cloned as a repertoire in combination with the light chain of the antago-

35

nistic Fab. Affinity driven selections and off-rate screening then allow the identification of the best performing VH within the family.

It will be appreciated that the light chain shuffling and heavy chain shuffling steps may, in practice, be performed in either order, i.e. light chain shuffling may be performed first and followed by heavy chain shuffling, or heavy chain shuffling may be performed first and followed by light chain shuffling. Both possibilities are encompassed within the scope of the invention.

From light chains or heavy chains of VH/VL pairings (e.g. Fabs) with improved affinity and potency the sequences of, in particular, the CDRs can be used to generate engineered variants in which mutations of the individual Fabs are combined. It is known that often mutations can be additive, meaning that combining these mutations may lead to an even more increased affinity.

Germlining and Formatting for Human Therapeutic Use

The VH and VL-encoding gene segments of selected expression clones encoding VH/VL pairings exhibiting desirable antigen-binding characteristics (e.g. phage clones encoding scFVs or Fabs) may be subjected to downstream processing steps and recloned into alternative expression platforms, such as vectors encoding antigen binding polypeptide formats suitable for human therapeutic use (e.g. full length antibodies with fully human constant domains).

Promising “lead” selected clones may be engineered to introduce one or more changes in the nucleotide sequence encoding the VH domain and/or the VL domain, which changes may or may not alter the encoded amino acid sequence of the VH domain and/or the VL domain. Such changes in sequence of the VH or VL domain may be engineered for any of the purposes described elsewhere herein, including germlining or humanisation, codon optimisation, enhanced stability, optimal affinity etc.

The general principles germlining or humanisation described herein apply equally in this embodiment of the invention. By way of example, lead selected clones containing camelid-encoded VH and VL domains may be germlined/humanised in their framework regions (FRs) by applying a library approach. After alignment against the closest human germline (for VH and VL) and other human germlines with the identical canonical folds of CDR1 and CDR2, the residues to be changed in the FRs are identified and the preferred human residue selected, as described elsewhere herein in detail. Whilst germlining may involve replacement of camelid-encoded residues with an equivalent residue from the closest matching human germline this is not essential, and residues from other human germlines could also be used.

The germlining of a VH domain having an amino acid sequence homologous to a member of the human VH3 family will often involve replacement/substitution of a number of residues, which already deviate in publically known *Lama glama*, *Lama pacos* or *Camelus dromedarius* derived germline sequences. Permitted amino acid substitutions for germlining/humanisation of a VH3 domain of *Lama glama*, *Lama pacos* or *Camelus dromedarius*, and in particular *Lama glama* include, but are not limited to, amino acid replacements at any one or any combination of positions 71, 83 and 84 in the framework region (using Kabat numbering). Such replacement(s) will involve substitution of the camelid-encoded residue(s) at these positions with a different amino acid, which may be a natural or non-natural amino acid, and is preferably an amino acid known to occur at the equivalent position in a human-encoded VH3 domain. For example, Alanine at position 71 might be replaced with serine or alanine, Lysine at position 83 might be replaced with Arginine

36

and Proline at position 84 might be replaced with Alanine. Accordingly, particular non-limiting embodiments of the antigen binding polypeptide of the invention include variants comprising a camelid (and more specifically llama, alpaca or dromedary) VH domain exhibiting sequence homology to a human VH3 domain, which VH domain includes amino acid substitutions (versus the camelid-encoded sequence) at one or more or all of positions 71, 83 and 84 (using Kabat numbering). In particular, variants with one or more or any combination of the following substitutions are permitted: A 10 changed to S at position 71, K changed to R at position 83 or P changed to A at position 84.

Once the amino acid sequences of the lead VH and VL domains (following potency optimisation, as appropriate) are 15 known, synthetic genes of VH and VL can be designed, in which residues deviating from the human germline are replaced with the preferred human residue (from the closest matching human germline, or with residues occurring in other human germlines, or even the camelid wild type residue). At 20 this stage the gene segments encoding the variable domains may be re-cloned into expression vectors in which they are fused to human constant regions of the Fab, either during gene synthesis or by cloning in an appropriate display vector.

The resulting VH and VL synthetic genes can be recombinant into a Fab library or the germlined VH can be recombinant with the wild type VL (and vice versa, referred to as “hybrid” libraries). Affinity-driven selections will allow the isolation of the best performing germlined version, in case of the “hybrid” libraries, the best performing germlined VH can 25 be recombinant with the best performing germlined VL.

Amino acid and nucleotide sequence information for the germlined Fabs can be used to generate codon-optimized synthetic genes for the production of full length human IgG of the preferred isotype (IgG1 for ADCC and CDC, IgG2 for 30 limited effector functions, IgG4 as for IgG2, but when monovalent binding is required). For non-chronic applications and acute indications bacterially or mammalian cell produced human Fab can produced as well.

Combining steps of the above-described processes, in a 40 particular non-limiting embodiment the present invention provides a method of producing an expression vector encoding a chimeric antigen binding polypeptide immunoreactive with a target antigen, said method comprising the steps of:
 a) actively immunising a camelid (including but not limited to 45 Llama or alpaca), thereby raising conventional camelid antibodies against a target antigen;
 b) preparing cDNA or genomic DNA from a sample comprising lymphoid tissue (e.g. circulating B cells) from said immunised camelid;
 c) amplifying regions of said cDNA or genomic DNA to 50 obtain amplified gene segments, each gene segment comprising a sequence of nucleotides encoding a VH domain or a sequence of nucleotides encoding a VL domain of a camelid conventional antibody;
 d) cloning the gene segments obtained in c) into expression vectors, such that each expression vector contains a gene segment encoding a VH domain and a gene segment encoding a VL domain and directs expression of an antigen binding polypeptide comprising said VH domain and said VL 55 domain, thereby producing a library of expression vectors;
 e) screening antigen binding polypeptides encoded by the library obtained in step d) for immunoreactivity with said target antigen, and thereby selecting an expression vector encoding an antigen binding polypeptide immunoreactive with said target antigen;
 f) optionally performing a light chain shuffling step and/or a 60 heavy chain shuffling step to select an expression vector

37

encoding a potency-optimised antigen binding polypeptide immunoreactive with said target antigen;
 g) optionally subjecting the gene segment encoding the VH domain of the vector selected in step e) or step f) and/or the gene segment encoding the VL domain of the vector selected in step e) or step f) to germlining and/or codon optimisation; and
 h) cloning the gene segment encoding the VH domain of the vector selected in part e) or f) or the germlined and/or codon optimised VH gene segment produced in step g) and the gene segment encoding the VL domain of the vector selected in part e) or f) or the germlined and/or codon optimised VL gene segment produced in step g) into a further expression vector, in operable linkage with a sequence of nucleotides encoding one or more constant domains of a human antibody, thereby producing an expression vector encoding a chimeric antigen binding polypeptide comprising the VH and VL domains fused to one or more constant domains of a human antibody.

The invention also extends to expression vectors prepared according to the above-described processes, and to a method of producing an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:
 a) preparing expression vector encoding an antigen binding polypeptide immunoreactive with a target antigen using the method described above;
 b) introducing said expression vector into host cell or cell-free expression system under conditions which permit expression of the encoded antigen binding polypeptide; and
 c) recovering the expressed antigen binding polypeptide.

In one embodiment, the latter process encompasses bulk production-scale manufacture of the antigen-binding polypeptide of the invention, particularly bulk-scale manufacture of therapeutic antibodies intended for use as pharmaceutically active agents, by recombinant expression. In such embodiments, the expression vector prepared in step a) and the host cell/expression system used in step b) are selected to be suitable for large-scale production of recombinant antibodies intended for administration to human patients. The general characteristics of suitable vectors and expression systems for this purpose are well known in the art.

The invention will be further understood with reference to the following non-limiting experimental examples.

Examples 1 to 9 illustrate the process of raising an antibody against an example antigen denoted "cytokine x", starting from immunization of llamas. The same general protocol can be adapted for any target antigen in any camelid species, hence the precise identity of "cytokine x" is not material. The process is also illustrated for preparation of Fabs binding IL-1 Beta (Example 15 onwards).

Various publications are cited in the foregoing description and throughout the following examples, each of which is incorporated by reference herein in its entirety.

General Protocol

Example 1

Immunization of Llamas

Immunizations of llamas (*Lama glama*) and harvesting of peripheral blood lymphocytes as well as the subsequent extraction of RNA and amplification of antibody gene fragments were performed as described by De Haard and colleagues (De Haard et al., J. Bact. 187: 4531-4541 (2005)). One llama was immunized intramuscularly with recombinant human Cytokine x using Freund's complete adjuvant or an appropriate animal-friendly adjuvant Stimune (Cedi Diag-

38

nostics BV, The Netherlands). Cytokine x (recombinantly expressed in engineered human cell line) was purchased. Prior to immunization the lyophilized cytokine x was reconstituted in PBS (Dulbecco) at a concentration of 250 µg/ml. The llama received 6 injections at weekly intervals, the first two injections with 100 µg of cytokine per injection, the four last injections with 50 µg for each boost. Four days after the last immunization a blood sample (PBL1) of 150 ml was collected from the animal and serum was prepared. Ten days after the last immunization a second blood sample (PBL2) of 150 ml was taken and serum was prepared. Peripheral blood lymphocytes (PBLs), as the genetic source of the llama immunoglobulins, were isolated from the blood sample using a Ficoll-Paque gradient (Amersham Biosciences) yielding between 1 and 5×10^8 PBLs. The maximal diversity of antibodies is expected to be equal to the number of sampled B-lymphocytes, which is about 10% (between 9.2-23.2% (De Genst et al., Dev. Comp. Immunol. 30:187-98 (2006)) of the number of PBLs ($1-5 \times 10^7$). The fraction of conventional antibodies in llama serum is up to 80% of the amount of total immunoglobulin, which might be extrapolated to a similar fraction of B-lymphocytes that produce the conventional antibodies. Therefore, the maximal diversity of conventional antibodies in the 150 ml blood sample is calculated as $0.8-4 \times 10^7$ different molecules. Total RNA was isolated from PBLs according to the method of Chomczynski et al. Anal. Biochem. 162:156-159 (1987)).

Example 2

Enrichment of Antigen Reactive B Cells by Panning or FACS Sorting (Optional)

In order to reduce the complexity of the sampled B cell repertoire enabling the efficient cloning of the recombinatorial Fab phage display library, antigen reactive B cells were enriched by a FACS sorting (Weitkamp et al., J. Immunol. Meth. (2003) 275: 223-237) using fluorescently labelled antigen and a mAb recognizing camelid conventional antibody specifically (as B cell marker) or by a panning procedure on immobilized antigen (Lightwood et al., J. Immunol. Meth. 316:133-143 (2006)).

PBLs from immunized animals were isolated via a density centrifugation on Ficoll-Paque as described above. Optionally co-purified red blood cells were lysed by resuspending the PBL pellet in 20 ml of lysis buffer (8.29 g/L NH4Cl, 1.09 g/L KHCO3 and 37 mg/L EDTA) at room temperature followed by centrifugation for 10 minutes at 200×g. Optional was also the depletion of monocytes by adhering these to the plastic surface of T150 culture flask. To achieve this cells were resuspended in 70 ml RPMI (Invitrogen) supplemented with 10% foetal calf serum, Glutamax, 25 mM Hepes, penicillin-streptomycin (Invitrogen) and 0.38% sodium citrate and incubated for 2 hours at 37° C. and 5% CO2 in the flasks. The supernatant fraction containing the B selected was recovered and cells were counted.

Bulk sorting in FACS of (living) B cells displaying target specific conventional antibodies was performed by simultaneous staining with the fluorescently labeled mAb specifically recognizing camelid conventional antibodies and target antigen, labeled with yet another fluorescent dye. Between 1,000 and 100,000 antigen specific cells were sorted and used for RNA extraction by applying the protocol of Gough and colleagues (Gough, Anal. Biochem. 173:93-95 (1988)) or by using the TRIzol kit (Invitrogen). Total RNA was converted

39

into random primed cDNA as template for the amplification of the antibody heavy and light chain variable genes (see Example 3 and further).

Example 3

Amplification and Cloning of Variable Region Genes

Random primed cDNA was prepared from 80 µg of PBL RNA using the superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). RNA was heat-denatured for 5 min at 65° C. in the presence of 2.5 µM of random hexanucleotide primer and 500 µM dNTPs in 8 independent reaction of 20 µl reaction. Subsequently, buffer and dithiothreitol were added according to the suppliers instructions, as well as 640 units of RNaseOUT (40 units/µl, Invitrogen), and 3200 units of Super-scriptII reverse transcriptase (200 units/µl; Invitrogen) in a total final volume of 8×40 µl. After 50 min at 50° C., 5 min at 85° C. and 1 min at 1° C. RNase H was added (~4U) and incubated for 20 min at 37° C. The pooled cDNA was cleanup using QIAquick PCR Purification Kit according to supplier's recommendation and used for PCR.

Primers annealing to the 3' end of CH1 and 5' and 3' end of VH were designed on the basis of germline sequences from llama and dromedary, for which the deposited sequences could be retrieved from IMGT and other databases following the citations from De Genst and colleagues (De Genst et al, Dev. Comp. Immunol. 30:187-198 (2006)). For design of oligonucleotides for amplification of the light chain the rearranged and somatically mutated dromedary sequences were used that were published in a thesis study (I. Legssyer, Free University Brussels).

All primary PCRs were carried out with separate BACK primers annealing to the 5' end of the variable region and combined with FOR primers annealing to the 3' end of CH1, on relatively large amounts of random primed cDNA as template (up to 2.5 µl corresponding to 6 µg of total RNA) to maintain maximal diversity. The heavy chain derived amplicons can be reamplified with a combination of JHFOR primers, annealing to the 3' end of VH and containing a naturally occurring BstEII site, and SfiI-tagged VHBACK primers annealing to the 5' end of the VH gene, and subsequently cloned as VH fragments. The light chain V-genes were obtained by PCR with a set of CKFOR or CLFOR primer annealing to the 3' end of the constant domain and BACK primers priming at the 5' end of the V-regions. The amplicons from the first PCR reactions were reamplified with extended CH1 FOR (containing a NotI site) or CKFOR and CLFOR primers (containing an AscI site) and subsequently cloned as llama Fab fragments. Alternatively, the DNA segments can be reamplified with primers tagged with restriction sites (FOR primers with AscI site and FR4 based BACK primers with XhoI site) and cloned as VL fragments thus creating chimeric Fab's containing llama derived V regions combined with human C regions.

PCR was performed in a volume of 50 µl reactions using Phusion polymerase (Finnzymes) and 500 pM of each primer for 28 cycles (1 min at 96° C., 1 min at 60° C., and 1 min at 72° C. All products were purified from agarose gel with the QIAex-II extraction kit (Qiagen). As input for reamplification to introduce restriction sites, 100-200 ng of purified DNA fragment was used as template in a 100-µl reaction volume. The large amount of input, ensuring the maintenance of variability, was checked by analysis of 4 µl of the "unamplified" PCR mixture on agarose gel.

40

Example 4

Construction of the Primary and Secondary Camelid Fab Repertoires

For the construction of the primary heavy chain and the two primary light chain repertoires, the PCR products, appended with restriction sites, were gel-purified prior to digestion and the different VH, VK, and VL families combined into three groups. The VHCH1 fragments were digested with SfiI and NotI and the VKCK and VLCL fragments were digested with ApaLI and AscI, and cloned into the phagemid vector pCB3 (similar to vector pCES1 with adapted multiple cloning site). The digested fragment (1 to 2 µg) were ligated to digested and purified PCB3 (2 to 4 µg) using T4-DNA ligase (Fermentas) at room temperature for several hours and then at 37° C. for 1-2 hours. The desalting ligation mixture for light or heavy chain pools was used for electroporation of the *E. coli* strain TG1, to create the one-chain libraries.

Alternatively, the VH fragments, 1.5 µg in total, may be digested with SfiI and BstEII (present in the VH) and ligated in a 100-200-hl reaction mixture with 9 units of T4-DNA ligase at room temperature to 4 µg, gel-purified vector PCB4 (similar to vector PCB3, but with the pill gene deleted). In addition, the VH gene segments may be cloned via SfiI and BstEII and the VK/VL gene segments via ApaLI and XhoI, yielding the chimeric Fd and VKCK and VLCL.

The Fab library was obtained by cloning of light chain fragments, digested from plasmid DNA prepared from the light chain repertoires, into the plasmid collection containing the heavy chain repertoires. Plasmid DNA, isolated from at least 3×10⁹ bacteria of the VL library (the donor vector), was digested with ApaLI and AscI for cloning of the gel purified DNA fragments in the acceptor vector that already contained the heavy chain libraries, thus creating a separate Fab library with kappa light chains and another library consisting of Fabs with a lambda light chain with a size of 1-10×10⁸ clones. Similarly, the VLCL or VKCK from the single chain library can be extracted from agarose gel using ApaLI/AscI and cloned into the VHCH library vector using the same restriction site.

The rescue of phagemid particles with helper phage M13-KO7 or VCSM-13 was performed on 2-liter scale, using representative numbers of bacteria from the library for inoculation, to ensure the presence of at least 10 bacteria from each clone in the start inoculum. For selections, 10¹³ colony-forming units were used with antigens immobilized in immunotubes (Maxisorp tubes, Nunc) or in 96 wells microtiterplates (Maxisorp, Nunc) or with soluble biotinylated antigens. The amount of the immobilized antigens was reduced 10-100 fold during subsequent selection rounds, starting at 10 µg/ml at round 1. Antigens were biotinylated at a ratio of 3 to 10 molecules of NHS-Biotin (Pierce) per molecule of antigen according to the suppliers recommendations and tested for their bioactivity in a bioassay. Unless stated otherwise, the antigens were used for selection at concentrations of 1 to 10 nM during round 1 and 10 pM to 1 nM during subsequent rounds.

Example 5

Selection of the Library

The rescue of phagemid particles with helper phage M13-KO7 or VCSM-13 was performed on 2-liter scale, using representative numbers of bacteria from the library for inoculation, to ensure the presence of at least 10 bacteria from each clone in the start inoculum. For selections, 10¹³ colony-forming units were used with antigens immobilized in immunotubes (Maxisorp tubes, Nunc) or in 96 wells microtiterplates (Maxisorp, Nunc) or with soluble biotinylated antigens. The amount of the immobilized antigens was reduced 10-100 fold during subsequent selection rounds, starting at 10 µg/ml at round 1. Antigens were biotinylated at a ratio of 3 to 10 molecules of NHS-Biotin (Pierce) per molecule of antigen according to the suppliers recommendations and tested for their bioactivity in a bioassay. Unless stated otherwise, the antigens were used for selection at concentrations of 1 to 10 nM during round 1 and 10 pM to 1 nM during subsequent rounds.

Example 6

Screening for Antagonistic Cytokine x Specific Fab's

Soluble Fab was produced from individual clones as described in Marks et al. (Marks et al., J. Mol. Biol. 222:581-

41

597 (1991)), but preferably as monoclonal phage (Lee et al., Blood 108:3103-3111 (2006)) to boost the sensitivity. Culture supernatants containing soluble Fab or Fab displaying phage were tested in ELISA with directly coated antigen or captured via immobilized streptavidin. Recombinant human cytokine x and streptavidin were coated at 10 µg/ml in 0.1 M NaHCO₃, pH 9.6, for 16 h at 4° C. Following 3 washes with PBS, 0.1% (v/v) Tween 20, biotinylated antigen was added for 30 to 60 minutes at room temperature at a concentration of 0.5 µg/ml. The plates were blocked during 30 min at room temperature with 2% (w/v) semi-skim milk powder (Marvel) in PBS or with 1% casein solution (in PBS). The culture supernatant was diluted 1- or 5-fold in 2% (w/v) Marvel/PBS and incubated 2 h; bound Fab was detected with anti-myc antibody 9E10 (5 µg/ml) recognizing the myc-peptide tag at the carboxyl terminus of the heavy Fd chain, and rabbit anti-mouse-HRP conjugate (Dako). Following the last incubation, staining was performed with tetramethylbenzidine and H₂O₂ as substrate and stopped by adding 0.5 volume of 1M H₂SO₄; the optical density was measured at 450 nm. Clones giving a positive signal in ELISA (over 2 times background), were analyzed by BstNI or Hinfl fingerprinting of the PCR products obtained by amplification with the oligonucleotide primers M13-reverse and geneIII-forward (4) or of the separate Fd and VKCK or VLCL amplicons.

Screening for the Fab's capacity to interfere with binding of cytokine x to its receptor was performed in an appropriate receptor ligand binding ELISA. For this, low amounts of biotinylated cytokine x were incubated with Fab in culture supernatant on cytokine x-Receptor coated plates and bound cytokine x was subsequently detected with streptavidin-HRP conjugate. Positive hits were sequenced and Fab purified for determining their potency (IC₅₀) in the in vitro receptor ligand assay and to assess their affinity in BIACore on immobilized cytokine x.

Large scale induction of soluble Fab fragments from individual clones was performed on a 50-ml or 250-ml scale in 2×TY containing 100 µg/ml carbenicillin and 2% glucose. After growth at 37° C. to an OD₆₀₀ of 0.9, the cells were pelleted (10 min at 2,934×g) and resuspended in 2×TY with carbenicillin and 1 mM isopropyl-1-thio-D-galactopyranoside (IPTG). Alternative the De Bellis procedure (De Bellis and Schwartz, NAR (1990) 18(5): 1311) was followed using 0.2% in stead of 2% glucose, thus permitting the direct addition of IPTG to the medium of the late log phase cells. Bacteria were harvested after 3.5 h of growth at 30° C. by centrifugation (as before); periplasmic fractions were prepared by resuspending the cell pellet in 1 ml of ice-cold PBS. After 2-16 h of rotating head-over-head at 4° C., the spheroplasts were removed by two centrifugation steps; after spinning during 10 min at 3,400×g, the supernatant was clarified by an additional centrifugation step during 10 min at 13,000×g in an Eppendorf centrifuge. The periplasmic fraction obtained was directly used in the different functional assays (target binding ELISA, in vitro receptor—ligand binding assays and BIACore).

For sequencing, plasmid DNA was prepared from 5-ml cultures grown at 30° C. in LB-medium, containing 100 µg/ml carbenicillin and 2% glucose, using the Qiagen Mini-kit (Qiagen) or on amplicons with vector primers M13-reverse and geneIII-forward, which anneal at the borders of the Fab insert.

Example 7

Large Scale Production and Purification of Lead Fab's

Fab inserts from 3 to 6 different leads were recloned via ApaLI—NotI in an expression vector (coded pCB5) identical

42

to pCB3 including the hexahistidine and C-MYC tags fused to the carboxyterminus of the Fd, but lacking the bacteriophage M13 gene3. In parallel the V regions were recloned with the appropriate combination of restriction enzymes and sequentially cloned in gene3 deleted vectors containing human CH1 and CK or CL for the expression of chimeric Fabs. After fingerprint analysis, individual clones obtained after recloning were grown on 50-ml or 250-ml scale and periplasmic fractions were prepared as described above. Fab fragment was IMAC purified and the correctly formed Fab was further purified via Size Exclusion Chromatography using a Superdex 75HR column (Amersham Pharmacia Biotech). Depending on the cell based assay endotoxin was removed by passage over an anion exchange column (Source30Q, GE Healthcare), which was sensitized overnight in 1 M NaOH and subsequently equilibrated in D-PBS. The yield was determined by measuring the optical density at 280 nm using a molar extinction coefficient of 13 for Fabs.

The purified Fab's were tested in the in vitro receptor—ligand binding assay and BIACore to confirm the observations made with the Fab fragment as produced by the gene3 containing pCB3 vector. Finally the potency of the Fab was determined in the bioassay.

Example 8

In this example the llama derived lead Fabs against cytokine x were humanized by using a soft randomization procedure targeting a small set of framework residues and by monovalent display of the resulting Fab library on the surface of filamentous phage in order to identify high affinity framework sequences via affinity based selection (US20030190317 A1, incorporated herein by reference). For instance, for dromedary derived germline VH (IGHV1S20) a small library was generated for positions 5 (Val, Leu), 55 (Gly, Ala), 83 (Ala, Ser), 95 (Lys, Arg), 96 (Ser, Ala) and 101 (Met, Val) maintaining 70% of the wild type residues (IMGT numbering). Amino acids in the hypervariable loops could be addressed in a similar way.

Site-directed mutagenesis to correct PCR errors or to introduce additional specific single codon changes was performed essentially as described by Kunkel et al. Curr. Protoc. Mol. Biol. CH8U8.1 (2001) or alternatively Synthetic genes encoding the variants ordered from GeneArt. The template for site-directed experiments was single-stranded DNA from a humanized Fab clone.

Site directed mutagenesis was also used to directly change a limited number of amino acid codons for humanization or modification purposes in the DNA encoding the wild type or humanized Fabs.

After selection the individual leads were tested on affinity and potency and the best leads were chosen for reformatting into human Fab/IgGs.

Example 9

Expression of Human Fab Fragments and Human Monoclonal Antibodies

Starting from the humanized VH and VL regions expression of humanized Fabs was performed as described in Rauchenberger et al. J. Biol. Chem. 278:38194-204 (2003). For the expression of human monoclonal antibodies two separate expression vectors, one for the light chain and one for the heavy chain construct were constructed based on the pcDNA 3.1 vector. The expression vector for the light chain contained either the human C kappa or human C lambda

sequence downstream of a CMV promoter as well as restriction sites allowing the cloning of the light chain construct as KPN1 BsmB1 fragments downstream of the CMV promoter and in frame with the light chain constant domain. The expression vector for the heavy chain contained then human CH1-hinge-CH2-CH3 sequence downstream of a CMV promoter as well as restriction sites allowing the cloning of the VH construct as KPN1 BsmB1 fragments downstream of the CMV promoter and in frame with the heavy chain constant domains.

The VL and VH fragments were cloned into the appropriate expression vectors as KPN1 BsmB1 fragments containing the Kozak sequence followed by the mouse IgG kappa leader sequences in frame with the respective VL or VH sequence. These sequences were obtained by gene synthesis and optimized for expression in mammalian cells (Geneart).

For full length IgG production VH and VL expression vectors constructs were co-transfected into mammalian cells (HEK-293 (transient) or CHO(stable)). Supernatant from transiently transfected cells or from stably transfected cells was purified via protein A chromatography.

Monoclonal antibodies or Fabs were tested in receptor binding assays and in bioassays and the best leads were selected for further development.

Example 10

Camelid Vs Human Homology Analysis

Methodology

Sequences of germline llama and dromedary J regions, which encode for FR4 were compared with human sequences and were completely identical (10 out of 10 residues match); the only exception is IGHJ4, which contains Glutamine (instead of Leucine or Methionine) on position 6 in FR4 (alignments shown below). For somatically mutated VLambda FR4 from dromedary 9 out of 10 residues match (90% homology), since most of the available sequences have Histidine in stead of Lysine or Glutamate or Glutamine on position 6 (alignment shown below). Finally there is 90% identity (9 out of 10

residues) in FR4 of the set of six available somatically mutated dromedary VKappa sequences, because position 3 residue Serine deviates from what is found in the human germline JK segments, i.e. Glutamine, Proline and Glycine (alignment shown below).

For VH, VLambda and VKappa the analysis is supported by alignments (see below). Sequence alignment was done with closest human germline sequence, having identical H1 and H2 canonical folds.

Residues which don't align, but which appear in another family member (or subclass) of the same germline are considered as homologous, based on the assumption that it is feasible to mutate them back to said closest human germline sequence.

Canonical structures are compared using the following programs: <http://www.bioinf.org.uk/abs/chothia/html> and http://www.bioc.unizh.ch/antibody/Seduences/Germlines/VBase_hVK.html. Residues of analyzed camelid antibodies (or from other species) which do not fit exactly the canonical fold algorithm are checked for their appearance in the sequence of members of the matching human germline family with the same combination of canonical folds, or mentioned residues allowing the folds are checked for their appearance within the family of camelid antibodies to which the analyzed antibody belongs.

Results are presented in the following sections:

- 10.1—Dromedary VH
- 10.2—*Lama glama* VH
- 10.3—VL 1-40
- 10.4—VL 2-18
- 10.5—VL 3-1
- 10.6—VL 3-12
- 10.7—VKappa 2-40
- 10.8—J(H) region comparisons of Ilama and human
- 10.9—Comparison of light chain J regions
- 10.10—*Lama pacos* VH germline homology
- 10.11—*Lama glama* derived VH homology analysis
- 10.12—*Lama glama* derived VL analysis
- 10.1 Dromedary VH

IGHV gene	FR1 - IMGT (1-26)		CDR1 - IMGT (27-38)		FR2 - IMGT (39-55)		CDR2 - IMGT (56-65)	
	1	10	20	30	40	50	60	
M99679, IGHV3-53	EVQLVESGG.GLIQPGGSLRLSCAAS	GFTVSSNY	MSWVRQAPGKGLEWVSV	IYSGGST
AF000603, IGHV1S1	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245151, IGHV1S2	CVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245152, IGHV1S3	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWARQAPGKGLEWVSG	IYSDGST
AJ245153, IGHV1S4	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245154, IGHV1S5	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245155, IGHV1S6	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245157, IGHV1S7	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245158, IGHV1S8	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRKAQGKGLEWVSG	IYSDGST
AJ245159, IGHV1S9	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSS	NTSDGST
AJ245160, IGHV1S10	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSGYY	MSWVRQAPGRGLEWVSG	IYSDGTT
AJ245164, IGHV1S11	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245165, IGHV1S12	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245167, IGHV1S13	AVQLVESGG.GSVQAGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245168, IGHV1S14	QVQLVESGG.GSVQAGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST
AJ245170, IGHV1S15	AVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYW	MYWVRQAPGKGLEWVSG	IYSDGST
AJ245171, IGHV1S16	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYW	MYWVRQAPGKRLEWVSG	IYSDGST
AJ245173, IGHV1S17	QVQLVESGG.GSVQAGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSA	IPSDGST
AJ245174, IGHV1S18	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYA	MSWVRQAPGKGLEWVSA	INSRGST
AJ245156, IGHV1S19	EVQLVESGG.GLVQPGGSLRLSCAAS	GFTFSSYY	MSWVRQAPGKGLEWVSG	IYSDGST

- continued

IGHV gene	FR3 - IMGT (66-104)					CDR3 - IMGT (105-115)
	70	80	90	100	110	
M99679, IGHV3-53	YYADSVK.	GRFTISRDNSKNTLYLQMNSLRAEDTAVYVC				AR.....
AF000603, IGHV1S1	YYGDSVK.	GRFTISRDNAKNMLYLQMNSLKPEDTAVYYC				AG.....
AJ245151, IGHV1S2	YYGDSVK.	GRFTISRDNAKNMLYLQMNSLKPEDTAMYYC				
AJ245152, IGHV1S3	YYGDSVK.	GRFTISRDNAKNMLYLQMNSLKPEDTAMYYC				
AJ245153, IGHV1S4	YYGDSVK.	GRFTISRDNAKNTLYLQMNSLKPEDTAMYYC				
AJ245154, IGHV1S5	YYGDSVK.	GRFTISRDNAKNMLYLQVNMSLKPEDTAVYYC				
AJ245155, IGHV1S6	YYGDSVK.	GRFTISRDNAKHMLYLQMHSLKPEDTAMYYC				
AJ245157, IGHV1S7	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245158, IGHV1S8	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245159, IGHV1S9	YYGDSVK.	GRFTISRDNAKNMLYLQMNSLKPEDTAMYYC				
AJ245160, IGHV1S10	YYGDSVR.	GRFTISRDNAKNMLYLQMNSLKPEDTAMCYC				
AJ245164, IGHV1S11	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTSMYYC				
AJ245165, IGHV1S12	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245167, IGHV1S13	YYSDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245168, IGHV1S14	YYGDSVK.	GRFTISRDAKNMLYLQMNSLMPEDTAMYYC				
AJ245170, IGHV1S15	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245171, IGHV1S16	YYGDSVK.	GRFTISRDAKNMLYLQMNSLKPEDTAMYYC				
AJ245173, IGHV1S17	NYADSVK.	GRFTISRDNAKNTVYLQMNSLKPEDTAMYYC				
AJ245174, IGHV1S18	HYADSMK.	GRFTISRDNAKVLYLQMNSLKPEDTAMYYC				
AJ245156, IGHV1S19	IYSDGST.	GRFTISQDNAKNTVYLQMNSLKPEDTAMYYC				

A) Sequence Comparisons

Sequences in comparison to human IGHV3-23 and other human germlines:

55 GSA can be considered more variable/beginning of CDR2

68 G also human A exist in the same context
(IGHV1S1718)→should be replaceable by A

83 A present in many other human VH3 class germlines
 86 N/A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

86 MV also human T exist in the same context → should be
1 1 1 T

replaceable by T
95 K also in human germlines 3 15407273

95 K also in human germlines 3-1349723
96 P also in human germline 3-19

Sequence Homology: 2626 (FR1)+1717 (FR2)+3839
90% also in human germline 3-19
101 M not found in human IGHV3 class

Sequence Homology: 2020 (FR1), 1117
(FR3)=8182=99%

B) Canonical Folds Analysis CDR H1 and H2
1) Analysis of germline Dromedary VH sequences IGHV1S1

to IGHV1S19 reveals a canonical fold 1 for CDR1 and fold 1

²⁵ for CDR2, so identical to the folds of human germline VH3-13 and VH3-53, confirming the data published by Nguyen and colleagues (EMBO J (2000), 19(5), p 921-930). The analysis for dromedary IGHV1S1 and human IGHV3-53 are shown below as examples using auto-generated SDR templates:

IGHV1S1

CDR H1 Class ?

! Similar to class 1/10A, but:

35 ! H94 (Chothia Numbering) is deleted.

CDR H2 Class 19A [1gig]

IGHV3-53

CDR H1 Class ?

! Similar to class 1, but:

⁴⁰ ! H94 (Kabat Numbering) is deleted.

CDR H2 Class 1 chothia:human [1gig]

- A) Sequence Comparisons:
- 3 S not in class 2 but also in 3-27 and 5-52
 - 14 T not in class 2 but also in class 1-44/47
 - 13 T not in class 2 but in many other germlines of class 3 and in many other germline classes as well
 - 45 L not in class 2, only in class 1
 - 53 L in 2-33, as well as in classes 1, 4, 5, 7, 8, 10
 - 66 K in classes 1, 2, 3
 - 68 N/L/A/G somatic mutation and also human residue P is found in Camv151 and Camv131
 - 71 I in other class 2 members and in class 1-41/51 and classes 3, 4, 9, 10

2) Position L93 Serine (S, in CDR3) should be Glycine (G), but Serine present in three of the 8 aligned camelid VLs is the most often found residue in human germline VL2, as in the human IGLV2-18 used for comparison

⁵ NOTE: Position 93 (Chothia) compares to 109 in IMGT nomenclature used for the sequence comparison.

Conclusions:

Canonical fold number 2/14 for CDR1 expected and fold 1/7(A) for CDR2, i.e. identical to what is found in human germline VL2.

10.5 VL 3-1

IGLV gene	FR1 - IMGT (1-26)		CDR1 - IMGT (27-38)		FR2 - IMGT (39-55)		CDR2 - IMGT (56-65)
	1	10	20	30	40	50	60
X57826, IGLV3-1	SYELTQPPS.VSVSPGQTASITCSGD	KLDGKY.....	ACWYQQKPGQSPVVLVIY	QDS.....			
Camv119	QSVLTQPSA.VSVSLGETARITCQGG	NFGSYY.....	SNWYQQKPGQAPVVLVIY	KDS.....			
Camv120	QSVLTQPSA.VSVSLGETARITCQGG	DFGDYY.....	VSWYQQKPGQSPVVLVIY	KDT.....			
Camv18	TALTQPSA.VSVSLGETARITCQGG	NFGSYY.....	TSWYQQKPEEAPVVVIY	KDT.....			
Camv118	QAVLSQPSA.VSVSLGETARITCQGD	NFGSYY.....	FSWYQQKPGQAPVVLVIY	RNS.....			
Camv123	QSVLTQPSA.VSVSLGQTARITCQGG	ILGSKK.....	TNWYQQKPGQAPVVLVIY	GDD.....			
IGLV gene	FR3 - IMGT (66-104)		CDR3 - IMGT (105-115)				
	70	80	90	100	110		
X57826, IGLV3-1	KRPSGIP.ERFSGSN	.SGNTATLTLISGTQAMDEADYYC	QAWDSSTA....				
Camv119	ARPSGIP.ERFSGSS	SGGTATLTLISGAQAEDEADYYC	QSGSSSA-SA---V	FGGGTHLTVLG			
Camv120	LRPSGIP.ERFTGSS	SGGAATLTLISGAQAEDEADYYC	QSETSSA-T---V	FGGGTHLTVLG			
Camv18	ERPSGIP.ERFSASS	SGDTATLTLISGAQAEDEADYYC	QSGSSSA-NAP-V	FGGGTKLTVLG			
Camv118	NRPSGIP.ERFSASS	SGGTATLTLISGAQAEDEADYYC	QSADSSGRNAR-A	FGGGTKLTVLG			
Camv123	SRPSGIP.ERFSGSR	SGGTATLTLISGAQAEDEADYYC	QLLDSTDSSSYWW	FGGGTHLTVLG			

- 89 M somatic mutation (?) as also human residue L is fund in Camv131
- 96 S in classes 1, 2, 4, 5
- 97 A not found in human germline
- Sequence homology: 23/26 (FR1)+16/17 (FR2)+38/39 (FR3)=78/82=94% homology
- B) Canonical Folds Analysis:
- Z73642, IGLV2-18: Results using auto-generated SDR templates
- CDR L1 Class ?
- ! Similar to class ?1/4C, but:
- ! L32 (Chothia Numbering)=R (allows: Y)
- ! L90 (Chothia Numbering)=L (allows: S)
- ! L93 (Chothia Numbering)=S (allows: G)
- CDR L2 Class 1/7A [11mk]
- Camv159 Results using auto-generated SDR templates
- CDR L1 Class ?
- ! Similar to class ?/14C, but:
- ! L28 (Chothia Numbering)=N (allows: S)
- ! L93 (Chothia Numbering)=S (allows: G)
- CDR L2 Class 1/7A [11mk]
- Analysis of the camelid lambda light chain variable sequences aligning to human germline IGLV2-18 reveals a canonical fold 214 for CDR1 and fold 1/7A for CDR2, so identical to the folds of CDR1 and 2 of human germline VL2 family. The analysis for Camv159 is shown as an example: CDR L2 gives a perfect match for canonical fold 1/7A, while for CDR L1 only two key residues are questionable for giving a perfect match with canonical fold 2/14C, which now will be discussed individually.
- 1) Position L28 Asparagine (N, in CDR1) should be Serine (S), but Aspartate (D) found in Camv133 is the most often found residue in human germline VL2 sequences
- ³⁵ C) Sequence Comparisons:
- 1 Q primer encoded
- 2 S/T primer encoded
- 3 V/A primer encoded
- 5 S primer encoded
- 8 S also in 3-27 and 4-60
- 9 A also in 3-19/32
- 15 L in 3-9/16/19/32
- 17 E not in human class 3 but human Q exists in Camv123 in same context
- 20 R in all other human class 3 sequences and others
- 24 Q in 3-19/32
- 26 G somatic mutation/part of CDR; human D exists in Camv118 in same context
- 39 V/T/F somatic mutation/part of CDR
- 40 N/S somatic mutation/part of CDR
- 49 A in many other class 3
- 66 A/L/N/S somatic mutation/part of CDR
- 80 S in 3-16/19/10/25/27
- 85 G not in class 3 but in classes 6 and 7
- 94 A in 3-19/10/9
- 97 E in 3-10/16/19
- Sequence homology: 26/26 (FR1)+17/17 (FR2)+38/39 (FR3)=81/82=99% homology
- D) Canonical Folds Analysis:
- 60 Analysis of the above listed camelid lambda light chain variable sequences on the UCL webpage <http://www.bioinf.org.uk/abs/chothia.html> shows that CDR-L1 adopts canonical fold 11, while CDR-L2 has canonical fold 7. This corresponds with the canonical folds found in all human germline IGLV3 family members (see Pluckthun homepage http://www.bioc.unizh.ch/antibody/Sequences/Germlines/VBase_hVK.html). The canonical fold is determined by the

55

length of the CDRs and certain key residues within and outside of the CDR. The analysis of e.g. Camv120 is shown below:

CDR L1 Class ?

- ! Similar to class 2/11A, but:
- ! L2 (Chothia Numbering=S (allows: I)
- ! L25 (Chothia Numbering=G (allows: A)
- ! L26 (Chothia Numbering=G (allows: S)
- ! L28 (Chothia Numbering=F (allows: NSDE)
- ! L29 (Chothia Numbering=G (allows: IV)
- ! L51 (Chothia Numbering=D (allows: ATGV)
- ! L71 (Chothia Numbering=A (allows: YF)
- ! L90 (Chothia Numbering=S (allows: HQ)

CDR L2 Class 1/7A [11mk]

CDR L2 gives a perfect match for canonical fold 1/7A, while for CDR L1 certain key residues are questionable for giving a perfect match with canonical fold 2/11A, which now will be discussed individually.

- 1) Position L2 Serine (S) should be Isoleucine (I), but human IGLV3-5 (which also has fold 11) has Serine (S) residue found in these camelid VLs.
- 2) L25 Glycine (G) is found in all human VL3 family members
- 3) L26 Glycine (G) should be Serine (S), but Aspartate (D) found in Camv118 is most often used in human VL3 members
- 4) L28 Phenylalanine (F, in CDR1) should be Asparagine (N), Serine (S), Aspartate (D) or Glutamate (E), but Leucine (L) found in Camv123 is the most often used residue in human VL3

5) L29 Glycine (G, in CDR1) is found in 4 of the 9 human VL3 germlines

6) L51 Aspartate (D, in CDR2) is most often used in human VL3

7) L71 Alanine (A, FR3) is most often used in human VL3

8) L90 Serine (S, CDR3) is most used residue in human VL3

Conclusions:

- 2) Canonical fold number 11 for CDR1 is expected and fold 7 for CDR2, i.e. identical to what is found in human germline VL3

Note: Chothia Numbering 51, 71, and 90 compares to IMGT numbering 57, 87, and 106

10.6 VL 3-12

56

13 M not any human germline
14 S in many other germlines of class 3 and in many other germline classes as well

15 L in 3-16/19/32 and in many other classes

- 5 16 G almost everywhere other than in this particular germline

18 T in many other germlines of class 3 and in many other germline classes as well

20 K not in human class 3 sequences but in class 4

24 Q in 3-19/32

26 G somatic mutation/part of CDR

39 A in many other germlines of class 3

48 not in any human germline

49 A in many other germlines of class 3 and in many other germline classes as well

80 K in 3-32 and many other germline classes

85 not in class 3 but in class 7

87 A in many other germlines of class 3 and in many other germline classes as well

94 T in 3-1

95 K not in class 3 but in 2-33 and 6-57

97 E in 3-10/16/19 and in many other germline classes

Sequence homology: 22/26 (FR1)+16/17 (FR2)+37/39 (FR3)=75/82=91% homology

Most likely homology underestimated due to somatic mutations and because only one family member is found.

B) Canonical Folds Analysis:

Z73658, IGLV3-12: Results using auto-generated SDR templates

CDR L1 Class ?

- ! Similar to class 2/11A, but:

! L2 (Chothia Numbering)=Y (allows: I)

! L25 (Chothia Numbering)=G (allows: A)

! L26 (Chothia Numbering)=N (allows: S)

! L28 (Chothia Numbering)=I (allows: NSDE)

! L29 (Chothia Numbering)=G (allows: IV)

- 35 ! L51 (Chothia Numbering)=D (allows: ATGV)

! L71 (Chothia Numbering)=T (allows: YF)

! L90 (Chothia Numbering)=V (allows: HQ)

CDR L2 Class 1/7A [11mk]

Camv11: Results using auto-generated SDR templates

CDR L1 Class ?

- ! Similar to class 2/11B, but:

! L25 (Chothia Numbering)=G (allows: A)

! L26 (Chothia Numbering)=G (allows: N)

IGKV gene	leader	FR1 - IMGT (1-26)	CDR1 - IMGT (27-38)	FR2 - IMGT (39-55)	CDR2 - IMGT (56-65)
		1 10 20	30 40 50	60	
Z73658, IGLV3-12		SYELTQPHS . VSVATAQMARI TCGGN	NIGSKA	VHWYQQKPGQDPVLYIY SDS	NRPSG
Camv111		QSVL TQPST . ASMSLGQTAKITCQGG	SLRGYA	AHWWYQQKPGAA PVLYIY NDN	NRPSG
IGKV gene		FR3 - IMGT (66-104)	CDR3 - IMGT (105-115)	FR4	
		70 80 90 100 110			
Z73658, IGLV3-12	Camv111	IP . ERFSGSN . PGNTTTLTISRI EAGDEADYYC	QVWDSSSDH . .		
		IP . ERFSGSK . . SGGTATLTISRTKAED EADYYC	LSHDMDSN - RVV FGGGTHLTVLG		

A) Sequence Comparisons:

1 Q primer encoded

2 S primer encoded

3 V primer encoded

5 S primer encoded

8 S also in 3-27 and 4, 5

9 T not in any human germline

11 A not in class 3 but in classes 1, 2, 4, and 9

- 60 ! L29 (Chothia Numbering)=R (allows: P)

! L34 (Chothia Numbering)=H (allows: Y)

! L46 (Chothia Numbering)=L (allows: M)

! L71 (Chothia Numbering)=A (allows: V)

! L90 (Chothia Numbering)=S (allows: A)

! L93 (Chothia Numbering)=M (allows: N)

CDR L2 Class 1/7A [11mk]

Remarks: more difficult to align, especially FR1. These are somatically mutated sequences, meaning that variations in FR can be expected as well. Deviations from canonical fold analysis are very comparable in IGLV3-12, so most likely adopts comparable canonical folds. For CDR L2 fold 1-7A shows a perfect match, CDR L2 will adopt fold 2-11 just as in human counterpart.

Conclusion:

Adopts canonical fold 2/11 for CDR1 and fold 1/7A for CDR2, so identical to human germline VL3.

Only one family member found, which is somatically mutated and therefore it is difficult to draw conclusions.

10.7 VKappa 2-40

96 P not in class 2 but in classes 1, 3
99 A not in class 2 but in classes 5, 6
100 A/V not in claps 2 but in classes 1, 3, 4, 5, 6, 7

Sequence homology: 17/26 (FR1)+17/17 (FR2)+31/39 (FR3)=66/82=80% homology

5 Most likely homology underestimated due to somatic mutations and because all sequences seem to belong to the same class.

B) Canonical Folds Analysis:

10 X59314, IGKV2-40 Results using auto-generated SDR templates

CDR L1 Class ?

! Similar to class 3/17A, but:

! L90 (Chothia Numbering)=Q (allows: N)

IGKV gene	FR1 - IMGT (1-26)	CDR1 - IMGT (27-38)	FR2 - IMGT (39-55)	CFR2 - IMGT (56-65)
	1 10 20 30 40 50 60			
X59314, IGKV2-40	DIVMTQTPLSLPVTPGEPASISCRSS	QSLLDDGNTY	LDWYLQKPGQSPQLIY TLS	
Kp6	DIVMTQSPSSVTASVGEKVTINCKSS	QSVFDTSRQKSF	LNWHRQRPGQSPRLIY YAS	
Kp48	DIVMTQSPSSVTASVGEKVTINCKSS	QSVFSSSSQKSL	LWHQQRPGQSPRLIY YAS	
Kp3	DIVMTQSPSSVTASVGEKVTINCKSS	QHVISVSNQKSY	LNWYQQRPGQSPRLIY YAS	
Kp20	DIVMTQSPSSVTASVGEKVTINCKSS	QSVLSSSNQKSY	LNWYQQRPGQSPRLIY YAS	
Kp7	DIVMTQSPSSVLASVGEKVTINCKSS	QSVLSSSNQKSY	LNWYQQRPGQSPRLIY YAS	
Kp10	DIVMTQSPSSVTASVGEKVTINCKSS	QSVFASSSSQKSQ	LAWHQQRPGQSPRLIY YAS	
Kp1	DIVMTQSPSSVTASVGEKVTINCKSS	QNLVSDSNQRSL	LAWHQQRPGQSPRKLY YAS	
IGKV gene	FR3 - IMGT (66-104)	CDR3 - IMGT (105-115)		
	70 80 90 100 110			
X59314, IGKV2-40	YRASGV.P.DRFGSG..SGTDFTLKISRVEAEDVGVYYC	MQR1EFP . . .		
Kp6	TRQASGV.P.DRFGSG..STTDFTLTISSSVQPEDAAYVYC	QQAFNVQPS FGSGTRLEIKR		
Kp48	ARASGV.P.DRFGSG..STTDFTLTISSSVQPEDAAYVYC	QQYSGSPPT FGSGTRLEIKR		
Kp3	TRESGIP.DRFGSG..STTDRALTISSVQPEDAAYVYC	QQAYSTPYS FGSGTRLEIKR		
Kp20	TRESGIP.DRFGSG..STTDFTLTISSSVQPEDAAYVYC	QQAYSAPYS FGSGTRLEIKR		
Kp7	TRESGIP.DRFGSG..STTDRTLTISSSVQPEDAAYVYC	QQAVSKPYN FGNGTRLEIKR		
Kp10	TRESGIP.DRFGSG..STTDFTLTISSSVQPEDAAYVYC	QHLYSAPYS FGSGTRLEIKR		
Kp1	TRTSGTP.DRFGSG..STTDFTLTISSSVQPEDAAYVYC	QQGKKDPLS FGSGTRLEIKR		

A) Sequence Comparisons:

7 S primer encoded

9 S only in human kappa 1 not kappa 2 family

11 V only in human kappa 1-12 not kappa 2 family

12 T/L not in human kappa germline

13 A not in class 2 but in class 1 and 5

14 S no in class 2 but in class 1, 3, 4, 7

15 V only in class 1

19 V not in class 2 but in class 1, 5, 6

20 T not in class 2 but in class 1, 3, 4, 6, 7

22 N not in class 2 but class 4

24 K in classes 2, 4, 5

40 N/A somatic mutation, human D also exists in KP48

42 H somatic mutation, human Y also exists in KP3/20/7

43 Q/R Q also found in classes 1, 2, 3, 4, 5, 6 and 7; R is 55 somatic mutation

51 R in 2-24 and 2-30 as well as is class 3

52 R/K R in 2-30 and 1-17; human L also exists

66 TA in classes 1, 3, 4 but not in 2; somatic mutation/part of CDR

68 QE somatic mutation, human A also exists in KP48

71 I somatic mutation; human V also exists in same context in various dromedary kappa chains

84 T not in any human kappa germline

90 T not in class 2 but in classes 1, 3, 4, 5, 6, 7

93 S not in class 2 but in classes 1, 3, 4, 6

95 Q not class 2 but in classes 1, 3, 4

40 ! L93 (Chothia Numbering)=E (allows: NS)

CDR L2 Class 1/7A [11mk]

Kp6 Results using auto-generated SDR templates

CDR L1 Class ?

45 ! Similar to class 3/17A, but:

! L29 (Chothia Numbering)=V (allows: L)

! L90 (Chothia Numbering)=Q (allows: N)

CDR L2 Class 1/7A [11mk]

Analysis of the camelid kappa light chain variable sequences

50 aligning to human germline IGLV2-40 reveals a canonical fold 3/17A for CDR1 and fold 1/7A for CDR2, so identical to the folds of CDR1 and 2 of human germline IGKV2-40.

Dromedary Kp6 was analyzed as an example. CDR2 gives a perfect match for canonical fold 1, while for CDR1 a number of residues are questionable for giving a perfect match with canonical fold 3/17A, which now will be discussed individually.

1) Position L29 Valine (V, in CDR1) should be Leucine (L) for having canonical fold 3 for CDR1, but this residue is present 60 in dromedary Kp1 sequence

2) Position L90 Glutamine (Q, in CDR3) occurs as well in human germline VBase_VK4_1, which also has canonical folds 3 for CDR1 (in combination with fold 1 for CDR2)

Conclusions:

65 Canonical fold 1 for CDR2 expected and most probably fold number 3/17A for CDR1 and fold 1 for CDR2, i.e. identical to what is found in human germline.

US 9,315,576 B2

59

NOTE: Positions 90 (Chothia) compares to position 107 in IMGT nomenclature used for the sequence comparison.

10.8 J(H) Region Comparisons of Human and Llama

Human		
IGHJ Genes	---CDR3--- -----FR4----	
	1 10 20	
	
J00256, IGHJ1ABYFQH	WGQGTLVTVSS
J00256, IGHJ2YWFDL	WGRGTLVTVSS
J00256, IGHJ3AFDV	WGQGTMVTVSS
J00256, IGHJ5NWFDS	WGQGTLVTVSS
J00256, IGHJ6	YYYYYGMDV	WGQGTTVTVSS
Llama:		
IGHJ Genes	---CDR3--- -----FR4----	
	1 10	
	
AF305952, IGHJ2	GYRYLEV	WGQGTLVTVSS
AF305952, IGHJ3	NALDA	WGQGTLVTVSS
AF305952, IGHJ4	EYDY?	WGQGTVTVSS
AF305952, IGHJ5	PQFEY?	WGQGTLVTVS
AF305952, IGHJ6 (1)	DFGS	WGQGTLVTVS

Sequence Analysis:

The J(H) regions derived from llama show a perfect homology to their human counterparts. There is a 100% sequence identity. The only exception is the 6th residue of FR4 in llama IGHJ4 being Gln (Q). This residue is not found in human J(H) regions at this position.

10. 9 Comparison of Light Chain J Regions

Lambda J:		
Kabat numbering ..97 98.....108		
-- CDR3 -- ---FR4----		
	-J-lambda-	
X04457, IGLJ1
M15641, IGLJ2	YV	FGTGTKVTVL
	YV	FGGGTKLTVEL

60

-continued

5	M15642, IGLJ3 X51755, IGLJ4 X51755, IGLJ5 M18338, IGLJ6 X57155, IGLJ7 Camv119 etc. Camv18/18/4 10 10 10	VV FGGGKLTVEL FV FGGGTQLIIL WV FGEGTWLTVL NV FGSGTKVTVL AV FGGGTQLTVL .. FGGGTHLTVLG (38/44 analyzed sequences) .. FGGGKLTVLG (3/44 analyzed sequences) .. FGGGTRLTVLG (3/44 analyzed sequences)

Sequence Analysis:

The first 2 residues of the human germline J are considered part of the CDR3. They are often changed during the joining process. The best match of dromedary J-lambda regions is with IGLJ2 and 3. 9/10 amino acids are identical: 90% sequence identity. Only His or Arg in position 103 (Kabat) do not match. Arg is positively charged (as Lys) and even His can be considered somewhat positively charged. Therefore exchange to the human Lys should be possible.

Kappa J:		
Kabat numbering ..97 98.....108		
-- CDR3 -- ---FR4----		
25	Kappa	
30	J00242, IGKJ1 J00242, IGKJ2 J00242, IGKJ3 J00242, IGKJ4 J00242, IGKJ5 Kp6/48/3/20/10/1 Kp7	WT FGQGTVKVEIK YT FGQGTVKLEIK FT FGPGTKVDIK LT FGGGTVKVEIK IT FGQGTRLEIK FSGSGTRLEIKR FGNGTRLEIKR
35		(6/7 analyzed sequences) (1/7 analyzed sequences)

Sequence Analysis:

The first 2 residues of the human germline J regions are considered part of the CDR3. They are often changed during the joining process. Best match of dromedary J-kappa is with human IGKJ5. 9/10 amino acids match: 90% sequence identity.

10. 10 *Lama Pacos* VH Germline Analysis

		% %		FR1		FR2			
Name	Ident	Homol	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	CDR1		CDR2			
			V Q L V Q S G A E V K P G A S V K V S C K A S G Y						
X92343 GHV1-	46*01	Q	V Q L V Q S G A E V K P G A S V K V S C K A S G Y						
LpVHL-s6	89.2%	91.9%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y						
(AM939701)	LpVHL-s2	89.2%	91.9%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y					
(AM939697)	LpVHL-s3	87.8%	90.5%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y					
LpVHL-s4	89.2%	91.9%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y						
(AM939698)	LpVHL-s5	89.2%	91.9%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y					
(AM939699)	LpVHL-s5Ps	89.2%	91.9%	E V Q L V Q S G A E V K P G A S V K V S C K A S G Y					
(AM939700)	M99660 GHV3-	E	V Q L V Q S G A E V K P G A S V K V S C K A S G Y						
23*01	AM939712	94.6%	98.6%	E V Q L V Q S G A E V K P G A S V K V S C K A S G F					
AM939713	89.2%	94.6%	Q L Q V Q S G A E V K P G A S V K V S C K A A S G F						
AM939730	93.2%	97.3%	E V Q L V Q S G A E V K P G A S V K V S C A A S G F						
AM939731	91.9%	97.3%	E V Q L V Q S G A E V K P G A S V K V S C A A S G F						
AM939744	86.5%	93.2%	Q V Q L V Q S G A E V K P G A S V K V S C A A S G L						
AM939726	93.2%	97.3%	Q L Q V Q S G A E V K P G A S V K V S C A A S G F						
AM939727	93.2%	97.3%	Q L Q V Q S G A E V K P G A S V K V S C A A S G F						
AM939739	94.6%	97.3%	E V Q L V Q S G A E V K P G A S V K V S C A A S G F						
AM939740	94.6%	98.6%	Q L Q V Q S G A E V K P G A S V K V S C A A S G F						
AM939741	94.6%	98.6%	E V Q L V Q S G A E V K P G A S V K V S C A A S G F						
AM939742	90.5%	95.9%	Q L V Q S G A E V K P G A S V K V S C A A S G F						
AM939743	93.2%	97.3%	E V Q L V Q S G A E V K P G A S V K V S C A A S G F						
	% %	FR1		CDR1		FR2			
Name	Ident	Homol	28 29 30 31 32 33 34 35 35a 35b 35c 36 37 38 39 40 41 42 43 44 45 46 47 48 49						
X92343 GHV1-	46*01	T F T S Y M H	W V R Q A P G Q G L E W M G						
LpVHL-s6	89.2%	91.9%	T F T S Y Y I D	W V R Q A P G Q G L E W M G					
(AM939701)	LpVHL-s2	89.2%	91.9%	T F T S Y Y I D	W V R Q A P G Q G L E W M G				
(AM939697)	LpVHL-s3	87.8%	90.5%	T F T S Y Y I D	W V R Q A P G Q G L E W M G				
(AM939698)	LpVHL-s4	89.2%	91.9%	T F T S Y Y I D	W V R Q A P G Q G L E W M G				
(AM939699)	LpVHL-s5Ps	89.2%	91.9%	T F T S Y Y I D	W V R Q A P G Q G L E W M G				
(AM939700)	M99660 GHV3-	T	F S S Y A M S	W V R Q A P G Q G L E W V S					
23*01	AM939712	94.6%	98.6%	T F S D Y A M S	W V R Q A P G Q G L E W V S				
AM939713	89.2%	94.6%	T F S D Y A M S	W V R Q A P G Q G L E W V S					
AM939730	93.2%	97.3%	T F S D Y A M S	W V R Q A P G Q G L E W V S					

-continued

-continued

Name		Ident		Homol		%		%		FR1		FR2	
AM939744	86.5%	93.2%	R	D	N	A	K	N	T	L	Y	L	Q
AM939726	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q
AM939727	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q
AM939739	94.6%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q
AM939740	94.6%	98.6%	R	D	N	A	K	N	T	L	Y	L	Q
AM939741	94.6%	98.6%	R	D	N	A	K	N	T	L	Y	L	Q
AM939742	90.5%	95.9%	R	D	N	A	K	N	T	L	Y	L	Q
AM939743	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q
U29481IGHV3-23*03	%	%	E	V	Q	L	L	E	S	G	G	G	G
AM939716	94.6%	97.3%	E	V	Q	L	V	E	S	G	G	G	S
AM939728	90.5%	94.6%	E	V	R	L	V	E	S	G	G	G	F
AM939738	91.9%	95.9%	Q	V	Q	L	V	E	S	G	G	G	R
AM939710	89.2%	93.2%	Q	V	Q	L	V	E	S	G	G	G	L
AM939748	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	L
AM939750	94.6%	98.6%	Q	V	Q	L	V	E	T	G	G	G	S
AM939751	91.9%	95.9%	Q	L	Q	L	V	E	S	G	G	G	F
AM939767	90.5%	94.6%	Q	V	Q	L	V	E	S	G	G	G	F
AM939768	93.2%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939707	93.2%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939708	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939709	91.9%	95.9%	E	V	Q	L	V	E	S	G	G	G	L
AM939732	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939733	89.2%	94.6%	Q	V	Q	L	V	E	S	G	G	G	F
AM939717	90.5%	95.9%	Q	V	Q	L	V	E	S	G	G	G	F
AM939734	94.6%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939735	91.9%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939736	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939737	94.6%	98.6%	Q	V	Q	L	V	E	S	G	G	G	F
U29481IGHV3-23*03	%	%	E	V	Q	L	V	E	S	G	G	G	F
AM939716	94.6%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939728	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939738	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939710	89.2%	93.2%	T	F	S	S	Y	A	M	S	S	S	T
AM939748	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939750	94.6%	98.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939751	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939767	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939768	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939707	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939708	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939709	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939732	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939733	89.2%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939717	90.5%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939734	94.6%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939735	91.9%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939736	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939737	94.6%	98.6%	Q	V	Q	L	V	E	S	G	G	G	F
U29481IGHV3-23*03	%	%	T	F	S	S	Y	A	M	S	S	S	S
AM939716	94.6%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939728	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939738	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939710	89.2%	93.2%	T	F	S	S	Y	A	M	S	S	S	T
AM939748	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939750	94.6%	98.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939751	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939767	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939768	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939707	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939708	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939709	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939732	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939733	89.2%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939717	90.5%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939734	94.6%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939735	91.9%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939736	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939737	94.6%	98.6%	Q	V	Q	L	V	E	S	G	G	G	F
U29481IGHV3-23*03	%	%	T	F	S	S	Y	A	M	S	S	S	S
AM939716	94.6%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939728	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939738	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939710	89.2%	93.2%	T	F	S	S	Y	A	M	S	S	S	T
AM939748	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939750	94.6%	98.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939751	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939767	90.5%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939768	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939707	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939708	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939709	91.9%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939732	93.2%	97.3%	T	F	S	S	Y	A	M	S	S	S	S
AM939733	89.2%	94.6%	T	F	S	S	Y	A	M	S	S	S	S
AM939717	90.5%	95.9%	T	F	S	S	Y	A	M	S	S	S	S
AM939734	94.6%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939735	91.9%	97.3%	E	V	Q	L	V	E	S	G	G	G	F
AM939736	93.2%	97.3%	Q	V	Q	L	V	E	S	G	G	G	F
AM939737	94.6%	98.6%	Q	V	Q	L	V	E	S	G	G	G	F

-continued

67

US 9,315,576 B2

68

Name	% Ident	Homol	CDR2												FR3															
			V	I	Y	S	G	S	T	Y	A	D	S	V	K	G	R	F	T	I	S									
U294811GHV3-23*03	93.2%	97.3%	T	F	S	S	Y	D	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	D			
AM939732	89.2%	94.6%	T	L	G	S	Y	D	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	C			
AM939733	90.5%	95.9%	T	F	G	S	Y	D	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	Y			
AM939717	94.6%	97.3%	T	F	S	S	Y	A	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	Y			
AM939734	91.9%	97.3%	T	F	D	N	Y	A	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	Y			
AM939735	93.2%	97.3%	T	F	S	S	Y	A	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	Y			
AM939736	94.6%	98.6%	T	F	S	S	Y	A	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	D			
AM939737	94.6%	98.6%	T	F	S	S	Y	A	M	S			W	V	R	Q	A	P	G	K	G	L	E	W	V	S	Y			
U294811GHV3-23*04	94.6%	97.3%	S	I	Y	S							Y	S	S	N	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939716	90.5%	94.6%	S	I	Y	S							Y	S	S	S	N	T	Y	A	D	S	V	K	G	R	F	T	I	S
AM939728	91.9%	95.9%	S	I	Y	S							Y	S	S	S	N	T	Y	A	D	S	V	K	G	R	F	T	I	S
AM939738	89.2%	93.2%	T	I	N	S							D	G	S	S	N	T	Y	A	D	S	V	K	G	R	F	T	I	S
AM939710	93.2%	97.3%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939748	93.2%	97.3%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939750	94.6%	98.6%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939751	91.9%	95.9%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939767	90.5%	94.6%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939768	93.2%	97.3%	G	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939707	93.2%	97.3%	S	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939708	93.2%	97.3%	S	I	Y	S							D	G	S	D	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939709	91.9%	95.9%	T	I	Y	S							D	G	S	N	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939732	93.2%	97.3%	D	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939733	89.2%	94.6%	C	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939717	90.5%	95.9%	Y	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939734	94.6%	97.3%	Y	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939735	91.9%	97.3%	Y	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939736	93.2%	97.3%	Y	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
AM939737	94.6%	98.6%	D	I	N	S							G	G	S	S	T	Y	A	D	S	V	K	G	R	F	T	I	S	
U294811GHV3-23*05	96%	96%																												
AM939716	94.6%	97.3%	T	D	N	S	K	N	T	L	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	C				
AM939728	90.5%	94.6%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	S	E	D	T	A	V	Y	C				
AM939738	91.9%	95.9%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939710	89.2%	93.2%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939748	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939750	94.6%	98.6%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939751	91.9%	95.9%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939767	90.5%	94.6%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939768	93.2%	97.3%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939707	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939708	93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				
AM939709	91.9%	95.9%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C				

-continued

				FR1												FR2																
				FR1						CDR1						FR2																
Name	Ident	Homol	%	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27		
AM939732		93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	C					
AM939733		89.2%	94.6%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
AM939717		90.5%	95.9%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
AM939734		94.6%	97.3%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
AM939735		91.9%	97.3%	R	D	N	A	K	N	T	V	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
AM939736		93.2%	97.3%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
AM939737		94.6%	98.6%	R	D	N	A	K	N	T	L	Y	L	Q	M	N	S	L	K	P	E	G	T	A	V	Y	Y	C				
L338511GHV3-74*01				E	V	Q	L	V	E	S	G	G	G	G	G	G	S	L	R	L	R	L	S	C	A	A	S	G	F			
AM939749		94.6%	98.6%	Q	V	Q	L	V	E	S	G	G	G	G	G	G	S	L	R	L	R	L	R	S	C	A	A	S	G	F		
AM939724		93.2%	98.6%	Q	V	Q	L	V	E	S	G	G	G	G	G	G	S	L	R	L	R	L	R	S	C	A	A	S	G	F		
AM939725		89.2%	95.9%	Q	V	Q	L	V	E	S	G	G	G	G	G	G	S	L	R	L	R	L	R	S	C	A	A	S	G	F		
AM939745		87.8%	93.2%	E	V	Q	L	V	E	S	G	G	G	G	G	G	S	L	R	L	R	L	R	S	C	A	A	S	G	F		
AM939723		93.2%	97.3%	Q	L	Q	L	Q	E	S	G	G	G	G	G	G	S	Q	T	L	S	L	T	C	A	V	S	G	G			
30-2*03				Q	V	Q	L	Q	E	S	G	G	G	G	G	G	S	Q	T	L	S	L	T	C	A	V	Y	G	G			
LpVHZ-s7		78.4%	81.1%	Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
(AM939704)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
Z142381GHV4-30-4*01				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
LpVHZ-s2		86.5%	86.5%	E	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
(AM939769)				Q	V	Q	R	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	A	S	G
LpVHZ-s3		82.4%	82.4%	E	V	Q	V	Q	R	Q	E	S	G	P	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	A	S	G
(AM939770)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	A	S	G
LpVHZ-s4		82.4%	82.4%	E	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
(AM939771)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
LpVHZ-s5		87.8%	87.8%	Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
(AM939772)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	A	V	G
LpVHZ-s6		82.4%	86.5%	E	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
(AM939773)				Q	V	Q	L	Q	E	S	G	P	D	L	V	K	P	S	Q	M	L	S	L	T	C	T	V	S	G			
LpVHZ-s11 Ps		82.4%	82.4%	Q	V	Q	L	Q	E	S	G	P	D	L	V	K	P	S	Q	M	L	S	L	T	C	T	V	S	G			
(AM939703)				Q	V	Q	L	Q	E	S	G	P	D	L	V	K	P	S	Q	M	L	S	L	T	C	T	V	S	G			
LpVHZ-s8		82.4%	82.4%	Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	A	S	G
(AM939705)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G
LpVHZ-s9 Ps		83.8%	83.8%	Q	V	Q	L	*	E	S	G	P	G	G	D	L	V	K	P	S	Q	T	L	S	L	T	C	T	V	S	G	
(AM939706)				Q	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	M	L	S	L	T	C	T	L	S	G
LpVHZ-s10		83.8%	83.8%	E	V	Q	L	Q	E	S	G	P	G	G	G	G	L	V	K	P	S	Q	M	L	S	L	T	C	T	L	S	D
(AM939702)																																
Name	Ident	Homol	%	28	29	30	31	32	33	34	35	35a	35b	35c	36	37	38	39	40	41	42	43	44	45	46	47	48	49				
L338511GHV3-74*01				T	F	S	S	Y	W	M	H					W	V	R	Q	A	P	G	K	G	L	V	W	V	S			
AM939749		94.6%	98.6%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				
AM939724		93.2%	98.6%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				
AM939745		89.2%	95.9%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				
AM939723		91.9%	97.3%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				
AM939736		93.2%	97.3%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				
AM939737		94.6%	98.6%	T	F	S	S	S	Y	W	M	N	N	S	W	V	R	Q	A	P	G	K	G	L	E	W	V	S				

-continued

Name	Ident	Homol	CDR2												CDR3													
			%	%	50	51	52	52a	52b	52c	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70
L33851 IGHV3-			R	I	N	S	D	G	S	S	T	S	Y	A	D	S	V	K	G	R	F	T	I	S				
74*01			Y	I	Y		Y	S	D	T	Y	Y	A	A	D	S	V	K	G	R	F	T	I	S				
AM939749	94.6%	98.6%	G	I	Y	S		G	G	S	T	S	Y	A	D	S	M	K	K	G	Q	F	T	I	S			
AM939724	93.2%	98.6%	A	I	N	S		G	G	S	T	S	Y	A	D	S	M	K	K	G	Q	F	T	I	S			
AM939725	89.2%	95.9%	A	I	N	S		C	G	S	T	S	Y	A	D	S	V	K	G	R	F	T	I	S				
AM939745	87.8%	93.2%	A	I	N	S		G	G	S	T	Y	Y	A	D	S	V	K	G	R	F	T	I	S				
AM939723	93.2%	97.3%	A	S	I	Y		Y	S	G	S	T	Y	Y	N	P	S	L	K	S	R	V	T	I	S			
X922291 IGHV4-																												
30-2*03																												
LpVH2-s7	78.4%	81.1%	A	I	—			Y	S	G	S	T	Y	Y	S	P	S	L	K	S	H	T	S	I	S			
(AM939704)																												
Z142381 IGHV4-																												
30-4*01																												
LpVH2-s2	86.5%	86.5%	A	I	A			Y	S	G	S	T	Y	Y	S	P	S	L	K	S	R	T	S	I	S			
(AM939769)																												
LpVH2-s3	82.4%	82.4%	A	I	A			Y	S	G	S	T	Y	Y	S	P	S	L	K	S	R	T	S	I	S			
(AM939700)																												
LpVH2-s4	82.4%	82.4%	A	I	A			Y	S	G	S	T	Y	Y	S	P	S	L	K	S	H	T	S	I	S			
(AM939771)																												
LpVH2-s5	87.8%	87.8%	A	I	A			Y	S	G	S	T	Y	Y	S	P	S	L	K	S	R	T	S	I	S			
(AM939722)																												
LpVH2-s6	82.4%	86.5%	A	I	A			Y	D	G	S	T	Y	Y	S	P	S	L	K	S	H	T	S	I	S			

-continued

Color Codes

Residue found in closest matching germline

Residue found in other germlines of the same subclass (VH3,
VK4, . . . !)

Residue found in other germlines of the same class (VH, VK 5
or VL)

Residue not found in other germlines of the same class (VH,
VK or VL)

Primer not found in any germline of the same class (VH, VK
or VL) 10

Primer-encoded residue

Scores

% Identity: fraction of framework residues which is found in
the closest matching germline

% Homology: fraction of framework residues which is found 15
in the closest matching germline or other germlines of the
same subclass

10. 11 *Lama Glama* Derived VH Analysis

Name	%	Ident	Homol	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6
AJ879486 IGHV3-23*04		S-VH1		E	V	Q	L	V	E	S	G	G	G	G	P	G	G	S	C
S-VH3	88.5%		93.1%	E	V	Q	L	V	E	S	G	G	G	G	P	G	G	S	A
S-VH4	87.4%		90.8%	E	V	Q	L	V	O	S	G	G	G	G	P	H	G	S	A
L33851 IGHV3-74*01	92.0%		96.6%	E	V	Q	L	V	Q	E	S	G	G	G	P	G	G	S	C
S-VH2	93.2%		95.5%	E	V	Q	L	V	Q	E	S	G	G	G	P	G	G	S	A
S-VH6	93.1%		96.6%	E	V	Q	L	V	Q	E	S	G	G	G	P	G	G	S	A
S-VH5	93.1%		96.6%	E	V	Q	L	V	E	S	G	G	G	G	P	G	G	S	A
				%	6	6	6	6	7	7	7	7	7	7	7	7	8	8	8
				Ident	Homol	6	7	8	9	0	1	2	3	4	5	6	7	a	b
																	c	3	4
																		5	6
																		7	8
AJ879486 IGHV3-23*04		S-VH1		R	F	T	I	S	R	D	N	S	K	N	T	L	Y	L	Q
S-VH3	88.5%		93.1%	R	F	T	V	S	R	D	N	T	K	N	T	L	Y	L	Q
S-VH4	87.4%		90.8%	R	F	T	I	S	R	D	N	A	K	N	T	V	Y	L	Q
L33851 IGHV3-74*01	92.0%		96.6%	R	F	T	I	S	R	D	N	A	K	N	A	T	L	Y	L
S-VH2	93.2%		95.5%	R	F	T	I	S	R	D	N	A	K	N	T	L	Y	L	Q
S-VH6	93.1%		96.6%	R	F	T	I	S	R	D	N	A	K	N	T	L	Y	L	Q
S-VH5	93.1%		96.6%	R	F	T	I	S	R	D	N	A	K	N	T	L	Y	L	Q
				%	2	2	3	3	3	3	3	3	3	3	3	3	4	4	4
				Ident	Homol	7	8	9	0	1	2	3	4	5	6	7	8	9	0
																	1	2	3
																	4	5	6
																	7	8	9
																	0	1	2
AJ879486 IGHV3-23*04		S-VH1		F	T	E	S	S	Y	A	M	S	W	V	R	Q	A	P	G
S-VH3	88.5%		93.1%	F	T	F	G	R	Y	A	G	M	S	W	V	R	Q	A	P
S-VH4	87.4%		90.8%	F	A	F	S	S	A	G	M	S	W	V	R	Q	A	P	G
L33851 IGHV3-74*01	92.0%		96.6%	F	T	F	G	S	D	M	H	M	W	V	R	Q	A	P	G
S-VH2	93.2%		95.5%	F	T	E	S	S	Y	W	M	H	W	V	R	Q	A	P	G
S-VH6	93.1%		96.6%	F	T	F	S	S	A	V	M	S	W	V	R	Q	A	P	G
S-VH5	93.1%		96.6%	F	T	F	S	S	A	V	M	S	W	V	R	Q	A	P	G
				%	8	9	9	9	9	9	9	9	9	9	9	1	1	1	1
				Ident	Homol	9	0	1	2	3	4	5	6	7	8	9	0	a	b
																	c	d	
																	e	f	
																	g	1	2
																	3	4	5
																	6	7	
AJ879486 IGHV3-23*04		S-VH1		V	Y	Y	C	A	K	A	R	S	T	A	E	S	N	W	I
S-VH3	88.5%		93.1%	V	Y	Y	C	A	R	S	T	A	E	S	N	W	I	P	
S-VH4	87.4%		90.8%	V	Y	Y	C	N	A	G	F	P	S	T	I	A	T	I	F
L33851 IGHV3-74*01	92.0%		96.6%	V	Y	Y	C	A	K	P	S	T	I	A	T	I	L	F	
S-VH2	93.2%		95.5%	V	Y	Y	C	A	R	S	T	I	A	T	I	L	F		
S-VH6	93.1%		96.6%	V	Y	Y	C	A	R	S	T	I	A	T	F	G	S	W	G
S-VH5	93.1%		96.6%	V	Y	Y	C	T	G	R	F	G	F	T	S	W	G	Q	G
				%	8	9	9	9	9	9	9	9	9	9	9	1	1	1	1
				Ident	Homol	9	0	1	2	3	4	5	6	7	8	9	0	a	b
																	c	d	
																	e	f	
																	g	1	2
																	3	4	5
																	6	7	

-continued

US 9,315,576 B2

82

10. 12 *Lama Glama* Derived VL Analysis

81

Name	% Homol	1	2	3	4	5	6	7	8	9	1	2	3	4	5	6	7
D869941 GLV3-25*02		S	Y	E	L	T	Q	P	P	S	V	S	P	G	Q	T	A
VIL25,28	93.1%	N	F	M	L	T	Q	P	P	S	V	S	P	G	Q	T	A
ZT3672 IGLV5-37*01	Q	P	V	L	T	Q	P	P	S	S	A	S	P	G	E	S	R
VIL2,12,15	97.5%	Q	A	V	V	V	T	Q	P	S	L	S	P	G	S	S	S
ZT3650 GLV8-61*01	Q	T	V	V	V	T	Q	E	P	S	F	S	P	G	T	L	S
VIL3,5	90.0%	Q	A	V	V	V	T	Q	E	P	S	L	S	G	L	S	S
VIL17-24,29-32	90.0%	Q	A	V	V	V	T	Q	E	P	S	L	S	G	T	L	S
VIL10	91.3%	S	S	E	L	T	Q	D	P	S	L	S	V	G	T	V	T
VIL4,6,7,8,9,13,14	97.5%	S	Y	E	L	T	Q	D	P	S	L	S	V	E	T	V	T
Name	% Homol	1	2	3	4	5	6	6	6	6	6	6	6	6	6	7	7
D869941 GLV3-25*02		R	F	S	G	S	S	G	S	S	G	S	T	R	V	T	L
VIL25,28	93.1%	R	F	S	G	S	S	K	D	A	S	A	N	T	R	A	T
ZT3672 IGLV5-37*01	97.5%	R	F	S	G	S	K	D	A	S	A	N	K	A	L	I	L
VIL2,12,15	90.0%	R	F	S	G	S	I	L	G	S	I	N	K	A	V	L	T
ZT3650 GLV8-61*01	90.0%	R	F	S	G	S	I	S	G	S	I	N	K	A	T	I	T
VIL3,5	91.3%	R	F	S	G	S	I	S	G	S	I	N	K	A	V	L	T
VIL17-24,29-32	90.0%	R	F	S	G	S	I	S	G	S	I	N	K	A	T	I	T
VIL10	91.3%	R	F	S	G	S	I	S	G	S	I	N	K	A	L	I	T
VIL4,6,7,8,9,13,14	97.5%	R	F	S	G	S	I	S	G	S	I	N	K	A	L	T	G
Name	% Homol	1	2	7	7	2	2	3	3	3	3	3	3	3	3	3	4
D869941 GLV3-25*02																	
VIL25,28	93.1%																
ZT3672 IGLV5-37*01	97.5%	D	I	N	S	V	S	T	S	Y	D	I	S	P	Y	W	Y
VIL2,12,15	90.0%	G	S	V	S	V	T	S	N	Y	P	S	W	W	Y	Y	Q
ZT3650 GLV8-61*01	90.0%	G	S	V	S	V	T	S	N	Y	P	G	W	Y	Q	Q	Q
VIL3,5	91.3%	G	S	V	S	V	T	S	N	Y	P	A	W	Y	Q	Q	A
VIL17-24,29-32	90.0%	G	S	V	S	V	T	S	S	N	Y	P	G	W	Y	Q	A
VIL10	91.3%	G	S	V	S	V	T	S	S	N	Y	P	A	W	Y	Q	P
VIL4,6,7,8,9,13,14	97.5%	G	S	V	S	V	T	S	S	N	Y	P	G	W	Y	Q	A
Name	% Homol	5	6	7	8	8	8	8	9	0	1	2	3	4	5	5	5
D869941 GLV3-25*02		D	Y	Y	C	C	Q	S	A	D	S	S	N	G	N		
VIL25,28	93.1%	D	Y	Y	C	C	Q	S	A	W	P	S	S	G	N		
ZT3672 IGLV5-37*01	97.5%	D	Y	Y	C	C	Q	S	A	Y	M	S	G	S	Y		
VIL2,12,15	90.0%	D	Y	Y	C	C	Q	S	A	Y	L	S	G	S	N	Y	
ZT3650 GLV8-61*01	90.0%	D	Y	Y	C	C	Q	S	A	Y	V	S	G	S	N	Y	P
VIL3,5	91.3%	D	Y	Y	C	C	Q	S	A	Y	L	S	G	S	D	I	
VIL17-24,29-32	90.0%	D	Y	Y	C	C	Q	S	A	Y	V	S	G	S	D	I	

-continued

Name	% Ident	% Homol	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
U41644 IGKV2D-29*02			D	I	V	M	T	Q	T	P	L	S	L	S	V	T	P	G
KAPPA 33-36, 38, 39, 42, 44	86.3%	90.0%	D	I	V	M	T	Q	T	P	G	S	L	S	V	V	P	G
KAPPA 41, 43, 44	86.3%	90.0%	D	I	V	M	T	Q	T	P	G	S	L	S	V	V	P	G
KAPPA 40, 44	86.3%	90.0%	D	I	V	M	T	Q	T	P	G	S	L	S	V	V	P	G
KAPPA 37, 46, 48	83.3%	90.0%	E	I	V	L	T			P	G	S	L	S	V	V	P	G
Name	% Ident	% Homol	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	
U41644 IGKV2D-29*02			W	Y	L	Q	K	P	G	Q	S	P	Q	L	L	I	Y	
KAPPA 33-36, 38, 39, 42, 44	86.3%	90.0%	W	L	L	Q	K	P	G	Q	S	P	Q	R	L	I	Y	
KAPPA 41, 43, 44	86.3%	90.0%	W	L	L	Q	K	P	G	Q	S	P	Q	R	L	I	Y	
KAPPA 40, 44	86.3%	90.0%	W	L	L	Q	K	P	G	Q	S	P	Q	R	L	I	Y	
KAPPA 37, 46, 48	83.3%	90.0%													2	2	2	2
Name	% Ident	% Homol	17	18	19	20	21	22	23	24	25	26	27	a	27	27	27	27
U41644 IGKV2D-29*02			Q	P	A	S	I	S	C	K	S	S	Q	S	L	L	H	
KAPPA 33-36, 38, 39, 42, 44	86.3%	90.0%	E	S	A	S	I	S	C	K	A	S	Q	S	L	V	H	
KAPPA 41, 43, 44	86.3%	90.0%	E	S	A	S	I	S	C	K	A	S	Q	S	L	V	H	
KAPPA 40, 44	86.3%	90.0%	E	S	A	S	I	S	C	K	A	S	Q	S	L	V	L	
KAPPA 37, 46, 48	83.3%	90.0%	E	S	A	S	I	S	C	K	A	S	Q	S	L	V	R	
Name	% Ident	% Homol	50	51	52	53	54	55	56	57	58	59						
U41644 IGKV2D-29*02			E	V	S	N	R	F	S	G	V	P						
KAPPA 33-36, 38, 39, 42, 44	86.3%	90.0%	Q	V	S	N	R	G	S	G	V	P						
KAPPA 41, 43, 44	86.3%	90.0%	Q	V	S	N	R	G	S	G	V	P						
KAPPA 40, 44	86.3%	90.0%	Q	V	S	N	R	G	S	G	V	P						
KAPPA 37, 46, 48	83.3%	90.0%	Q	V	S	N	R	G	S	G	V	P						
Name	% Ident	% Homol	27	28	29	30	31	32	33	34								
U41644 IGKV2D-29*02			S	D	G	K	T	Y	L	Y								
KAPPA 33-36, 38, 39, 42, 44	86.3%	90.0%	S	D	G	K	T	Y	L	Y								
KAPPA 41, 43, 44	86.3%	90.0%	S	D	G	K	T	Y	L	Y								
KAPPA 40, 44	86.3%	90.0%	S	D	G	K	T	Y	L	Y								
KAPPA 37, 46, 48	83.3%	90.0%	S	D	G	K	T	Y	L	Y								

Example 11

Analysis of Key Residues for Canonical Folds of H1 and H2 and Comparison of H1 and H2 Residues with Human Germline

Structural analysis of antibodies revealed the relationship between the sequence and the shape of the binding site formed by the complementarity determining regions (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987); Tramontano et al., J. Mol. Biol. 215:175-82 (1990)). Despite their high sequence variability, five of the six loops adopt just a small repertoire of main-chain conformations, called “canonical structures”. These conformations are first of all determined by the length of the loops and secondly by the presence of key residues at certain positions in the loops and in the framework regions that determine the conformation through their packing, hydrogen bonding or the ability to assume unusual main-chain conformations.

We have analyzed the predicted canonical structures of H1 and H2 for the germline dromedary and llama VH segments based on the length of these loops and the presence of the previously mentioned key residues. The comparison was made with the key residues as they occur in the closest matching human germline in terms of the presence of identical combination of canonical folds and overall sequence homology (Table 1); in addition the amino acids compatible with the corresponding canonical fold as proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)) are shown. For the dromedary germline VH family IGHV1S(1-19), which has canonical fold 1 for H1 (coded as H1: 1 in Table 1) and fold 1 for H2 (H2: 1), and family IGHV1S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2), the key residues 24, 26, 27, 29, 34 and 94 for the canonical fold of H1

are shown along with these from the analogue human germline family with the same canonical fold combination (upper part of Table 1). Also for dromedary germline VH family IGHV1S(1-19) with fold 1 for H1 (H1: 1) and fold 1 for H2 (H2: 1), and family IGHV1S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 1) the key residues 52a or 54 or 55 in combination with residue 71 are shown along with these from the analogue human germline families with the same canonical fold combinations (lower part Table 1).

The analysis clearly demonstrates the "human nature" of the canonical loops, since the key residues found in the camelid VH segments are identical to what is found in the corresponding human VH segments. For example, all 19 germline VH segments from dromedary coded IGHV1S(1-19) have Alanine on position 19, Glycine on 26, Phenylalanine on 27 and 29 and Methionine on 34 as they predominantly occur in human germline family 3 members, which like these dromedary germline sequences have a canonical fold type 1 for H1 and fold type 1 for H2. Position 94 is encoded only in a single germline dromedary (out of the total of 39 germline VH segments) meaning that a proper analysis is not possible. Nguyen and colleagues (Nguyen et al., EMBO J. 19:921-930 (2000)) noticed that the dromedary germline VH and VHH segments "span from the conserved octamer (i.e. recombination signal) to the Cysteine residue 92 of FR3" (end of citation), whereas the human segments encode two additional residues (93 and 94). However, we will discuss this residue during the analysis of the only six known somatically mutated VH segments derived from llama derived conventional antibodies.

There are virtually no exceptions for the perfect match with the human germline segments and the key residues proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)), besides residue 52a for llama germline IGHV1S6 for canonical fold type 2 for loop H2, which has Serine on this position, while the human analogue uses Threonine. It is encouraging to observe that in four of the six published llama VH derived from somatically mutated conventional antibodies (Vu et al., Mol. Immunol. 34:1121-31 (1997)) Threonine is found on position 52a. It is worthwhile to mention that Serine and Threonine are closely related, since they both have a polar hydroxyl group and small sidegroups, suggesting that it might be possible to exchange both residues during humanization.

Glutamine on position 71, which occurs in 1 out of 19 dromedary germline VH segments with a canonical fold type 1 for loop H2 and in 4 out of 16 dromedary germline VH with a canonical fold type 2 for H2, seems to be rather extraordinary. The H2 loop packs against the residue at site 71 and the position of the loop relative to the framework is mainly determined by the size of the residue at this site. Canonical structures 2 and 3 are found in H2 loops with 6 residues. Structure 2 occurs when residues 52a and 71 are small or medium sized hydrophobic residues, while canonical fold 3 occurs when residue 71 is Arginine or Lysine. It can not be predicted how often the dromedary germline segments with Glutamine on position 71 will be used in somatically mutated conventional antibodies, but the humanization of this residue in antibody leads with this particular residue needs to be carefully examined. The presence of Arginine and Glutamine on position 71 in the dromedary IGHV1S(20, 22, 23, 24) family members with canonical fold 2 for H2 is rather unexpected, but on the other hand human germline VH1 family members VH1-9,

VH1-10 and VH1-11 with canonical fold 2 for H2 have Arginine as well, while VH5 member 5-1 with fold 2 for H2 carries Glutamine on this position.

As Chothia and colleagues did when discussing the structural repertoire of the human VH segments (Chothia et al., J. Mol. Biol. 227:799-817 (1992)) we examined the individual amino acid residues of the H1 and H2 loops of the dromedary and llama VH segments along with the key residues and compared these with the human counterparts having the same canonical fold combination (Table 2). For dromedary germline VH family IGHV1S(1-19) with canonical fold 1 for H1 and fold 1 for H2, and family IGHV1S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 and fold 2 for H2 the H1 residues 26 to 33 and the are shown together with the key residues 24 and 94 located outside of H1 (Table 2A). In addition, for dromedary germline VH family IGHV1S(1-19) with canonical fold 1 for H1(H1: 1) and fold 1 for H2 (H2: 1), and family IGHV1S(20, 22, 23, 24) with fold 1 for H1 (H1: 1) and fold 3 for H2 (H2: 3), and family IGHV1S(21, 25-39) with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) and llama germline IGHV1S8 with fold 1 for H1 (H1: 1) and fold 2 for H2 (H2: 2) the H2 residues 52 to 56 were analyzed with key residue 71, which is located outside H2 (Table 2B).

It is surprising to see the very high degree of sequence homology in the variable loops, especially in H1 there are hardly differences with the relevant human sequences. For instance, germline dromedary family IGHV1S(1-19) with canonical fold combination H1: 1 H2: 1 contains predominantly Alanine on position 24, Glycine on 26, Phenylalanine on 27, Threonine on 28, Phenylalanine on 29, Serine on 30 and 31, Tyrosine on 33, Methionine on 34 and Serine on 35, which completely match the human germline family 3 members that share the same combination of H1 and H2 canonical folds. Exceptions are residue 27 (Phenylalanine) and 32 (Serine) of the only publicly known llama germline VH segment, but again in 4 out of 6 somatically mutated llama VH which are publicly known (Vu et al., Mol. Immunol. 34:1121-1131 (1997)). Tyrosine is present on 32 as is found in the analogue human germlines. The same high degree of sequence homology is found for the H2 loops of dromedary germline VH segments with the exception of residue 54 of family IGHV1S(1-19). Especially dromedary family IGHV1S(21, 25-39) deviates on a number positions in the H2 loop (i.e. 53, 54, 56 and 58). The H2 loop of the llama germline VH segment with the same fold scores much better, but as well contains a number of deviating residues on position 50, 52, 52a, 54, 55 and 58, but the interpretation is rather difficult, since the analysis was performed with the only known germline segment. The analysis of somatically mutated VH derived from llama shows that certain residues on these positions occur, which also appear in the corresponding human germline sequences, although infrequently (f.i. Glycine on 50, Asparagine on 52 and 58, Threonine on 52a and Glycine on 55).

We also analyzed the panel of six publicly known somatically mutated VH sequences from llama (Vu et al., Mol. Immunol. 34:1121-31 (1997)). Below the alignment with human VH3 member 3-23 is shown, demonstrating a very high degree of sequence homology: overall, only 3 deviating residues were observed, one of which is encoded by the primer used for amplification, while the other two occur in human germlines of the same class. Even the CDRs show to have a very high degree of sequence homology: CDR1 is probably identical, while only three residues of CDR2 are

different. Canonical fold analysis reveals that two VH have fold 1 for H1 and fold 2 for H2, as was observed for the only available llama derived germline VH, but the other four have fold 1 for H1 and fold 3 for H2 as occurs in 3-23 and the majority of the human family VH3 germline segments. This might be suggesting that these are derived from other, not yet known germline VH segments. Examination of the key residues supporting the canonical folds gives the perfect match with those occurring in human germline with the same canonical fold combination as was already observed for the llama germline VH segment listed in Table 1. It is very interesting to see that key residue 94 in these somatically mutated sequences is Lysine (2 out of 5), Serine (1 out of 5) and Arginine (1 out of 5), which are all found in the human germlines with the same fold combination or are proposed by Morea and colleagues (Morea et al., Methods 20:267-279 (2000)).

11.1 Somatically Mutated Llama VH from Conventional Antibodies

IGHV gene	FR1 - IMGT (1-26)			CDR1 - IMGT (27-38)			FR2 - IMGT (39-55)			CDR2 - IMGT (56-65)		
	1	10	20	30	40	50	60					
M99660, IGHV3-23	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSY...		MSWVRQAPGKGLEWVSA	ISGGSGST...							
IVH28	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSYD...		MSWVRQAPGKGLEWVSA	INSGGIST...							
IVH69	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSHY...		MSWVRQDPPEKGLEWVSE	IATGGTIT...							
IVH47	EVQLVESGG.GLVQPGGSLRLSCAAS	GLTFDDY...		MSWVRQAPGKGLEWVST	IYTHSPNT...							
IVH48	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSYV...		MSXVRQAPGKGPEWVSG	VNTDGRSI...							
IVH70	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSLY...		MSWVRQPGKGLEWVST	IHTASGST...							
IVH71	EVQLVESGG.GLVQPGGSLRLSCAAS	GPTFSSYD...		MSWVRQAPGKGLEWVSG	IYSDGTT...							
IGHV gene	FR3 - IMGT (66-104)				CDR3 - IMGT (105-115)							
	70	80	90	100	110							
M99660, IGHV3-23	YYADSVK.GRFTISRDNKNTLYLQMNSLRAEDTAVYYC	AK...				WGQGTLVTVSS						
IVH28	YNADSMK.GRFTISRDNNAKNTVYLMNSLKPEDTAVYYC	NADTWYCDQLDSSDY				WGQGTLVTVSS						
IVH69	SYADSVK.GRFTISRDNANNMFLQNMNLKPEDTALYYC	VRRGRAIA...	FDV			WGQGTLVTVSS						
IVH47	YYADSVK.GRFTISRDNNAKNTLYLQMNSLKSDDTALYYC	AKEWVGSVVEGRYRG				WGQGTLVTVSS						
IVH48	TYADSVK.GRFTISRDNNAKNTLYLQMNSLKDPTAVYYC	TKIICVTGRPGYDY				WGQGTLVTVSS						
IVH70	TYADSVQ.FRFLVSRDNNAKNTLYLQMDSLKPEDTARYYC	ASAII LGW...	YDY			WGQGTLVTVSS						
IVH71	YDGDSVK.GRFTISRDNNAKMLYLQMNSLKPEDTAVYYC	ASAIRGW...	YDY			WGQGTLVTVSS						

A) Sequence Homology:

- 1) position 5 Valine (primer encoded) also found in f.i. IGHV3-15
- 2) position 83 Alanine is found more often in human VH3 germlines than Serine of 3-23
- 3) position 95/96 Lysine/Proline occurs in IGHV3-15/49/73 as Lysine/Threonine
- 4) CDR1 is completely human-like, in CDR2 only residues 57, 58 and 59 seem to deviate from human germline 3-23 (57 Serine, 58 Glycine, 59 Serine)
- 5) FR4 gives perfect match with human J1, J4 and J5

B) Canonical Fold Analysis

- 1) combination fold 1 for H1 and fold 2 for H2 for IVH28 and IVH69 (as in 3 out of 11 human germline family VH1 members and both human germline family VH5 members)
- 2) for IVH47, 48, 70 and 71 combination fold 1 for H1 and fold 3 for H2 as found in 3-23 and majority of family VH3 members

Examples of Analysis:

IVH28:

CDR H1 Class ?

? Similar to class 1/10A, but:

5 ! H33 (Chothia Numbering)=D (allows: YAWGTLV)

! H94 (Chothia Numbering)=A (allows: RKGSHN)

CDR H2 Class ?

? Similar to class 2/10A, but:

10 ! H33 (Chothia Numbering)=D (allows: YWGATL)

! H59 (Chothia Numbering)=N (allows: Y)

! H71 (Chothia Numbering)=R (allows: VAL)

IVH47:

CDR H1 Class 1/10A [2fbj]

CDR H2 Class ?

? Similar to class 3/10B, but:

! H52 (Chothia Numbering)=Y (allows: SFWH)

! H53 (Chothia Numbering)=H (allows: DGSN)

Example 12

Analysis Key Residues for Canonical Folds of L1(λ) and L2(λ) and Comparison of L1(λ) and L2(λ) Residues with Human Germline

Also the predicted canonical structures of L1 and L2 were analyzed for the somatically mutated dromedary VLambda segments based on length of the loops and the presence of the key residues relevant for the canonical folds. The comparison was made with the key residues occurring in the closest matching human germline with the same combination of canonical folds and overall sequence homology (Table 3). For the somatically mutated dromedary VL family VL3-1 (Camv18, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL60 family VL3-1232 (Camv11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL1-40(Camv144) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camv15, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the key residues 2, 25, 29, 30, 33 and 71 relevant for the canonical fold of L1 are shown along with these from the analogue human germline family

with the same canonical fold combination (upper part of Table 3). For somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-1232 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the key residues 48 and 64 important for the canonical fold of L2 are shown along with the key residues from the analogue human germline families having the same canonical fold combinations (lower part Table 3).

As observed for VH the analysis reveals the "human nature" of both canonical loops L1 and L2, because here also the key residues of the camelid VL λ segments are identical to those of the corresponding human VL λ segments. For example, in dromedary VL3-1232, VL1-40 and VL2-18 all key residues of L1 are identical to those occurring in the corresponding human germlines, and in dromedary VL3-1, VL3-1232 and VL2-18 the key residues of L2 completely match with the corresponding human germline VL segments. Basically there are only two exceptions. First of all, L2 key residue 64 of VL1-40 is Glutamate, which is rather different from Glycine that is present in human germline V λ 1 with the same L1 L2 combination of canonical folds as VL1-40. It is difficult to draw general conclusions, since VL1-40 only consists of an orphan (i.e. Camvl44). The second exception is VL3-1, where Phenylalanine is the most dominantly occurring L1 key residue on position 30, whereas Leucine is frequently found in human V λ family 3 members that share fold 11 for L1 and fold 7 for L2 with VL3-1. However, Leucine is also present in one out of the five VL3-1 members.

We analyzed the individual amino acid residues of the L1 and L2 loops of the somatically mutated dromedary VL λ segments along with the key residues and made the comparison with the human counterparts sharing the same canonical fold combination (Table 4). For the somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-1232 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), the L1 residues 27 to 33 together with key residue 71 outside L1 are compared with the same residues present in the corresponding human germline V λ with same combination of folds for L1 and L2 (upper part of Table 4A). For dromedary somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the L1 residues 26 to 33 together with key residues 2 and 71 outside L1 are compared with the same residues present in the corresponding human germline V λ family with same combination of folds for L1 and L2 (lower part of Table A). In addition, for somatically mutated dromedary VL family VL3-1 (Camvl8, 18, 19, 20 and 23), with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL family VL3-1232 (Camvl11) with fold 11 for L1 (L1: 11) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL1-40 (Camvl44) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7), and somatically mutated dromedary VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60 and 65) with fold 14 for L1 (L1: 14) and fold 7 for L2 (L2: 7) the L2 residues 49 to 53 together with key residues 48 and 64 located outside L2 are compared with the same residues present in the corresponding human germline V λ family with the same

combination of canonical folds for L1 and L2 (Table 4B). There is a high degree of sequence homology between the L1, L2 and key residues with the human germline sequences and only few exceptions exist, which mainly can be found in the orphan members of the VL3-1232 and VL1-40 families. For L1 of VL3-1232 residues 27, 28, 30, 30a and 30 b deviate from the corresponding human germline V λ family 3, while for the same loop residues 30b, 31 and 32 of VL1-40 are different from the matching human germline V λ family 1. In the orphan member of VL3-1232 L2 residue 50 differs from the human analogue, while for the only member of VL1-40 key residue 64 differs from the human analogue. A fundamental difference can be observed for L1 residue 28 of dromedary family VL2-18 (Asparagine or Glutamate versus Serine in analogue human V λ family 2).

Example 13

Analysis Key Residues for Canonical Folds of L1(κ) and L2(κ) and Comparison of L1(κ) and L2(κ) Residues with Human Germline

The predicted canonical structures of L1(κ) and L2(κ) were analyzed for the somatically mutated dromedary VKappa segments based on loop length and presence of key residues. As before the comparison was made with the key residues occurring in the closest matching human germline with the same combination of canonical folds and overall sequence homology (Table 5). For the somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48), with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the key residues 2, 25, 29, 30e, 33 and 71 relevant for the canonical fold of L1 are shown along with these from the analogue human VKappa germline family 2 with the same canonical fold combination. In addition the key residues compatible with the corresponding canonical fold as proposed by Morea et al. are shown in the bottom line. There is a perfect match for key residues 2, 25, 33 and 71 and to a certain degree for residue 29. Residue 30e of the dromedary VKappa is Glutamine in stead of Glycine, but Morea and colleagues (Morea et al., Methods 20:267-279 (2000)) suggested this residue to be perfectly compatible with the fold 3 for L1.

For the same somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48) with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the key residues 48 and 64 determining the canonical fold of L1 are shown together with these from the analogue human VKappa germline family 2. Here again the match is perfect.

The individual amino acid residues of the L1 and L2 loops of the somatically mutated dromedary VKappa segments along with the key residues were compared with those occurring in the human counterpart (VK family 2) that shares the same canonical fold combination (Table 6). For the somatically mutated dromedary VK family VK2-40 (Kp1, 3, 6, 7, 10, 20 and 48) with fold 3 for L1 (L1: 3) and fold 1 for L2 (L2: 1) the L1 and L2 residues were compared with those found in germline VK family 2 that has the identical canonical loop combination. The majority of the residues are shared between the dromedary somatically mutated VK and the human germline, such as Isoleucine on position 2, Serine on 25, 26 28 and 30b, Glutamine on 27, Tyrosine on 32, Leucine on 33 and Phenylalanine on 71. However, a few differ from the human analogue, i.e. Valine on 29 (although Leucine of human germline also occurs in the dromedary VK), Phenylalanine on 30 (again human residue Leucine is found as well in dromedary VK), Serine on 30a (human residue Glutamate occurs infre-

quently in dromedary VK), Serine on 30c, Asparagine on 30d, Glutamine on 30e, Lysine on 30f and finally Serine on 31.

Together with the key residues the residues of the L2 loop of the somatically mutated dromedary VKappa segments were compared those occurring in the human counterpart (VK family 2) that shares the same canonical fold combination (Table 6). Here again a perfect match was observed from residue Isoleucine on 48, Tyrosine on 49, Serine on 52 and Glycine on 64, while deviations were found on position 50 (Tyrosine instead of Threonine from human VK family 2), and 51 (Alanine on 51 instead of Leucine).

Overall Conclusion

This analysis of the camelid VH and VL sequences demonstrates a very high homology if not identity to the human key residues defining the canonical folds as well as to the residues found in the hypervariable loops themselves. This suggests that the vast majority of the camelid immunoglobulin sequences will adopt the canonical folds as found in the human germlines, not only for the individual hypervariable loops but as well as for the combination of canonical folds found in human VH and VL.

TABLE 1

Sites of key residues for determining canonical folds in germline dromedary and llama VH. Number between brackets indicates frequency of residue as found in dromedary/llama or human germline; numbering of key residues according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5 th ed. (1991)) and key residues proposed by Morea and colleagues. (Morea et al., Methods 2000). Ha: b indicates canonical fold b for loop Ha.													
Sequence	structure	Canonical family	Closest hu GL	H1 key residues						H2 key residues			
				24	26	27	29	34	94	52a	54	55	71
GI Drom IGHV1S(1-19)	H1: 1	(3-53)		A(19) A(23); G(1)	G(19) G(24)	F(19) F(24)	F(19); F(22); V(2)	M(19) M(23); T(1)	G(1); -(18)				
Hu GI family 3										R(18); K(5); T(1)			
GI Drom IGHV1S(20, 22, 23, 24)	H1: 1	(3-23)		A(4) A(23); G(1)	G(4) G(24)	F(4) F(24)	F(4); F(22); V(2)	M(4) M(23); T(1)	—				
Hu GI family 3										R(18); K(5); T(1)			
GI Drom IGHV1S(21, 25-39)	H1: 1	(V _{1-4,1b})		A(16) A(19); V(2)	G(15); A(1); G(21)	F(16) Y(18); F(1); G(2)	F(14); S(1); Y(1) F(20);	M(13); I(2); V(1) M(13); L(1)	—				
Hu GI family 1										R(17); T(2); A(1)			
GI Llama IGHV1S6	H1: 1	(3-23)		A(1) A(19); V(2)	G(1) G(21)	F(1) Y(18); F(1); G(2)	F(1); F(20); L(1) F(2);	M(1) M(13); I(5); L(2); V(1)	A(1)				
Hu GI family 1										R(17); T(2); A(1)			
GI Drom IGHV1S(1-19)	H1: 1 (Morea)			A; V; S; T	G	F; Y; S; D	F; L; I Y; W	M; V; I; R; G; N; K; S					
Hu GI family 1	H2: 1 (Morea)									—	G(19) G(4)	R(18); Q(1)	
GI Drom IGHV1S(20, 22, 23, 24)	H2: 3	(3-23)								—	—	R(4)	
Hu GI family 3	H2: 3 (Morea)									—	G; D	K; R; V; I	
GI Drom IGHV1S(21, 25-39)	H2: 2 (V _{1-4,1b})									—	G(4)	—	R(4)
Hu GI family 1										—	G(13); S(3)		R(14)
GI Drom IGHV1S6	H2: 2 (Morea)									—	G; S; N; D	—	R; K
Hu GI family 1										—			
GI Llama IGHV1S6	H2: 2 (Morea)									S(10); T(6)	G(16) G(7)	R(8); K(4); Q(4)	
Hu GI family 1										P(3); T(2); A(2)		A(3); T(2); L(2)	
										P; T; A	G; N;	A; L; T	D; S
										S(1)	—	T(1)	
										P(3); T(2); A(2)	G(7)	A(3); T(2); L(2)	
										P; T; A	G; N;	A; L; T	D; S

TABLE 2(A)

H1: 1 residue no.															
	2	2	2	2	2	3	3	3	3	3	3	3	4	3	9
	4	6	7	2	9	0	1	1a	1b	2	3	*	5	*	*
Fam- ily 3	GI Drom IGHV1S(1- 19) Hu GL	A(19); A(3); G(1)	G(19); G(4)	F(19); F(4)	T(19); T(4)	F(19); V(2); F(2)	S(19); S(4)	S(19); S(4)	—	—	Y(19); N(2); Y(2)	Y(14); D(2); W(2); A(1); Y(2); A(1); D(1)	M(19); M(4)	S(17); Y(2)	G(1); R
Fam- ily 3	GI Drom IGHV1S(20, 22, 23, 24) Hu GL	A(4); A(16)	G(4); G(16)	F(4); F(16)	T(4); T(16)	F(4); F(16)	S(4); S(13); S(11); D(3)	S(4); S(11); D(4); N(1)	—	—	Y(4); Y(15); H(1)	W(3); Y(1); A(6); G(3); Y(2); W(2); S(1); E(1); T(1)	M(4); M(15); T(1)	Y(3); S(1); H(9); S(5); N(2)	— R(11); K(5)
Fam- ily 1	GI Drom IGHV1S(21, 25-39) Hu GL	A(16); A(6); V(1)	G(15); A(1); G(7)	F(16); Y(5); G(2)	T(16); T(7); Y(1)	F(14); S(1); S(2)	S(16); S(16); D(1)	S(16); S(6); D(1)	—	—	Y(15); C(1); Y(7)	W(7); A(4); D(3); Y(1); C(1); A(4); G(2); Y(1)	M(13); I(2); V(1); D(3); I(4); M(3)	Y(8); S(8); S(4); N(2); N(2); H(1)	— R(4); T(1); -(1)
Fam- ily 1	GI Llama IGHV1S Hu GL	A(1); A(6); V(1)	G(1); G(7); G(2)	F(1); Y5); T(7)	T(1); F(1)	F(1); T(5); D(1)	S(1); S(6); D(1)	S(1); S(1); D(1)	—	—	S(1)	A(1); A(4); G(2); M(3)	M(1); I(4); M(3)	S(1); S(4); N(2); H(1)	A(1); R(4); T(1); -(1)

TABLE 2(B)

H2: 1 residue no.															
	5	5	5	5	5	5	5	5	5	5	5	5	5	7	
	0	1	2	2a	2b	2c	3	4	5	6	7	8	*		
Fam- ily 3	GI Drom IGHV1S(1- 19) Hu GL	G(17); A(2); Y(2); A(2)	I(18); N(1); I(4)	Y(16); N(2); T(1)	—	—	—	S(19)	D(18); R(1); G(3); A(1)	G(19); G(4)	S(18); G(1)	T(19); T(4)	Y(17); N(1); H(1)	R(18); Q(1)	
Fam- ily 3	GI Drom IGHV1S(20, 22, 23, 24) Hu GL	T(3); G(1)	I(4); I(15); Y(5); Y(4); G(2); A(2); R(1); N(1); L(1)	N(4); S(12); S(1); N(2); W(1); K(1); G(2); Q(1)	S(4); Y(5); S(5); S(5); W(3); G(2); A(2); P(3); Y(2); L(1); T(1); P(2); T(2); Q(4)	—	—	G(3); D(1)	G(4); G(13); S(3)	G(3); S(1)	S(3); N(1)	T(4); T(6); K(6); I(4)	Y(4); Y(12); G(2); T(1); N(1)	R(4); R(16)	
Fam- ily 1	GI Drom IGHV1S(21, 25-39) Hu GL	A(9); S(4); T(2); G(1); W(4); R(1); G(1); L(1)	I(16); I(6); V(1)	N(10); Y(6); S(2); N(2); I(2); D(1)	S(10); T(6)	—	—	G(14); A(2)	G(16); N(2); T(2); F(1); D(1)	G(16); G(7)	S(16); N(4); I(1); I(2)	T(16); T(3); T(1); P(2); A(2)	Y(16); N(4); T(3); T(2); I(1)	R(8); K(4); Q(4)	

TABLE 2(B)-continued

Comparison of H2 sequences for dromedary and llama germline VH with human germlines;
numbering according to Kabat et al. (Sequences of Proteins of Immunological Interest,
5th ed. (1991)). Asterisks indicate key residues important for canonical folds.

Family	GI Llama	H2: 1												7	
		residue no.													
		5	5	5	5	5	5	5	5	5	5	5	5		
		0	1	2	2a	2b	2c	3	4	5	6	7	8	*	
1	IGHV1S6	W(4); I(6); S(2); P(3); — —	Y(1)	S(1)	— —	Y(1)	N(2); T(2);	N(2)	G(7)	N(4); T(3);	N(4); T(1);	Y(1)	T(1); A(3);		
	Hu GL	R(1); V(1); N(2); T(2); G(1); I(2); A(2); L(1)	D(1)	E(1)	I(2); F(1); D(1)	E(1)	L(1); T(1); P(2); T(2);	A(2)	I(1); A(1)	T(1); E(1)	A(2)	T(2);	L(2);		

TABLE 3

Sites of key residues for determining canonical folds in somatically mutated dromedary VLambda sequences;
numbering according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991))
and key residues proposed by Morea and colleagues (Morea et al., Methods 2000)

Sequence	structure	Canonical	Closest hu	L1(λ) key residues								64
				GL family	2	25	29	30	33	71	48	
Som Mut Drom VL3-1 (Camvl8, 18, 19, 20, 23) Hu GI V λ family 3	L1: 11 (or 2)	(IGLV3-1*01)	—	G(5)	—	F(4); L(1)	T(2);	T(4);				
			—	G(10)	—	L(6); I(3);	A(1);	A(1)				
						M(1)	V(1);	A(5);				
							F(1)	T(3);				
							A(6);	V(2)				
							V(3);					
							E(1)					
Som Mut Drom VL3-12/32 (Camvl11) Hu GI V λ family 3	L1: 2 (Morea) L1: 11 (or 2)	(IGLV3-1*01)	—	G	—	I	V	A				
			—	G(1)	—	L(1)	A(1)	T(1)				
			—	G(10)	—	L(6); I(3);	A(6);	A(5);				
						M(1)	V(3);	T(3);				
							E(1)	V(2)				
Som Mut Drom VL1-40 (Camvl44) Hu GI V λ family 1	L1: 2 (Morea) L1: 14 (or 6)	(IGLV1-40*01)	—	G	—	I	V	A				
			S(1)	G(1)	N(1)	—	V(1)	A(1)				
			S(2)	G(2)	N(2)	—	V(2)	A(2)				
Som Mut Drom VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60, 65) Hu GI V λ family 2	L1: λ 6 (Martin)		S	G	N	—	V	A				
	L1: 14 (or 6)	(IGLV2-18*02)	S(11); G(12)	D(12)	—	V(12)	A(11);					
			A(1)	G(6)	D(6)	—	V(6)	V(1)				
			S(6)					A(6)				
Som Mut Drom VL3-1 (Camvl8, 18, 19, 20, 23) Hu GI V λ family 3	L1: λ 6 (Martin) L2: 7	(IGLV3-1*01)	S	G	N	—	V	A				
									I(4);	G(3);		
									L(1)	A(2)		
									I(10)	G(10)		
Som Mut Drom VL3-12/32 (Camvl11) Hu GI V λ family 3	L2: 1 (Morea)								I; V	G		
	L2: 7	(IGLV3-1*01)							I(1)	G(1)		
									I(10)	G(10)		
Som Mut Drom VL1-40 (Camvl44) Hu GI V λ family 1	L2: 1 (Morea)								I; V	G		
	L2: 7	(IGLV1-40*01)							I(1)	E(1)		
									I(2)	G(2)		
Som Mut Drom VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60, 65) Hu GI V λ family 2	L2: 1 (Morea)								I; V	G		
	L2: 7	(IGLV2-18*02)							I(12)	G(11);		
									I(6)	S(1)		
										G(6)		
Hu GI V λ family 2	L2: 6 (Morea)								I; V	G		

TABLE 4(A)

L1: 11 residue no.																
	0 2	2 6	2 7	2 8	2 9	3 0	3 0a	3 0b	3 0c	3 1	3 2	3 3	3 1	7		
Fam- ily 3	Som Mut Drom VL3-1 (Camvl8, 18, 19, 20, 23) Hu GI Vλ family 3	— — D(1); D(6); N(3); E(1)	— — D(1); I(1); N(3); A(3); S(2); K(1); V(1)	G(4); N(3); — — I(3); M(1)	N(3); D(1); P(3); R(1); K(3); E(1)	— L(1); L(6); I(3); M(1)	F(4); G(5); S(4); Y(4); D(1); S(4); K(6); K(3); D(1); E(1)	S(4); D(1); K(1); Y(1); N(1); E(1); Q(1); G(1); S(1)	— — — — — — — — —	Y(4); T(2); A(5); K(1); A(1); A(3); Y(7); V(1); T(3); A(1); F(1); V(2); S(1); A(6); N(1); V(3); E(1)						
Fam- ily 3	Som Mut Drom VL3-12/32 (Camvl11) Hu GI Vλ family 3	— — D(6); N(3); E(1)	— — A(3); S(2); K(1); V(1)	S(1); L(1); — N(3); A(3); E(1)	L(1); — — I(3); P(3); M(1)	R(1); L(6); G(5); S(4); C(1); R(1); D(1); E(1)	N(1); G(5); S(4); C(1); K(3); Y(1); N(1); G(1)	Y(1); Y(19); Y(19); C(1); K(6); Y(1); N(1); Q(1); S(1)	— — — — — — — — —	A(1); A(1); A(1); Y(7); A(6); A(3); A(1); V(3); T(3); S(1); E(1); V(2); N(1)						
Fam- ily 1	Som Mut Drom VL1-40 (Camvl44) Hu GI Vλ family 1	S(1); S(2)	S(1); S(2)	S(1); S(2)	S(1); N(2)	I(1); I(2)	G(1); G(2)	G(1); A(2)	G(1); G(2)	S(1); Y(2)	G(1); D(1); V(1)	V(1)	G(1); V(1)	A(1); VA(2)		
Fam- ily 2	Som Mut Drom VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60, 65) Hu GI Vλ family 2	S(11); A(1); S(6)	T(12); T(6); S(6)	S(10); R(2); S(6)	N(9); D(3); D(6)	D(11); G(1)	V(12); V(6)	G(12); G(6)	G(5); R(4); K(2); A(1); G(3); S(2); D(1)	Y(12); Y(6); Y(6); N(5); R(1); D(1)	N(11); A(1); Y(3); N(5); R(1); L(1); V(1)	Y(12); Y(12); V(12); A(11); A(6)				

35

TABLE 4(B)

L2: 7 residue no.											
	4	8	4	5	5	5	5	5	6	4	*
	*	9	0		1	2	3				*
Fam- ily 3	Som Mut Drom VL3-1 (Camvl8, 18, 19, 20, 23) Hu GI Vλ family 3	I(4); L(1); I(10)	Y(5); Y(10); Q(1); R(1); S(1); G(1); Y(1)	K(3); E(2); K(2); D(1); S(1); S(1); Y(1)	R(1); D(8); K(1); D(1)	D(4); N(1); S(2); T(2); S(1); S(9); N(1)	A(1); N(1); S(1)	L(1); E(1); G(3); A(2)			
Fam- ily 3	Som Mut Drom VL3-12/32 (Camvl11) Hu GI Vλ family 3	I(1); I(10)	Y(1); Y(10); E(2); K(2); D(1); Q(1); R(1); S(1); G(1); Y(1)	N(1)	D(1)	N(1)	N(1)	N(1)	G(1)		
Fam- ily 1	Som Mut Drom VL1-40 (Camvl44) Hu GI Vλ family 1	I(1); I(2)	Y(1); Y(2)	G(1); G(2)	N(1)	S(1)	N(1)	N(2)	E(1)	G(2)	
Fam- ily 2	Som Mut Drom VL2-18 (Camvl5, 17, 30-33, 36, 52, 57, 59, 60, 65) Hu GI Vλ family 2	I(12); I(6)	Y(12); Y(6)	Q(11); E(4); D(1); N(1)	D(1)	V(9); I(2); N(10); S(1); D(1)	K(12); Y(12); K(3); N(2); T(1)	G(11); G(11); S(1)			

TABLE 5

Sites of key residues for determining canonical folds in somatically mutated VKappa sequences; numbering according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)) and key residues proposed by Morea and colleagues (Morea et al., Methods 2000).

Sequence	Canonical structure	Closest hu GL family	L1(κ) key residues				L2(κ) key residues			
			2	25	29	30e	33	71	48	64
Som Mut Drom VK2-40 (Kp1, 3, 6, 7, 10, 20, 48)	K1: 3	IGKV2-40 (2_1 or 011*/01)	I(7)	S(7)	V(6); L(1)	Q(7)	L(7)	F(7)		
Hu GI VK family 2			I(1)	S(1)	L(1)	G(1)	L(1)	F(1)		
	K1: 3 (Morea)		I	S	L; V	E; Q;	L	F		
Som Mut Drom VK2-40 (Kp1, 3, 6, 7, 10, 20, 48)	K2: 1	IGKV2-40 (2_1 or 011*/01)						I(7)	G(7)	
Hu GI VK family 2								I(1)	G(1)	
	H2: 1 (Morea)							I, V	G	

TABLE 6

Comparison of (A) L1 and (B) L2 sequences of dromedary VKappa with human germline; numbering according to Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed. (1991)). Asterisks indicate key residues important for canonical folds.

L1(κ): 11 residue no.													
	2	5	2	2	2	9	3	3	3	3	3	3	
	*	*	6	7	8	*	0	0a	0b	0c	0d		
Fam-ily 2	Som Mut Drom VK2-40 (Kp1, 3, 6, 7, 10, 20, 48)	I(7) I(1)	S(7) S(1)	S(7) S(1)	Q(7) Q(1)	S(5); N(1); H(1) S(1)	V(6); L(1); L(1) V(1)	F(3); D(1); I(1); A(1) D(1)	S(5); T(1); S(1)	S(4); D(1); T(1); S(1)	S(7) D(1) D(1)	N(4); S(2); R(1) D(1)	
Hu GI VK family 2 (011*/01)													
L1(κ): 11 residue no.													
	3	3	3	3	3	3	7	4	8	4	5	6	
	0e	0f	1	2		*	*	*	9	0	1	2	
Fam-ily 2	Som Mut Drom VK2-40 (Kp1, 3, 6, 7, 10, 20, 48)	Q(7) Q(1)	K(6); R(1)	S(7) T(1)	Y(3); L(2); Q(1); F(1)	L(7); L(1)	F(7); F(1)	I(7); I(1)	Y(7); Y(1)	Y(7); T(1)	A(7); L(1)	S(7); S(1)	G(7); G(1)
Hu GI VK family 2 (011*/01)													

Example 14

Sequence Analysis of Somatically Mutated VH, VK and VL from Llama

From four llamas peripheral blood lymphocytes were isolated, RNA extracted and random primed cDNA synthesized as described before (de Haard et al, JBC 1999). Amplification of VHCH1, VLCL and VKCK was performed and the amplicons were cloned in vector pCB3 yielding heavy chain or light chain libraries. After screening of clones with PCR to check for the presence of the antibody domain insert, individual clones were grown and plasmid DNA was purified for sequence analysis.

Section 14.A shows the lambda light chain variable regions grouped into families according to the closest human germline analogue with the same CDR1 and CDR2 length and presumably having the same canonical fold combination. The lambda germlines most frequently used in humans, i.e. VL1,

VL2 and VL3, are also often found in the analyzed llama sequences and in addition VL4, VL5, VL6 (not shown in section 14.A) and VL8, meaning that 7 out of the 10 lambda families as found in humans are used as well in the llama. Section 14.B shows two of the three kappa light chain variable regions (i.e. VK1, and VK4; VK2 is not shown), which occur in about 50% of kappa containing human antibodies. Members of the VK3 family, which is used most frequently (50%) in human antibodies, were not identified, but it can well be that the used primers for amplification are responsible for this and that these have to be adapted. Section 14.0 shows the alignment of the VH sequences revealing a high sequence homology to the most often used human VH3 segment (occurs 34% in human antibodies) and VH1 (17%). It must be noted that the recent publication of Achour et al (J Immunol 2008) mentions the presence of a VH2 family in the germline of Alpaca which is most closely related to the human VH 4 family (see example 10.10).

Overall it can be concluded that camelids use a high diversity of heavy chain and light chain families similar to what is

105

found in the human immune system, meaning that by active immunization with human disease targets an excellent choice of lead antibodies can be expected with a high sequence homology to human antibodies, which therefore can be easily engineered for therapeutic applications.

106

US 9,315,576 B2

107

108

-continued

-continued

Kappa#53	ETLITQSPSSYTASGEKVTINC	KSSQSVGSNSNOKSLIN	WIOQRGQSPRLLY	YASTRDA	GIPDRFSGSGSATDDFLTLTISVOPEDAAYTC	OVNIAPIYT	FSGGTKVBLK	FRGTTKVBLK		
Kappa#50	ETLITQSPSSYTASGEKVTINC	KSSQSVFS	SNOKNLG	WIOQRGQSPRLIN	WASTRES	GVPDRFSGSGSTTDFLTINQPDEAAVYC	QCKSAPLT	FSGGTKVBLK		
Kappa#20	DIVMTQSPSSYTASGEKVTINC	KSSQSVYSSNOKNLT	WIOQRGQSPRLLY	WASTRES	GVPDRFSGSGSLTTDFLTLTISVOPEDAAYTC	OQGTSVPLT	FSGGTKVBLK	FSGGTKVBLK		
Kappa#48	ETLITQSPSSYTASGEKVTINC	KSSQSVLILSNOKNLV	WIOQRGQSPRLLY	WASTRES	GVPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QCGTIPV	FSGGTRLEIK	FSGGTRLEIK		
Kappa#55	EIVLTQSPSSYTASGEKVTINC	KSSQSVYSSNOKNLV	WIOQRGQSPRLLY	WASTRES	GVPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QCGYSSPHS	FSGGTRLEIK	FSGGTRLEIK		
Kappa#9	ETLITQSPSSYTASGEKVTINC	KSSQSVLILRSQDNKLV	WIOQRGQSPRLLY	WASTRES	GVPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QCGYSPRYS	FSGGTRLEIK	FSGGTRLEIK		
Kappa#51	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKVLIA	WIOQRGQSPRLLY	WASTRES	GVPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QCGYSAPAS	FSGGTRLEIK	FSGGTRLEIK		
Kappa#10	DIVMTQSPSSYTASGEKVTINC	KSSQNVLIS	SNOKVLN	WIOQRGQSPRLLY	WASTRES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QCGYSIPT	FSGGTRLEIK	FSGGTRLEIK	
Kappa#54	DIVMTQSPSSYTASGEKVTINC	KSSQSVLISANOKVLIA	WIOQRGQSPRLLY	WASTRES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYARPH	FSGGTRLEIK	FSGGTRLEIK		
Kappa#11	DIVMTQSPSSYTASGEKVTINC	KSSQSVLILSNOKVLIA	WIOQRGQSPRLLY	WASTRES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYARPH	FSGGTRLEIK	FSGGTRLEIK		
Kappa#36	DIVMTQSPSSYTASGEKVTINC	KSSQSVVSGSOKSLIN	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYATPST	FSGGTRBVI	FSGGTRBVI		
Kappa#49	DIVMTQSPSSYTASGEKVTINC	KSSQSVLILSNOKVLIA	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYASPAT	FSGGTRBVI	FSGGTRBVI		
Kappa#52	ETLITQSPSSYTASGEKVTINC	KSSQSVLISANOKVLIA	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYSYPLT	FSGGTRBVI	FSGGTRBVI		
Kappa#13	ETLITQSPSSYTASGEKVTINC	KSSQSVLNNSNOKVLIA	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI		
Kappa#11	ETLITQSPSSYTASGEKVTINC	KSSQNVLISANOKVLIA	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI		
Kappa#22	DIVMTQSPSSYTASGEKVTINC	KSSQSVVSGSOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHS	FSGGTRBVI	FSGGTRBVI		
Kappa#24	DIVMTQSPSSYTASGEKVTINC	KSSQSVLILSNOKVLIA	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHS	FSGGTRBVI	FSGGTRBVI		
Kappa#25	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLISANOKVLIA	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#12	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#34	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#48	EIVLTQSPSSYTASGEKVTINC	EIVLTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#21	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#24	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOEL	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#22	DIVMTQSPSSYTASGEKVTINC	DIVMTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#45	EIVLTQSPSSYTASGEKVTINC	EIVLTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
Kappa#46	EIVLTQSPSSYTASGEKVTINC	EIVLTQSPSSYTASGEKVTINC	KSSQSVLNNSNOKSLIN	WIOQRGQSPRLLY	YASTOES	GIPDRFSGSGSTTDFLTLTISVOPEDAAYTC	QDAYTYPHT	FSGGTRBVI	FSGGTRBVI	
VH1 (1-02)	QVOLVOSGAEVTKPGASVKVSKASGYFT	G--YMH	WVRQAPQGQGLWMG	WINP--NSGGHNYAQFKGQ	RVTMTRDTSISTAYMELSRLESDDTAVYCCAR	SGRYELDY	WGKGHQTVYSS	WGKGHQTVYSS		
1C2	EVQVLVOSGAELRNPGASVKVSKASGYFT	S--YYD	WVRQAPQGQGLWMG	RIDP--EDGGTXYAQFKGQ	RVTFTADTSSTAYVLESSLSEDTDATVYCCAR	SGRYELDY	WGKGHQTVYSS	WGKGHQTVYSS		
1G5	EVQVLVOSGAELRNPGASVKVSKASGYFT	S--YYE	WVRQAPQGQGLWMG	RIDP--EDGGTXYAQFKGQ	RVTFTADTSSTAYVLESSLSEDTDATVYFCAT	SGATMSDLDSFGS	WGKGHQTVYSS	WGKGHQTVYSS		
VH3 (3-23)	EVQLLVGGGVQPGESLRLSAAASGFTS	S--YAMS	WVRQAPQGKGLMVS	AISG--SGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	PSTSWSNTNYGMDY	WGKGHQTVYSS	WGKGHQTVYSS		
5B12	EVQLYVEGGVQPGESLRLSAAASGFTS	D--FPNM	WVRQAPQGKGLMVS	VISR--NGGSTYYAESWKG	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	ARTGST	LGGQHQTVYSS	LGGQHQTVYSS		
1G4	EVQLYVEGGVQPGESLRLSAAASGFTS	D--YGM	WVRQAPQGKGLMVS	GITW--NGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	ARTGST	WGKGHQTVYSS	WGKGHQTVYSS		
5G7	EVQLYVEGGVQPGESLRLSAAASGFTS	T--YMS	WVRQAPQGKGLMVS	GINT--GGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	DURJYSSDREVN	WGKGHQTVYSS	WGKGHQTVYSS		
VH9	EVQLYVEGGVQPGESLRLSAAASGFTS	T--YAMT	WVRQAPQGKGLMVS	TVDA--SGATYYAQSVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	DURJYSSDREVN	WGKGHQTVYSS	WGKGHQTVYSS		
VH7_76	EVQLYVEGGVQPGESLRLSAAASGFTS	D--FAMI	WVRQAPQGKGLMVS	SINN--GGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	EGYTSYYAUGHAHDY	WGKGHQTVYSS	WGKGHQTVYSS		
VH8	EVQLYVEGGVQPGESLRLSAAASGFTS	R--YMS	WVRQAPQGKGLMVS	YIDS--GGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	DPRHSWYTYGMDY	WGKGHQTVYSS	WGKGHQTVYSS		
VH98	EVQLYVEGGVQPGESLRLSAAASGFTS	I--TAMS	WVRQAPQGKGLMVS	VINS--GGGSTYYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	GGVGHSHNYYAMDY	WGKGHQTVYSS	WGKGHQTVYSS		
VH89	EVQLYVEGGVQPGESLRLSAAASGFTS	N--TAMA	WVRQAPQGKGLMVS	DINS--LGNNIIFYSKVK	RFTI ARDKTKTLYLQNSNLSRAEDTDATVYCCVA	DASALSWSPALEV	WGKGHQTVYSS	WGKGHQTVYSS		
VH82	EVQLMQGGGLAQPGESLRLSAAASGFTS	N--HMY	WVRQAPQGKGLMVS	AISS--SGSSYYDSVKG	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	DESRGIEPGWSIY	WGKGHQTVYSS	WGKGHQTVYSS		
VH8	S--SDMS	WVRQAPQGKGLMVS	GINS--GGGSTYYGENSHV	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	YDGSWYTYGMDY	WGKGHQTVYSS	WGKGHQTVYSS	WGKGHQTVYSS		
VH6	EVQLYVEGGVQPGESLRLSAAASGFTS	S--THIS	WVRQAPQGKGLMVS	LIGR--MGADIIYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	ELINMEPEWASYD	WGKGHQTVYSS	WGKGHQTVYSS		
VH7_73	EVQLYVEGGVQPGESLRLSAAASGFTS	K--TAMS	WVRQAPQGKGLMVS	NIDA--NSELITYADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	DPRHSWYTYGMDY	WGKGHQTVYSS	WGKGHQTVYSS		
VH10	EVQLYVEGGVQPGESLRLSAAASGFTS	D--TGT	WVRQAPQGKGLMVS	VISS--SGGNTKYDSVKG	RFTI SDRKAKUNVYLQNSNLSRAEDTDATVYCCAK	RIEGMGTYGMDY	WGKGHQTVYSS	WGKGHQTVYSS		
VH9	EVQLYVEGGVQPGESLRLSAAASGFTS	D--TGT	WVRQAPQGKGLMVS	SIYI--FVGNTYYADSYVK	RFTI SDRAGNTLYLQNSNLSRAEDTDATVYCCAK	SPENTYYNGS	WGKGHQTVYSS	WGKGHQTVYSS		
VH90	EVQLYVEGGVQPGESLRLSAAASGFTS	S--TAMS	WVRQAPQGKGLMVS	TISS--GGASTMADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	SPCLVNTYNGS	WGKGHQTVYSS	WGKGHQTVYSS		
VH77	EVQLYVEGGVQPGESLRLSAAASGFTS	S--TAMS	WVRQAPQGKGLMVS	TISS--GGASTMADSYVK	RFTI SDRNASKTLYLQNSNLSRAEDTDATVYCCAK	SPCLVNTYNGS	WGKGHQTVYSS	WGKGHQTVYSS		

-continued

VH_74	EVOLVQSGGELVOPGGSLRSLUSCAASGGFAFS	D--YDMS WROAPGKGLEWVS IIVS-- GDGRIFTYADSMKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA DSYHAATGLEQ	WGCGTQTVSS
VH_67	EVOLVQSGGELVOPGGSLRSLUSCAASGERFT	D--YDMS WROAPGKGLEWVS SIYS-- LGDPTTYSADSVKG RFTISRDNGKD TYLEMNSLSDDTGLYCCAR DRHGMGTFRDY	WGCGTQTVSS
VH_79	EVOLVQSGGELVOPGGSLRSLUSCAASGF	R--YMMW WROAPGKGLEWVS GMIT-- GSDYYTIAVSVG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA GGYIDADEHS	WGCGTQTVSS
VH_75	EVOLVQVWGRLLGAPGGSLRSLUSCAASGFPFS	I--YEMM WFRQPEKGARMVS DIKX-- SGGRITTA SVKG RFTASRDNAKNTYLQIQLNSLKEPD TAVYCAA PTSMMWSPDY	WGCGTQTVAS
VH_110	EVOLVQSGGELVOPGGSLRSCAVSGFTF1	Y--YGMIS WROAPGKGLEWVS TISN-- GESTANTYADSVKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA I STELGNTLDA	WGCGSLVTVSS
VH_109	EVOLVQSGGELVOPGGSLRSLUSCTASGFTFS	S--YGIS WROAPGKGLEWVS SVTG-- DGLSTIALDSVKG RFTITRDNGAKNTYLQIQLNSLKEPD TAVYCAA LDVYVMDGMDY	WGKGTLVTVSS
VH_103	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFR	S--YMMN WROAPGKGLEWVS VSS-- GEGETTYADSVKG RFTISRDNAQNTYLQIQLNSLKEPD TAVYCAA ESGEPGMDEV	WGKGTLVTVSS
VH_84	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFS	S--YAMS WROAPGKGLEWVS GINS-- GGGSTSYADSVKG RFTISRDNGAKNTYLQIQLNSLKEPD TAVYCAA WEVYVLDFFS	WGCGTQTVSS
VH_113	EVOLVQSGGELVOPGGSLRSLUSCAAGFTFS	T--YMMW WROAPGKGLEWVA TITS-- LEGSONTYADSVKG RFTISRDNAKNTYLQIQLNSLKEPD MAOYCCVR GGLGYDZEH	WGCGTQTVSS
VH_87	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFS	S--AYMN WROAPGKGLEWVS GLIN-- YES TS YADSVKG RFTISRDNTVNTVYLQIQLNSLKEPD TAVYCAR VGNMWSSDVA	WGCGTQTVSS
VH_105	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFS	N--YMMW WROAPGKGLEWVS SUDT-- SGCGITMYADSVKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA ALGNNAFDA	WGKGTLVTVSS
VH_101	EVOLVQSGGELVOPGGSLRSLUSCTSGFTFS	T--QGMN WROAPGKGLEWVS GIDS-- RENTINYADSVKG RFTOSRDNAKMLYLQIQLRPPDTAMYCIN TGPMYTNY	WGCGTQTVSS
VH_108	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFS	S--YMMW WROAPGKGLDWIS GISM-- GGASTTYAARSVD RFTISRDNTKNTYLQIQLSRLREDTAVYWCTR GNYPYDY	WGCGTQTVSS
VH_106	EVQLVQSGGELVOPGGSLRSLUSCAASGFNF	D--YPMT WROAPGKGLEWVA SIYS-- GISTTYYFDPSVKG RFTISRDNTKNTYLQIQLSDDTAVYCAN PRRNY	WGCGTHVTVSS
VH3 (3-13)	EVQLVQSGGELVOPGGSLRSLUSCAASGFTFS	S--YDMH WROAPGKGLEWVS AIG-- TAGDTYPPGSVKG RFTISRDNAKNSLYLQIQLNSLRAGDTAVYCAR	WGCGTQTVSS
VH_115	EVOLVQSGGELVOPGGSLRSLUSCAASGFTSS	T--YAMS WROAPGKGLEWVS TIN-- GADFTSYDTSVKG RFTISRDNTKNTYLQIQLNSLKEPD TACYCCAR GLSCLNWWGFDY	WGKGTLVTVSS
VH_85	EVQLVQSGGELVOPGGSLRSLUSCAASGFTFS	T--YMMW WROAPGKGLEWVS SID-- NUGFTTYSEDVKG RFTISGDNPARTYLYLQIQLNSVKEPD DTALYCVR GYVNDYERMDY	WGCGTQTVSS
VH_114	EVOLVQSGGELVOPGGSLRSLUSCTASGFTFS	T--HTMS WROAPGKGLEWVS GIN-- SAYGTYIDTSVKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA VVDTWDDEVY	WGKGTLVTVSS
VH_78	EVQLVQSGGELVOPGGSLRSLUSCAASRFQF	TT--SGMT WROAPGKGLEWVN TIN-- SGGLTSA DSVKG RFTISRDNGKNTYLQIQLNSLKEPD TAVYCAN LLEIGH	WGKGTLVTVSS
3B5	EVOLVQSGGELVOPGGSLRSLUSCAASGFTFS	S--YMMW WROAPGKGLEWVS TIT-- KGGSTYTSADSVKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA SNSC3THWEFEYYGHDY	WGCGTQTVSS
3A3	EVQLVQSGGELVOPGGSLRSLUSCAASGFTFG	N--YDMS WROAPGKGPEWWS GIN-- SCGKTYSSADSVKG RFTISRDNAKNTYLQIQLNSLKEPD TAVYCAA GIVTLGS	WGCGTQTVSS

115

Example 15

Generating Fabs Against IL-1 Beta

Unless otherwise indicated, the materials and protocols used in the following study were analogous to those used in examples 1-9.

Llamas were Successfully Immunized with IL-1 Beta

Two llamas (*Lama glama*) were immunized with human IL-1 Beta according to a standard protocol (as described in Example 1).

Sera from both llamas were tested for the presence of antibodies against IL-1 Beta by ELISA prior (day 0) and after immunization (day 28). As shown in FIG. 1, a specific signal against IL-1 Beta was observed in ELISA after immunization, even after 10,000 fold dilution of the serum. This high antibody titer indicates a specific and appropriate immune response.

Fab Libraries with Good Diversity were Constructed

PBLs isolated from both immunized llamas were used for RNA extraction, RT-PCR and PCR-cloning of Fab in a phagemid using the strategy described by de Heard et al (JBC 1999), to obtain a diverse library of good diversity (2.5×10^8).

The following primers were used:

Name	Sequence
Primers for cloning of lambda light chain	
HuVI1A-BACK-ApaLI	GCC TCC ACC AGT GCA CAGTCTGTGYT GACKCAGCC
HuVI1B-BACK-ApaLI	GCC TCC ACC AGT GCA CAGTCTGTGYT GACCGCAGCC
HuVI1C-BACK-ApaLI	GCC TCC ACC AGT GCA CAGTCTGTGCT GACCGCAGCC
HuVI2-BACK-ApaLI	GCC TCC ACC AGT GCA CAGTCTGCCCT GACTCAGCC
HuVI3A-BACK-ApaLI	GCC TCC ACC AGT GCA CTT TCCTATG AGCTGACWCAGCC
HuVI3B-BACK-ApaLI	GCC TCC ACC AGT GCA CTT TCTTCCTG AGCTGACTCAGGA
HuVI4-BACK-ApaLI	GCC TCC ACC AGT GCA CAGCYTGTGCT GACTCAATC
HuVI5-BACK-ApaLI	GCC TCC ACC AGT GCA CAGGCTGTGCT GACTCAGCC
HuVI6-BACK-ApaLI	GCC TCC ACC AGT GCA CTT AATTTTA TGCTGACTCAGCC
HuVI7/8-BACK-ApaLI	GCC TCC ACC AGT GCA CAGRCTGTGGT GACYCAGGA
HuVI9-BACK-ApaLI	GCC TCC ACC AGT GCA CWGCCTGTGCT GACTCAGCC
HuVI10-BACK-ApaLI	GCC TCC ACC AGT GCA CAGGCAGGGCT GACTCAGCC
caClambda1-FOR	CTAACACTGGGAGGGGGACACCGCTTTCTC
caClambda2-FOR	CTAACACTGGGAGGGNCTCACNGTCTTCTC
Primers for cloning of kappa light chain	
HuVκ1B-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GACATCC AGWTGACCCAGCTCTCC
HuVκ2-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GATGTTG TGATGACTCAGCTCTCC
HuVκ3B-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GAAATTG TGWTGACRCAGCTCTCC
HuVκ2/4-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GAYATYG TGATGACCCAGWCTCC
HuVκ5-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GAAACGA CACTCACCGCAGCTCTCC
HuVκ6-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GAAATTG TGCTGACTCAGCTCTCC
HuVκ4B-BACK-ApaLI	GCC TCC ACC AGT GCA CTT GATATTG TGATGACCCAGACTCC

116

-continued

Name	Sequence
caCHkapFOR-AscI	GCC TCC ACC GGG CGC GCC TTA TTA GCAGTGTCTCCGGTCGAAGCTCTGG
caCHkap2FOR-AscI	GCC TCC ACC GGG CGC GCC TTA TTA RCARTGYTNCGRTCRRAA
Non-tagged primers for cloning of Heavy chain (step 1)	
VH1a-BACK	CAGGTKCAGCTGGTGCAGTCTGG
VH5a-BACK	GARGTGCAGCTGGTGCAGTCTGG
VH4a-BACK	CAGSTGCAGCTGCAGGAGTCTGG
VH4b-BACK	CAGGTGCAGCTACACGAGTCTGG
VH2b-BACK	CAGGTCAACCTTGARGGAGTCTGG
Non-tagged primers for cloning of Heavy chain (step 2)	
VH1a-BACK-SfiI	CTC GCA ACT GCG GCC CAG CCG GCC ATG GCCCAGGTKCAGCTGGTGCAGTCTGG
VH5a-BACK-SfiI	CTC GCA ACT GCG GCC CAG CCG GCC ATG GCCCAGGTGCAGCTGGTGCAGTCTGG
VH4a-BACK-SfiI	CTC GCA ACT GCG GCC CAG CCG GCC ATG GCCCAGSTGCAGCTGCAGGAGTCTGG
VH4b-BACK-SfiI	CTC GCA ACT GCG GCC CAG CCG GCC ATG GCCCAGGTGCAGCTACACGAGTCTGG
VH2b-BACK-SfiI	CTC GCA ACT GCG GCC CAG CCG GCC ATG GCCCAGGTACACCTTGARGGAGTCTGG

Independent V λ C λ and V κ C κ libraries were constructed using a single (tagged)-PCR step (30 cycles) to conserve a greater clonal diversity.

The VHCH1 libraries were built in parallel using a two step PCR (25 cycles with non tagged primers (step 1) followed by 10 cycles of tagged primers (step 2)).

Next, the light chain from the V λ C λ and V κ C κ libraries are re-cloned separately in the VHCH1-expressing vector to create the “Lambda” and “Kappa” llama Fab-library respectively (two for each immunized llama). Quality control of the libraries was routinely performed using PCR.

Up to 93% of the clones tested randomly contained full length Fab sequences, indicating a high quality of the libraries.

Human IL-1 Beta Specific Fabs were Selected

Phage display was used to identify a large diversity of llama Fabs binding to biotinylated IL-1 Beta. Biotinylated IL-1 Beta was used for capturing to conserve the active conformation of the protein. After two rounds of selection, a good enrichment compared to control was observed. Phage ELISA revealed presence of clones expressing cytokine specific Fabs (data not shown).

The phage binding to biotinylated IL-1 Beta were eluted by pH shock. Sequential dilutions of the output (10^{-1} to 10^{-5}) were used to infect fresh *E. coli* TG1 cells. The number of colonies obtained indicate the number of phage bound during the selection. In the example above, 5 μ l of output gave around 10^5 phage when selection was done with 100 nM and 10 nM of biot-IL-1 Beta. Compared to the 10^2 phages obtained by non-specific binding, this gives a 1000 fold enrichment.

94 Single clones were grown and used to produce monoclonal phage. These phage were used in a phage ELISA. Many phage showed good binding to biot-IL-1 Beta after two rounds of selection on biotinylated IL-1 Beta.

Human IL-1 Beta Specific Fabs have High Starting Homology to Human Germline

Target specific VH and V λ domains were matched with those common human germlines showing an identical CDR1 and CDR2 length and corresponding canonical folds. Subsequently the closest human germline was selected based on sequence homology in their framework regions. Non-matching amino acid residues were checked for their presence in

other, related human germlines. In case there was no match, these residues were counted as foreign.

TABLE 7

Overall sequence homology of llama VH to human germline		
Closest Human Germline	Matching Clones	% Sequence Homology
IGHV1-2	1C2/2B7/2C12	93
	2D8	94
	1G5/2D7	93
	2E12/2G7	94
	1F2	98
IGHV3-23	1G4	92
	5G7	95
	5B12	92
	1A1/2B8/2B9	98
	1C3/1E3/2A7	98
IGHV3-13	1E2	94
	3A3/3B6/3E2/3E3	95
	3B5/4F1	98
IGHV3-20	4H1	94
	4H4	93

TABLE 8

Overall sequence homology of llama VL to human germline		
Closest Human Germline	Matching Clones	% Sequence Homology
IGLV8-61	1E2	90
	1F2	90
	3E2/3E3/3A3	86
	3B5/4F1	86
IGLV2-18	3B6	91
	1G4 VL	96
IGLV5-52	1C2/2B7/2D7	95
	2E12/2G7	96
	2D8	95

Discussion and Conclusions:

A total of 14 target specific VH families, 9 target specific V λ families and 3 V κ families were identified based on this very first selection

This initial panel of 14 anti-IL-1 Beta WT VH's and 12 anti-IL-1 Beta WT VL's shows a remarkably high sequence homology to the human germline.

33% of those VH domains have a starting homology of 95% or more to the human situation and about 44% of the VL domains have a starting homology of 95% or more to the human situation, eliminating the need for further humanization.

VH domain 2D8 is a humanized version of VH 1C2 because it has one deviating amino acid residue less as compared to the closest human germline. Its corresponding VL domain (VL 2D8), had a starting homology of 95% which was further increased to 96% by 1 back mutation (VL 2G7) to the closest human germline.

All VH and VL domains, without a single exception, exhibited human 3-D binding site structures (i.e. identical combinations of canonical folds for CDR1 and CDR2 as occurring in the matching human germline segments) when assessed using the methodology described above (data not shown).

Humanization of Fab 1E2 and 1F2

Humanization was performed on two IL-1 Beta specific Fabs coded 1E2 and 1F2. Based on the alignment against the closest human germlines, mutations in their VH and V λ framework regions were proposed (FIG. 2). The germlining of VH matching to the human VH3 family will often involve a number of residues, which already deviate in publically known *Lama glama*, *Lama pacos* or *Camelus dromedarius* derived germline sequences. For instance, Alanine on position 71 (numbering according to Kabat) and Lysine on 83 and Proline on 84 might be changed into Serine (although Alanine exists in certain human germline VH3 members), Arginine (although Lysine is used by a number of human VH3 germlines) and Alanine, respectively. For light chain variable sequences no germline sequences are available for Camelids, but it is very likely that a number of deviations in FRs from human germline exists that will be changed in the majority of lead antibodies. Besides the fully humanized (hum) and the wild type (wt) V regions, also a "safe variant" with only three wild type residues remaining was proposed (safe).

Fab 1E2 was formatted in a step-by-step approach, whereby the different versions (wt, safe and fully humanized) of the V λ fused to the human constant domain were combined with various versions of the VH fused to the human constant CH1 domain to generate the Fabs indicated in Table 9.

TABLE 9

Fab 1E2 formats				
VH 1E2 + hum CH1				
	wt	safe	hum	
VL 1E2 + humCL	wt	wt 1E2	wt/safe	wt/hum
	safe	safe/wt	safe 1E2	safe/hum
	hum	hum/wt	hum/safe	hum 1E2

The genes of these Fabs were ordered as synthetic genes with GeneArt (Germany) and were subsequently produced in *E. coli*, purified and tested for their ability to bind biot-IL-1 Beta. For this the Fabs were captured on an anti-myc coated Maxisorp plate. Biotinylated human IL-1 Beta was added and bound cytokine was detected using HRP-conjugated streptavidin. The read out of this assay is represented in FIG. 3 below.

The replacement of the wild type constant domains CH1 and C λ by their human counterpart did not affect the binding capacity.

Partial (wt V λ /safe VH) and complete (wt V λ /hum VH) humanization of the VH domain of 1E2 generated a functional Fab.

The humanized variants of clone 1F2 were tested with phage expressing gene3-Fabs fusions (FIG. 4). Phage were produced from 4 independent clones for each construct:

wt 1F2 and wt 1E2 (llama V λ and VH fused to human C λ and CH1)

safe variant 1F2 and safe variant 1E2 (partially humanized V λ fused to human CA and CH1)

hum 1F2 and hum 1E2 (fully humanized V λ and VH fused to human C λ and CH1)

119

Four clones for each Fab were tested to overcome clonal variation (due to bacterial growth, phage production efficiency and toxicity etc.). Phage ELISA was performed by capturing of biotinylated IL-1 Beta on neutravidin coated Maxisorp plate and subsequent incubation of crude phage extract (i.e. bacterial medium). After extensive washing, bound phages were detected with an anti-M13-HRP monoclonal antibody. The same phage preparations when tested on

120

tion against biotinylated IL-1 Beta. Detection of the bound biotinylated IL-1 Beta happened through HRP labeled streptavidin. A reduced signal indicated the competition of a specific Fab with the blocking mouse monoclonal antibody, suggesting antagonism.

A positive control was included in well G12 by spiking in a large amount of the competing mouse monoclonal (well 12G in Table 10).

TABLE 10

	Results of competition assay											
	6A						6C					
	1	2	3	4	5	6	7	8	9	10	11	12
A	0.268	0.621	0.670	0.691	0.704	0.823	0.353	0.737	0.726	0.544	0.551	0.626
B	0.668	0.546	0.444	0.632	0.614	0.627	0.442	0.641	0.558	0.693	0.565	0.548
C	0.756	0.541	0.386	0.572	0.763	0.593	0.517	0.537	0.518	0.588	0.473	0.435
D	0.521	0.790	0.203	0.792	0.801	0.263	0.619	0.483	0.631	0.592	0.455	0.603
E	0.798	0.545	0.359	0.528	0.281	0.655	0.618	0.516	0.651	0.493	0.575	0.367
F	0.747	0.611	0.520	0.599	0.203	0.204	0.605	0.373	0.550	0.516	0.602	0.392
G	0.498	0.477	0.539	0.693	0.663	0.197	0.554	0.589	0.807	0.528	0.634	0.363
H	0.628	0.493	0.552	0.900	0.858	0.635	0.270	0.574	0.559	0.598	0.593	0.378

neutravidin coated wells (without biotinylated IL-1 Beta) did not give signals (data not shown).

Back mutations in the framework regions of 1F2 VL and VH domains to the closest human germline successfully yield partially (safe) and fully (hum) humanized variants, maintaining antigen specificity.

Successful Formatting of Camelid Variable Domains with Human Constant Domains

The VL and VH variable domains of the IL-1 Beta specific clone 1E2 were successfully fused to the human C λ and CH1 constant domains, resulting in a "chimeric" Fab which was produced and purified.

This chimeric 1E2 Fab was produced by performing the induction for 4 h at 37° C. (o/d) or for 16 h and 28° C. (on) from the pCB5 phagemid (Agene3). The wild type llama 1E2 Fab was produced by performing induction for 16 h at 30° C. from pCB3 (gene3 containing phagemid). After purification, these Fabs were loaded on SDS-PAGE with (reducing) or without (non-reducing) DTT. Coomassie staining was performed, nicely showing the presence of these Fabs or their composing light and heavy chains at the expected molecular weight band (not shown).

The purified llama and chimeric 1E2 Fabs described above were captured on anti-myc coated maxisorp plates. After incubation with biotinylated human IL-1 Beta and extensive washing, the biotinylated IL-1 Beta bound to the Fab was detected using HRP-conjugated streptavidin. Both the purified llama and chimeric 1E2 Fabs exhibited functional target binding (FIG. 5). This finding demonstrates the feasibility to associate Camelid derived variable domains with the constant domains of human IgGs.

A Subset of Fabs Showed Functional Inhibition of the Target

The table below shows the OD values resulting from the following ELISA experiment. Wells were coated with a mouse monoclonal antibody known to inhibit the binding of IL1-Beta with its receptor (provided by Diaclone SAS).

Biotinylated IL-1 Beta was added to the wells together with periplasmic extracts of Fabs identified after 2 rounds of selec-

A number of Fabs were identified which successfully compete with the blocking mouse monoclonal antibody (indicated by shaded cells in Table 10). Sequence analysis of the competing clones revealed the presence of three Fabs with different VH, which were present in 48 screened clones (part of the plate coded 6A in Table 10). The sequence alignments against the closest human germline and the structural homology analysis of the VH of the antagonistic Fab 1A1 (giving a signal of 0.205 in the competition assay of Table 10), 1B3 (signal of 0.444) and the related clone 1G1 (signal of 0.498) and finally 1C3 (signal of 0.386) are shown below.

All three have a very high degree of sequence homology with the matching human germline and have the identical canonical fold combinations as found in the human germline. This was also observed for the lambda light chain in the three antagonistic leads (data not shown). Fab 1A1 competes strongly with the antagonistic reference monoclonal antibody (IC50 of 12 µg/ml in ELISA based competition assay), whereas Fab 1C3 hardly shows competition (only at concentrations of more than 50 µg/ml). However, in the bioassay 1C3 is more potent (IC50 of 3 µg/ml) than 1A1 (IC50 of 10 µg/ml), which suggests a different epitope recognition. The high frequency of different antagonistic Fabs (3 different antibodies in 48 screened clones) and the difference in epitope recognition as found for two of these illustrates the high diversity of antibodies as the result of the outbred nature of the *lama*. The high degree of sequence homology with human germline V regions combined with the high diversity of (potent) antibodies and the broad epitope coverage enables the identification of panels of therapeutic antibodies from immunized camels.

US 9,315,576 B2

121

122

IGHV gene Kabat FR/CDR	FR1-Kabat	CDR1 Kabat	FR2-Kabat	CDR2 Kabat
IMGT numbering	1 10 20 30 40 50 60 70			
M99550, IGHV3-20 VH-A1A, 3B3, 3D9	EVQLVESGG.GLVQPGGSLRLSCAASGFTF VH-A1A, 3B3, 3D9	SSYA....MS WVRQAPGKGLEWVS AISGSGGST..YYADSVK.G	
IGHV gene Kabat FR/CDR	FR3-Kabat	CDR2 Kabat	FR4 (IGHJ)	
IMGT numbering	80 90 100 110 120 130			
M99550, IGHV3-20 VH-A1A, 3B3, 3D9	RFTISRDNAKNTLYLQMNSLKSEDTAVYYCAK RFTISRDNAKNTLYLQMNSLKSEDTAVYYCAK	PPYSDVGEYDY	WGQGTQVTVSS

15

5 V primer encoded and also in all other class 3 except 3-23
 83 A occurs in all VH3 family members except 3-23
 95 K also in IGHV3-13/49/66/72 and classes 5 and ?
 96 S not in class 3 but in class 1
 127 Q not in human germline

Overall homology
 84/86 framework residues=98% homology
 Canonical folds analysis
 CDR H1 Class 1/10A [2fbj]
 20 CDR H2 Class ?
 !Similar to class 3/10B, but:
 !H56 (Cothia Numbering)=λ (allows: SETNDR)

IGHV gene Kabat FR/CDR	CDR1 Kabat	CDR2 Kabat	FR1-Kabat	Kabat	FR2-Kabat	Kabat	FR4 (IGHJ)
IMGT numbering	1 10 20 30 40 50 60 70						
N99540, IGHV3-88 VH-ICA, IE3, 2A7	EVQLLESGG.GLVQPGGSLRLSCAASGFTF EVQLVESGG.GLVQPGGSLRLSCAASGFTF	SSYA....MS WVRQAPGKGLEWVS AISGSGGST..YYADSVK.G SSYN....MY WVRQAPGKGLEWVS AINTGGRT..YYADSVK.G				
IMGT numbering	80 90 100 110 120 130						
M99550, IGHV3-20 VH-A1A, 3B3, 3D9	RFTISRDNAKNTLYLQMNSLSEDTAVYYCAK RFTISRDNAKNTLYLQMNSLSEDTAVYYCAK	GTSADGSSWYVPADGYDY	WGQGTQVTVSS			

5 V primer encoded and also in all other class 3 except 3-23
 40 83 A occurs in all VH3 family members except 3-23
 95 K also in IGHV3-13/49/66/72 and classes 5 and 7
 96 S not in class 3 but in class 1
 127 O not in human germline
 Overall homology
 84/86 framework residues=98% homology
 Canonical folds analysis
 CDR H1 Class 1/10A [2fbj]
 CDR H2 Class ?
 !Similar to class 2/10A, but:
 !H71 (Cothia Numbering)=R (allows: VAL)

IMGT numbering	1 10 20 30 40 50 60 70	CDR1 Kabat	FR2-Kabat	CDR2 Kabat
IGHV1-2 VH-1B3, 1G2, 2B8 VH-1G1, 2B7	EVQLVQSGA.EVKPGASVKVSKASGYTF TGYYMM.... EVQLVQSGA.EVKPGASVKVSKASGYTF TSYYID.... EVQLVQSGA.EVKPGASVKVSKASGYTF TSYYID....	WVRQAPGQGLWEMG RINFNSGGT NYAQKGQ.G WVRQAPGQGLWEMG RINFNSGGT NYAQKGQ.G WVRQAPGQGLWEMG RINFNSGGT NYAQKGQ.G	
IMGT numbering	80 90 100 110 120 130	FR2-Kabat	Kabat	FR4 (IGHJ)
K07445, IGHV1-2 VH-1B3, 1G2, 2B8 VH-1G1, 2B7	RVTSTRDTSTSTAYMELSLRSLSDSTVVYCAR RVTSTRDTSTSTAYMELSLRSLSDSTVVYCAR RVTSTRDTSTSTAYMELSLRSLSDSTVVYCLR	MGQGTQVTVSS MGQGTQVTVSS MGQGTQVTVSS	

123

1 E primer encoded, occurs as well in IGHV1-f
 11 L occurs in class 2, 3, 4, 6 and 7
 12 R not in human germline
 13 N not in human germline
 78 F occurs in class 7
 85 G occurs in class 7
 80 A present in two class 1 members
 84 T occurs in half of class 1 members
 89 V not in human germline
 93 S present in majority of class 1 members
 97 E present in majority of class 1 members
 127 Q not in human germline
 Overall homology
 79/86 framework residues=92% homology
 Canonical folds analysis
 CDR H1 Class ?
 !Similar to class 1/10A, but:
 !H35 (Cothia Numbering)=D (allows: HENOSYT)
 !H30 (Cothia Numbering)=V (allows: LM)
 CDR H2 Class ?
 !Similar to class 2/10A, but:
 !H53 (Cothia Numbering)=R (allows: AGYSKTN)

Example 16

The following example demonstrates the functional diversity which can be achieved with the current invention, in comparison with the established mouse monoclonal antibody approach.

10 BALB/c mice were immunized with a recombinant produced cytokine with a small molecular weight. After completion of the immunization protocol, the animals were sacrificed, and hybridomas were generated by immortalizing their spleen cells. Supernatant of the resulting hybridomas was tested in the cytokine binding ELISA and subsequently in a suitable bioassay. One highly potent antagonist and one weaker antagonist could be identified.

Also, 4 llamas were immunized with the same recombinant produced cytokine, using the general protocol described herein. After completion of the immunization protocol, peripheral B lymphocytes were harvested and their RNA was extracted and purified. Using a set of llama specific primers, Fab libraries were generated using the phage display technique. Those Fabs were tested in the cytokine/cytokine receptor binding ELISA. 5 different VH families could be identified from the first 2 llamas, and 6 additional different VH families from the next 2 llamas, which blocked the cytokine/receptor interaction with high potency, meaning that those VH domains contained uniquely different CDRs, both in length and amino acid sequence.

Thus a higher functional diversity could be achieved from a small number of outbred llamas as opposed to a higher number of inbred BALB/c mice. All VH families obtained by active immunisation of llamas exhibited an extraordinary sequence homology as compared to the closest human germline and had the same canonical fold combinations for CDR1 and CDR2 as the matching human germlines.

Example 17

The following table summarises the results of amino acid sequence homology comparisons between germline VH domains of alpaca (*Lama pacos*) and the closest matching human germline VH domains. % homology was calculated using the same algorithm as described herein for *Lama glama*. Raw VH sequence data for *Lama pacos* is not shown:

124

TABLE 11

5	Alpaca (<i>Lama pacos</i>) germline VH family	amino acid sequence homology germline VH of <i>Lama pacos</i> vs human	
		Frequency	% amino acid sequence homology with closest matching human germline VH
VH3		70% (36/51)	≥95%
VH1		10% (5/51)	90-92%
10	VH2 (NB <i>Lama pacos</i> VH2 aligns to human VH4)	20% (10/51)	81-88%

The following table is provided to cross-reference nucleotide and amino acid sequences listed herein with the sequence listing submitted in ST.25 format for searching purposes.

TABLE 12

20	cross-reference to sequence identifiers	
	SEQ ID No.	Sequence name
25	1	M99679, IGHV3-53
	2	AF000603, IGHV1S1
	3	AJ245151, IGHV1S2
	4	AJ245152, IGHV1S3
	5	AJ245153, IGHV1S4
	6	AJ245154, IGHV1S5
	7	AJ245155, IGHV1S6
	8	AJ245157, IGHV1S7
	9	AJ245158, IGHV1S8
	10	AJ245159, IGHV1S9
	11	AJ245160, IGHV1S10
	12	AJ245164, IGHV1S11
	13	AJ245165, IGHV1S12
	14	AJ245167, IGHV1S13
	15	AJ245168, IGHV1S14
	16	AJ245170, IGHV1S15
	17	AJ245171, IGHV1S16
	18	AJ245173, IGHV1S17
	19	AJ245174, IGHV1S18
	20	AJ245156, IGHV1S19
	21	M99660, IGHV3-23
	22	AJ245177, IGHV1S20
	23	AJ245178, IGHV1S21
	24	AJ245183, IGHV1S22
	25	AJ245185, IGHV1S23
	26	AJ245186, IGHV1S24
	27	AJ245187, IGHV1S25
	28	AJ245189, IGHV1S26
	29	AJ245191, IGHV1S27
	30	AJ245192, IGHV1S28
	31	AJ245193, IGHV1S29
	32	AJ245194, IGHV1S30
	33	AJ245195, IGHV1S31
	34	AJ245179, IGHV1S32
	35	AJ245180, IGHV1S33
	36	AJ245182, IGHV1S34
	37	AJ245190, IGHV1S35
	38	AJ245196, IGHV1S36
	39	AJ245197, IGHV1S37
	40	AJ245181, IGHV1S38
	41	AJ245198, IGHV1S39
	42	AJ245199, IGHV1S40P
	43	AF305949, IGHV1S6
	44	M94116, IGLV1-40
	45	Camvl44
	46	Z73642, IGLV2-18
	47	Camvl17
	48	Camvl33
	49	Camvl36
	50	Camvl59
	51	Camvl30
	52	Camvl32
	53	Camvl57
	54	Camvl5

125

TABLE 12-continued

cross-reference to sequence identifiers	
SEQ ID No.	Sequence name
55	Camvl65
56	Camvl51
57	Camvl31
58	Camvl60
59	Camvl52
60	X57826, IGLV3-1
61	Camvl19
62	Camvl20
63	Camvl8
64	Camvl18
65	Camvl23
66	Z73658, IGLV3-12
67	Camvll
68	X59314, IGKV2-40
69	Kp6
70	Kp48
71	Kp3
72	Kp20
73	Kp7
74	Kp10
75	Kp1
76	J00256,IGHJ1
77	J00256,IGHJ2
78	J00256,IGHJ3
79	J00256,IGHJ4
80	J00256,IGHJ5
81	J00256,IGHJ6
82	AF305952,IGHJ2
83	AF305952,IGHJ3
84	AF305952,IGHJ4
85	AF305952,IGHJ5
86	AF305952,IGHJ6 (1)
87	X04457,IGLJ1
88	M15641,IGLJ2
89	M15642,IGLJ3
90	X51755,IGLJ4
91	X51755,IGLJ5
92	M18338,IGLJ6
93	X51755,IGLJ7
94	Camvl19 etc.
95	Camvl8/18/4
96	Camvl58/28/5
97	J00242,IGKJ1
98	J00242,IGKJ2
99	J00242,IGKJ3
100	J00242,IGKJ4
101	J00242,IGKJ5
102	Kp6/48/3/20/10/1
103	Kp7 (1/7 analyzed)
104	M99660,IGHV3-23
105	IVH28
106	IVH69
107	IVH47
108	IVH48
109	IVH70
110	IVH71
111	HuVL1-1(3/4/5)
112	LAMBDA#14
113	LAMBDA#16
114	LAMBDA#46
115	LAMBDA#45
116	LAMBDA#15
117	HuVL1-2
118	LAMBDA#47
119	LAMBDA#18
120	LAMBDA#32
121	LAMBDA#28
122	LAMBDA#29
123	LAMBDA#27
124	LAMBDA#17
125	LAMBDA#4
126	LAMBDA#7
127	LAMBDA#8
128	LAMBDA#5
129	HuVL2-1
130	LAMBDA#1

126

TABLE 12-continued

cross-reference to sequence identifiers	
SEQ ID No.	Sequence name
5	
131	LAMBDA#8 (2)
132	LAMBDA#5 (2)
133	LAMBDA#11
134	HuVL3-2
135	LAMBDA#13
136	LAMBDA#40
137	LAMBDA#2
138	LAMBDA#14 (2)
139	HuVL4-1
140	LAMBDA#10
141	HuVL5-1
142	LAMBDA#3
143	LAMBDA#7 (2)
144	LAMBDA#9
145	LAMBDA#26
146	LAMBDA#12
147	HuVL8-1
148	LAMBDA#42
149	LAMBDA#31
150	HuVK1-1
151	KAPPA#39
152	KAPPA#22
153	KAPPA#24
154	KAPPA#21
155	KAPPA#23
156	KAPPA#7
157	KAPPA#19
158	KAPPA#25b
159	I_8
160	KAPPA#43
161	KAPPA#44
162	KAPPA#20b
163	HuVK4-1
164	KAPPA#53
165	KAPPA#50
166	KAPPA#20
167	KAPPA#48
168	KAPPA#55
169	KAPPA#9
170	KAPPA#51
171	KAPPA#10
172	KAPPA#54
173	KAPPA#49
174	KAPPA#52
175	KAPPA#13
176	KAPPA#11
177	KAPPA#36
178	KAPPA#25
179	KAPPA#12
180	KAPPA#34
181	KAPPA#48b
182	KAPPA#21 (2)
183	KAPPA#24 (2)
184	KAPPA#22b
185	KAPPA#45
186	KAPPA#46
187	VH1(1-02)
188	1C2
189	1G5
190	VH3(3-23)
191	5B12
192	1G4
193	5G7
194	VH_99
195	VH_76
196	VH_86
197	VH_98
198	VH_89
199	VH_82
200	VH_68
201	VH_73
202	VH_107
203	VH_94
204	VH_90
205	VH_77
206	VH_74

TABLE 12-continued

cross-reference to sequence identifiers	
SEQ ID No.	Sequence name
207	VH_67
208	VH_79
209	VH_75
210	VH_110
211	VH_109
212	VH_103
213	VH_84
214	VH_113
215	VH_87
216	VH_105
217	VH_101
218	VH_108
219	VH_106
220	VH3(3-13)
221	VH_115
222	VH_85
223	VH_114
224	VH_78
225	3B5
226	3A3
227	HuV1A-BACK-ApaLI
228	HuV1B-BACK-ApaLI
229	HuV1C-BACK-ApaLI
230	HuV12-BACK-ApaLI
231	HuV13A-BACK-ApaLI
232	HuV13B-BACK-ApaLI
233	HuV14-BACK-ApaLI
234	HuV15-BACK-ApaLI
235	HuV16-BACK-ApaLI
236	HuV17/8-BACK-ApaLI
237	HuV19-BACK-ApaLI
238	HuV110-BACK-ApaLI
239	caClambda1-FOR
240	caClambda2-FOR
241	HuV1k1B-BACK-ApaLI
242	HuV1k2-BACK-ApaLI
243	HuV1k3B-BACK-ApaLI
244	HuV1k2/4-BACK-ApaLI
245	HuV1k5-BACK-ApaLI
246	HuV1k6-BACK-ApaLI
247	HuV1k4B-BACK-ApaLI
248	caCHkapFOR-AscI
249	caCHkap2FOR-AscI
250	VH-1A1, 2B8, 2B9
251	VH-1C3, 1E3, 2A7
252	VH-1B3, 1G2, 2D8
253	VH-1G1, 2B7
254	X07448, IGHV1-2
255	1F2 VH
256	Humanized VH 1F2
257	Safe Variant VH 1F2
258	X92218, IGHV3-66
259	1E2 VH
260	Humanized VH 1E2
261	Safe Variant VH 1E2
262	Z73650, IGLV8-61
263	1F2 VL
264	Humanized 1F2 VL
265	Safe Variant VL 1F2
266	1E2 VL
267	Humanized VL 1E2
268	Safe Variant VL 1E2
269	X92343 IGHV1-46*01
270	LpVH1-s6 (AM939701)
271	LpVH1-s2 (AM939697)
272	LpVH1-s3 (AM939698)
273	LpVH1-s4 (AM939699)
274	LpVH1-s5 Ps (AM939700)
275	M99660 IGHV3-23*01
276	AM939712
277	AM939713
278	AM939730
279	AM939731
280	AM939744
281	AM939726
282	AM939727

TABLE 12-continued

cross-reference to sequence identifiers	
SEQ ID No.	Sequence name
5	
283	AM939739
284	AM939740
285	AM939741
286	AM939742
287	AM939743
288	U29481 IGHV3-23*03
289	AM939716
290	AM939728
291	AM939738
292	AM939710
293	AM939748
294	AM939750
295	AM939751
296	AM939767
297	AM939768
298	AM939707
299	AM939708
300	AM939709
301	AM939732
302	AM939733
303	AM939717
304	AM939734
305	AM939735
306	AM939736
307	AM939737
308	L33851 IGHV3-74*01
309	AM939749
310	AM939724
311	AM939725
312	AM939745
313	AM939723
314	X92229 IGHV4-30-2*03
315	LpVH2-s7 (AM939704)
316	Z14238 IGHV4-30-4*01
317	LpVH2-s2 (AM939769)
318	LpVH2-s3 (AM939770)
319	LpVH2-s4 (AM939771)
320	LpVH2-s5 (AM939772)
321	LpVH2-s6 (AM939773)
322	LpVH2-s11 Ps (AM939703)
323	LpVH2-s8 (AM939705)
324	LpVH2-s9 Ps (AM939706)
325	LpVH2-s10 (AM939702)
326	AJ879486 IGHV3-23*04
327	S-VH1
328	S-VH3
329	S-VH4
330	S-VH2
331	S-VH6
332	S-VH5
333	D86994 IGLV3-25*02
334	VL25-28
335	Z73672 IGLV5-37*01
336	VL2, 12, 15
337	Z73650 IGHV8-61*01
338	VL3, 5
339	VL17-24, 29-32
340	VL10
341	VL4, 6, 7, 8, 9, 13, 14
342	U41644 IGKV2D-29*02
343	KAPPA 33-36, 38, 39, 42, 4
344	KAPPA 41, 43, 44
345	KAPPA 40, 44
346	KAPPA 37, 46, 48
347	VH1a-BACK
348	VH5a-BACK
349	VH4a-BACK
350	VH4b-BACK
351	VH2b-BACK
352	VH1a-BACK-SfiI
353	VH5a-BACK-SfiI
354	VH4a-BACK-SfiI
355	VH4b-BACK-SfiI
60	
356	VH2b-BACK-SfiI
65	

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 356

<210> SEQ ID NO 1

<211> LENGTH: 97

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Ile	Gln	Pro	Gly	Gly
1														
														15

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Val	Ser	Ser	Asn
														30	
20								25							

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Ley	Glu	Trp	Val
														45	
35								40							

Ser	Val	Ile	Tyr	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys
														60	
50								55							

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu
														80	
65								70							

Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
														95	
85								90							

Arg

<210> SEQ ID NO 2

<211> LENGTH: 97

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 2

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Ile	Gln	Pro	Gly	Gly
1														
														15

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
														30	
20								25							

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Ley	Glu	Trp	Val
														45	
35								40							

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
														60	
50								55							

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr	Leu
														80	
65								70							

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
														95	
85								90							

Gly

<210> SEQ ID NO 3

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 3

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Ile	Gln	Pro	Gly	Gly	
1															
														15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
														30	
20								25							

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Ley	Glu	Trp	Val
														45	
35								40							

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
														60	
50								55							

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Leu Tyr Leu

US 9,315,576 B2

131

132

-continued

65	70	75	80
----	----	----	----

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 4
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 4

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Tyr Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Leu Tyr Leu
65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 5
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 5

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 6
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 6

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Leu Tyr Leu
65 70 75 80

-continued

Gln Val Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 7

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 7

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Met Leu Tyr Leu
 65 70 75 80

Gln Met His Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 8

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 8

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Met Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 9

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 9

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Tyr Met Ser Trp Val Arg Lys Ala Gln Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Met Leu Tyr Leu
 65 70 75 80

-continued

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
85							90						95	

<210> SEQ ID NO 10
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 10

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5	10	15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20						25		30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35						40		45						

Ser	Ser	Asn	Thr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
	50						55		60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr	Leu
	65						70		75		80				

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85	90					95	

<210> SEQ ID NO 11
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 11

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5	10	15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr
	20						25		30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Arg	Gly	Leu	Glu	Trp	Val
	35						40		45						

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Gly	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Arg
	50						55		60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr	Leu
	65						70		75		80				

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Cys	Tyr	Cys
							85	90				95		

<210> SEQ ID NO 12
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 12

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5	10	15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20						25		30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35						40		45						

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
	50						55		60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
	65						70		75		80				

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ser	Met	Tyr	Tyr	Cys
							85	90				95		

US 9,315,576 B2

137

-continued

138

 85 90 95

<210> SEQ ID NO 13
 <211> LENGTH: 95
 <212> TYPE: PRT
 <213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 13

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5	10	15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20	25	30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40	45						

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
							50	55	60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
							65	70	75						

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85	90	95					

<210> SEQ ID NO 14

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 14

Ala	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ser	Val	Gln	Ala	Gly	Gly
1														
							5	10	15					

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20	25	30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40	45						

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
							50	55	60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
							65	70	75						

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85	90	95					

<210> SEQ ID NO 15

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 15

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ser	Val	Gln	Ala	Gly	Gly
1														
							5	10	15					

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20	25	30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40	45						

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
							50	55	60						

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
							65	70	75						

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85	90	95					

-continued

<210> SEQ_ID NO 16
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 16

Ala	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5			10				15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
								20		25			30		

Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
								35		40			45		

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
	50						55			60					

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
65							70			75			80		

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85			90			95	

<210> SEQ_ID NO 17
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 17

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5			10				15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
								20		25			30		

Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Arg	Leu	Glu	Trp	Val
								35		40			45		

Ser	Gly	Ile	Tyr	Ser	Asp	Gly	Ser	Thr	Tyr	Tyr	Gly	Asp	Ser	Val	Lys
	50						55			60					

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Lys	Ala	Lys	Asn	Met	Leu	Tyr	Leu
65							70			75			80		

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85			90			95	

<210> SEQ_ID NO 18
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 18

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ser	Val	Gln	Ala	Gly	Gly	
1							5			10				15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
								20		25			30		

Asp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
								35		40			45		

Ser	Ala	Ile	Asn	Ser	Asp	Gly	Ser	Thr	Asn	Tyr	Ala	Asp	Ser	Val	Lys
							50			55			60		

Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr	Leu
65							70			75			80		

Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85			90			95	

-continued

```

<210> SEQ ID NO 19
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 19

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Arg Gly Ser Thr His Tyr Ala Asp Ser Met Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Val Leu Tyr Leu
65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

```

```

<210> SEQ ID NO 20
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 20

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Gly Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Gln Asp Asn Ala Lys Asn Thr Val Tyr Leu
65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

```

```

<210> SEQ ID NO 21
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1           5           10          15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20          25          30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35          40          45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50          55          60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65          70          75          80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85          90          95

Ala Lys

```

-continued

<210> SEQ ID NO 22
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 22

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5			10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
	20						25			30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
	35						40			45						

Ser	Gly	Ile	Asn	Ser	Asp	Gly	Ser	Asn	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50						55			60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr	
	65						70			75			80			

Leu	Gln	Met	Asn	Ser	Leu	Lys	Ser	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	
		85					90			95						

<210> SEQ ID NO 23
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 23

Ala	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5			10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
	20						25			30						

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
	35						40			45						

Ser	Gly	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val		
	50						55			60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Val	Leu	Tyr	
	65						70			75			80			

Leu	Lys	Leu	Ser	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	
		85					90			95						

<210> SEQ ID NO 24
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 24

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5			10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
	20						25			30						

Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
	35						40			45						

Ser	Thr	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val		
	50						55			60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr	
	65						70			75			80			

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	
		85					90			95						

-continued

<210> SEQ ID NO 25
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 25

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1					5			10				15			
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25				30					
Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35				40				45						
Ser	Thr	Ile	Asn	Ser	Gly	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50				55				60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr
	65				70			75				80			
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
					85			90				95			

<210> SEQ ID NO 26

<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 26

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1					5			10				15			
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25				30					
Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Pro	Glu	Trp	Val
	35				40				45						
Ser	Thr	Ile	Asn	Ser	Gly	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50				55				60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr
	65				70			75				80			
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90				95			

<210> SEQ ID NO 27

<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 27

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1					5			10				15			
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25				30					
Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Arg	Lys	Gly	Leu	Glu	Trp	Val
	35				40				45						
Ser	Thr	Ile	Asn	Ser	Ala	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50				55				60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
	65				70			75				80			
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90				95			

-continued

<210> SEQ ID NO 28
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 28

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Thr Ile Asn Ser Ala Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 29
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 29

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 30
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 30

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 31

US 9,315,576 B2

149**150**

-continued

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 31

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5		10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20		25			30			

Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35		40			45			

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
							50		55			60		

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
							65		70			75			80

Leu	Gln	Leu	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85		90			95			

<210> SEQ ID NO 32

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 32

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5		10			15			

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20		25			30			

Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35		40			45			

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
							50		55			60			

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
							65		70			75			80

Leu	Gln	Leu	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85		90			95			

<210> SEQ ID NO 33

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 33

Ala	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5		10			15			

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20		25			30			

Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35		40			45			

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
							50		55			60			

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
							65		70			75			80

Leu	Gln	Leu	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
							85		90			95			

<210> SEQ ID NO 34

<211> LENGTH: 96

US 9,315,576 B2

151

-continued

<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 34

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20				25								30		
Trp	Val	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
					35			40					45		
Ser	Ser	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55								60		
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Lys	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
	65				70			75					80		
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90					95		

<210> SEQ ID NO 35

<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 35

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20				25								30		
Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
					35			40					45		
Ser	Ser	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55								60		
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Lys	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
	65				70			75					80		
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90					95		

<210> SEQ ID NO 36

<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 36

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20				25								30		
Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Ala	Leu	Gln	Trp	Val
					35			40					45		
Ser	Ser	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55								60		
Lys	Gly	Pro	Leu	Thr	Ile	Ser	Lys	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
	65				70			75					80		
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90					95		

<210> SEQ ID NO 37

<211> LENGTH: 96
<212> TYPE: PRT

152

-continued

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 37

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25							30		

Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55				60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Gln	Asp	Asn	Ala	Lys	Asn	Thr	Arg	Tyr
	65				70			75			80				

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
	85					90						95			

<210> SEQ ID NO 38

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 38

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25				30					

Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Ala	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55				60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Gln	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
	65				70			75			80				

Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
	85					90						95			

<210> SEQ ID NO 39

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 39

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ser	Val	Gln	Ala	Gly	Gly	
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20					25				30					

Asp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
	50				55				60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Gln	Asp	Asn	Ala	Lys	Asn	Met	Leu	Tyr
	65				70			75			80				

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
	85					90						95			

<210> SEQ ID NO 40

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

US 9,315,576 B2

155

-continued

<400> SEQUENCE: 40

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Ser	Ser	Tyr	
					20			25					30		

Trp	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
					35			40				45			

Ser	Ser	Ile	Tyr	Thr	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
					50			55				60			

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Lys	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
					65			70				75			80

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90				95			

<210> SEQ ID NO 41

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 41

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Ala	Phe	Thr	Tyr	Ser	Ser	Cys
					20			25					30		

Cys	Met	Tyr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Phe	Glu	Trp	Val
					35			40				45			

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
					50			55				60			

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Gln	Asp	Asn	Ala	Lys	Asn	Thr	Arg	Tyr
					65			70				75			80

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90				95			

<210> SEQ ID NO 42

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<222> LOCATION: (26)...(26)

<223> OTHER INFORMATION: Unknown amino acid

<400> SEQUENCE: 42

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10					15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Xaa	Phe	Thr	Phe	Ser	Ser	Tyr
					20			25				30			

Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
					35			40				45			

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	
					50			55				60			

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Gln	Asp	Asn	Ala	Lys	Asn	Thr	Arg	Tyr
					65			70				75			80

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
					85			90				95			

<210> SEQ ID NO 43

156

-continued

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 43

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1															
							5	10	15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Ser
								20	25	30					

Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
								35	40	45					

Ser	Ser	Ile	Tyr	Ser	Tyr	Ser	Ser	Asn	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
								50	55	60					

Lys	Ser	Arg	Phe	Thr	Ile	Ser	Thr	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
								65	70	75	80				

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
								85	90	95					

Ala Ala

<210> SEQ_ID NO 44

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

Gln	Ser	Val	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ala	Pro	Gly	Gln
1															
								5	10	15					

Arg	Val	Thr	Ile	Ser	Cys	Thr	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Ala	Gly
								20	25	30					

Tyr	Asp	Val	His	Trp	Tyr	Gln	Gln	Leu	Pro	Gly	Thr	Ala	Pro	Lys	Leu
								35	40	45					

Leu	Ile	Tyr	Gly	Asn	Ser	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe
							50	55	60						

Ser	Gly	Ser	Lys	Ser	Gly	Thr	Ser	Ala	Ser	Leu	Ala	Ile	Thr	Gly	Leu
							65	70	75	80					

Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Tyr	Asp	Ser	Ser
							85	90	95						

Leu Ser Gly

<210> SEQ_ID NO 45

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 45

Gln	Ser	Val	Leu	Thr	Gln	Pro	Pro	Ser	Met	Ser	Gly	Ser	Leu	Gly	Gln
1															
								5	10	15					

Arg	Val	Thr	Ile	Ser	Cys	Thr	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Gly	Gly
							20	25	30						

Ser	Gly	Val	Gln	Trp	Phe	Gln	Gln	Leu	Pro	Gly	Thr	Ala	Pro	Lys	Leu
							35	40	45						

Leu	Ile	Tyr	Gly	Asn	Ser	Asn	Arg	Ala	Ser	Gly	Ile	Pro	Asp	Arg	Phe
							50	55	60						

Ser	Glu	Ser	Lys	Ser	Gly	Ser	Ser	Ala	Ser	Leu	Thr	Ile	Thr	Gly	Leu
							65	70	75	80					

Gln	Ala	Asp	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Ser	Tyr	Asp	Asn	Arg
							85	90	95						

US 9,315,576 B2

159

-continued

Leu Ser Gly Pro Val Phe Gly Gly Thr Lys Leu Thr Val Leu Gly
 100 105 110

<210> SEQ ID NO 46
 <211> LENGTH: 99
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 46

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln
 1 5 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr
 20 25 30

Asn Arg Val Ser Trp Tyr Gln Gln Pro Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Leu Tyr Thr Ser Ser
 85 90 95

Ser Thr Phe

<210> SEQ ID NO 47
 <211> LENGTH: 130
 <212> TYPE: PRT
 <213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 47

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
 1 5 10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr
 20 25 30

Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val
 35 40 45

Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala
 50 55 60

Pro Lys Leu Leu Ile Tyr Gln Asp Ser Lys Arg Asn Ser Gly Ile Pro
 65 70 75 80

Asp Arg Phe Ser Gly Ser Lys Ser Asp Asn Thr Ala Ser Met Thr Ile
 85 90 95

Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr
 100 105 110

Arg Ser Thr Tyr His Ser Leu Phe Gly Gly Thr His Leu Thr Val
 115 120 125

Leu Gly
 130

<210> SEQ ID NO 48
 <211> LENGTH: 130
 <212> TYPE: PRT
 <213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 48

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
 1 5 10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr

US 9,315,576 B2

161**162**

-continued

20 25 30

Pro Gly Gln Thr Val Thr Ile Thr Cys Thr Gly Thr Arg Asp Asp Val
 35 40 45

Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala
 50 55 60

Pro Lys Leu Leu Ile Tyr Gln Ile Asn Lys Arg Leu Ser Gly Ile Pro
 65 70 75 80

Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile
 85 90 95

Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr
 100 105 110

Arg Asp Leu Asn Thr Leu Val Phe Gly Gly Thr His Leu Thr Val
 115 120 125

Leu Gly
 130

<210> SEQ ID NO 49

<211> LENGTH: 130

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 49

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
 1 5 10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr
 20 25 30

Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val
 35 40 45

Gly Gly Tyr Asn Tyr Val Ser Arg Tyr Gln Gln Leu Pro Gly Thr Ala
 50 55 60

Pro Lys Leu Leu Ile Tyr Gln Ile Asn Lys Arg Ala Ser Gly Ile Pro
 65 70 75 80

Asp Arg Phe Ser Gly Ser Arg Ser Gly Asn Thr Ala Ser Met Thr Ile
 85 90 95

Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr
 100 105 110

Arg Ala Thr Asn Ser Ile Val Phe Gly Gly Thr His Leu Thr Val
 115 120 125

Leu Gly
 130

<210> SEQ ID NO 50

<211> LENGTH: 130

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 50

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
 1 5 10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr
 20 25 30

Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val
 35 40 45

Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala
 50 55 60

Pro Lys Phe Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Ile Pro

US 9,315,576 B2

163

-continued

164

65	70	75	80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile			
85	90	95	
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Leu			
100	105	110	
Arg Ser Ser Gly Asn Ala Val Phe Gly Gly Thr His Leu Thr Val			
115	120	125	
Leu Gly			
130			

<210> SEQ ID NO 51
<211> LENGTH: 130
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius
<400> SEQUENCE: 51

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly			
1	5	10	15
Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr			
20	25	30	
Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val			
35	40	45	
Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala			
50	55	60	
Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Ile Pro			
65	70	75	80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile			
85	90	95	
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr			
100	105	110	
Arg Asn Trp Ala Asn Leu Pro Phe Gly Gly Thr His Leu Thr Val			
115	120	125	
Leu Gly			
130			

<210> SEQ ID NO 52
<211> LENGTH: 130
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius
<400> SEQUENCE: 52

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly			
1	5	10	15
Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr			
20	25	30	
Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Gly Val			
35	40	45	
Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Arg Gln Leu Pro Gly Thr Ala			
50	55	60	
Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Ile Pro			
65	70	75	80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile			
85	90	95	
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr			
100	105	110	
Arg Asn Gly Asn Asn Ala Val Phe Gly Gly Thr His Leu Thr Val			

US 9,315,576 B2

165

-continued

115 120 125

Leu Gly
130

<210> SEQ_ID NO 53
<211> LENGTH: 130
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 53

Met Ala Trp Ala Leu Leu Leu	Leu Thr Leu Leu Thr Gln Gly Thr Gly
1 5	10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val	Gly Thr
20 25	30

Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val	
35 40	45

Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala	
50 55	60

Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Ile Pro	
65 70	75 80

Asp Arg Phe Ser Ser Ser Lys Ser Asp Asn Thr Ala Ser Met Thr Ile	
85 90	95

Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr	
100 105	110

Arg Ser Arg Asp Asn Ala Val Phe Gly Gly Thr His Leu Thr Val	
115 120	125

Leu Gly
130

<210> SEQ_ID NO 54
<211> LENGTH: 130
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 54

Met Ala Trp Ala Leu Leu Leu	Leu Thr Leu Leu Thr Gln Gly Thr Gly
1 5	10 15

Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val	Ser Gly Thr
20 25	30

Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val	
35 40	45

Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Glu Thr Ala	
50 55	60

Pro Lys Leu Leu Ile Tyr Asp Val Asp Lys Arg Ala Ser Gly Ile Pro	
65 70	75 80

Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile	
85 90	95

Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr	
100 105	110

Arg Ser Gly Asp Asn Ala Ala Phe Gly Gly Thr Arg Leu Thr Val	
115 120	125

Leu Gly
130

<210> SEQ_ID NO 55
<211> LENGTH: 111
<212> TYPE: PRT

166

-continued

Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Pro Ser Gly Ile Pro
65 70 75 80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Val Ser Leu Thr Ile
85 90 95
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Thr Cys Ala Ser Tyr
100 105 110
Lys His Thr Tyr Asn Ala Val Phe Gly Gly Thr His Leu Thr Val
115 120 125
Leu Gly
130

<210> SEQ ID NO 58
<211> LENGTH: 133
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 58

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
1 5 10 15
Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr
20 25 30
Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Arg Asp Asp Val
35 40 45
Gly Lys Tyr Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Ile Pro
65 70 75 80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Ile
85 90 95
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Val
100 105 110
Arg Asp Tyr Asp Asn Asn Glu Phe Val Val Phe Gly Gly Thr His
115 120 125
Leu Thr Val Leu Gly
130

<210> SEQ ID NO 59
<211> LENGTH: 130
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 59

Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly
1 5 10 15
Ser Trp Ala Gln Ser Ala Leu Thr Gln Pro Ser Ser Val Ser Gly Thr
20 25 30
Pro Gly Gln Thr Val Thr Ile Ser Cys Thr Gly Thr Ser Asn Asp Val
35 40 45
Gly Arg Tyr Ala Tyr Val Ser Trp Tyr Gln His Leu Pro Gly Thr Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Gln Val Asn Lys Arg Ala Ser Gly Thr Pro
65 70 75 80
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Met Thr Thr
85 90 95
Ser Gly Leu Gln Ser Ala Asp Glu Ala Asp Tyr Tyr Cys Ser Ala Tyr
100 105 110

-continued

Arg Ser Asn Asp Gly Pro Val Phe Gly Gly Gly Thr His Leu Thr Val
 115 120 125

Leu Gly
 130

<210> SEQ ID NO 60

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 60

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
 1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala
 20 25 30

Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
 35 40 45

Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
 50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala
 85 90 95

<210> SEQ ID NO 61

<211> LENGTH: 108

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 61

Gln Ser Val Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Glu
 1 5 10 15

Thr Ala Arg Ile Thr Cys Gln Gly Asn Phe Gly Ser Tyr Tyr Ala
 20 25 30

Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Leu Tyr
 35 40 45

Lys Asp Ser Ala Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
 50 55 60

Ser Ser Gly Gly Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu
 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Gly Ser Ser Ser Ala Ser Ala
 85 90 95

Val Phe Gly Gly Gly Thr His Leu Thr Val Leu Gly
 100 105

<210> SEQ ID NO 62

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 62

Gln Ser Val Leu Thr Gln Pro Ser Ala Val Ser Val Pro Leu Gly Glu
 1 5 10 15

Thr Ala Arg Ile Thr Cys Gln Gly Asp Phe Gly Asp Tyr Tyr Val
 20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
 35 40 45

-continued

Lys Asp Thr Leu Arg Pro Ser Gly Ile Pro Glu Arg Phe Thr Gly Ser
50 55 60

Ser Ser Gly Gly Ala Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Glu Thr Ser Ser Ala Thr Val
85 90 95

Phe Gly Gly Gly Thr His Leu Thr Val Leu Gly
100 105

<210> SEQ ID NO 63

<211> LENGTH: 108

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 63

Thr Ala Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Glu Thr
1 5 10 15

Ala Arg Ile Thr Cys Gln Gly Gly Asn Phe Gly Ser Tyr Tyr Thr Ser
20 25 30

Trp Tyr Gln Gln Lys Pro Glu Glu Ala Pro Val Val Val Ile Tyr Lys
35 40 45

Asp Thr Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Ala Ser Ser
50 55 60

Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu Asp
65 70 75 80

Glu Ala Asp Tyr Tyr Cys Gln Ser Gly Ser Ser Ser Ala Asn Ala Pro
85 90 95

Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105

<210> SEQ ID NO 64

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 64

Gln Ala Val Leu Ser Gln Pro Ser Ala Val Ser Val Ser Leu Gly Glu
1 5 10 15

Thr Ala Arg Ile Thr Cys Gln Gly Asp Asn Phe Gly Ser Tyr Tyr Phe
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35 40 45

Arg Asn Ser Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Ala Ser
50 55 60

Ser Ser Gly Gly Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Arg Asn
85 90 95

Ala Arg Ala Phe Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110

<210> SEQ ID NO 65

<211> LENGTH: 111

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 65

Gln Ser Val Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Gln

US 9,315,576 B2

175**176**

-continued

1	5	10	15
Thr Ala Arg Ile Thr Cys Gln Gly Gly Ile Leu Gly Ser Lys Lys Thr			
20	25	30	
Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr			
35	40	45	
Gly Asp Asp Ser Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser			
50	55	60	
Arg Ser Gly Gly Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu			
65	70	75	80
Asp Glu Ala Asp Tyr Tyr Cys Gln Leu Leu Asp Ser Thr Asp Ser Ser			
85	90	95	
Ser Tyr Trp Val Phe Gly Gly Thr His Leu Thr Val Leu Gly			
100	105	110	

<210> SEQ_ID NO 66

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

1	5	10	15
Ser Tyr Glu Leu Thr Gln Pro His Ser Val Ala Thr Ala Gln			
Met Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ala Val			
20	25	30	
His Trp Tyr Gln Gln Lys Pro Gly Gln Asp Pro Val Leu Val Ile Tyr			
35	40	45	
Ser Asp Ser Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser			
50	55	60	
Asn Pro Gly Asn Thr Thr Leu Thr Ile Ser Arg Ile Glu Ala Gly			
65	70	75	80
Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Asp His			
85	90	95	

<210> SEQ_ID NO 67

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 67

1	5	10	15
Gln Ser Val Leu Thr Gln Pro Ser Thr Ala Ser Met Ser Leu Gly Gln			
Thr Ala Lys Ile Thr Cys Gln Gly Ser Leu Arg Asn Tyr Ala Ala			
20	25	30	
His Trp Tyr Gln Gln Lys Pro Gly Ala Ala Pro Val Leu Val Ile Tyr			
35	40	45	
Asn Asp Asn Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser			
50	55	60	
Lys Ser Gly Gly Thr Ala Thr Leu Thr Ile Ser Arg Thr Lys Ala Glu			
65	70	75	80
Asp Glu Ala Asp Tyr Tyr Cys Leu Ser Arg Asp Met Ser Asp Ser Asn			
85	90	95	
Arg Val Val Phe Gly Gly Thr His Leu Thr Val Leu Gly			
100	105	110	

<210> SEQ_ID NO 68

<211> LENGTH: 101

<212> TYPE: PRT

-continued

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 68

Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Pro	Val	Thr	Pro	Gly
1					5				10				15		

Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Gln	Ser	Leu	Leu	Asp	Ser
					20			25				30			

Asp	Asp	Gly	Asn	Thr	Tyr	Leu	Asp	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln
					35			40			45				

Ser	Pro	Gln	Leu	Leu	Ile	Tyr	Thr	Leu	Ser	Tyr	Arg	Ala	Ser	Gly	Val
					50			55			60				

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	
65					70			75			80			

Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Met	Gln
					85			90			95				

Arg	Ile	Glu	Phe	Pro											
				100											

<210> SEQ ID NO 69

<211> LENGTH: 114

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 69

Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1					5			10			15				

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Phe	Asp	Thr
					20			25			30				

Ser	Arg	Gln	Lys	Ser	Phe	Leu	Asn	Trp	His	Arg	Gln	Arg	Pro	Gly	Gln
					35			40			45				

Ser	Pro	Arg	Arg	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Arg	Gln	Ser	Gly	Val
					50			55			60				

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65					70			75			80				

Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
					85			90			95				

Ala	Phe	Asn	Val	Gln	Pro	Ser	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile
					100			105			110				

Lys Arg

<210> SEQ ID NO 70

<211> LENGTH: 114

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 70

Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1					5			10			15				

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Phe	Ser	Ser
					20			25			30				

Ser	Ser	Gln	Lys	Ser	Leu	Leu	Asp	Trp	His	Gln	Gln	Arg	Pro	Gly	Gln
					35			40			45				

Ser	Pro	Arg	Arg	Leu	Ile	Tyr	Tyr	Ala	Ser	Ala	Arg	Ala	Ser	Gly	Val
					50			55			60				

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65					70			75			80				

US 9,315,576 B2

179**180**

-continued

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln	85	90	95
---	----	----	----

Tyr Ser Gly Ser Pro Pro Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile	100	105	110
---	-----	-----	-----

Lys Arg

<210> SEQ ID NO 71

<211> LENGTH: 114

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 71

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Val Gly	1	5	10	15
---	---	---	----	----

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln His Val Ile Ser Val	20	25	30
---	----	----	----

Ser Asn Gln Lys Ser Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln	35	40	45
---	----	----	----

Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Arg Glu Ser Gly Ile	50	55	60
---	----	----	----

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Ala Leu Thr	65	70	75	80
---	----	----	----	----

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln	85	90	95
---	----	----	----

Ala Tyr Ser Thr Pro Tyr Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile	100	105	110
---	-----	-----	-----

Lys Arg

<210> SEQ ID NO 72

<211> LENGTH: 114

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 72

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Val Gly	1	5	10	15
---	---	---	----	----

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Ser Ser	20	25	30
---	----	----	----

Ser Asn Gln Lys Ser Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln	35	40	45
---	----	----	----

Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Arg Glu Ser Gly Ile	50	55	60
---	----	----	----

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr	65	70	75	80
---	----	----	----	----

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Phe Tyr Cys Gln Gln	85	90	95
---	----	----	----

Ala Tyr Ser Ala Pro Tyr Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile	100	105	110
---	-----	-----	-----

Lys Arg

<210> SEQ ID NO 73

<211> LENGTH: 114

<212> TYPE: PRT

<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 73

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Val Leu Ala Ser Val Gly

US 9,315,576 B2

181**182**

-continued

1	5	10	15												
Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Leu	Ser	Ser
		20			25			30							
Ser	Asn	Gln	Lys	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Gln
		35			40			45							
Ser	Pro	Arg	Leu	Leu	Ile	Thr	Tyr	Ala	Ser	Thr	Arg	Glu	Ser	Gly	Ile
		50			55			60							
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
	65		70			75			80						
Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Val	Val	Tyr	Tyr	Cys	Gln	Gln
		85			90			95							
Ala	Tyr	Ser	Lys	Pro	Tyr	Asn	Phe	Gly	Asn	Gly	Thr	Arg	Leu	Glu	Ile
		100			105			110							

Lys Arg

<210> SEQ ID NO 74
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 74

1	5	10	15												
Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Thr	Ser	Val	Thr	Ala	Ser	Val	Gly
Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Phe	Ala	Ser
		20			25			30							
Ser	Ser	Gln	Lys	Ser	Gln	Leu	Ala	Trp	His	Gln	Gln	Arg	Pro	Gly	Gln
		35			40			45							
Ser	Pro	Arg	Arg	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Arg	Glu	Ser	Gly	Val
	50		55			60									
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
	65		70			75			80						
Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	His
		85			90			95							
Leu	Tyr	Ser	Ala	Pro	Tyr	Ser	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile
		100			105			110							

Lys Arg

<210> SEQ ID NO 75
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 75

1	5	10	15												
Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Asn	Leu	Val	Ser	Asp
		20			25			30							
Ser	Asn	Gln	Arg	Ser	Leu	Leu	Ala	Trp	His	Gln	Gln	Arg	Pro	Gly	Gln
		35			40			45							
Ser	Pro	Arg	Lys	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Arg	Thr	Ser	Gly	Thr
	50		55			60									
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
	65		70			75			80						
Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
		85			90			95							

-continued

Gly Lys Lys Asp Pro Leu Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile
 100 105 110

Lys Arg

<210> SEQ ID NO 76
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 76

Ala Glu Tyr Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 1 5 10 15

Ser

<210> SEQ ID NO 77
 <211> LENGTH: 17
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 77

Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser
 1 5 10 15

Ser

<210> SEQ ID NO 78
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 78

Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 1 5 10 15

<210> SEQ ID NO 79
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 79

Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1 5 10 15

<210> SEQ ID NO 80
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 80

Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1 5 10 15

<210> SEQ ID NO 81
 <211> LENGTH: 20
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 81

Tyr Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
 1 5 10 15

Thr Val Ser Ser
 20

US 9,315,576 B2

185

-continued

<210> SEQ ID NO 82

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 82

Gly	Tyr	Arg	Tyr	Leu	Glu	Val	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val
1				5				10				15			

Ser Ser

<210> SEQ ID NO 83

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 83

Asn	Ala	Leu	Asp	Ala	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
1					5			10			15				

<210> SEQ ID NO 84

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 84

Glu	Tyr	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser
1				5				10			15			

<210> SEQ ID NO 85

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 85

Pro	Gln	Phe	Glu	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser
1					5			10			15			

<210> SEQ ID NO 86

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 86

Asp	Phe	Gly	Ser	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser
1					5			10					

<210> SEQ ID NO 87

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 87

Tyr	Val	Phe	Gly	Thr	Gly	Thr	Lys	Val	Thr	Val	Leu
1					5			10			

<210> SEQ ID NO 88

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 88

Val	Val	Phe	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu
1					5			10		

-continued

<210> SEQ ID NO 89
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 89

Val Val Phe Gly Gly	Gly Thr Lys Leu Thr Val Leu
5	10

<210> SEQ ID NO 90
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 90

Phe Val Phe Gly Gly	Gly Thr Gln Leu Ile Ile Leu
5	10

<210> SEQ ID NO 91
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 91

Trp Val Phe Gly Glu Gly	Thr Glu Leu Thr Val Leu
5	10

<210> SEQ ID NO 92
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 92

Asn Val Phe Gly Ser Gly	Thr Lys Val Thr Val Leu
5	10

<210> SEQ ID NO 93
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 93

Ala Val Phe Gly Gly	Gly Thr Gln Leu Thr Val Leu
5	10

<210> SEQ ID NO 94
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 94

Phe Gly Gly Gly Thr His	Leu Thr Val Leu Gly
5	10

<210> SEQ ID NO 95
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 95

Phe Gly Gly Gly Thr Lys	Leu Thr Val Leu Gly
5	10

<210> SEQ ID NO 96
<211> LENGTH: 11

-continued

<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 96

Phe Gly Gly Thr Arg Leu Thr Val Leu Gly
1 5 10

<210> SEQ ID NO 97
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 97

Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> SEQ ID NO 98
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 98

Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 99
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 99

Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
1 5 10

<210> SEQ ID NO 100
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 100

Leu Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> SEQ ID NO 101
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 101

Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 102
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

<400> SEQUENCE: 102

Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys Arg
1 5 10

<210> SEQ ID NO 103
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Camelus dromedarius

US 9,315,576 B2

191**192**

-continued

<400> SEQUENCE: 103

Phe	Gly	Asn	Gly	Thr	Arg	Leu	Glu	Ile	Lys	Arg
1				5				10		

<210> SEQ ID NO 104

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 104

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10			15				

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20				25				30						

Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35				40				45						

Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50				55			60							

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70			75		80					

Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
	85				90				95						

Ala	Lys	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser			
	100				105										

<210> SEQ ID NO 105

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 105

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5			10		15					

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ala	Phe	Ser	Ser	Tyr
	20				25			30							

Asp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35				40				45						

Ser	Ala	Ile	Asn	Ser	Gly	Gly	Ile	Ser	Thr	Tyr	Asn	Ala	Asp	Ser	Met
	50				55			60							

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
65					70			75		80					

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
	85				90			95							

Asn	Ala	Asp	Thr	Trp	Tyr	Cys	Asp	Gln	Leu	Asp	Ser	Ser	Asp	Tyr	Trp
	100				105			110							

Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser						
	115			120											

<210> SEQ ID NO 106

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 106

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Arg
1					5			10		15					

Ser Leu Arg Val Ser Tyr Ala Ala Ser Gly Phe Thr Phe Ser Ser His

US 9,315,576 B2

193**194**

-continued

20

25

30

Tyr Met Ser Trp Val Arg Gln Asp Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ser Glu Ile Ala Thr Gly Gly Thr Ile Thr Ser Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Asn Asn Met Leu Phe
 65 70 75 80

Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95

Val Arg Arg Gly Arg Ala Ile Ala Phe Asp Val Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 107

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 107

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Asp Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Thr Ile Tyr Thr His Ser Arg Asn Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Asp Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95

Ala Lys Glu Trp Val Gly Ser Val Val Glu Gly Arg Tyr Arg Gly Trp
 100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 108

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<222> LOCATION: (36)..(36)

<223> OTHER INFORMATION: Unknown amino acid

<400> SEQUENCE: 108

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Val Met Ser Xaa Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Gly Val Asn Thr Asp Gly Arg Ser Ile Thr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

-continued

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Thr Lys Ile Cys Thr Val Ile Thr Gly Arg Pro Gly Tyr Asp Tyr Trp
100 105 110

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 109

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 109

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Leu
20 25 30

Tyr Met Ser Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Thr Ile His Thr Ala Ser Gly Ser Thr Phe Tyr Ala Asp Ser Val
50 55 60

Gln Gly Arg Phe Leu Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asp Ser Leu Lys Pro Glu Asp Thr Ala Arg Tyr Tyr Cys
85 90 95

Ala Ser Ala Ile Leu Gly Trp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> SEQ ID NO 110

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 110

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Tyr Ser Asp Gly Thr Thr Tyr Asp Gly Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Ala Ala Val Tyr Tyr Cys
85 90 95

Ala Ser Ala Ile Arg Gly Trp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> SEQ ID NO 111

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

-continued

<210> SEQ_ID NO 114
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 114

Asn	Phe	Met	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ser	Pro	Gly	Gln
1						5			10				15		

Lys Phe Thr Ile Ser Cys Thr Gly Ser Ser Ser Asp Ile Gly Asn Asn
20 25 30

Tyr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Thr Asp Lys Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln
65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Asn Leu
85 90 95

Gly Thr Tyr Val Phe Gly Gly Thr Ser Val Thr Val Leu
100 105 110

<210> SEQ_ID NO 115
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 115

Asn	Phe	Met	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ser	Pro	Gly	Gln
1						5			10				15		

Lys Phe Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Glu Asn
20 25 30

Phe Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Thr Asp Lys Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln
65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Asn Leu
85 90 95

Gly Thr Tyr Val Phe Gly Gly Thr Ser Val Thr Val Leu
100 105 110

<210> SEQ_ID NO 116
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 116

Asn	Phe	Met	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ser	Pro	Gly	Gln
1						5			10				15		

Lys Phe Thr Ile Ser Cys Thr Gly Ser Asn Asn Asn Ile Gly Asn Asn
20 25 30

Tyr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Asn Asn Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

US 9,315,576 B2

201

202

-continued

Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln
 65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Glu Ser Leu
 85 90 95

Ser Gly Arg Tyr Val Phe Gly Gly Thr Lys Leu Ala Val Leu
 100 105 110

<210> SEQ ID NO 117

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 117

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
 1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
 20 25 30

Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
 85 90 95

Leu Ser Gly

<210> SEQ ID NO 118

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 118

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Ser Asn Asp Ile Gly Arg Tyr
 20 25 30

Asn Tyr Val Ala Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Leu Ile Tyr Ala Val Ser Tyr Arg Ala Ser Gly Ile Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80

Gln Ser Gly Asp Glu Ala Asp Tyr Tyr Cys Val Ser Tyr Arg Ser Gly
 85 90 95

Gly Thr Asn Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 119

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 119

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15

Thr Leu Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Tyr Gly
 20 25 30

-continued

Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45
 Leu Ile Tyr Arg Val Ser Tyr Arg Pro Ser Gly Ile Pro Asp Arg Phe
 50 55 60
 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80
 Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Thr Ser Tyr Thr Tyr Lys
 85 90 95
 Gly Gly Gly Thr Ala Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 120

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 120

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15
 Thr Val Thr Ile Ser Cys Ala Gly Thr Arg Thr Asp Val Gly Tyr Gly
 20 25 30
 Asp Tyr Val Ser Trp Tyr Gln His Val Pro Asn Thr Ala Pro Arg Leu
 35 40 45
 Leu Ile Tyr Ala Val Ser Ala Arg Ala Ser Gly Ile Pro Ser Arg Phe
 50 55 60
 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80
 Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Arg Asp Gly
 85 90 95
 Asn Tyr Ala Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 121

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 121

Gln Ala Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15
 Ala Val Thr Ile Ser Cys Ala Gly Thr Gly Ser Asp Val Gly Tyr Gly
 20 25 30
 Asp Tyr Val Ser Trp Tyr Gln Gln Leu Pro Asp Thr Ala Pro Lys Leu
 35 40 45
 Leu Val Tyr Ala Val Asn Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe
 50 55 60
 Ser Gly Ser Arg Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80
 Gln Ser Glu Asp Glu Gly Asp Tyr Tyr Cys Ala Ser Tyr Arg Ser Tyr
 85 90 95
 Asn Asn Tyr Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 122

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

-continued

<400> SEQUENCE: 122

Asn	Phe	Met	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ser	Pro	Gly	Lys
1						5			10					15	
Thr	Val	Thr	Ile	Ser	Cys	Ala	Gly	Thr	Ser	Ser	Asp	Val	Gly	Tyr	Gly
			20				25						30		
Asn	Tyr	Val	Ser	Trp	Tyr	Gln	Gln	Leu	Pro	Gly	Met	Ala	Pro	Lys	Leu
						35		40			45				
Leu	Leu	Tyr	Asn	Ile	Asn	Lys	Arg	Ala	Ser	Gly	Ile	Ala	Asp	Arg	Phe
						50		55			60				
Ser	Gly	Ser	Lys	Ser	Gly	Asn	Thr	Ala	Ser	Leu	Thr	Ile	Ser	Gly	Leu
			65			70			75				80		
Gln	Ser	Glu	Asp	Glu	Ala	Val	Tyr	Tyr	Cys	Ala	Ser	Tyr	Arg	Ser	Gly
						85		90			95				
Asn	Asn	Tyr	Val	Phe	Gly	Gly	Thr	Glu	Leu	Thr	Val	Leu			
				100			105				110				

<210> SEQ ID NO 123

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 123

Gln	Ser	Ala	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Thr	Leu	Gly	Lys
1						5			10				15		
Thr	Val	Thr	Ile	Ser	Cys	Ala	Gly	Thr	Asn	Ser	Asp	Ile	Gly	Asp	Tyr
			20				25						30		
Asn	Phe	Val	Ser	Trp	Tyr	Gln	His	Leu	Pro	Gly	Met	Ala	Pro	Lys	Leu
						35		40			45				
Leu	Ile	Tyr	Asp	Val	Asn	Lys	Arg	Ala	Ser	Gly	Ile	Ala	Asp	Arg	Phe
			50			55			60						
Ser	Gly	Ser	Lys	Ser	Gly	Asn	Thr	Ala	Ser	Leu	Thr	Ile	Ser	Gly	Leu
			65			70			75				80		
Gln	Ser	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Ser	Tyr	Arg	Ser	Ser
						85		90			95				
Asn	Asn	Tyr	Val	Phe	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu			
				100			105				110				

<210> SEQ ID NO 124

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 124

Gln	Ala	Gly	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Gly	Ser	Leu	Gly	Lys
1						5			10				15		
Thr	Ile	Thr	Ile	Ser	Cys	Ala	Gly	Thr	Arg	Asn	Asp	Ile	Gly	Gly	His
			20				25						30		
Gly	Tyr	Val	Ser	Trp	Tyr	Gln	Gln	Leu	Pro	Gly	Thr	Ala	Pro	Lys	Leu
						35		40			45				
Leu	Ile	Tyr	Lys	Ile	Asn	Thr	Arg	Ala	Ser	Gly	Ile	Pro	Asp	Arg	Phe
			50			55			60						
Ser	Gly	Ser	Lys	Ser	Gly	Asn	Thr	Ala	Ser	Leu	Thr	Ile	Ser	Gly	Leu
			65			70			75				80		
Gln	Ser	Glu	Asp	Glu	Ala	Asp	Tyr	Phe	Cys	Val	Ala	Asp	Ile	Asn	Gly
						85		90			95				

-continued

Asp Thr Asn Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 125

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 125

Ser Ser Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Ser Asn Asp Ile Gly Ala His
 20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Leu Ile Asn Lys Val Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
 65 70 75 80

Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Tyr Arg Thr Gly
 85 90 95

Asp Ala Arg Ile Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 126

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 126

Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Lys
 1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Ile Gly Tyr Gly
 20 25 30

Asn Tyr Val Ser Trp Tyr Gln Leu Leu Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Leu Ile Tyr Asp Val Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Gln Ala Tyr Leu Thr Ile Ser Gly Leu
 65 70 75 80

Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ser Tyr Arg Glu Pro
 85 90 95

Asn Asn Phe Val Ser Gly Gly Thr His Leu Val Val Leu
 100 105 110

<210> SEQ ID NO 127

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 127

Gln Ser Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Leu Gly Lys
 1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Ile Gly Asp Ile Gly Ala Gly
 20 25 30

Asn Tyr Val Ser Trp Tyr Arg Gln Thr Pro Gly Thr Ala Pro Lys Leu
 35 40 45

Leu Leu Tyr Glu Val Asn Lys Arg Thr Ser Gly Ile Pro Asp Arg Phe

US 9,315,576 B2

209**210**

-continued

50 55 60

Ala Gly Ser Arg Ser Gly Asn Thr Ala Ser Leu Ile Ile Ser Gly Leu
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Arg Ile Gly
 85 90 95

Ser Arg Gly Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 128

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 128

Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Leu Gly Lys
 1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Trp Ser Asp Ile Gly Gly Tyr
 20 25 30

Asn Tyr Ile Ser Trp Tyr Arg Gln Leu Pro Gly Thr Ala Pro Arg Leu
 35 40 45

Leu Ile Tyr Glu Val Asp Lys Arg Ala Pro Gly Ile Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Thr Thr Ala Ser Leu Val Ile Ser Gly Leu
 65 70 75 80

Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Lys Ser Ser
 85 90 95

Glu Asn Ala Val Phe Gly Gly Thr His Leu Thr Val Val
 100 105 110

<210> SEQ ID NO 129

<211> LENGTH: 99

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 129

Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln
 1 5 10 15

Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr
 20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
 35 40 45

Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser
 85 90 95

Asn Asn Phe

<210> SEQ ID NO 130

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 130

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
 1 5 10 15

-continued

Thr Leu Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Tyr Gly
20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45

Leu Ile Tyr Arg Val Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Arg Ser Thr
85 90 95

Gly Thr Ala Val Phe Gly Gly Thr His Leu Ser Val Leu
100 105 110

<210> SEQ ID NO 131

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 131

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
1 5 10 15

Thr Val Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Tyr Gly
20 25 30

Asn Tyr Val Ser Trp Tyr Gln Lys Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45

Leu Ile Tyr Ala Val Ser Tyr Arg Ala Ser Gly Ile Pro Asp Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Arg Asp Ser
85 90 95

Asn Asn Ala Val Phe Gly Gly Thr His Leu Thr Ala Leu
100 105 110

<210> SEQ ID NO 132

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 132

Leu Pro Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Leu Gly Lys
1 5 10 15

Ser Leu Thr Ile Ser Cys Ala Gly Thr Ser Ser Asp Val Gly Asn Gly
20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45

Leu Ile Tyr Arg Val Thr Ser Arg Ala Ser Gly Val Pro Asp Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Tyr Lys Arg Gly
85 90 95

Gly Thr Ser Val Phe Gly Gly Thr His Leu Thr Val Leu
100 105 110

<210> SEQ ID NO 133

<211> LENGTH: 110

-continued

100 105

<210> SEQ ID NO 136
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 136

Gln Ala Val Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Gln
1 5 10 15

Thr Ala Arg Leu Thr Cys Gln Gly Asp Asn Val Glu Thr Ala Gly Thr
20 25 30

Ser Trp Tyr Arg Gln Lys Pro Gly Gln Ala Pro Ser Leu Ile Ile Tyr
35 40 45

Gly Asp Ser Ser Arg Pro Ser Glu Ile Ser Glu Arg Phe Ser Ala Ser
50 55 60

Thr Ser Gly Asn Thr Ala Thr Leu Thr Ile Thr Gly Ala Gln Ala Glu
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Leu Ser Ala Asp Ser Asp Leu Asp Ser
85 90 95

Val Phe Gly Gly Thr Leu Leu Thr Val Leu
100 105

```

<210> SEQ ID NO 137
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 137

Gln Ala Gly Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Gln
1           5           10          15

Thr Ala Arg Ile Thr Cys Arg Gly Asp Ser Leu Glu Arg Tyr Gly Ala
20          25          30

Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Arg Val Gln Val Ile Tyr
35          40          45

Gly Asp Asp Ile Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50          55          60

Arg Leu Gly Gly Thr Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu
65          70          75          80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ser Asp Ser Ser Gly Tyr Met
85          90          95

Asn Asp Phe Ser Ser Arg Thr His Leu Thr Val Leu
100         105

```

```

<210> SEQ ID NO 138
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 138

Gln Ser Ala Leu Thr Gln Pro Ser Ala Val Ser Val Ser Leu Gly Gln
1           5           10          15

Thr Ala Glu Ile Thr Cys Arg Gly Arg Asn Phe Glu Ser Gly Phe Pro
20          25          30

His Trp Tyr Arg Gln Lys Pro Gly Gln Ser Pro Glu Leu Val Met Phe
35          40          45

Ile Val Asn Asn Arg Trp Ser Gly Ile Pro Asp Arg Phe Ser Gly Thr
50          55          60

```

-continued

Arg Ser Gly Asp Ala Ala Thr Leu Thr Ile Thr Gly Val Gln Ala Glu
 65 70 75 80
 Asp Glu Ala Asp Tyr Tyr Cys Gln Met Trp Asp Gly Glu Gly Ala Val
 85 90 95
 Phe Gly Gly Thr His Leu Thr Val Leu
 100 105

<210> SEQ ID NO 139
<211> LENGTH: 103
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 139

Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Leu Leu Gly Ala
 1 5 10 15
 Ser Ile Lys Leu Thr Cys Thr Leu Ser Ser Glu His Ser Thr Tyr Thr
 20 25 30
 Ile Glu Trp Tyr Gln Gln Arg Pro Gly Arg Ser Pro Gln Tyr Ile Met
 35 40 45
 Lys Val Lys Ser Asp Gly Ser His Ser Lys Gly Asp Gly Ile Pro Asp
 50 55 60
 Arg Phe Met Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Thr Phe Ser
 65 70 75 80
 Asn Leu Gln Ser Asp Asp Glu Ala Glu Tyr His Cys Gly Glu Ser His
 85 90 95
 Thr Ile Asp Gly Gln Val Gly
 100

<210> SEQ ID NO 140
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 140

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Ser Leu Gly Ala
 1 5 10 15
 Ser Ala Lys Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Asn
 20 25 30
 Val Asp Trp Tyr Gln Gln Val Pro Gly Lys Ser Pro Trp Phe Leu Met
 35 40 45
 Arg Val Gly Ser Ser Gly Val Gly Ser Lys Gly Ser Gly Val Ser Asp
 50 55 60
 Arg Phe Ser Gly Ser Ser Ser Gly Leu Glu Arg Tyr Leu Thr Ile Gln
 65 70 75 80
 Asn Val Gln Glu Glu Asp Glu Ala Glu Tyr Ile Cys Gly Ala Asp His
 85 90 95
 Ala Ser Ser Met Tyr Thr Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 141
<211> LENGTH: 104
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 141

Gln Pro Val Leu Thr Gln Pro Pro Ser Ser Ser Ala Ser Pro Gly Glu
 1 5 10 15

219**220**

-continued

Ser Ala Arg Leu Thr Cys Thr Leu Pro Ser Asp Ile Asn Val Gly Ser
 20 25 30

Tyr Asn Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Tyr
 35 40 45

Leu Leu Tyr Tyr Ser Asp Ser Asp Lys Gly Gln Gly Ser Gly Val
 50 55 60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Thr Gly Ile
 65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
 85 90 95

Met Ile Trp Pro Ser Asn Ala Ser
 100

<210> SEQ_ID NO 142

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 142

Leu Pro Val Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly Ala
 1 5 10 15

Ser Ala Arg Leu Thr Cys Ser Leu Asn Ser Gly Thr Ile Val Gly Gly
 20 25 30

Tyr His Ile Asn Trp Tyr Gln Gln Lys Ala Gly Ser Pro Pro Arg Tyr
 35 40 45

Leu Leu Arg Phe Tyr Ser Asp Ser Asn Lys His Gln Gly Ser Gly Val
 50 55 60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Leu
 65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys
 85 90 95

Gly Ile Tyr Asp Ser Asn Thr Gly Thr Tyr Val Phe Gly Gly Thr
 100 105 110

Lys Leu Thr Val Leu
 115

<210> SEQ_ID NO 143

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 143

Leu Pro Val Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly Ala
 1 5 10 15

Ser Ala Arg Leu Thr Cys Val Leu Ser Ser Gly Thr Val Val Gly Gly
 20 25 30

Tyr His Ile Asn Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Tyr
 35 40 45

Leu Leu Arg Phe Tyr Ser Asp Ser Ser Lys Gln Gln Gly Ser Gly Val
 50 55 60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Leu
 65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys
 85 90 95

Gly Thr Tyr His Ser Asn Thr Gly Thr Tyr Val Phe Gly Gly Thr
 100 105 110

-continued

Lys Leu Thr Val Leu
115

<210> SEQ ID NO 144

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 144

Leu	Pro	Val	Leu	Asn	Gln	Pro	Pro	Ser	Leu	Ser	Ala	Ser	Pro	Gly	Glu
1															
									5	10			15		

Ser	Ala	Arg	Leu	Thr	Cys	Ser	Leu	Ser	Ser	Glu	Thr	Ile	Val	Gly	Gly
									20	25		30			

Tyr	Gln	Ile	Ala	Trp	Tyr	Gln	Gln	Thr	Ala	Gly	Ser	Pro	Pro	Arg	Tyr
									35	40		45			

Leu	Leu	Arg	Phe	Tyr	Ser	Asp	Ser	Asn	Lys	His	Gln	Gly	Ser	Gly	Val
									50	55		60			

Pro	Ser	Arg	Phe	Ser	Gly	Ser	Lys	Asp	Ala	Ser	Ala	Asn	Ala	Gly	Ile
									65	70		75		80	

Leu	Phe	Ile	Ser	Gly	Leu	Gln	Pro	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys
									85	90		95			

Gly	Ile	Tyr	His	Tyr	Asn	Ser	Asp	Thr	Tyr	Val	Phe	Gly	Gly	Thr	
									100	105		110			

Arg Leu Thr Val Leu
115

<210> SEQ ID NO 145

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 145

Leu	Pro	Val	Leu	Thr	Gln	Pro	Pro	Ser	Leu	Ser	Ala	Ser	Pro	Gly	Ser
1															
									5	10		15			

Ser	Val	Arg	Leu	Thr	Cys	Thr	Leu	Ser	Ser	Gly	Lys	Ser	Val	Gly	Met
									20	25		30			

Tyr	Asp	Ile	Ser	Trp	Tyr	Gln	Gln	Lys	Ala	Gly	Ser	Pro	Pro	Arg	Tyr
									35	40		45			

Leu	Leu	Tyr	Tyr	Tyr	Ser	Asp	Thr	Ser	Asn	His	Gln	Gly	Ser	Gly	Val
									50	55		60			

Pro	Ser	Arg	Phe	Ser	Gly	Ser	Lys	Asp	Ala	Ser	Ala	Asn	Ala	Gly	Leu
									65	70		75		80	

Leu	Leu	Ile	Ser	Gly	Leu	Gln	Pro	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys
									85	90		95			

Ala	Thr	Gly	Asp	Arg	Ser	Ser	Asn	Pro	His	Val	Phe	Gly	Gly	Thr	
									100	105		110			

Lys Leu Thr Val Leu
115

<210> SEQ ID NO 146

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 146

Gln	Ser	Val	Leu	Thr	Gln	Pro	Pro	Ser	Leu	Ser	Ala	Ser	Pro	Gly	Ser
1															
									5	10		15			

Ser Val Arg Leu Thr Cys Thr Leu Ser Ser Ala Asn Ser Val Asp Asn

-continued

20	25	30
----	----	----

Tyr Tyr Ile Ser Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Tyr
35 40 45

Leu Leu Tyr Tyr Tyr Ser Asp Ser Tyr Met Gln Arg Asp Ser Gly Leu
50 55 60

Pro Asp Arg Phe Ser Val Ser Lys Asp Ala Ser Thr Asn Ala Gly Leu
65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys
85 90 95

Ala Ser Gly Asp Arg Asn Ser Asn Pro His Ser Val Phe Gly Gly Gly
100 105 110

Thr His Leu Thr Val Leu
115

<210> SEQ ID NO 147

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 147

Gln Thr Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
1 5 10 15

Thr Val Thr Leu Thr Cys Ala Ser Ser Thr Gly Ala Val Thr Ser Gly
20 25 30

Tyr Tyr Pro Asn Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Ala
35 40 45

Leu Ile Tyr Ser Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe
50 55 60

Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Val
65 70 75 80

Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Tyr Tyr Gly Gly
85 90 95

Ala Gln

<210> SEQ ID NO 148

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 148

Gln Ala Val Val Ser Gln Glu Pro Ser Leu Ser Val Ser Pro Gly Gly
1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Thr Ser
20 25 30

Asn Tyr Pro Gly Trp Phe Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
35 40 45

Leu Ile Tyr Ser Thr Ser Ser Arg His Ser Gly Val Pro Ser Arg Phe
50 55 60

Ser Gly Ser Ile Ser Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
65 70 75 80

Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Asp Ile Gly Ser
85 90 95

Tyr Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 149

-continued

<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 149

```
Gln Thr Val Val Thr Gln Glu Pro Ser Leu Ser Val Ser Pro Gly Gly
1           5          10          15

Thr Val Thr Leu Thr Cys Gly Leu Thr Ser Gly Ser Val Thr Ala Ser
20          25          30

Asn Leu Pro Gly Trp Phe Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
35          40          45

Leu Ile Phe Asp Thr Ile Tyr His His Ser Gly Val Pro Ser Arg Phe
50          55          60

Ser Gly Ser Ile Ala Gly Asn Lys Ala Thr Leu Thr Ile Thr Gly Ala
65          70          75          80

Gln Pro Glu Asp Glu Gly Asp Tyr Phe Cys Val Leu Trp Met Asp Arg
85          90          95

Ile Glu Ala Gly Ser Ile Met Phe Gly Gly Thr His Leu Ser Val
100         105         110

Val
```

<210> SEQ ID NO 150
<211> LENGTH: 95
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 150

```
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5          10          15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20          25          30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35          40          45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50          55          60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro
85          90          95
```

<210> SEQ ID NO 151
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 151

```
Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
1           5          10          15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Thr Glu
20          25          30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile
35          40          45

Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
50          55          60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
65          70          75          80

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Ser Ser Pro Tyr
```

US 9,315,576 B2

227**228**

-continued

85	90	95
----	----	----

Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
100 105

<210> SEQ ID NO 152

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 152

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly	1	5	10	15
---	---	---	----	----

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Thr Glu	20	25	30
---	----	----	----

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile	35	40	45
---	----	----	----

Tyr Asp Arg Ser Arg Leu Gln Ile Gly Val Pro Ser Arg Phe Ser Gly	50	55	60
---	----	----	----

Ser Gly Ser Gly Thr Thr Tyr Thr Leu Thr Ile Ser Asp Leu Glu Ala	65	70	75	80
---	----	----	----	----

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Asp Ser Trp Pro Tyr	85	90	95
---	----	----	----

Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys
100 105

<210> SEQ ID NO 153

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 153

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly	1	5	10	15
---	---	---	----	----

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Asn Thr Glu	20	25	30
---	----	----	----

Leu Ser Trp Tyr Gln Gln Lys Pro Glu Gln Pro Pro Lys Leu Leu Ile	35	40	45
---	----	----	----

Tyr Ala Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly	50	55	60
---	----	----	----

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala	65	70	75	80
---	----	----	----	----

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Ser Asp Trp Pro Leu	85	90	95
---	----	----	----

Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
100 105

<210> SEQ ID NO 154

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 154

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly	1	5	10	15
---	---	---	----	----

Asp Arg Val Thr Ile Thr Cys Gln Ala Thr Gln Ser Ile Asn Thr Glu	20	25	30
---	----	----	----

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile	35	40	45
---	----	----	----

-continued

Tyr Glu Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
 65 70 75 80

Glu Asp Leu Ala Thr Tyr Tyr Cys Met Ala Asp Leu Asp Trp Pro Leu
 85 90 95

Val Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
 100 105

<210> SEQ ID NO 155
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

<400> SEQUENCE: 155

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Thr Glu
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Lys Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
 65 70 75 80

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Gly Tyr Ser Ser Pro Leu
 85 90 95

Thr Phe Gly Gln Gly Thr Glu Val Asp Leu Lys
 100 105

<210> SEQ ID NO 156
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

<400> SEQUENCE: 156

Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Thr Glu
 20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ser
 65 70 75 80

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Ser Trp Pro Leu
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Thr
 100 105

<210> SEQ ID NO 157
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

<400> SEQUENCE: 157

-continued

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Thr Glu
 20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
 65 70 75 80

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Ser Trp Pro Arg
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 158

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 158

Asp Ile Val Met Thr Gln Thr Pro Pro Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Arg Asn Glu
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
 65 70 75 80

Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Asp Ser Trp Pro Leu
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
 100 105

<210> SEQ ID NO 159

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 159

Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Gly Ala Ser Thr Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala
 65 70 75 80

Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Ile Pro Val
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Arg
 100 105

-continued

<210> SEQ ID NO 160
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 160

Ala	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Leu	Gly
1															
															15
Asp	Arg	Val	Thr	Ile	Thr	Cys	Gln	Ala	Ser	Gln	Ser	Ile	Ser	Ser	Tyr
20															30
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Lys	Leu	Leu	Ile
35															45
Tyr	Gly	Ala	Ser	Arg	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
50															60
Ser	Gly	Ser	Gly	Thr	Ser	Phe	Thr	Leu	Thr	Ile	Ser	Gly	Leu	Glu	Ala
65															80
Glu	Asp	Ala	Gly	Thr	Tyr	Tyr	Cys	Gln	Leu	Tyr	Gly	Ser	Arg	Pro	Ser
85															95
Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Leu	Lys						
100															105

<210> SEQ ID NO 161
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 161

Val	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Leu	Gly
1															
															15
Asp	Arg	Val	Thr	Ile	Thr	Cys	Gln	Ala	Ser	Gln	Ser	Ile	Ser	Asn	Tyr
20															30
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Lys	Leu	Val	Ile
35															45
Tyr	Gly	Ala	Ser	Arg	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
50															60
Ser	Gly	Ser	Gly	Thr	Ser	Phe	Thr	Leu	Thr	Ile	Ser	Gly	Leu	Glu	Ala
65															80
Glu	Asp	Ala	Gly	Thr	Tyr	Tyr	Cys	Gln	Gln	Tyr	Tyr	Ser	Thr	Tyr	Ser
85															95
Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile	Lys						
100															105

<210> SEQ ID NO 162
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 162

Asp	Ile	Gln	Leu	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Leu	Gly
1															
															15
Asp	Ile	Val	Thr	Ile	Thr	Cys	Gln	Ala	Ser	Gln	Ser	Ile	Thr	Thr	Glu
20															30
Leu	Ser	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Thr	Pro	Lys	Leu	Leu	Ile
35															45
Tyr	Gly	Ala	Phe	Arg	Leu	Gln	Ala	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
50															60
Ser	Arg	Ser	Gly	Thr	Thr	Phe	Thr	Leu	Thr	Ile	Ser	Gly	Leu	Glu	Ala

-continued

65	70	75	80
Glu Asp Leu Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Ser Trp Pro Pro			
85	90	95	
Tyr Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile Lys			
100	105		

<210> SEQ ID NO 163
<211> LENGTH: 101
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 163

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly			
1	5	10	15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser			
20	25	30	
Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln			
35	40	45	
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val			
50	55	60	
Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr			
65	70	75	80
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln			
85	90	95	
Tyr Tyr Ser Thr Pro			
100			

<210> SEQ ID NO 164
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 164

Glu Thr Thr Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Val Gly			
1	5	10	15
Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Gly Ser Gly			
20	25	30	
Ser Asn Gln Lys Ser Ile Leu Asn Trp Ile Gln Gln Arg Pro Gly Gln			
35	40	45	
Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Arg Asp Ala Gly Ile			
50	55	60	
Pro Asp Arg Phe Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr			
65	70	75	80
Ile Arg Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln			
85	90	95	
Val Asn Ile Ala Pro Tyr Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile			
100	105	110	

Arg

<210> SEQ ID NO 165
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 165

Glu Ile Val Met Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Ala Gly			
1	5	10	15

-continued

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe Gln Ser
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Gly Trp Tyr Gln Gln Arg Ile Gly Gln
35 40 45

Ser Pro Arg Leu Leu Ile Asn Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Asn Pro Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
85 90 95

Gly Lys Ser Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Leu
100 105 110

Lys

<210> SEQ ID NO 166

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 166

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Val Thr Ala Ser Ile Gly
1 5 10 15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Arg Leu Gly Gln
35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Leu Thr Thr Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Phe Cys Gln Gln
85 90 95

Gly Tyr Ser Val Pro Leu Thr Phe Gly Arg Gly Thr Lys Val Glu Leu
100 105 110

Lys

<210> SEQ ID NO 167

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 167

Glu Thr Thr Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Ala Gly
1 5 10 15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Leu Asp
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Leu Gly Gln
35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gln Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
85 90 95

Gly Ile Thr Ile Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Leu
100 105 110

239

240

-continued

Lys

```

<210> SEQ ID NO 168
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 168

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Ala Gly
1           5           10          15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20          25          30

Ser Asp Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln
35          40          45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50          55          60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
65          70          75          80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
85          90          95

Gly Tyr Ser Ser Pro His Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile
100         105         110

```

Lys

```

<210> SEQ ID NO 169
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 169

Glu Thr Thr Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Ala Gly
1           5           10          15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg
20          25          30

Ser Asp Gln Lys Asn Val Leu Ser Trp Tyr Gln Gln Arg Leu Gly Gln
35          40          45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50          55          60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
65          70          75          80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
85          90          95

Gly Tyr Ser Arg Pro Tyr Ser Phe Gly Asn Gly Thr Arg Leu Glu Ile
100         105         110

```

Lys

```
<210> SEQ ID NO 170
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 170

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Val Thr Ala Ser Ala Gly
1           5           10          15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Asn Asn
20          25          30
```

-continued

Ser Asp Gln Lys Ile Tyr Leu Ala Trp Tyr Gln Gln Arg Leu Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Glu Tyr Ser Ala Pro Ala Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile
 100 105 110

Lys

<210> SEQ ID NO 171

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 171

Asp Ile Val Met Thr Gln Ser Pro Gly Ser Val Thr Ala Ser Thr Gly
 1 5 10 15

Glu Asn Ile Thr Ile Asn Cys Lys Ser Ser Gln Asn Val Leu Leu Ser
 20 25 30

Ser Asp Gln Lys Asn Tyr Leu Asn Trp Tyr Gln Gln Arg Leu Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Lys Ser Gly Ile
 50 55 60

Pro Asp Arg Phe Ser Gly Arg Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Asn Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Gly Tyr Ser Ile Pro His Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile
 100 105 110

Lys

<210> SEQ ID NO 172

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 172

Asp Ile Val Met Thr Gln Thr Pro Thr Ser Val Thr Ala Ser Ala Gly
 1 5 10 15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
 20 25 30

Ala Asn Gln Lys Val Tyr Leu Ala Trp Tyr Gln Gln Arg Leu Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Phe Arg Trp Thr Ser Thr Arg Gln Pro Gly Ile
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Arg Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Ala Tyr Ala Arg Pro His Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile
 100 105 110

Lys

-continued

```

<210> SEQ ID NO 173
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 173

Asp Ile Val Met Thr Gln Thr Pro Thr Ser Val Thr Ala Ser Ala Gly
1           5           10          15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20          25          30

Ala Asn Gln Lys Val Tyr Leu Ala Trp Tyr Gln Gln Arg Leu Gly Gln
35          40          45

Ser Pro Arg Leu Leu Phe Arg Trp Thr Ser Thr Arg Gln Pro Gly Ile
50          55          60

Pro Asp Arg Phe Ser Val Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
65          70          75          80

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
85          90          95

Ala Tyr Ala Arg Pro His Thr Phe Gly Ser Gly Thr Arg Leu Glu Ile
100         105         110

```

Lys

<210> SEQ ID NO 174
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 174

Glu	Ile	Val	Met	Thr	Gln	Ser	Pro	Thr	Ser	Val	Thr	Ala	Ser	Val	Gly
1					5					10					15
Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Tyr	Ser
	20						25						30		
Ala	Asn	Gln	Lys	Val	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Arg	Leu	Gly	Gln
	35					40						45			
Ser	Pro	Arg	Leu	Leu	Phe	Tyr	Trp	Thr	Ser	Thr	Arg	Gln	Ser	Gly	Ile
	50				55					60					
Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Ser	Phe	Thr	Leu	Thr
	65			70					75					80	
Ile	Ser	Gly	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
				85					90					95	
Ala	Tyr	Thr	Arg	Pro	His	Thr	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile
	100						105						110		

Arg
 <210> SEQ_ID NO 175
 <211> LENGTH: 113
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama
 <400> SEQUENCE: 175

 Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Val Gly
 1 5 10 15

 Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Lys Ser Gly
 20 25 30

 Ser Asn Gln Ile Thr Tyr Leu Asn Trp Tyr Gln Gln Thr Pro Gly Gln
 25 30 35

-continued

Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Gln Glu Leu Gly Ile
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Ala Tyr Ser Ala Pro Phe Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile
 100 105 110

Lys

<210> SEQ ID NO 176

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 176

Glu Thr Thr Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Val Gly
 1 5 10 15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Val Ser Gly
 20 25 30

Ser Asn Gln Lys Ile Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Gln Glu Ser Gly Ile
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Gly Ala Ser Ala Pro Val Ser Phe Gly Ser Gly Thr Arg Leu Glu Ile
 100 105 110

Lys

<210> SEQ ID NO 177

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 177

Asp Ile Val Met Thr Gln Thr Pro Ser Ser Val Thr Ala Ser Val Gly
 1 5 10 15

Glu Thr Val Thr Ile Gly Cys Lys Ser Ser Gln Ser Val Val Ser Gly
 20 25 30

Ser Ser Gln Lys Ser Phe Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Ile Tyr Tyr Ala Ser Thr Leu Glu Leu Gly Ile
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Val Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Ala Tyr Ser Thr Pro Ser Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile
 100 105 110

Arg

<210> SEQ ID NO 178

<211> LENGTH: 113

-continued

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 178

Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Arg	Ser	Val	Thr	Ala	Ser	Val	Gly
1							5			10				15	

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Leu	Ser	Gly
	20						25						30		

Ser	Asn	Gln	Lys	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Thr	Arg	Pro	Gly	Gln
	35					40				45					

Ser	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Gln	Glu	Ser	Gly	Ile
	50					55			60						

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65				70				75			80				

Ile	Ser	Gly	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
	85					90				95					

Ala	Tyr	Ser	Ala	Pro	Ala	Thr	Phe	Gly	Gln	Gly	Thr	Thr	Val	Glu	Val
	100					105				110					

Ile

<210> SEQ_ID NO 179

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 179

Asp	Val	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1								5		10				15	

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Arg	Ser	Gly
	20						25			30					

Ser	Asn	Glu	Lys	Ser	Ser	Leu	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Gln
	35					40				45					

Ser	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Gln	Glu	Ser	Gly	Ile
50					55				60						

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65				70				75			80				

Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
	85					90				95					

Ala	Tyr	Ser	Tyr	Pro	Ile	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Leu
	100					105				110					

Lys

<210> SEQ_ID NO 180

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 180

Asp	Val	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1								5		10				15	

Glu	Lys	Val	Thr	Ile	Asp	Cys	Lys	Ser	Ser	Gln	Ile	Leu	Val	Ser	Gly
	20						25			30					

Ser	Asp	Gln	Lys	Ser	Tyr	Leu	Ser	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Gln
	35					40				45					

Ser	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Gln	Lys	Leu	Gly	Ile
50					55				60						

-continued

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65					70			75			80				

Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
					85			90			95				

Thr	Tyr	Glu	Ala	Pro	Tyr	Ser	Phe	Gly	Asn	Gly	Thr	Arg	Leu	Glu	Ile
					100			105			110				

Lys

<210> SEQ ID NO 181

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 181

Glu	Ile	Val	Met	Thr	Gln	Thr	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1					5			10			15				

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Val	Leu	Ala
					20			25			30				

Ser	Asn	Gln	Lys	Thr	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Gln
					35			40			45				

Ser	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Gln	Gln	Leu	Gly	Ile
					50			55			60				

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65					70			75			80				

Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
					85			90			95				

Ala	Leu	Ser	Ala	Pro	Tyr	Ser	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile
					100			105			110				

Lys

<210> SEQ ID NO 182

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 182

Asp	Val	Val	Met	Thr	Gln	Ser	Pro	Ser	Ser	Val	Thr	Ala	Ser	Val	Gly
1					5			10			15				

Glu	Lys	Val	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Val	Val	Ser	Gly
					20			25			30				

Ser	Asn	Gln	Lys	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Arg	Pro	Gly	Gln
					35			40			45				

Ser	Pro	Arg	Leu	Leu	Ile	Tyr	Tyr	Ala	Ser	Thr	Gln	Glu	Leu	Gly	Ile
					50			55			60				

Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Thr	Thr	Asp	Phe	Thr	Leu	Thr
65					70			75			80				

Ile	Ser	Ser	Val	Gln	Pro	Glu	Asp	Ala	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
					85			90			95				

Ala	Tyr	Ser	Thr	Pro	Tyr	Ser	Phe	Gly	Ser	Gly	Thr	Arg	Leu	Glu	Ile
					100			105			110				

Lys

<210> SEQ ID NO 183

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Lama glama

-continued

Ala Ser Ser Leu Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Leu
 100 105 110

Lys

<210> SEQ ID NO 186

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 186

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Val Thr Ala Ser Ala Gly
 1 5 10 15

Glu Lys Val Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
 20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Leu Gly Gln
 35 40 45

Ser Pro Arg Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Thr Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Phe Gln Pro Glu Asp Ala Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

Tyr Leu Ser Gly Val Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
 100 105 110

<210> SEQ ID NO 187

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 187

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
 20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg

<210> SEQ ID NO 188

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 188

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Arg Asn Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

-continued

Gly Arg Ile Asp Pro Glu Asp Gly Asp Thr Lys Tyr Ala Pro Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Ser Gly Arg Tyr Glu Leu Asp Tyr Trp Gly Leu Gly Thr Gln
 100 105 110

Val Thr Val Ser Ser
 115

<210> SEQ ID NO 189

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 189

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Arg Asn Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Glu Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95

Ala Thr Ser Gly Ala Thr Met Ser Asp Leu Asp Ser Phe Gly Ser Trp
 100 105 110

Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 190

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 190

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys

<210> SEQ ID NO 191

<211> LENGTH: 122

-continued

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 191

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5		10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Thr	Thr	Ser	Gly	Phe	Thr	Phe	Glu	Asp	Tyr
	20					25						30			

Pro	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Val	Ile	Ser	Arg	Asn	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Glu	Ser	Met
	50					55				60					

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
65					70			75			80				

Leu	Val	Met	Asn	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
	85					90			95						

Thr	Lys	Pro	Ser	Thr	Ser	Trp	Ser	Thr	Asn	Tyr	Gly	Met	Asp	Tyr	Trp
	100					105				110					

Gly	Lys	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser						
	115				120										

<210> SEQ ID NO 192

<211> LENGTH: 115

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 192

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5		10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Asp	Asp	Tyr
	20					25				30					

Gly	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Gly	Ile	Thr	Trp	Asn	Gly	Gly	Thr	Asn	Tyr	Ala	Asp	Ser	Val	
	50					55			60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Ser	Ala	Lys	Asn	Met	Val	His
65					70			75			80				

Leu	Gln	Met	Asp	Ser	Leu	Lys	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
	85					90			95						

Ala	Lys	Ala	Tyr	Arg	Gly	Ser	Thr	Leu	Gly	Gln	Gly	Thr	Gln	Val	Thr
	100					105				110					

Val	Ser	Ser													
	115														

<210> SEQ ID NO 193

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 193

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1							5		10				15		

Ser	Leu	Arg	Val	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr
	20					25				30					

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
	35					40				45					

Ser	Gly	Ile	Asn	Thr	Gly	Gly	Asp	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

US 9,315,576 B2

259

-continued

50	55	60														
Met	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Ser	
65																80
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Leu	Tyr	Tyr	Cys	
																85 90 95
Ala	Arg	Asp	Leu	Arg	Asp	Tyr	Tyr	Ser	Asp	Tyr	Thr	Phe	Val	Asn	Trp	
																100 105 110
Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser							
																115 120

<210> SEQ_ID NO 194

<211> LENGTH: 128

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 194

1	5	10	15												
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly

20	25	30													
Ser	Leu	Arg	Leu	Ser	Cys	Ser	Ala	Ser	Gly	Phe	Arg	Phe	Ser	Thr	Tyr

35	40	45													
Ala	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Val	Trp	Val

50	55	60													
Ser	Thr	Val	Asp	Ala	Ser	Gly	Ala	Thr	Thr	Ser	Tyr	Ala	Glu	Ser	Val

65	70	75	80												
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Thr	Lys	Gly	Ala	Leu	Tyr

85	90	95													
Leu	Gln	Met	Asn	Ser	Leu	Lys	Phe	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys

100	105	110													
Gly	Thr	Arg	Ser	Gly	Thr	Trp	Trp	Arg	Gly	Ser	Tyr	Ile	Tyr	Thr	Glu

115	120	125													
Ser	Glu	Glu	Asn	Gly	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser

<210> SEQ_ID NO 195

<211> LENGTH: 125

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 195

1	5	10	15												
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Ser	Gly	Gly

20	25	30													
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asp	Tyr

35	40	45													
Ala	Met	Ile	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val

50	55	60													
Ser	Ser	Ile	Asn	Asn	Gly	Gly	Trp	Ser	Thr	Arg	Tyr	Ala	Asp	Ser	Val

65	70	75	80												
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr

85	90	95													
Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Leu	Tyr	Tyr	Cys

100	105	110													
Ala	Arg	Glu	Gly	Tyr	Tyr	Ser	Asp	Tyr	Ala	Ala	Val	Gly	His	Ala	Tyr

115	120	125													
Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser			

260

-continued

US 9,315,576 B2

261

-continued

<210> SEQ ID NO 196
<211> LENGTH: 124
<212> TYPE: PRT
<213> ORGANISM: *Lama glama*
<400> SEQUENCE: 196

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr
20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45

Ser Tyr Ile Asp Ser Asp Gly Ala Thr Thr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Asn
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Asp Asp Ala Gly Val Tyr Tyr Cys
85 90 95

Ala Ser Phe Gly Ser Ser Ala Tyr Ser Trp Gly Tyr Leu Gly Met Asp
100 105 110

His Trp Gly Lys Gly Ala Leu Val Thr Val Phe Ser
115 120

<210> SEQ ID NO 197
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: *Lama glama*
<400> SEQUENCE: 197

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr
20 25 30

Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Val Ile Asn Ser Gly Gly Asp Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Gly Val Leu Gly His Ser Asn Tyr Tyr Ala Met Asp Tyr
100 105 110

Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 198
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: *Lama glama*
<400> SEQUENCE: 198

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly Leu Thr Ala Ser Asn Thr
20 25 30

Ala Met Ala Trp Val Arg Gln Val Pro Gly Lys Gln Leu Glu Trp Val
35 40 45

262

-continued

Ser Asp Ile Asn Ser Leu Gly Asn Asn Ile Phe Tyr Ser Lys Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ala Arg Asp Lys Thr Lys Asn Thr Leu Val
 65 70 75 80

Leu Ser Met Asn Ser Leu Ser Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Val Ala Asp Ala Ser Ala Leu Ser Trp Ser Arg Pro Ala Leu Glu Val
 100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Asp
 115 120

<210> SEQ ID NO 199

<211> LENGTH: 123

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 199

Glu Val Gln Leu Met Gln Ser Gly Gly Gly Leu Ala Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Asn His
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Ser Ser Gly Ser Ser Thr Tyr Tyr Ile Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Lys Gly Val Tyr Tyr Cys
 85 90 95

Gly Lys Asp Glu Ser Arg Gly Ile Glu Pro Gly Trp Gly Ser Ile Tyr
 100 105 110

Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 200

<211> LENGTH: 123

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 200

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Ser
 20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Thr Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Gly Glu Ser Met
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Ser Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Thr Arg Tyr Asp Ser Phe Gly Trp Asn Val Arg Tyr Gly Met Asp Tyr
 100 105 110

Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser
 115 120

-continued

<210> SEQ_ID NO 201
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 201

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Asp	Leu	Val	Gln	Pro	Gly	Gly	
1							5				10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr
20 25 30

His Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ile Ile Gly Arg Trp Gly Ala Asp Ile Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Thr Ala Glu Leu Asn Trp Glu Pro Glu Asn Ala Tyr Ser Asp His Trp
100 105 110

Gly Gln Gly Thr Gln Val Thr Val Ser Ser
115 120

<210> SEQ_ID NO 202
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 202

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5			10			15		

Ser Leu Arg Leu Ser Cys Val Gly Ser Gly Ile Thr Phe Ser Lys Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Asn Ile Asp Ala Asn Ser Glu Leu Thr Thr Tyr Glu Asp Thr Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Thr Lys Asp Pro Arg Asn Ser Trp Tyr Thr Tyr Gly Met Asp Tyr Gly
100 105 110

Gly Lys Gly Thr Leu Val Val Val Ser Ser
115 120

<210> SEQ_ID NO 203
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 203

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
1							5			10			15		

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

-continued

Tyr Met Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

Ser Val Ile Ser Ser Ser Gly Gly Asn Thr Lys Tyr Ser Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Met Val Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Arg Ile Glu Gly Met Gly Tyr Gly Met Asp Tyr Trp Gly
100 105 110

Lys Gly Thr Pro Val Thr Val Ser Ser
115 120

<210> SEQ_ID NO 204

<211> LENGTH: 121

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 204

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30

Gly Lys Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ser Ile Tyr Ile Phe Val Gly Asn Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Thr Asn Leu Lys Pro Glu Asp Thr Ala Lys Tyr Phe Cys
85 90 95

Val Lys Ser Pro Glu Trp Thr Tyr Tyr Gly Met Asp Ser Trp Gly
100 105 110

Lys Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ_ID NO 205

<211> LENGTH: 121

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 205

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Thr Ile Ser Ser Gly Gly Ala Ser Thr Thr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ser Phe Gly Leu Val Thr Gly Val Tyr Phe Gly Ser Trp Gly
100 105 110

-continued

Gln Gly Thr Gln Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 206
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Lama glama
<400> SEQUENCE: 206

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1			5			10				15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ala	Phe	Ser	Asp	Tyr
20				25						30					

Asp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Ley	Glu	Trp	Val
35					40					45					

Ser	Ile	His	Val	Ser	Gly	Asp	Gly	Arg	Ile	Phe	Tyr	Ala	Asp	Ser	Met
50				55					60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Met	Tyr
65					70				75			80			

Leu	Gln	Leu	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
85					90				95						

Ala	Ala	Asp	Ser	Tyr	His	Ala	Ala	Thr	Gly	Tyr	Leu	Glu	Gln	Trp	Gly
100					105					110					

Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser							
115					120										

<210> SEQ ID NO 207
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Lama glama
<400> SEQUENCE: 207

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1			5			10				15						

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Arg	Phe	Thr	Asp	Tyr
20				25						30					

Tyr	Met	Gly	Trp	Ile	Arg	Gln	Thr	Pro	Gly	Lys	Gly	Ley	Glu	Trp	Val
35				40						45					

Ser	Ser	Ile	Tyr	Ser	Leu	Gly	Asp	Pro	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
50				55					60						

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Gly	Lys	Asp	Thr	Val	Tyr
65					70				75			80			

Leu	Glu	Met	Asn	Ser	Leu	Lys	Ser	Asp	Asp	Thr	Gly	Ley	Tyr	Tyr	Cys
85					90				95						

Ala	Arg	Asp	His	Arg	Gly	Trp	Gly	Thr	Ile	Arg	Tyr	Asp	Tyr	Trp	Gly
100					105					110					

Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser							
115					120										

<210> SEQ ID NO 208
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Lama glama
<400> SEQUENCE: 208

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1				5			10			15					

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Arg Tyr

-continued

20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Met Thr Thr Gly Ser Asp Tyr Ile Tyr Ser Ala Val Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Phe Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Gly Gly Val Ile Asp Ala Asp His Phe Glu Ser Trp Gly Gln
 100 105 110

Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 209

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 209

Glu Val Gln Leu Val Gly Val Trp Gly Arg Leu Gly Ala Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ile Tyr
 20 25 30

Phe Met Ser Trp Phe Arg Gln Arg Pro Glu Lys Gly Ala Arg Met Val
 35 40 45

Ser Asp Ile Asp Lys Ser Gly Gly Arg Thr Thr Tyr Ala Pro Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ala Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Thr Ile Asn Thr Leu Glu Pro Asn Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Pro Thr Ser Ser Met Trp Ser Pro Gly Asp Tyr Trp Gly Gln
 100 105 110

Gly Thr Gln Val Thr Val Ala Ser
 115 120

<210> SEQ ID NO 210

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 210

Glu Val Gln Leu Val Gln Ser Gly Gly Asp Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Val Ser Cys Ala Val Ser Gly Phe Thr Phe Ile Tyr Tyr
 20 25 30

Gly Met Ser Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Ser Thr Ile Ser Asn Gly Gly Ser Thr Ala Asn Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Glu Met Asn Asp Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95

Ala Arg Ile Ser Thr Glu Leu Gly Asn Thr Leu Asp Ala Trp Gly Gln

-continued

100

105

110

Gly Ser Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 211

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 211

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ser Val Thr Gly Asp Gly Leu Ser Thr Thr Ala Ile Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Thr Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Asn Asn Leu Lys Leu Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Leu Asp Val Tyr Val Asp Tyr Gly Met Asp Tyr Trp Gly Lys
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 212

<211> LENGTH: 120

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 212

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30

Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Val Ser Ser Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

Ala Arg Glu Ser Gly Gly Pro Gly Met Asp Leu Glu Val Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 213

<211> LENGTH: 119

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 213

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

-continued

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asn Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Trp Glu Val Val Thr Leu Asp Phe Gly Ser Trp Gly Gln Gly
 100 105 110

Thr Gln Val Thr Val Ser Ser
 115

<210> SEQ ID NO 214
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 214

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Gly Phe Thr Phe Ser Thr Tyr
 20 25 30

Trp Met Tyr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Thr Ile Thr Ser Leu Gly Gly Ser Gln Trp Tyr Val Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Met Ala Gln Tyr Tyr Cys
 85 90 95

Val Arg Gly Leu Tyr Gly Tyr Asp Tyr Glu His Trp Gly Gln Gly
 100 105 110

Thr Gln Val Thr Val Ser Ser
 115

<210> SEQ ID NO 215
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 215

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ala
 20 25 30

Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Leu Thr Asn Tyr Gly Ser Thr Ser Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Val Asn Thr Val Tyr
 65 70 75 80

Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp Thr Gly Leu Tyr Tyr Cys
 85 90 95

-continued

Ala Arg Val Gly Asn Met Trp Ser Ser Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Gln Val Thr Val Ser Ser
 115

<210> SEQ ID NO 216

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 216

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Asp Thr Ser Gly Gly Ile Thr Met Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95

Ala Lys Ala Leu Gly Tyr Asn Ala Phe Asp Ala Trp Gly Arg Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

<210> SEQ ID NO 217

<211> LENGTH: 118

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 217

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Val
 1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Phe Thr Phe Ser Thr Gln
 20 25 30

Gly Met Asn Trp Val Arg Gln Pro Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Ser Arg Gly Asn Thr Thr Asn Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr
 65 70 75 80

Leu Gln Met Asn Asp Leu Arg Pro Asp Asp Thr Ala Met Tyr Tyr Cys
 85 90 95

Thr Asn Thr Gly Pro Trp Tyr Thr Tyr Asn Tyr Trp Gly Gln Gly Thr
 100 105 110

Gln Val Thr Val Ser Ser
 115

<210> SEQ ID NO 218

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 218

US 9,315,576 B2

279**280**

-continued

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Ile
 35 40 45

Ser Gly Ile Ser Val Gly Gly Ala Ser Thr Tyr Tyr Ala Arg Ser Val
 50 55 60

Gln Asp Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Trp Cys
 85 90 95

Thr Arg Gly Gly Asn Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln
 100 105 110

Val Thr Val Ser Ser
 115

<210> SEQ ID NO 219
 <211> LENGTH: 114
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

<400> SEQUENCE: 219

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asp Asp Tyr
 20 25 30

Pro Met Thr Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Ser Ile Tyr Ser Gly Ile Ser Thr Thr Tyr Tyr Pro Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Thr Asn Asp Ala Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Asp Leu Lys Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Asn Pro Arg Arg Asn Tyr Trp Gly Gln Gly Thr His Val Thr Val
 100 105 110

Ser Ser

<210> SEQ ID NO 220
 <211> LENGTH: 97
 <212> TYPE: PRT
 <213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 220

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Gly Thr Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala

281

282

-continued

85 90 95

Arg

<210> SEQ ID NO 221
 <211> LENGTH: 121
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

<400> SEQUENCE: 221

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1					5					10				15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Ser	Ser	Thr	Tyr
								20		25				30	
Ala	Met	Ser	Trp	Val	Arg	Gln	Gly	Pro	Gly	Lys	Ala	Leu	Glu	Trp	Val
						35		40				45			
Ser	Thr	Ile	Asn	Gly	Ala	Asp	Phe	Thr	Ser	Tyr	Val	Asp	Ser	Val	Lys
					50		55				60				
Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Thr	Lys	Asn	Thr	Leu	Tyr	Leu
					65		70			75				80	
Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
					85			90					95		
Lys	Gly	Leu	Ser	Gly	Leu	Asn	Trp	Tyr	Gly	Phe	Gly	Asp	Tyr	Trp	Gly
					100			105					110		
Gln	Gly	Thr	Gln	Val	Thr	Val	Ser	Ser							
					115			120							

<210> SEQ ID NO 222
 <211> LENGTH: 121
 <212> TYPE: PRT
 <213> ORGANISM: Lama glama

 <400> SEQUENCE: 222

 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 20 25 30

 Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
 35 40 45

 Gly Ser Ile Asp Asn Asp Gly Phe Thr Tyr Tyr Ser Glu Asp Val Lys
 50 55 60

 Gly Arg Phe Thr Ile Ser Gly Asp Asn Ala Arg Asn Thr Leu Tyr Leu
 65 70 75 80

 Gln Ile Asn Ser Val Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Val
 85 90 95

 Arg Gly Val Tyr Tyr Met Asp Tyr Glu Pro Arg Met Asp Tyr Trp Gly
 100 105 110

 Lys Gly Thr Leu Val Thr Val Ser Ser

<210> SEQ ID NO 223
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 223

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

-continued

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr His
 20 25 30

Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asn Ser Ala Tyr Gly Thr Ile Tyr Ile Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Val
 85 90 95

Gln Val Val Asp Thr Trp Asp Glu Tyr Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Gln Val Thr Val Ser Ser
 115

<210> SEQ ID NO 224
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 224

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Gly Thr Ser
 20 25 30

Gly Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Thr Ile Asn Ser Gly Gly Leu Thr Thr Ser Ala Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asp Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Asn Leu Leu Glu Leu Gly His Trp Gly Arg Gly Thr Gln Val Thr Val
 100 105 110

Ser Ser

<210> SEQ ID NO 225
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 225

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Thr Ile Thr Lys Gly Gly Ser Thr Tyr Tyr Ser Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Lys Ser Asn Ser Gly Thr His Trp Tyr Glu Tyr Tyr Gly Met Asp Tyr

-continued

100	105	110
-----	-----	-----

Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 226

<211> LENGTH: 115

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 226

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
35 40 45

Ser Gly Ile Asn Ser Gly Gly Lys Thr Tyr Ser Ala Asp Ser Val Lys
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80

Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ile
85 90 95

Leu Gly Ile Val Thr Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr
100 105 110

Val Ser Ser
115

<210> SEQ ID NO 227

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 227

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1 5 10 15

Ala Gly Thr Cys Thr Gly Thr Gly Tyr Thr Gly Ala Cys Lys Cys Ala
20 25 30

Gly Cys Cys
35

<210> SEQ ID NO 228

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 228

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1 5 10 15

Ala Gly Thr Cys Thr Gly Thr Gly Tyr Thr Gly Ala Cys Gly Cys Ala
20 25 30

Gly Cys Cys
35

<210> SEQ ID NO 229

<211> LENGTH: 35

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 229

Gly	Cys	Cys	Thr	Cys	Cys	Ala	Cys	Cys	Ala	Gly	Thr	Gly	Cys	Ala	Cys
1															
						5				10					15

Ala	Gly	Thr	Cys	Thr	Gly	Thr	Cys	Gly	Thr	Gly	Ala	Cys	Gly	Cys	Ala
						20				25					30

Gly	Cys	Cys													
															35

<210> SEQ ID NO 230
 <211> LENGTH: 35
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 230

Gly	Cys	Cys	Thr	Cys	Cys	Ala	Cys	Cys	Ala	Gly	Thr	Gly	Cys	Ala	Cys
1															
															15

Ala	Gly	Thr	Cys	Thr	Gly	Cys	Cys	Thr	Gly	Ala	Cys	Thr	Cys	Ala	
						20				25					30

Gly	Cys	Cys													
															35

<210> SEQ ID NO 231
 <211> LENGTH: 38
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 231

Gly	Cys	Cys	Thr	Cys	Cys	Ala	Cys	Cys	Ala	Gly	Thr	Gly	Cys	Ala	Cys
1															
															15

Thr	Thr	Thr	Cys	Cys	Thr	Ala	Thr	Gly	Ala	Gly	Cys	Thr	Gly	Ala	Cys
						20				25					30

Trp	Cys	Ala	Gly	Cys	Cys										
															35

<210> SEQ ID NO 232
 <211> LENGTH: 38
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 232

Gly	Cys	Cys	Thr	Cys	Cys	Ala	Cys	Cys	Ala	Gly	Thr	Gly	Cys	Ala	Cys
1															
															15

Thr	Thr	Thr	Cys	Cys	Thr	Ala	Thr	Gly	Ala	Gly	Cys	Thr	Gly	Ala	Cys
						20				25					30

Thr	Cys	Ala	Gly	Gly	Ala										
															35

<210> SEQ ID NO 233
 <211> LENGTH: 35
 <212> TYPE: PRT
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR Primer

-continued

<400> SEQUENCE: 233

```

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Ala Gly Cys Tyr Thr Gly Thr Gly Cys Thr Gly Ala Cys Thr Cys Ala
20          25          30

Ala Thr Cys
35

```

<210> SEQ ID NO 234

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 234

```

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Ala Gly Gly Cys Thr Gly Thr Gly Cys Thr Gly Ala Cys Thr Cys Ala
20          25          30

Gly Cys Cys
35

```

<210> SEQ ID NO 235

<211> LENGTH: 38

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 235

```

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Thr Thr Ala Ala Thr Thr Thr Ala Thr Gly Cys Thr Gly Ala Cys
20          25          30

Thr Cys Ala Gly Cys Cys
35

```

<210> SEQ ID NO 236

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 236

```

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Ala Gly Arg Cys Thr Gly Thr Gly Cys Thr Gly Ala Cys Tyr Cys Ala
20          25          30

Gly Gly Ala
35

```

<210> SEQ ID NO 237

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 237

291**292**

-continued

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
 1 5 10 15

Trp Gly Cys Cys Thr Gly Thr Gly Cys Thr Gly Ala Cys Thr Cys Ala
 20 25 30

Gly Cys Cys
 35

<210> SEQ ID NO 238
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 238

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
 1 5 10 15

Ala Gly Gly Cys Ala Gly Gly Cys Thr Gly Ala Cys Thr Cys Ala
 20 25 30

Gly Cys Cys
 35

<210> SEQ ID NO 239
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 239

Cys Thr Ala Ala Cys Ala Cys Thr Gly Gly Gly Ala Gly Gly Gly
 1 5 10 15

Gly Ala Cys Ala Cys Cys Gly Thr Cys Thr Thr Cys Thr Cys
 20 25 30

<210> SEQ ID NO 240
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 240

Cys Thr Ala Ala Cys Ala Cys Thr Gly Gly Gly Ala Gly Gly Gly Asn
 1 5 10 15

Cys Thr Cys Ala Cys Asn Gly Thr Cys Thr Thr Cys Thr Cys
 20 25 30

<210> SEQ ID NO 241
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 241

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
 1 5 10 15

Thr Thr Gly Ala Cys Ala Thr Cys Cys Ala Gly Trp Thr Gly Ala Cys
 20 25 30

Cys Cys Ala Gly Thr Cys Thr Cys Cys
 35 40

-continued

```
<210> SEQ ID NO 242
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 242

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5                   10                  15

Thr Thr Gly Ala Thr Gly Thr Thr Gly Thr Gly Ala Thr Gly Ala Cys
20          25                  30
```

```
<210> SEQ ID NO 243
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 243

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5                   10                  15

Thr Thr Gly Ala Ala Ala Thr Thr Gly Thr Gly Trp Thr Gly Ala Cys
20          25                  30

Arg Cys Ala Gly Thr Cys Thr Cys Cys
25          30
```

```

<210> SEQ ID NO 244
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 244

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5                   10                  15

Thr Thr Gly Ala Tyr Ala Thr Tyr Gly Thr Gly Ala Thr Gly Ala Cys
20          25                  30

Cys Cys Ala Gly Trp Cys Thr Cys Cys
35          40

```

```

<210> SEQ ID NO 245
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 245

Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5                   10                  15

Thr Thr Gly Ala Ala Ala Cys Gly Ala Cys Ala Cys Thr Cys Ala Cys
20          25                  30

Gly Cys Ala Gly Thr Cys Thr Cys Cys
35          40

```

-continued

<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 246

```
Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Thr Thr Gly Ala Ala Ala Thr Thr Gly Thr Gly Cys Thr Gly Ala Cys
20          25          30

Thr Cys Ala Gly Thr Cys Thr Cys Cys
35          40
```

<210> SEQ ID NO 247
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 247

```
Gly Cys Cys Thr Cys Cys Ala Cys Cys Ala Gly Thr Gly Cys Ala Cys
1           5          10          15

Thr Thr Gly Ala Thr Ala Thr Thr Gly Thr Gly Ala Thr Gly Ala Cys
20          25          30

Cys Cys Ala Gly Ala Cys Thr Cys Cys
35          40
```

<210> SEQ ID NO 248
<211> LENGTH: 48
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 248

```
Gly Cys Cys Thr Cys Cys Ala Cys Cys Gly Gly Gly Cys Gly Cys Gly
1           5          10          15

Cys Cys Thr Thr Ala Thr Ala Gly Cys Ala Gly Thr Gly Thr Cys
20          25          30

Thr Cys Cys Gly Gly Thr Cys Gly Ala Ala Gly Cys Thr Cys Cys Thr
35          40          45
```

<210> SEQ ID NO 249
<211> LENGTH: 42
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 249

```
Gly Cys Cys Thr Cys Cys Ala Cys Cys Gly Gly Gly Cys Gly Cys Gly
1           5          10          15

Cys Cys Thr Thr Ala Thr Ala Arg Cys Ala Arg Thr Gly Tyr Cys
20          25          30

Thr Asn Cys Gly Arg Thr Cys Arg Ala Ala
35          40
```

<210> SEQ ID NO 250
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Lama glama

-continued

<400> SEQUENCE: 250

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Trp Asn Gly Gly Ala Thr Tyr Tyr Ala Glu Ser Met
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Pro Tyr Tyr Ser Asp Tyr Val Gly Val Glu Tyr Asp Tyr Trp
 100 105 110
 Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 251

<211> LENGTH: 127

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 251

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Asn Thr Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Gly Thr Ser Ala Asp Gly Ser Ser Trp Tyr Val Pro Ala Asp
 100 105 110
 Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 115 120 125

<210> SEQ ID NO 252

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 252

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Arg Asn Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30
 Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr

299**300**

-continued

65	70	75	80
Val Glu Leu Ser Ser	Leu Arg Ser Glu Asp	Thr Ala Val Tyr	Tyr Cys
85	90	95	
Ala Arg Ser Gly Arg Tyr	Glu Leu Asp Tyr Trp	Gly Gln Gly	Thr Gln
100	105	110	
Val Thr Val Ser Ser			
115			

<210> SEQ ID NO 253

<211> LENGTH: 117

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 253

1	Gl	u Val Gln Leu Val Gln Ser Gly Ala Glu Leu Arg Asn Pro Gly Ala	
	5	10	15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr			
20	25	30	
Tyr Thr Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met			
35	40	45	
Gly Arg Ile Asp Pro Glu Asp Gly Asp Thr Lys Tyr Ala Gln Lys Phe			
50	55	60	
Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr			
65	70	75	80
Val Glu Leu Thr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys			
85	90	95	
Leu Arg Ser Gly Ala Tyr Glu Leu Asp Tyr Trp Gly Gln Gly Thr Gln			
100	105	110	
Val Thr Val Ser Ser			
115			

<210> SEQ ID NO 254

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 254

1	Gln	Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
	5	10	15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr			
20	25	30	
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met			
35	40	45	
Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe			
50	55	60	
Gln Gly Arg Val Thr Ser Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr			
65	70	75	80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Val Val Tyr Tyr Cys			
85	90	95	

Ala Arg

<210> SEQ ID NO 255

<211> LENGTH: 116

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 255

US 9,315,576 B2

301**302**

-continued

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Gly Ile Asn Thr Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Asp Trp Met Ala Thr Thr Pro Trp Gly Gln Gly Thr Gln Val
 100 105 110

Thr Val Ser Ser
 115

<210> SEQ ID NO 256
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 256

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asn Thr Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Asp Trp Met Ala Thr Thr Pro Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

<210> SEQ ID NO 257
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 257

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Gly Ile Asn Thr Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val
 50 55 60

-continued

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Asp Trp Met Ala Thr Thr Pro Trp Gly Gln Gly Thr Gln Val
 100 105 110
 Thr Val Ser Ser
 115

<210> SEQ ID NO 258
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 258

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn
 20 25 30
 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Arg

<210> SEQ ID NO 259
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 259

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30
 Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Asn Ala Ala Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60
 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
 65 70 75 80
 Gln Met Asn Ser Leu Gln Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala
 85 90 95
 Asn Leu Pro Arg Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 100 105 110

<210> SEQ ID NO 260
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 260

-continued

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ala Ala Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Asn Leu Pro Arg Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 100 105 110

<210> SEQ ID NO 261
 <211> LENGTH: 111
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 261

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ala Ala Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Gln Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Asn Leu Pro Arg Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser
 100 105 110

<210> SEQ ID NO 262
 <211> LENGTH: 98
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 262

Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly
 1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser
 20 25 30

Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
 35 40 45

Leu Thr Tyr Ser Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
 65 70 75 80

Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser
 85 90 95

-continued

Gly Ile

<210> SEQ ID NO 263
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 263

Gln	Ala	Val	Val	Thr	Gln	Glu	Pro	Ser	Leu	Ser	Val	Ser	Pro	Gly	Gly
1				5				10				15			

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Thr Asn

20				25				30						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Asn Tyr Pro Gly Trp Phe Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr

35				40				45						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Leu Ile Tyr Asn Thr Asn Asn Arg His Ser Gly Val Pro Ser Arg Phe

50				55				60						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Ser Gly Ser Ile Ser Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala

65				70				75				80		
----	--	--	--	----	--	--	--	----	--	--	--	----	--	--

Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Leu Tyr Met Ser Ser

85				90				95						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Gly Ser Asn Asn Ala Val Phe Gly Gly Thr His Leu Thr Val Leu

100				105				110						
-----	--	--	--	-----	--	--	--	-----	--	--	--	--	--	--

Gly

<210> SEQ ID NO 264
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 264

Gln	Thr	Val	Val	Thr	Gln	Glu	Pro	Ser	Phe	Ser	Val	Ser	Pro	Gly	Gly
1				5				10			15				

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Thr Asn

20				25				30						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Asn Tyr Pro Gly Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr

35				40				45						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Leu Ile Tyr Asn Thr Asn Asn Arg Ser Ser Gly Val Pro Asp Arg Phe

50				55				60						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala

65				70				75				80		
----	--	--	--	----	--	--	--	----	--	--	--	----	--	--

Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Ala Leu Tyr Met Ser Ser

85				90				95						
----	--	--	--	----	--	--	--	----	--	--	--	--	--	--

Gly Ser Asn Asn Ala Val Phe Gly Gly Thr Lys Leu Thr Val Leu

100				105				110						
-----	--	--	--	-----	--	--	--	-----	--	--	--	--	--	--

Gly

<210> SEQ ID NO 265
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 265

Gln	Thr	Val	Val	Thr	Gln	Glu	Pro	Ser	Phe	Ser	Val	Ser	Pro	Gly	Gly
1				5				10			15				

US 9,315,576 B2

309**310**

-continued

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Thr Asn
20 25 30

Asn Tyr Pro Gly Trp Phe Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
35 40 45

Leu Ile Tyr Asn Thr Asn Asn Arg His Ser Gly Val Pro Ser Arg Phe
50 55 60

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
65 70 75 80

Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Ala Leu Tyr Met Ser Ser
85 90 95

Gly Ser Asn Asn Ala Val Phe Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

Gly

<210> SEQ ID NO 266

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 266

Gln Thr Val Val Thr Gln Glu Pro Ser Leu Ser Val Ser Pro Gly Gly
1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Ser Gly
20 25 30

Asn Tyr Pro Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr
35 40 45

Leu Ile Tyr Asn Thr Asn Ser Arg Tyr Ser Gly Val Pro Asn Arg Phe
50 55 60

Ser Gly Ser Ile Ser Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
65 70 75 80

Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Tyr Ile Gly Ser
85 90 95

Ser Ser Tyr Pro Val Val Phe Gly Gly Thr His Leu Thr Val Leu
100 105 110

Gly

<210> SEQ ID NO 267

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 267

Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly
1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Ser Gly
20 25 30

Asn Tyr Pro Gly Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
35 40 45

Leu Ile Tyr Asn Thr Asn Ser Arg Ser Ser Gly Val Pro Asp Arg Phe
50 55 60

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
65 70 75 80

Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Ala Val Tyr Ile Gly Ser
85 90 95

-continued

Ser Ser Tyr Pro Val Val Phe Gly Gly Thr Lys Leu Thr Val Leu
 100 105 110

Gly

<210> SEQ ID NO 268

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Humanized Antibody

<400> SEQUENCE: 268

Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly
 1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Thr Ser Gly
 20 25 30

Asn Tyr Pro Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr
 35 40 45

Leu Ile Tyr Asn Thr Asn Ser Arg Ser Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
 65 70 75 80

Gln Pro Asp Asp Glu Ser Asp Tyr Tyr Cys Ala Val Tyr Ile Gly Ser
 85 90 95

Ser Ser Tyr Pro Val Val Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

Gly

<210> SEQ ID NO 269

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 269

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 270

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 270

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Asn Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

-continued

35 40 45

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 271

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 271

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Gly Thr Pro Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 272

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 272

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Lys Pro Gly Ala
 1 5 10 15

Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Arg Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 273

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 273

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Lys Pro Gly Ala
 1 5 10 15

Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

-continued

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 274

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<222> LOCATION: (38)..(38)

<223> OTHER INFORMATION: Unknown amino acid

<400> SEQUENCE: 274

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 20 25 30

Tyr Ile Asp Trp Val Xaa Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Asn Tyr Ala Gln Lys Phe
 50 55 60

Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Val Glu Leu Ser Ser Leu Arg Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 275

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 275

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 276

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 276

Glu Val Gln Val Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

-continued

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Trp Asn Gly Gly Ser Thr Tyr Tyr Ala Glu Ser Met
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 277

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 277

Gln Leu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30

Gly Met Ser Trp Val Arg His Ser Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Ser Trp Asn Gly Gly Ser Thr Tyr Tyr Ala Glu Ser Met
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 278

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 278

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 279

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 279

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Tyr
 20 25 30

-continued

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 280

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 280

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15

Ser Leu Lys His Ser Cys Ala Ala Ser Gly Leu Thr Phe Gly Ser Tyr
 20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 281

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 281

Gln Leu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Thr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 282

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 282

Gln Leu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

-continued

35	40	45
----	----	----

Ser Thr Ile Asn Thr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 283

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 283

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 284

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 284

Gln Leu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 285

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 285

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

-continued

Ser Ala Ile Asn Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 286

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 286

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg His Ser Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Met
 50 55 60

Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 287

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 287

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Gly Gly Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 288

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 288

Glu Val Gln Leu Leu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

-continued

Ser Val Ile Tyr Ser Gly Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 289

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 289

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Tyr Ser Tyr Ser Ser Asn Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 290

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 290

Glu Val Arg Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
 20 25 30

Ala Met Ser Arg Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Tyr Ser Tyr Ser Ser Asn Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 291

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 291

Gln Val Gln Leu Val Glu Ser Val Gly Gly Leu Val Gln Asp Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Ser
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ser Ile Tyr Ser Tyr Ser Ser Asn Thr Tyr Asn Ala Asp Ser Val

-continued

50	55	60
----	----	----

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 292

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 292

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Val
 35 40 45

Ser Thr Ile Asn Ser Asp Gly Ser Asn Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Asp Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 293

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 293

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
 20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 294

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 294

Gln Val Gln Leu Val Glu Thr Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

-continued

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 295

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 295

Gln Leu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Gly Trp Ala Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Lys Ser Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 296

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 296

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Gly Trp Ala Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu
 65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 297

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 297

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 50 55 60

US 9,315,576 B2

331

332

-continued

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu
65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 298

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 298

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Val
35 40 45

Ser Ser Ile Tyr Ser Tyr Ser Asn Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Met Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 299

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 299

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Val
35 40 45

Ser Ser Ile Tyr Ser Tyr Ser Asn Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 300

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 300

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr
20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Ser Val
35 40 45

Ser Thr Ile Tyr Ser Tyr Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr

-continued

65	70	75	80
Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys			
85	90	95	

<210> SEQ ID NO 301
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 301

Gln Val Gln Leu Val Glu Ser Gly Gly	Gly Leu Val Gln Pro Gly Gly		
1	5	10	15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr			
20	25	30	
Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val			
35	40	45	
Ser Asp Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val			
50	55	60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr			
65	70	75	80
Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys			
85	90	95	

<210> SEQ ID NO 302
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 302

Gln Val Gln Leu Val Glu Ser Gly Gly	Gly Leu Val Gln Pro Gly Gly		
1	5	10	15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Gly Ser Tyr			
20	25	30	
Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val			
35	40	45	
Ser Cys Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val			
50	55	60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr			
65	70	75	80
Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys			
85	90	95	

<210> SEQ ID NO 303
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 303

Gln Val Gln Leu Val Glu Ser Gly Gly	Gly Leu Val Gln Pro Gly Gly		
1	5	10	15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Tyr			
20	25	30	
Asp Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val			
35	40	45	
Ser Tyr Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val			
50	55	60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr			
65	70	75	80

-continued

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 304

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 304

Glu Val Gln Val Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Tyr Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 305

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 305

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asn Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Tyr Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 306

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 306

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Tyr Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

-continued

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 307
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos
<400> SEQUENCE: 307

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Asp Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 308
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens
<400> SEQUENCE: 308

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val
 35 40 45

Ser Arg Ile Asn Ser Asp Gly Ser Ser Thr Ser Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 309
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos
<400> SEQUENCE: 309

Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Tyr Ser Asp Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys

US 9,315,576 B2

339

340

-continued

```
<210> SEQ_ID NO 310
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 310
```

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Asn Ser Gly Gly Gly Ser Thr Ser Tyr Ala Asp Ser Met
50 55 60

Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ_ID NO 311
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: *Lama pacos*

<400> SEQUENCE: 311
Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Tyr
20 25 30

Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Ala Ile Asn Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Met
 50 55 60

Lys	Gly	Gln	Phe	Thr	Ile	Ser	Ser	Asp	Asn	Ala	Arg	Asn	Thr	Leu	Tyr
65					70					75					80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 312
<211> LENGTH: 96

<212> TYPE: FRI
<213> ORGANISM: *Lama pacos*

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Tyr

Val Leu Ser Trp Val Cys His Ser Pro Gly Lys Gly Leu Glu Trp Val
25 10 15

Ser Ala Ile Asn Ser Cys Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
95 90 95

-continued

<210> SEQ ID NO 313
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 313

Gln	Leu	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5			10			15					

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Trp	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
35					40				45						

Ser Ala Ile Asn Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Val	Tyr
65				70			75		80						

Leu Gln Met Asn Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys
85 90 95

<210> SEQ ID NO 314
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 314

Gln	Leu	Gln	Leu	Gln	Glu	Ser	Gly	Leu	Val	Lys	Pro	Ser	Gln	
1					5			10		15				

Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30

Gly	Tyr	Ser	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu
35					40			45							

Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu	Lys	Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe
65				70			75		80						

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys

<210> SEQ ID NO 315
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 315

Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Ser	Gln
1					5			10		15					

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Ile Thr Thr Ser
20 25 30

Cys	Tyr	Ala	Trp	Ser	Cys	Ile	Cys	Gln	Pro	Pro	Glu	Lys	Gly	Leu	Glu
35					40			45							

Trp Met Ala Ala Ile Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu
50 55 60

Lys	Ser	His	Thr	Ser	Ile	Ser	Arg	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser
65					70			75		80					

Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr Cys

-continued

85	90	95
----	----	----

<210> SEQ ID NO 316
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Homo Sapiens

<400> SEQUENCE: 316

1	Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln	15
	5	10

20	Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly	30
	25	30

35	Asp Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu	45
	40	45

50	Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser	60
	55	60

65	Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe	80
	70	75

85	Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr	95
	90	95

Cys

<210> SEQ ID NO 317
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 317

1	Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln	15
	5	10

20	Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Thr Ser	30
	25	30

35	Tyr Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu	45
	40	45

50	Trp Met Gly Ala Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser	60
	55	60

65	Leu Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Asn Asn Gln Phe	80
	70	75

85	Ser Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr	95
	90	95

Cys

<210> SEQ ID NO 318
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 318

1	Glu Val Gln Val Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln	15
	5	10

20	Ala Leu Ser Leu Thr Cys Thr Ala Ser Gly Gly Ser Asn Thr Thr Ser	30
	25	30

35	Tyr Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu	45
	40	45

50	Trp Met Gly Ala Ile Ala Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser	60
	55	60

Leu Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Asn Asn Gln Phe

US 9,315,576 B2

345

346

-continued

Cys

```

<210> SEQ ID NO 319
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 319

Gln Val Gln Arg Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Met Leu Ser Leu Thr Cys Thr Ala Ser Gly Gly Ser Asn Thr Thr Ser
20 25 30

Tyr Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Met Gly Ala Ile Ala Tyr Asp Gly Ser Thr Tyr Tyr Ser Pro Ser
50 55 60

Leu Lys Ser His Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr
85 90 95

```

Cys

```

<210> SEQ ID NO 320
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 320

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Thr Ser
20 25 30

Tyr Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Met Gly Ala Ile Ala Tyr Asp Gly Ser Thr Tyr Tyr Ser Pro Ser
50 55 60

Leu Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr
85 90 95

```

Cys

```

<210> SEQ ID NO 321
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Lama pacos

<400> SEQUENCE: 321

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Leu Lys Pro Ser Gln
1           5                   10                  15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Ile Thr Thr Ser
20          25                  30

Tyr Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35          40                  45

```

-continued

Trp Met Gly Ala Ile Ala Tyr Asp Gly Ser Thr Tyr Tyr Ser Pro Ser
 50 55 60

Leu Lys Ser His Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe
 65 70 75 80

Ser Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr
 85 90 95

Cys

<210> SEQ_ID NO 322

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<222> LOCATION: (49)..(49)

<223> OTHER INFORMATION: Unknown amino acid

<400> SEQUENCE: 322

Gln Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
 1 5 10 15

Met Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Asn Thr Thr Ser
 20 25 30

Tyr Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35 40 45

Xaa Met Gly Ala Ile Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu
 50 55 60

Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
 65 70 75 80

Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ_ID NO 323

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 323

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Gly Ser Asn Thr Thr Ser
 20 25 30

Tyr Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35 40 45

Trp Met Gly Ala Ile Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu
 50 55 60

Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Asn Asn Gln Phe Ser
 65 70 75 80

Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Cys Val Tyr Tyr Cys
 85 90 95

<210> SEQ_ID NO 324

<211> LENGTH: 95

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<222> LOCATION: (48)..(48)

<223> OTHER INFORMATION: Unknown amino acid

<400> SEQUENCE: 324

-continued

Gln Val Gln Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr
 1 5 10 15
 Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Thr Ser Cys
 20 25 30
 Tyr Ala Trp Ser Trp Ile His Gln Pro Pro Gly Lys Gly Leu Glu Xaa
 35 40 45
 Met Gly Ala Ile Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu Lys
 50 55 60
 Ser His Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80
 Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 325

<211> LENGTH: 96

<212> TYPE: PRT

<213> ORGANISM: Lama pacos

<400> SEQUENCE: 325

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Met Leu Ser Leu Thr Cys Thr Leu Ser Gly Asp Ser Ile Thr Thr Ser
 20 25 30
 Cys Tyr Ala Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
 35 40 45
 Trp Met Gly Ala Ile Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu
 50 55 60
 Lys Ser Arg Thr Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Ser
 65 70 75 80
 Leu Gln Leu Ser Ser Val Thr Pro Glu Gly Thr Ala Val Tyr Tyr Cys
 85 90 95

<210> SEQ ID NO 326

<211> LENGTH: 98

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 326

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys

<210> SEQ ID NO 327

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

US 9,315,576 B2

351**352**

-continued

<400> SEQUENCE: 327

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Arg Tyr
 20 25 30
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45
 Ser Ala Ile Ser Trp Asn Ser Gly Arg Ile Tyr Asp Ala Glu Ser Met
 50 55 60
 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Thr Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ala Leu Lys Thr Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Ser Thr Ala Glu Ser Asn Trp Ile Pro
 100 105

<210> SEQ ID NO 328

<211> LENGTH: 102

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 328

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln His Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Ala
 20 25 30
 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Gly Val
 35 40 45
 Ser Ala Ile Asn Thr Arg Ser Gly Thr Thr Tyr Tyr Ala Asp Phe Thr
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Asn Ala Gly Phe Pro Ser
 100

<210> SEQ ID NO 329

<211> LENGTH: 107

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 329

Glu Glu Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Tyr
 20 25 30
 Asp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val
 35 40 45
 Ser Ala Ile Arg Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Pro Ser Thr Ile Ala Thr Ile Leu Phe

-continued

100

105

<210> SEQ ID NO 330

<211> LENGTH: 111

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 330

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly
1														
							5	10				15		

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
							20	25			30				

Tyr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40			45				

Ser	Ser	Ile	Tyr	Ser	Asp	Gly	Ser	Tyr	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
							50	55			60				

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
							65	70			75			80	

Leu	Gln	Met	Asn	Ser	Leu	Lys	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
							85	90			95				

Ala	Asn	Trp	Asp	Tyr	Ser	Gly	Ser	Tyr	Tyr	Ala	Pro	Ala	Thr	Phe
							100	105			110			

<210> SEQ ID NO 331

<211> LENGTH: 101

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 331

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1															
							5	10			15				

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Ala
							20	25			30				

Val	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40			45				

Ser	Gly	Ile	Gly	Ser	Gly	Gly	Ser	Thr	Thr	Ser	Tyr	Ala	Asp	Ser	Val
							50	55			60				

Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
							65	70			75			80	

Leu	Gln	Met	Asn	Ser	Leu	Lys	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
							85	90			95				

Thr	Gly	Arg	Gly	Phe
				100

<210> SEQ ID NO 332

<211> LENGTH: 101

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 332

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Ley	Val	Gln	Pro	Gly	Gly	
1															
							5	10			15				

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Ala
							20	25			30				

Val	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
							35	40			45				

Ser	Thr	Ile	Gly	Ala	Ala	Gly	Ser	Thr	Thr	Ser	Tyr	Ala	Asp	Ser	Val
							50	55			60				

-continued

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Gly Arg Gly Phe
 100

<210> SEQ ID NO 333
<211> LENGTH: 96
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 333

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
 1 5 10 15
 Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala
 20 25 30
 Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
 35 40 45
 Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
 50 55 60
 Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu
 65 70 75 80
 Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr
 85 90 95

<210> SEQ ID NO 334
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Lama glama
<400> SEQUENCE: 334

Asn Phe Met Leu Thr Gln Pro Ser Ala Leu Ser Val Thr Leu Gly Gln
 1 5 10 15
 Thr Ala Lys Ile Thr Cys Gln Gly Ser Leu Gly Ser Ser Tyr Ala
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
 35 40 45
 Asp Asp Asp Ser Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
 50 55 60
 Ser Ser Gly Gly Arg Ala Thr Leu Thr Ile Ser Gly Ala Gln Ala Glu
 65 70 75 80
 Asp Glu Gly Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Asn Ala
 85 90 95
 Val Phe Gly Gly Gly Thr His Leu Thr Val Leu
 100 105

<210> SEQ ID NO 335
<211> LENGTH: 104
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 335

Gln Pro Val Leu Thr Gln Pro Pro Ser Ser Ser Ala Ser Pro Gly Glu
 1 5 10 15
 Ser Ala Arg Leu Thr Cys Thr Leu Pro Ser Asp Ile Asn Val Gly Ser
 20 25 30

-continued

Tyr Asn Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Pro Pro Arg Tyr
 35 40 45

Leu Leu Tyr Tyr Ser Asp Ser Asp Lys Gly Gln Gly Ser Gly Val
 50 55 60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Thr Gly Ile
 65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys
 85 90 95

Met Ile Trp Pro Ser Asn Ala Ser
 100

<210> SEQ ID NO 336
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Lama glama

<400> SEQUENCE: 336

Gln Ala Val Leu Thr Gln Pro Pro Ser Leu Ser Ala Ser Pro Gly Ser
 1 5 10 15

Ser Val Arg Leu Thr Cys Thr Leu Ser Ser Gly Asn Ser Val Gly Ser
 20 25 30

Tyr Asp Ile Ser Trp Tyr Gln Gln Lys Ala Gly Ser Pro Pro Arg Tyr
 35 40 45

Leu Leu Tyr Tyr Ser Asp Ser Phe Asn His Gln Gly Ser Gly Val
 50 55 60

Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Leu
 65 70 75 80

Leu Leu Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys
 85 90 95

Ser Ala Tyr Lys Ser Gly Ser Tyr Asn Pro Thr Phe Gly Gly Thr
 100 105 110

Lys Leu Thr Val Leu
 115

<210> SEQ ID NO 337
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 337

Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly
 1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser
 20 25 30

Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr
 35 40 45

Leu Ile Tyr Ser Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe
 50 55 60

Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
 65 70 75 80

Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser
 85 90 95

Gly Ile

<210> SEQ ID NO 338
<211> LENGTH: 112
<212> TYPE: PRT

US 9,315,576 B2

359**360**

-continued

<213> ORGANISM: Lama glama

<400> SEQUENCE: 338

Gln	Ala	Val	Val	Thr	Gln	Glu	Pro	Ser	Leu	Ser	Val	Ser	Pro	Gly	Gly
1				5				10					15		

Thr	Val	Thr	Leu	Thr	Cys	Gly	Leu	Ser	Ser	Gly	Ser	Val	Thr	Ser	Ser
	20				25							30			

Asn	Tyr	Pro	Gly	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Thr
	35				40							45			

Leu	Ile	Tyr	Asn	Thr	Asn	Ser	Arg	Tyr	Ser	Gly	Val	Pro	Asn	Arg	Phe
	50				55						60				

Ser	Gly	Ser	Ile	Ser	Gly	Asn	Lys	Ala	Val	Leu	Thr	Ile	Thr	Gly	Ala
	65				70				75			80			

Gln	Pro	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Val	Tyr	Thr	Gly	Ser
	85				90				95						

Ser	Asn	Tyr	Pro	Ala	Val	Phe	Gly	Gly	Thr	His	Leu	Thr	Val	Leu
					100				105			110		

<210> SEQ ID NO 339

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 339

Gln	Ala	Val	Val	Thr	Gln	Glu	Pro	Ser	Leu	Ser	Val	Ser	Pro	Gly	Gly
1					5			10				15			

Thr	Val	Thr	Leu	Thr	Cys	Gly	Leu	Ser	Ser	Gly	Ser	Val	Thr	Thr	Ser
	20				25							30			

Asn	Tyr	Ala	Ala	Trp	Phe	Gln	Gln	Ala	Pro	Gly	Gln	Ala	Pro	Arg	Thr
	35				40							45			

Leu	Ile	Tyr	Lys	Thr	Asn	Ser	Arg	His	Ser	Gly	Val	Pro	Ser	Arg	Phe
	50				55				60						

Ser	Gly	Ser	Ile	Ser	Gly	Asn	Lys	Ala	Ala	Leu	Thr	Ile	Thr	Gly	Ala
	65				70				75			80			

Gln	Pro	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ser	Leu	Tyr	Pro	Gly	Ser
	85				90				95						

Asp	Ile	Ser	Val	Phe	Gly	Gly	Thr	His	Leu	Thr	Val	Leu
					100				105			110

<210> SEQ ID NO 340

<211> LENGTH: 112

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 340

Ser	Ser	Glu	Leu	Thr	Gln	Glu	Pro	Ser	Leu	Ser	Val	Ser	Pro	Gly	Gly
1					5			10				15			

Thr	Val	Thr	Leu	Thr	Cys	Gly	Leu	Ser	Ser	Gly	Ser	Val	Thr	Ser	Ser
	20				25							30			

Asn	Tyr	Pro	Gly	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Thr
	35				40							45			

Leu	Ile	Tyr	Asn	Thr	Asn	Ser	Arg	Tyr	Ser	Gly	Val	Pro	Asn	Arg	Phe
	50				55				60						

Ser	Gly	Ser	Ile	Ser	Gly	Asn	Lys	Ala	Ala	Leu	Thr	Ile	Thr	Gly	Ala
	65				70				75			80			

Gln	Pro	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Ala	Val	Tyr	Ile	Gly	Ser
	85				90				95						

-continued

Gly Gly Tyr Pro Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 341

<211> LENGTH: 110

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 341

Ser Tyr Glu Leu Thr Gln Asp Pro Ser Leu Ser Val Ser Pro Gly Glu
 1 5 10 15

Thr Val Thr Leu Thr Cys Gly Leu Asn Ser Gly Ser Val Thr Ser His
 20 25 30

Asn Tyr Pro Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr
 35 40 45

Leu Met Tyr Asn Thr Asn Ser Arg Tyr Pro Met Val Pro Pro Arg Phe
 50 55 60

Ser Gly Ser Ile Phe Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala
 65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Tyr Ile Arg Ser
 85 90 95

Arg Thr Leu Glu Phe Gly Gly Thr His Leu Thr Val Leu
 100 105 110

<210> SEQ ID NO 342

<211> LENGTH: 100

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 342

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser
 20 25 30

Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser
 85 90 95

Ile Gln Leu Pro
 100

<210> SEQ ID NO 343

<211> LENGTH: 111

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 343

Asp Ile Val Met Thr Gln Thr Pro Gly Ser Leu Ser Val Val Pro Gly
 1 5 10 15

Glu Ser Ala Ser Ile Ser Cys Lys Ala Ser Gln Ser Leu Val His Ser
 20 25 30

Asp Gly Lys Thr Tyr Leu Tyr Trp Leu Leu Gln Lys Pro Gly Gln Ser
 35 40 45

-continued

Pro Gln Arg Leu Ile Tyr Gln Val Ser Asn Arg Gly Ser Gly Val Pro
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Gly Val Lys Ala Glu Asp Ala Gly Val Tyr Tyr Cys Ala Gln Ala
85 90 95

Thr Tyr Tyr Val Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
100 105 110

<210> SEQ ID NO 344

<211> LENGTH: 113

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 344

Asp Ile Val Met Thr Gln Thr Pro Gly Ser Leu Ser Val Val Pro Gly
1 5 10 15

Glu Ser Ala Ser Ile Ser Cys Lys Ala Ser Gln Ser Leu Val His Ser
20 25 30

Asp Gly Lys Thr Tyr Leu Tyr Trp Leu Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Arg Leu Ile Tyr Gln Val Ser Asn Arg Gly Ser Gly Val Pro
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Gly Val Lys Ala Glu Asp Ala Gly Val Tyr Tyr Cys Ala Gln Ala
85 90 95

Ser Tyr Tyr Pro Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Leu
100 105 110

Lys

<210> SEQ ID NO 345

<211> LENGTH: 111

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 345

Asp Ile Val Met Thr Gln Thr Pro Gly Ser Leu Ser Val Val Pro Gly
1 5 10 15

Glu Ser Ala Ser Ile Ser Cys Lys Ala Ser Gln Ser Leu Val Leu Ser
20 25 30

Gly Gly Lys Thr Tyr Leu Tyr Trp Leu Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Arg Leu Ile Tyr Gln Val Ser Asn Arg Gly Ser Gly Val Pro
50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Gly Val Lys Ala Glu Asp Ala Gly Val Tyr Tyr Cys Thr Gln Ala
85 90 95

Thr Tyr Tyr Ile Thr Phe Gly Lys Gly Thr Arg Leu Glu Ile Lys
100 105 110

<210> SEQ ID NO 346

<211> LENGTH: 109

<212> TYPE: PRT

<213> ORGANISM: Lama glama

<400> SEQUENCE: 346

-continued

Glu Ile Val Leu Thr Thr Pro Gly Ser Leu Ser Val Val Pro Gly Glu
 1 5 10 15

Ser Ala Ser Ile Ser Cys Lys Ala Ser Gln Ser Leu Val Arg Ser Asp
 20 25 30

Gly Lys Thr Tyr Leu Tyr Trp Leu Leu Gln Lys Pro Gly Gln Ser Pro
 35 40 45

Gln Arg Leu Ile Tyr Gln Val Ser Asn Arg Gly Ser Gly Val Pro Arg
 50 55 60

Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Gly
 65 70 75 80

Val Lys Ala Glu Asp Ala Gly Val Tyr Tyr Cys Ala Gln Ala Thr Tyr
 85 90 95

Tyr Val Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys
 100 105

<210> SEQ ID NO 347
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 347

Cys Ala Gly Gly Thr Lys Cys Ala Gly Cys Thr Gly Gly Thr Gly Cys
 1 5 10 15

Ala Gly Thr Cys Thr Gly Gly
 20

<210> SEQ ID NO 348
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 348

Gly Ala Arg Gly Thr Gly Cys Ala Gly Cys Thr Gly Gly Thr Gly Cys
 1 5 10 15

Ala Gly Thr Cys Thr Gly Gly
 20

<210> SEQ ID NO 349
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 349

Cys Ala Gly Ser Thr Gly Cys Ala Gly Cys Thr Gly Cys Ala Gly Gly
 1 5 10 15

Ala Gly Thr Cys Thr Gly Gly
 20

<210> SEQ ID NO 350
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 350

-continued

Cys Ala Gly Gly Thr Gly Cys Ala Gly Cys Thr Ala Cys Ala Gly Cys
 1 5 10 15

Ala Gly Thr Cys Thr Gly Gly
 20

<210> SEQ ID NO 351
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 351

Cys Ala Gly Gly Thr Cys Ala Cys Cys Thr Thr Gly Ala Arg Gly Gly
 1 5 10 15

Ala Gly Thr Cys Thr Gly Gly
 20

<210> SEQ ID NO 352
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 352

Cys Thr Cys Gly Cys Ala Ala Cys Thr Gly Cys Gly Cys Cys Cys
 1 5 10 15

Ala Gly Cys Cys Gly Gly Cys Cys Ala Thr Gly Gly Cys Cys Cys Ala
 20 25 30

Gly Gly Thr Lys Cys Ala Gly Cys Thr Gly Gly Thr Gly Cys Ala Gly
 35 40 45

Thr Cys Thr Gly Gly
 50

<210> SEQ ID NO 353
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 353

Cys Thr Cys Gly Cys Ala Ala Cys Thr Gly Cys Gly Cys Cys Cys
 1 5 10 15

Ala Gly Cys Cys Gly Gly Cys Cys Ala Thr Gly Gly Cys Cys Gly Ala
 20 25 30

Arg Gly Thr Gly Cys Ala Gly Cys Thr Gly Gly Thr Gly Cys Ala Gly
 35 40 45

Thr Cys Thr Gly Gly
 50

<210> SEQ ID NO 354
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 354

Cys Thr Cys Gly Cys Ala Ala Cys Thr Gly Cys Gly Cys Cys Cys
 1 5 10 15

-continued

Ala Gly Cys Cys Gly Gly Cys Cys Ala Thr Gly Gly Cys Cys Cys Ala
20 25 30

Gly Ser Thr Gly Cys Ala Gly Cys Thr Gly Cys Ala Gly Ala Gly
35 40 45

Thr Cys Thr Gly Gly
50

<210> SEQ ID NO 355
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 355

Cys Thr Cys Gly Cys Ala Ala Cys Thr Gly Cys Gly Cys Cys Cys
1 5 10 15

Ala Gly Cys Cys Gly Gly Cys Cys Ala Thr Gly Gly Cys Cys Cys Ala
20 25 30

Gly Gly Thr Gly Cys Ala Gly Cys Thr Ala Cys Ala Gly Cys Ala Gly
35 40 45

Thr Cys Thr Gly Gly
50

<210> SEQ ID NO 356
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR Primer

<400> SEQUENCE: 356

Cys Thr Cys Gly Cys Ala Ala Cys Thr Gly Cys Gly Cys Cys Cys
1 5 10 15

Ala Gly Cys Cys Gly Gly Cys Cys Ala Thr Gly Gly Cys Cys Cys Ala
20 25 30

Gly Gly Thr Cys Ala Cys Cys Thr Thr Gly Ala Arg Gly Gly Ala Gly
35 40 45

Thr Cys Thr Gly Gly
50

The invention claimed is:

1. A process for preparing a chimeric antigen binding polypeptide that specifically binds to a human target antigen, 50 said polypeptide comprising a VH domain and a VL domain, said VH domain comprising hypervariable loops H1, H2 and H3, wherein said VH domain polypeptide is paired with a VL domain comprising hypervariable loops L1, L2 and L3, wherein said VH domain and said VL domain are each fused to one or more IgG constant domains of a human antibody, wherein each of the hypervariable loops H1-H3 and L1-L3 are obtained from a conventional antibody of a *Lama* species by active immunization of the *Lama* species with the human target antigen, wherein said conventional antibody is a heterotetrameric IgG antibody composed of two identical light chains and two identical heavy chains, and wherein at least one of the hypervariable loops H1, H2, L1, L2 and L3 exhibits a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1, H2, L1, L2 or L3 hypervariable loop which occurs in a human antibody, said process comprising:

(a) determining the nucleotide sequence encoding each of the hypervariable loops of the VH and/or the VL domain of a conventional antibody of a *Lama* species immunoreactive with said target antigen; and

(b) expressing a chimeric antigen binding polypeptide immunoreactive with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein each of the hypervariable loops of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).

2. The process of claim 1, wherein the conventional antibody of a *Lama* species of part (a) is obtained by immunising a *Lama* species, thereby raising a conventional antibody which is immunoreactive with said target antigen.

3. The process of claim 1, wherein step (a) comprises determining the nucleotide sequence encoding the VH and/or the VL domain of a conventional antibody of a *Lama* species immunoreactive with said target antigen; and step (b) comprises expressing an antigen binding polypeptide immunore-

371

active with said target antigen, said antigen binding polypeptide comprising a VH and a VL domain, wherein at least one of the VH domain or the VL domain has an amino acid sequence encoded by the nucleotide sequence determined in part (a).

4. The process of claim 1, wherein the antigen binding polypeptide expressed in step (b) comprises at least one constant domain of a non-camelid antibody, preferably a human antibody.

5. A process for preparing a recombinant antigen binding polypeptide that is immunoreactive with (or specifically binds to) a target antigen, said antigen binding polypeptide comprising a VH domain and a VL domain, said VH domain comprising hypervariable loops H1, H2 and H3, wherein said VH domain polypeptide is paired with a VL domain comprising hypervariable loops L1, L2 and L3, wherein each of the hypervariable loops H1-H3 and L1-L3 are obtained from a conventional antibody of a *Lama* species by active immunization of the *Lama* species with the target antigen, wherein said conventional antibody is a heterotetrameric IgG antibody composed of two identical light chains and two identical heavy chains, and wherein at least one of the hypervariable loops H1, H2, L1, L2 and L3 exhibits a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1, H2, L1, L2 or L3 hypervariable loop which occurs in a human antibody, said process comprising the steps of:

- (a) isolating a nucleic acid from a *Lama* species encoding at least one hypervariable loop of the VH and/or the VL domain of a conventional antibody of a *Lama* species immunoreactive with said target antigen;
- (b) preparing a polynucleotide comprising a nucleotide sequence encoding hypervariable loop(s) having amino acid sequence identical to the hypervariable loop(s) encoded by the nucleic acid isolated in step (a), which polynucleotide encodes an antigen binding polypeptide comprising a VH domain and a VL domain that is immunoreactive with (or specifically binds to) said target antigen, wherein said VH domain comprises hypervariable loops H1, H2 and H3, wherein said VH domain polypeptide is paired with a VL domain comprising hypervariable loops L1, L2 and L3, wherein each of the hypervariable loops H1-H3 and L1-L3 are obtained from a conventional antibody of a *Lama* species by active immunization of the *Lama* species with the target antigen, wherein said conventional antibody is a heterotetrameric IgG antibody composed of two identical light chains and two identical heavy chains, and wherein at least one of the hypervariable loops H1, H2, L1, L2 and L3 exhibits a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1, H2, L1, L2 or L3 hypervariable loop which occurs in a human antibody; and
- (c) expressing said antigen binding polypeptide from the recombinant polynucleotide of step (b), wherein said antigen binding polypeptide is not identical to the conventional antibody of a *Lama* species of part (a).

372

6. The process of claim 5 wherein (a) comprises isolating a nucleic acid of a *Lama* species encoding the VH domain and/or the VL domain of said antibody and altering the sequence of said nucleic acid such that it encodes a VH domain and/or a VL domain with one or more amino acid substitutions, deletions or additions.

7. The process of claim 5 wherein the recombinant polynucleotide prepared in step (b) additionally comprises a nucleotide sequence encoding one or more constant domains of a non-camelid antibody, preferably a human antibody.

8. The process of claim 5 wherein the *Lama* species is llama (*Lama glama*) or alpaca (*Lama pacos*).

9. The process of claim 5 wherein the target antigen is selected from the group consisting of: human antigens, viral antigens, bacterial antigens and a target antigens of therapeutic or diagnostic importance.

10. A method of producing an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:

- a) preparing an expression vector encoding a polynucleotide molecule encoding a VH domain and/or a VL domain of an antigen binding polypeptide, said VH domain comprising hypervariable loops H1, H2 and H3, and said VL domain comprising hypervariable loops L1, L2 and L3, wherein said VH domain and/or said VL domain are each fused to one or more IgG constant domains of a human antibody, wherein each of the hypervariable loops H1-H3 and L1-L3 are obtained from a conventional antibody of a *Lama* species by active immunization of the *Lama* species with the human target antigen, wherein said conventional antibody is a heterotetrameric IgG antibody composed of two identical light chains and two identical heavy chains, and wherein at least one of the hypervariable loops H1, H2, L1, L2 and L3 exhibits a predicted or actual canonical fold structure which is identical or substantially identical to a canonical fold structure of a corresponding H1, H2, L1, L2 or L3 hypervariable loop which occurs in a human antibody;
- b) introducing said expression vector into host cell or cell-free expression system under conditions which permit expression of the encoded antigen binding polypeptide; and
- c) recovering the expressed antigen binding polypeptide.

11. A method of producing an antigen binding polypeptide immunoreactive with a target antigen, the method comprising steps of:

- a) preparing an expression vector encoding an antigen binding polypeptide immunoreactive with a target antigen using the method of claim 10;
- b) introducing said expression vector into host cell or cell-free expression system under conditions which permit expression of the encoded antigen binding polypeptide; and
- c) recovering the expressed antigen binding polypeptide.

12. The process of claim 1 wherein the *Lama* species is llama (*Lama glama*) or alpaca (*Lama pacos*).

* * * * *